%PDF-1.6%âãÏÓ
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 9198/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-07-17T06:02:14-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-07-17T06:02:15-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-07-17T06:02:15-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:3377f01b-3c9e-5e4c-88a1-960016583544</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:9781fe1d-50de-4727-9e44-073511991c41</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:982928b7-5d59-44bd-8c19-d8a0b76c6023</stRef:instanceID>
            <stRef:documentID>xmp.did:b239edf2-8d6f-47e4-a188-2c47c7342adf</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-07-17T06:02:14-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1392107873</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1392107873</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-ItalicMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.00.2</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1552261271</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1552261271</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.01.2</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3030352917</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3030352917</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4073973744</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4073973744</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3691150952</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3691150952</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 11/Kids[14 0 R 15 0 R]/Type/Pages>>endobj14 0 obj<</Count 5/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R]/Parent 3 0 R/Type/Pages>>endobj15 0 obj<</Count 6/Kids[10 0 R 11 0 R 12 0 R 13 0 R 16 0 R 17 0 R]/Parent 3 0 R/Type/Pages>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 18 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 21 0 R>>/Font<</T1_0 22 0 R/T1_1 23 0 R/T1_2 24 0 R/T1_3 25 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 26 0 R>>/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 837>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 28 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 21 0 R>>/Font<</T1_0 23 0 R/T1_1 22 0 R/T1_2 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310035005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 889>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 29 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</T1_0 23 0 R/T1_1 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310035005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 32354>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</C2_0 31 0 R/TT0 32 0 R/TT1 33 0 R/TT2 34 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 35 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310035005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 15792>>/PageWidthList<</0 612.0>>>>>>>>endobj16 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 36 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</C2_0 31 0 R/TT0 33 0 R/TT1 32 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 35 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310035005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 11429>>/PageWidthList<</0 612.0>>>>>>>>endobj17 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 37 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</C2_0 31 0 R/TT0 32 0 R/TT1 33 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 38 0 R>>/XObject<</Fm0 35 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310035005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 32074>>/PageWidthList<</0 612.0>>>>>>>>endobj37 0 obj<</Length 12640>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 658.9473 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc -0.014 Tw 10 0 0 10 46 714.5273 Tm
[(G)0.5 (en)0.5 (eral)0.5 ( i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( ab)0.5 (o)0.5 (u)0.5 (t th)0.5 (e safe an)0.5 (d)0.5 ( effecti)0.5 (ve u)0.5 (se o)0.5 (f KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (.)]TJ
/C2_0 1 Tf
-0.025 Tc 0.025 Tw 0 -1.368 Td
[<003000480047004C0046004C0051004800560003>28 <0044005500480003>28.1 <00560052005000480057004C0050004800560003>28.1 <005300550048005600460055004C0045004800470003>28.1 <0049005200550003>28.1 <005300580055005300520056004800560003>28.1 <00520057004B004800550003>28.1 <0057004B004400510003>28.1 <0057004B0052005600480003>28.1 <004F004C00560057004800470003>28 <004C00510003>28 <00440003>28.1 <003300440057004C0048005100570003>28 <002C0051004900520055005000440057004C005200510003>28 <004F0048004400C00048005700110003>28.1 <002700520003>28.1 <0051005200570003>28.1 <0058005600480003>28 <002E00350024003D0024>74.4 <0037002C>-24.9 <0003>]TJ
/TT1 1 Tf
-0.02 Tc 0.003 Tw 0 -1.08 Td
[(for )0.5 (a )0.5 (condition )0.5 (for )0.5 (which it )0.5 (was not )0.5 (prescribed. )0.5 (Do )0.5 (not )0.5 (give )0.5 (KRAZA)74.3 (TI )0.5 (to other people, )0.5 (even )0.5 (if )0.5 (they have the )0.5 (same symptoms)-20 ( )]TJ
-0.021 Tc 0 Tw 0 -1.08 Td
[(that you have. It may harm them. )18.1 (Y)91.7 (ou can ask your pharmacist or healthcare provider for information about \KRAZA)74.1 (TI that is)-21 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.08 Td
[(writ)0.5 (t)0.5 (en f)0.5 (or healt)0.5 (h prof)0.5 (essionals.)]TJ
/TT0 1 Tf
0 -2.412 Td
[(W)0.5 (h)0.5 (at are th)0.5 (e i)0.5 (n)0.5 (g)0.5 (red)0.5 (i)0.6 (en)0.5 (ts i)0.6 (n)0.5 ( KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (?)]TJ
0 -1.548 Td
[(Acti)0.5 (ve i)0.5 (n)0.5 (g)0.5 (red)0.5 (i)0.5 (en)0.5 (t:)]TJ
/TT1 1 Tf
( adagrasib)Tj
/TT0 1 Tf
-0.006 Tc 0.072 Tw 0 -1.548 Td
(Inactive ingredients:)Tj
/TT1 1 Tf
[( colloidal silicon dioxide, crospovidone, magnesium stearate \(vegetable\ sourced\), mannitol, and)-6.1 ( )]TJ
/C2_0 1 Tf
-0.023 Tc 0.023 Tw 0 -1.08 Td
[<0050004C00460055005200460055005C00560057>0.5 <0044004F004F004C005100480003>5.3 <00460048004F004F0058004F0052005600480011>0.5 <0003>23.4 <0037>0.5 <004B00480003>5.3 <0057>0.5 <00440045004F00480057>0.5 <0003>5.2 <00BF004F00500003>5.3 <0046005200440057>0.5 <004C0051004A0003>5.3 <0046005200510057>0.5 <0044004C005100560003>5.3 <004B005C00530055005200500048004F004F005200560048000F>0.5 <0003>5.3 <00500044004F0057>0.5 <005200470048005B0057>0.5 <0055004C0051000F>0.5 <0003>5.2 <005000480047004C005800500003>5.3 <0046004B0044004C00510003>5.3 <0057>0.5 <0055004C004A004F005C004600480055004C0047004800560003>5.3 <000B00590048004A00480057>0.5 <00440045004F0048>-23.2 <0003>]TJ
/TT1 1 Tf
-0.014 Tw 0 -1.08 Td
[(sourced\),)0.5 ( polydext)0.5 (rose,)0.6 ( t)0.5 (alc,)0.6 ( and t)0.5 (it)0.5 (anium dioxide.)]TJ
-0.018 Tc 0 Tw 9 0 0 9 46 563.1874 Tm
[(Dist)0.5 (ribut)0.5 (ed )0.5 (by:)0.5 ( )0.5 (Brist)0.5 (ol-Myers )0.5 (Squibb )0.5 (Company)74.6 (,)0.5 ( )0.5 (Princet)0.5 (on,)0.5 ( )0.5 (NJ )0.5 (08543 )0.5 (USA)]TJ
0 -1.376 Td
[(KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( )0.5 (and )0.5 (t)0.5 (he KRAZ)0.5 (A)74.5 (T)0.5 (I)0.5 ( )0.5 (logo )0.5 (are )0.5 (t)0.5 (rademarks )0.5 (of)0.5 ( )0.5 (Mirat)0.5 (i )18.6 (T)0.5 (herapeut)0.5 (ics,)0.5 ( )0.5 (I)0.5 (nc.)0.5 (,)0.5 ( )0.5 (a )0.5 (Brist)0.5 (ol )0.5 (Myers )0.5 (Squibb )0.5 (company)74.5 (.)]TJ
0 -1.376 Td
[(F)0.5 (or )0.5 (more )0.5 (inf)0.5 (ormat)0.5 (ion,)0.5 ( )0.5 (go )0.5 (t)0.5 (o )0.6 (www)55.3 (.)0.5 (KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 (.)0.5 (com )0.5 (or )0.5 (call )0.5 (1-866-4-KRAZ)0.5 (A)74.6 (T)0.5 (I )0.5 (\(1-866-457-2928\))]TJ
ET
4 M 
36.5 528.928 539 202.38 re
S
q 1 0 0 1 36 489.7745 cm
0 0 m
540 0 l
S
Q
BT
-0.023 Tc -0.014 Tw 9 0 0 9 36 512.8745 Tm
[(T)0.5 (his Pat)0.5 (ient)0.5 ( I)0.5 (nf)0.5 (ormat)0.5 (ion has been approved by t)0.5 (he U.)0.5 (S.)0.5 ( F)0.5 (ood and Drug )55.6 (Administ)0.5 (rat)0.6 (ion.)]TJ
-0.018 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -2.111 Td
( )Tj
EMC 
52.492 0 Td
[(Revised:)0.5 ( )0.5 (07/)0.5 (2024)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-52.492 -1.671 Td
( )Tj
EMC 
-0.018 Tc 49.154 0 Td
[(1914-US-2400457 )0.5 ( )0.5 (07/)0.5 (24)]TJ
ET
/PlacedPDF /MC0 BDC 
q
236.563 457.96 138.874 19.075 re
W n
/GS0 gs
q 1 0 0 1 241.8615 458.4023 cm
0 0 m
-0.143 -0.296 -0.449 -0.487 -0.778 -0.487 c
-0.909 -0.487 -1.036 -0.458 -1.155 -0.401 c
-3.866 0.914 -5.299 3.23 -5.299 6.299 c
-5.299 9.764 l
-5.299 10.241 -4.911 10.628 -4.434 10.628 c
-3.958 10.628 -3.57 10.241 -3.57 9.764 c
-3.57 6.299 l
-3.57 3.905 -2.503 2.175 -0.4 1.155 c
0.028 0.947 0.208 0.429 0 0 c
-2.556 8.032 m
-2.556 7.542 -2.16 7.145 -1.67 7.145 c
-1.18 7.145 -0.783 7.542 -0.783 8.032 c
-0.783 15.104 l
-0.783 15.594 -1.18 15.991 -1.67 15.991 c
-2.16 15.991 -2.556 15.594 -2.556 15.104 c
h
0.187 8.237 m
0.187 7.748 0.584 7.351 1.074 7.351 c
1.564 7.351 1.961 7.748 1.961 8.237 c
1.961 17.746 l
1.961 18.236 1.564 18.632 1.074 18.632 c
0.584 18.632 0.187 18.236 0.187 17.746 c
h
2.93 7.583 m
2.93 7.094 3.327 6.697 3.817 6.697 c
4.307 6.697 4.704 7.094 4.704 7.583 c
4.704 16.119 l
4.704 16.609 4.307 17.006 3.817 17.006 c
3.327 17.006 2.93 16.609 2.93 16.119 c
h
5.674 6.454 m
5.674 5.979 6.059 5.594 6.534 5.594 c
7.009 5.594 7.394 5.979 7.394 6.454 c
7.394 12.222 l
7.394 12.697 7.009 13.082 6.534 13.082 c
6.059 13.082 5.674 12.697 5.674 12.222 c
h
f
Q
q 1 0 0 1 258.4387 466.4851 cm
0 0 m
0.002 0.053 l
1.118 0.437 1.809 1.108 1.809 2.307 c
1.809 2.49 l
1.809 3.866 0.691 4.998 -1.59 4.998 c
-4.746 4.998 l
-4.746 -5.739 l
-1.361 -5.739 l
0.856 -5.739 2.378 -4.625 2.378 -2.841 c
2.378 -2.733 l
2.378 -1.341 1.558 -0.322 0 0 c
-3.365 3.786 m
-1.787 3.786 l
-0.283 3.786 0.484 3.216 0.484 2.197 c
0.484 2.089 l
0.484 0.858 -0.581 0.463 -1.979 0.463 c
-3.365 0.463 l
h
0.964 -2.717 m
0.964 -4.046 -0.083 -4.543 -1.61 -4.543 c
-3.365 -4.543 l
-3.365 -0.672 l
-1.586 -0.672 l
-0.082 -0.672 0.964 -1.172 0.964 -2.548 c
h
6.89 2.39 m
7.288 2.39 l
7.288 1.132 l
6.966 1.132 l
5.678 1.132 4.834 0.488 4.834 -1.215 c
4.834 -5.739 l
3.546 -5.739 l
3.546 2.39 l
4.834 2.39 l
4.834 0.933 l
4.896 0.933 l
5.126 1.669 5.724 2.39 6.89 2.39 c
8.435 2.39 1.289 -8.129 re
9.865 4.214 m
9.865 3.586 9.579 3.292 9.079 3.292 c
8.578 3.292 8.293 3.586 8.293 4.214 c
8.293 4.842 8.578 5.154 9.079 5.154 c
9.579 5.154 9.865 4.842 9.865 4.214 c
16.87 -3.5 m
16.87 -5.065 15.705 -5.892 14.002 -5.892 c
12.284 -5.892 11.149 -5.156 11.057 -3.5 c
12.345 -3.5 l
12.391 -4.497 13.128 -4.819 14.002 -4.819 c
14.876 -4.819 15.582 -4.436 15.582 -3.592 c
15.582 -1.613 11.149 -2.978 11.149 0.227 c
11.149 1.562 12.13 2.543 13.925 2.543 c
15.567 2.543 16.656 1.731 16.778 0.151 c
15.49 0.151 l
15.413 1.102 14.754 1.47 13.925 1.47 c
12.99 1.47 12.407 1.04 12.407 0.227 c
12.407 -1.69 16.87 -0.509 16.87 -3.5 c
19.843 2.39 m
21.592 2.39 l
21.592 1.255 l
19.843 1.255 l
19.843 -3.239 l
19.843 -4.42 20.15 -4.665 20.932 -4.665 c
21.147 -4.665 21.392 -4.635 21.592 -4.619 c
21.592 -5.724 l
21.346 -5.77 21.024 -5.801 20.794 -5.801 c
19.199 -5.801 18.555 -5.172 18.555 -3.438 c
18.555 1.255 l
17.189 1.255 l
17.189 2.39 l
18.555 2.39 l
18.555 4.998 l
19.843 4.998 l
h
25.398 2.543 m
23.388 2.543 22.315 1.163 22.315 -1.076 c
22.315 -2.273 l
22.315 -4.512 23.388 -5.892 25.398 -5.892 c
27.407 -5.892 28.481 -4.512 28.481 -2.273 c
28.481 -1.076 l
28.481 1.163 27.407 2.543 25.398 2.543 c
27.177 -2.197 m
27.177 -4.129 26.502 -4.758 25.398 -4.758 c
24.293 -4.758 23.619 -4.129 23.619 -2.197 c
23.619 -1.153 l
23.619 0.78 24.293 1.409 25.398 1.409 c
26.502 1.409 27.177 0.78 27.177 -1.153 c
h
29.843 4.998 1.289 -10.737 re
43.559 4.998 m
45.746 4.998 l
45.746 -5.739 l
44.381 -5.739 l
44.381 3.51 l
44.304 3.51 l
41.558 -3.962 l
39.886 -3.962 l
37.172 3.51 l
37.095 3.51 l
37.095 -5.739 l
35.745 -5.739 l
35.745 4.998 l
38.039 4.998 l
40.745 -2.46 l
40.822 -2.46 l
h
52.011 2.39 m
53.315 2.39 l
49.711 -8.347 l
48.377 -8.347 l
49.282 -5.801 l
46.643 2.39 l
48.008 2.39 l
49.956 -3.945 l
50.018 -3.945 l
h
56.777 2.543 m
54.768 2.543 53.694 1.102 53.694 -1.076 c
53.694 -2.273 l
53.694 -4.512 54.768 -5.892 56.777 -5.892 c
58.388 -5.892 59.339 -5.003 59.661 -3.484 c
58.342 -3.484 l
58.111 -4.42 57.59 -4.758 56.777 -4.758 c
55.673 -4.758 54.997 -4.129 54.997 -2.197 c
54.997 -2.089 l
59.706 -2.089 l
59.706 -1.076 l
59.706 1.102 58.787 2.543 56.777 2.543 c
56.777 1.409 m
57.82 1.409 58.386 0.794 58.401 -1.076 c
54.999 -1.076 l
55.017 0.794 55.688 1.409 56.777 1.409 c
64.483 2.39 m
64.882 2.39 l
64.882 1.132 l
64.56 1.132 l
63.272 1.132 62.428 0.488 62.428 -1.215 c
62.428 -5.739 l
61.14 -5.739 l
61.14 2.39 l
62.428 2.39 l
62.428 0.933 l
62.49 0.933 l
62.719 1.669 63.318 2.39 64.483 2.39 c
71.385 -3.5 m
71.385 -5.065 70.22 -5.892 68.517 -5.892 c
66.799 -5.892 65.664 -5.156 65.572 -3.5 c
66.861 -3.5 l
66.907 -4.497 67.643 -4.819 68.517 -4.819 c
69.391 -4.819 70.097 -4.436 70.097 -3.592 c
70.097 -1.613 65.664 -2.978 65.664 0.227 c
65.664 1.562 66.646 2.543 68.441 2.543 c
70.081 2.543 71.171 1.731 71.294 0.151 c
70.005 0.151 l
69.928 1.102 69.269 1.47 68.441 1.47 c
67.505 1.47 66.922 1.04 66.922 0.227 c
66.922 -1.69 71.385 -0.509 71.385 -3.5 c
81.626 -2.901 m
81.626 -4.819 80.307 -5.892 78.282 -5.892 c
76.38 -5.892 74.815 -4.972 74.616 -2.917 c
76.042 -2.917 l
76.211 -4.129 77.07 -4.696 78.267 -4.696 c
79.632 -4.696 80.245 -3.883 80.245 -2.978 c
80.245 0.074 74.785 -1.69 74.785 2.314 c
74.785 4.031 76.15 5.151 78.052 5.151 c
79.892 5.151 81.426 4.246 81.518 2.13 c
80.092 2.13 l
79.969 3.433 79.141 3.955 78.037 3.955 c
76.732 3.955 76.165 3.187 76.165 2.375 c
76.165 -0.325 81.626 1.27 81.626 -2.901 c
87.447 1.409 m
87.384 1.409 l
87.036 2.126 86.375 2.543 85.53 2.543 c
83.52 2.543 82.6 1.163 82.6 -1.076 c
82.6 -2.273 l
82.6 -4.512 83.52 -5.892 85.53 -5.892 c
86.375 -5.892 87.036 -5.475 87.384 -4.758 c
87.447 -4.758 l
87.447 -5.739 l
87.447 -8.347 l
88.736 -8.347 l
88.736 2.39 l
87.447 2.39 l
h
85.683 -4.758 m
84.579 -4.758 83.904 -4.129 83.904 -2.197 c
83.904 -1.153 l
83.904 0.78 84.579 1.409 85.683 1.409 c
86.788 1.409 87.463 0.78 87.463 -1.153 c
87.463 -2.197 l
87.463 -4.129 86.788 -4.758 85.683 -4.758 c
94.653 2.39 m
95.942 2.39 l
95.942 -5.739 l
94.653 -5.739 l
94.653 -4.696 l
94.592 -4.696 l
94.285 -5.355 93.626 -5.892 92.598 -5.892 c
91.08 -5.892 90.144 -5.033 90.144 -3.116 c
90.144 2.39 l
91.448 2.39 l
91.448 -2.932 l
91.448 -4.236 91.985 -4.804 92.951 -4.804 c
93.887 -4.804 94.653 -4.175 94.653 -2.595 c
h
97.596 2.39 1.288 -8.129 re
103.818 2.543 m
102.961 2.543 102.308 2.126 101.963 1.409 c
101.901 1.409 l
101.901 2.39 l
101.901 4.998 l
100.613 4.998 l
100.613 -5.739 l
101.901 -5.739 l
101.901 -4.758 l
101.963 -4.758 l
102.308 -5.475 102.961 -5.892 103.818 -5.892 c
105.828 -5.892 106.748 -4.512 106.748 -2.273 c
106.748 -1.076 l
106.748 1.163 105.828 2.543 103.818 2.543 c
105.444 -2.197 m
105.444 -4.129 104.769 -4.758 103.665 -4.758 c
102.561 -4.758 101.886 -4.129 101.886 -2.197 c
101.886 -1.153 l
101.886 0.78 102.561 1.409 103.665 1.409 c
104.769 1.409 105.444 0.78 105.444 -1.153 c
h
111.218 2.543 m
110.36 2.543 109.707 2.126 109.362 1.409 c
109.3 1.409 l
109.3 2.39 l
109.3 4.998 l
108.012 4.998 l
108.012 -5.739 l
109.3 -5.739 l
109.3 -4.758 l
109.362 -4.758 l
109.707 -5.475 110.36 -5.892 111.218 -5.892 c
113.227 -5.892 114.147 -4.512 114.147 -2.273 c
114.147 -1.076 l
114.147 1.163 113.227 2.543 111.218 2.543 c
112.844 -2.197 m
112.844 -4.129 112.169 -4.758 111.064 -4.758 c
109.96 -4.758 109.285 -4.129 109.285 -2.197 c
109.285 -1.153 l
109.285 0.78 109.96 1.409 111.064 1.409 c
112.169 1.409 112.844 0.78 112.844 -1.153 c
h
99.027 4.214 m
99.027 3.586 98.741 3.292 98.241 3.292 c
97.74 3.292 97.455 3.586 97.455 4.214 c
97.455 4.842 97.74 5.154 98.241 5.154 c
98.741 5.154 99.027 4.842 99.027 4.214 c
f
Q
q 1 0 0 1 373.928 471.5152 cm
0 0 m
-0.73 0 -1.323 -0.594 -1.323 -1.323 c
-1.323 -2.053 -0.73 -2.646 0 -2.646 c
0.73 -2.646 1.323 -2.053 1.323 -1.323 c
1.323 -0.594 0.73 0 0 0 c
0 -2.832 m
-0.832 -2.832 -1.509 -2.155 -1.509 -1.323 c
-1.509 -0.491 -0.832 0.186 0 0.186 c
0.832 0.186 1.509 -0.491 1.509 -1.323 c
1.509 -2.155 0.832 -2.832 0 -2.832 c
f
Q
q 1 0 0 1 373.6636 470.2315 cm
0 0 m
0.284 0 l
0.377 0 0.45 0.024 0.502 0.07 c
0.554 0.118 0.581 0.182 0.581 0.263 c
0.581 0.348 0.557 0.414 0.508 0.461 c
0.46 0.507 0.387 0.531 0.292 0.533 c
0 0.533 l
h
0.308 -0.223 m
0 -0.223 l
0 -0.834 l
-0.276 -0.834 l
-0.276 0.755 l
0.283 0.755 l
0.466 0.755 0.608 0.714 0.708 0.632 c
0.807 0.55 0.857 0.431 0.857 0.275 c
0.857 0.168 0.831 0.079 0.78 0.008 c
0.729 -0.064 0.657 -0.119 0.566 -0.158 c
0.923 -0.82 l
0.923 -0.834 l
0.627 -0.834 l
h
f
Q
EMC 
Q
endstreamendobj35 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 334/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 20 0 R>>/Font<</TT0 39 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6949 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc 0.023 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.3099 Tm
[(KRAZ)0.5 (A)74.4 (T)0.5 (I)]TJ
0 Tc 0 Tw 8.4 0 0 8.4 85.8074 750.8058 Tm
(\256)Tj
-0.023 Tc 0.055 Tw 12 0 0 12 91.8007 747.3099 Tm
[( \(ad)0.5 (ag)0.5 (rasi)0.5 (b)0.5 (\))]TJ
ET
endstreamendobj39 0 obj<</BaseFont/UEAMSO+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 40 0 R/LastChar 174/Subtype/TrueType/ToUnicode 41 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 0 0 0 278 0 722 0 0 0 0 0 0 722 0 611 0 0 0 0 0 611 0 0 0 0 0 0 556 611 0 611 0 0 611 0 278 0 0 0 0 0 0 0 0 389 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj40 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 42 0 R/FontName/UEAMSO+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj41 0 obj<</Filter/FlateDecode/Length 309>>stream
H‰\‘Ínƒ0Çïy
ÛCÅGYh%„D»Mâ°í 1ÒQ Ş~N\uÒ"ÿÿí`;:×µˆŞİ¤\ Œv8OW§:¼F$)èA-·Søª±µ"¢àfkÓO¢( ú ç¼¸6•:ÜŠèÍitƒ¹ÀæëÜl!j®ÖşàˆfÊ4ö”è¥µ¯íˆ…°]­É?,ëbşŸ«EHÃ9áŸQ“ÆÙ¶
]k.(Š˜V	Å3­R ÑÿüIÎa]¯¾['ŠÔ‹ã˜ñùàùÈ|$Î’Àdˆù>÷'æñC˜qÆœy®˜+bÉy¤Ï#Y/½^²^z½Ì™sÏü–ôoå¬Ï½>ß3ï‰«§Àd|±·ª|Ù4¸÷T]£v††>úïS¶“Šò[ü
0 îG”éendstreamendobj42 0 obj<</Filter/FlateDecode/Length 19471/Length1 46402>>stream
H‰Œ•	TTW@«úÿ_º!²ŠŠİÿwÃïDÂG	Bpg1’èLâDAÅ5.d‚5¸á®,*¸á.ŠŠ7÷n\£¶£Ññ˜qèyMs˜Ì™““y}ª^½zUçwûUıôÉSãÀ2€ƒÈ¡ÃŞë	Îaf›“–ÃW<À0 ÏÏc§¥ËÎm¯å âÈø´ñ)Îug#$O_6{Ó` i€obB\Ì¸^o†„œbA¡	ÌáŒyÃT`BJúçú}-ó]INA_)`Â¶¾‘3#Í¹¿áSòÄ˜”¸„²¼R¶~ÀOK’n‚ë E‘ı´ÉqmñElö¬»¢:
¸k„^ìşÎ™«…x•—‹ Òˆ¼Ê1øF²Ÿ€ıYª«#øş2°Ÿ½I¨où{‰á¸7Ğn·³sB¹ã4à™V¶èÃø1»0!hs²Y¥rÄü÷`›/èâªÖ¸¹¿ÕÁÃÓËÛÇ·£_§Î]ü»ju’¬7*Æ·ßéônğ¯º¿×ã×={…¼ú›z÷ùmØ‡áEôí×ÀÀA¿üû?üñOC>ùÉ§Ã†ÿù/Ÿ}>bä¨Ñ_D‰±±ãââÇ'LHLJN™˜š6iò”ô©Ó¦Ï˜9ëËÙsæÎËøê¯_gÎ_ğ·¬o²s.Zümî’¥Ë–¯È[¹jõX·~ÃÆü‚Â¢M›·—lİ¶Û±³t×î={÷í?p°ìĞáò#GU?qNU®:sö\õù/]®Úºú+W¯]‡›·LæÛ–à=ÂÙECØUE¹hWÉªª\ 7”Kå¦rs¹ln!WÀ]â^óîüP~à-œ¯ˆ#_ò'‰úPÙÅm¢6I{J[­µëæéÖê^èŞH¾’V(‘>“FH£¤/¤9Ò~©Rª—LÒsé•Ô"w²Qî.÷Cä>r˜.£äTy¼\> ôŞz?½AoÔw×¬®ÒgêWèK*:¼¾†.ÉĞÍğ®a°!Æ 
ğĞ+ ¨7ÅCñQ:)]•@%X	QÂ”d%CÉT²”…Ê2¥@Ù¡ìUÊ•£J¥rA¹¬ÜTÃŒÆ~Æhc¬1Ş˜dLNŞİ¯¸K±Ş¦²…ÚÂlá¶¾¶¶=¶Ç6{ÓØæš_67µ´4Ù›ïŒ½°|¨ôª‘ªR.‹äÒ¹Y\&£¶˜+âj¸ù·øH>KX"Ô?†QÓ‘"(ZŒÔ£–¬­Ô¶è@—¡Ë×½”@ê$ÉÒ`)²Ú)C:(UI×¤ÛÒKé5{ì^ŒZ£ÖSîİN-‘QË•ó[©ul£6D?L?ŠQËm§æÉ¨u6èÚ¨EÆµR“†Zd;µ\%_ÙÖN­šQ»Á¨õi§gLdÔ¢ƒÓ5¿bÙ†6­íF-ÂÖß6ÈVokjŠjo¥&·d8¨Ùï±ú|Î¤õ£™ts\Ë‡æk˜ä,Á¦š¦óB›ëşS–ÏBóÏ‡ Xç<dÕmõµz[=­¬îV7«Æª¶ºZE+Y+gUYá‰ã?‚ÆùLV0Él|s§¤qúÓDf—=íÍtvã€†Ä†™åÖ‹÷‚[W5”4äYò,…– ËG~ƒŸe’e[õ°DXzYÍƒÌÍaæŞæPs/ss7³Áìoö1£é™Éjzdz`ºëÈ2U™›*LeÌ:mÚlÚehêgêk
4Lz“îşêÆc-Gâıâ½„
V‚ëÄµâqµóô˜Âİo¹×º=€‹míZ¬ës¬ƒó£±L2„,¦—
‡X´“P*9³]tLz¸ôtç’ïjPwtxÕ^m2~a¨CÔŸ2Íú³zÚO¼­}ÛéQ¯ûÙÜQgµ­2é¬ŸdVGµÛ#ÿø°v+^¦IøŸ Š æsQa,†X[ax@6Cú5,ƒà,‚•…È¾§ÏalƒÀKx…°ÎBì„±¹0ª!ÎÀ9¸çá\„ï!já2Ô@)Œ‡g°®@ÔC<+|‰0’ ’a"äC*L‚4˜S`*¤Ã4˜`Ì‚™ğ%ÌÙP0æ²¯üWğÂaÌÃ•¨ByÀM¸
Wã\ÍĞ‚„"º€×ázÜ€1ĞÕ¨A7,Ä"x?â&ÜŒ[°Kp+nÃí¸wb)îÂİ¸÷â>ø'\ÅlÌÁıx bBw|c9v@ôD/h„;è>x¢/vÄ…x+ğ8À“øúa'Ø»±3vÁSX‰şØµ¨ÃÓXoà_pî¡„2êÑ€gğ,Ãj<ğ"^Â Dxk°ë°¯@9¾ï`7‚ûğ ¯R6åĞBZD‹é[Ê¥%´”–ÑrZAy´’V	´šÖÀZKëh=m ”OTHE´‰6Ó*æù$*¡­´¶ÓÚI¥´‹vÓÚKûh?ŸÌ§Ğ:HetˆS9¡£tŒ*è8 “ô¢J:MUt†ÎÒ9ª¦ót.Ò%ºL5|ßÌ·ğvT'ğ‚  
.‚« 4TKuTOWé]§t“n‘‰Ìt›,Ô@t‡îÒ=ºOè!}OX­?!+=¥¿Ó3¼†×ñŞÄ[hÒx‰¢§è%z‹>¢¯ØQô;‰E±«¨u¢$Ê¢^4h¼5>_Í¿i®ïà.‹4àï>û{vŸç}ö!ÔPÒH ¥H“Ş	=DÏJ™ADAé]¼;QpNÔSOéBè-¡C	[ïæşØ¿vvvæ™Ïì~¿e%OË	9)§ä´œ‘³rNÎ»[®Ğ¹Ûî+v%î®»çî»ÒhUQ°ul]›h“l²M±©6Í¦c¢T’Êöu;ÑN²oØ7íd;ÅNµoÙiöm;İ¾cgØ™v–mçØ¹voûƒ<»08hÙÅv‰½–úWì}»Ì.·Ø¿Ù¿ÛØƒCÁáàHpÌ'À£v…ıÈ~l?±+í§v•]m×ØÏìZû¹]g¿°ëí»QªHœT•jR]jH¼Ô”ZR[¤Ô•DI’dI‰ÌÌ£6‘qÔ–ÚÑÃÔ:DFQGêD©u¥nÔzPOêE½©åR_êGıi ¤A4˜†Ğ#4”¥a‘’*i’.’)õ¤¾dÉ¹(ùR —$[HCšA3iÍ¦94—æÑ|Z@i-¦%ô.-¥÷hyTG#QâÕuU]S¨ëê†º©
U‘º­î¨b•®JÔ]uOİW>[àƒ&hˆ ‚¡ÊQ(e!ÊA,”‡
ªT„Jª¾Ê‚ÊPâ *TƒêPâ¡¦Ïhïø¼‘ ²U¨£B]H„$H†H…4H—i$Gä9*—åŠ\•k´2 êA}È‚lh !AchB?Ó/0^ñğ*L€×àu˜“àx&Ó¯0¦Òo´¶ÓÚI»h7í¡½ô;í£ıt€Ò!:LGè:JÇ(Ó	:I§è4¡³tÎÓEÊ§ºD—é
]¥ktnĞMºE…TD·éÃ[0c°•Ğ]ŒÅòtîc¬ˆ•°2•rÀŠ«`k0²aËÄÌ!;¬ŠÕ°:ÖÀx¬ÉQ.Ãe9kamLÀ:\c¹<WàŠ\‰+sãª\«sçš\‹ks×‰Nä$NæNå4Nç¬‹‰œÉõ¸>gq67à†œÃ¸17á¦ü ?ˆI˜ÌÍ¸9·à–ü·âÖÜ†Ûr;~˜ÛËu¹Á¸cÔF)ÊÑ0*QÇ¸3wá®Ü»sîÉ½¸7÷á\îËı¸?ˆF£e¢e£1<ñ`ÂğP~”‡ñcü8?ÁÃùI~ŠÿÂ#øi¹É#ù~–ÿÊÏñóü¿È/ñË<ŠGó˜3aÌ†90æÁ|X å,‚Å°Ş…¥ğ¼Ë`9•B)’Ûr
ä#Y!Ë'²R>•U²J1\†+z¢~COÖSõ4=CÏÒóô½D¿ï;À
½R¯ÒkôZ½NoÔ_éoõz³şEo‡«z·Ş§é£ú„>£/èKúŠ¾×à:Ü€›p
¡ncS| ”5ò™¬•¹+÷ä¾”º î@1”À]¸÷¡TZiĞZG @#¦`6ÃæØ[ùÓm°¶ÇØ»coì‡ƒtMŠãS8ŸÃ—pŒNÆq8Áç¢Iø&NÁ·ğm|gâlŸ‘æãB\ì{å{:—áø!~‚«ñsÜ€_â&ü¿Ã}³ùwân‰{ñ Á<<¥³ñæã¼EX‚¥¾÷XŸáËšr¦¼©¬óMœ©á[P-ŸèL]“dRLšÉ0õL–nd˜ÓÔ7¤–>í·1í4™‡M{ÓÁt4LgÓÅt5İLwÓÃô4½LoÓÇäš¾¦Ÿéo˜fß,ëdıÿç£C-Úıo>fˆf†›æiÙèÀº2.ÖUrU]¼KpI.Å¥¹—år\S×Üµrí\G×Õõt¹n€â†¹án„é•cÑ*Ñ8uTSyê¸:¡Nri„*„P‡‘CÚBÃPBFÃ2aÙ0&,Æ†åÃ
ê”:)ŒEnGîDŠ#%²CvÊ.Ù-{d¯ü.ûd¿ƒrÎÃ¸ù²9X|o›Í*'Ø|ü¨ÎëƒÁO²%˜üLÕİ}ïìí;T/5CÍ”­º¯î§ûëºÎï‡¥·Ô9Qª‰h‰À÷‘	Á7â¿[±#åÜ·Óír»aº–—‚+‚¹ê¡`–j­Æ¨9j®š§ÆÿTã…Í(3ÚŒ…-ò•l’¯åùVş%ßÉ÷òl…Ÿáø~ƒm°vÀNØ»aì…cÇáœ„SpÎÀY8çu¶ğû`.öÕ5u-]['x“Oàp|Ò;í=±—Wú(ÃÇ¼Ü.Ø»yk?áfÜâ½mÃí¸ÃÛ}Gáh¯øy|_ÔÉ:E§ê4¯ù¯zÉÓ¼ç©Şótïû5®3¼ê9:S×Óõu–ÎÖtCã•ŞÄ[XèÅà%¼ìÆx©±ŞéÆ›‘Şê3æY¯/úUà]¶ö2ÛzéÇñôzS½ádo8Û›,“íM'zÏ™^q3ÓÜ´ÀTLÕtc}CßÄMAõÿ®ƒê‘¤à?|WpTÕşÿsÏnB°<C wsI¤Ù„!À’ìÒHx¹ÀîæÑIJ,ˆ…ªá9a.iEFRK‹¼|œ@*ƒ:B))RTAÉ•R(ÂŞ~w"éŒÜ»ÿœÿœó¿ÿóÿıˆ¬÷¾‘jë‚³ÿÅô.ı[¿mÏ.TÖÿ@¥§Ón¾M	täP*$I7Q³¿úö%êEÓh=*ĞÔ‡¦S!jàDöP=o°Z—i4½@›­=¼ÌÚüó¨ÒoƒÏ$Óš„õÓQ©_Ö.RĞú-ÅRu¦Q4…ûPË)º^¤utŸ±nj/øß”KãhœuÈºCéT/×8Nwú*úıì´Ê­j@)d
uÊúœÒ(ˆÎâğäáf9Ü¨òWÒËœ¨ıĞKè/"/fkù÷@©f şšLtr.vœv\³~e]"'õ¤Aà©š.sO[d¼5Æ:C3i/} yí·YÎ”[3#c­W­÷©7íAÿ.rsüæîRë÷Ö[~†B#“@§=Í!t(ÿ¢oD­UKh*(FU®£ÖÄ§PK<'ÓNĞ`H;Ü>E¿#‹ì£ıt ºù'jş‹¨ø“ùÇ\†˜ùÕI…8¦mĞµ“’åvèÛ Tèh¢ëhtŒ8ÿa.æ9<=Ë«|N(qUÜ”±r¹üVŞu¤EÎE¾µ&Y7¨/%ÑOĞõÔB·ˆÆÿ_écô[×é?è9²¹
}ŒB6ºŠê(EL5b½Ø"ŞDnX«’Y2O>.Ê3ˆ‡Õ1á˜È×#/FŞŒ·öXÇá;]q~@£Ká[è=tc£ı”ÎÛşƒóGq)?*óy¯C?tİÇHIÑ7EŒ>P'~=-‹Ş¦[ìpF|*¾74‡–‚xw¢Òš´¿i_J—L“ƒåP9Y–¢'†w<2Â6ÇNÇûkˆ›
gó+ÔÔ+bÜM¿ûY„"UÙß…'-†&6¡Û|ºØó4ò	¬ğoX!	½ÓCà{$pOäGyWò2®C.{™7 Ó{@Ô“)Â#Æ‰©",*Q¿Õ¡*hÄ»¹ì”8-ZÀy‚f wÕ
µRm¦ödX =§­€f×j;´cÚ	í’ö•Ö«%Èò)¹X¾"·ÊFyäçx7ãlvwÜqÜq
g’³ŸsrÊ6çùgÌğ˜bô	'c®ÇÖ Lç:İ÷ˆDÄà ±Cô’µÜ‚‰ş,©$÷ÀS×i¬]ºÚxğÖ[$ÊöN§W*ì_Àû)‹S­ShL$ÏÑ.>+ÎÉ?‹ÑèbCœ(·jO8>nÚ‰l´F¼+ös5Š\1ClÔˆ/ò6ºÿ%­ãÇy>íäÎágy×ÒIÑG›Ê+(×Ú,$wâB¾Fà€–Ê
zŒøğH:K—#›dùòS­‡Eß Ïy;İf‡uÙMC6
#ËÔÃßW’õf#Îj‰È sÇ¨‘D1#œcäbºFÿ¥Ë}ğ¨<dÒK‘j¹I~a°2aˆ2Ú†¸«¢ñˆ˜‹ğ’Û£Yˆô8ä’aˆêb*¥
zYo­¥¬Örk‘5>ÂŞÛèCnókˆˆ&ìÈ¥ğ>OŸğjÄáøËù}O¤‚šé
÷åT†xhq,ÄÍ´uÕAÇQçPh{m€GŸ‡7ÇA‚r:NWè&ÇÂ6‰”A€ßlğ ¹"¨ |N¢Äì äñ¼6Iæã”eĞŞFÄóÄÆ5ä‰YtN³àHTú±8§zş)V¿.çİ˜©@ÖN§¯!wWÎ@Ï‹“Ö#k5ƒ§³ô%´mEùÊ@^ğñœu“¥
PNÅÜ ¼C#‘Y}Úè{ »(SøØB„v¥ş4ÒñÊˆL²²Eµv wŒ…ù×p{%Óh~\tƒw©7O¦¬Èğp‚5©øïQ.^•Vötd.}DÛa¯\ãó›æ;ftî¨œ‘Ù#²ùÑ°¡œ™áIÿá ‡ÒR)nıú÷KNJì›Ğ§w¯=º»ºuíß9®SlŒÓ!5Á”á7
BºJ)™fL˜i0&Â÷M„”©‚k”Š.Ó;®ôbåÏşo¥·u¥·}%»ô\ÊÍÌĞı†®ú½‰KK€í3‚ºj‰Â£ğš(Ü°Ûº¿o•OWÒıª`a•éùp\Cç¸|#¿2.3ƒâ:ìH%5œ0†£€Hğç4Ší¦T’áó«DÃgs ´T¸B—ü¾d·;˜™¡8¿Ü(Sdä©nèÊ’QÎ|%£WÛÒĞj½!£Ù¬orQYÈ_aT„g”Ú4º{@×§_èûİ‡÷ÈÔİMÖLßjİšf®šK÷cİöo0ˆ3°W¤„Ì®‡‹¦ê &VŠW‚¤nKbKÕ*_¥á·gBstÕÉÈ3ªÌ9!˜&ÉT4e‘{WR’w¯u’üº9-`¸ÕØd#öõkèEæ”E»½zbGLfFƒ«{«bºvkâ»ÜT¶ã¢Pt¹Mi×,Û…p¥—ëà$`@¦lû§2›Ìòl,ÃdìR°Hµê”2]9ö¼½_9R]†nŞ x€ÑrµãL¸mÆ™êºA6hûI»«VJO·]$&6c¢ã¬ÌŒ…Mb¸QãÒñõQ1tæúİnÛÀ«›¼T†ZRhëT–¼‹¼C<A%B6¦ù¦÷t³ä¦}{È€'7.'ê­bÓÚ?İ\}zú«r÷y º²_4Õ(*)è~3Ô¦Û¢iF­øìv\¤zæ´dÑ‰d-Š…SÎj_lñJ¦âãŒ:u…Òà”Ñ	Ö”+4¡õ7çvï¦˜Øû65Y×ì]Ñ¿ï¶µq©r<Ç£:Œ;pojàW¦‰¢i¥¦×W€dš†^`†Ìp“µ¤ÌĞ]†¹Wl[ÍèA›¬}«“UA}BTqœUP^ƒÁ«J¼¼êTWkp×¾İ»{W«ÕJ–%KF±„$Û 02^Ü
´±ƒËclL Áj«ÄÀgZ,Oh“N†ÁäMÛ)¥Ó0ÓhÂcC]&¥´å™4™L¦Ã:¥LãR·X«•L'Õãœ{µw´çïûÎ=»ù›}“:Báƒ[úÆ	&ı™ÌRDl<DxÃ1-¡3[LÊ“´Y…DÁ¢H‘£€ÌD‹Ğó¸qèNkPMB¿—*¦zô™Tw1…Ò0ÖçÀ4'#îˆ;Ã‰?¦Ós¦ˆî£°0½zÚÚDv‰!u™Z£ë%2ÇˆëÈ#_ÀG,"o˜
ÿR=’òäğ„ûí§í;fÅ™‚^@é´Òá^8‹£õ¤U¯j[ÑBHµ×ã÷‘—Ûöøşéw®jZ›>Çÿø+ôäæëCkë¿´N°#é„HÌr$ëÌšÒ ì$;•7!£'5‰Ë:‚G·cB°ãrLgä/Å£ªg°Ó¦P¼õÿÁT­¦­¡->OµW"tÍæG¾¶`àÅ‹oèØpÊÚ4şşì=_à_áeŸXÍ~øwkÆºÿk7ĞVNAöüğ$’J×M¾¢İ``¤|iÚä­3ÁÀìºÙi€k`¡ÅÂb±QY¦®D+Ä´:ˆÉ: î’w*w¨k=Ãvr©Â¹ qİä…&‹qA‹Ì+ŠLVÌ`hµbßÂJœPÊÇçMIDàiRVış Ê“ï˜:\~ÆÁçIÌäu'ù'|ŠÄ +xXÄbÀñÄ¶šğ"Û]ÜËæf²¹šbÏšÜ’@Ò©î‚ÛÓ¾,UL$R£bSbtïåÑ¦ÛIz*5zùòiF:·ôáw(‘ÄnslŞ0ö(hÑ’5.ÊTÉ‚LÍfÂJû•Á¹l¢üŠD(¼q¤ŠRñ¢õşHñ½ç¬+äë¸}ñÕ+¸Ûš§æ^"áâM›¯€9™§h÷$KÓËC„tLDãeo¦½~‰¦Ø+ˆ7E±Nì‡Ä»¢0"BëE(’	ıô3­†ˆ„Q]ƒ™€¾'4¿UÉCnx^"é2IrÃeˆäÜ(Nı§â8øÄáÀ?4ƒ2Ã¢ˆ”P1‰CS£ˆ\æŠœÇçÌ„Ä¼’Ä¨¢ *
ĞÊ©ì€Õ€†Y’A8ÛÇÅµ28Ó#ÃÎ¤“8‰#Œí 	`úò„Ú<•a GÏŞ«é.Ì & Pa·ÇßàpÕ$„½úåò@¶²’/SÛ¦*¸åa‡Ó ùÒÕq¹ğ³D}f 5ğCÂOØ1aL˜¤ıì¤pG¸'ßJ7'V<jp;á1ÄÙ*åz€¡GøO•wèıU.ÁsæœBW)”Ö8‘Ëf 6O"Vº3áq¤Y¾tÇ¬r9ÒBÒé£zÓBØáIC$×&\Š×ü+Ê•ıüºq­**4Âe›ÁY)¨ğ‘ÜGp#y¿V¼Nº¬ç­ïŞ§Š{ÈËÅßÎ=OÆşi­¤$Ï’Õ(‚fÍÚ]ë\[¥AÇ ú?¡‹¾§]ç
“™â—}J›Ö¥u¹$Yçn¯æuyõ6­Íõ×í9ı#Åñ,6ğıĞA~0p Ä¸ÏËU—¶YÛ£í×ŞĞ~¡‰ZØ©zNÕ¥V;ı¾x•îÅıŞc^âõ¢p$pjZ5’5[ÌÈ©ô¬m8ÆÆØ4»Æ6:Åáh2J¢‘ê¯2báW¡gsPrg²ÿ#D1tÈæÀ'ÚÛG›YX€İíæ tth§l¹úr&ù|şªm"Ñ¨Ûİ²¼­­Õ¨o¨F“İûxäƒKı{'¬ŸÿixË©Ï>Lm\;ó¹8µñêo²`åw­¿àô»™Hñg´'Ö×±ş[ªh«v	BÂd¹^›Ñe<)$Å^>•è—I $$s(\Â>¨Hy¼ÔT˜µí³w	S7ÕzÉ!‡ˆ@rñTeÏ6õ&æÊLªö_Lºu«¬Üb*UV/l­‘j Ä«[xÕê>˜½¿¢òAT *ì~÷¬«]"ØS…©3™
Û&Ü`€¿iÖB‘ÃTb&üÀÂ0iÓ¸@¤8’Qº.B^‰²)ËĞN{­YM˜"^Œ	[,A÷yRoº,Å9‚ãz­<ÄqYTq®<h:zıê’Ô¤½´îó(v¡:HI@™;õ uøÚu açÏõÛe[˜/Ö çN†MÔ†íML›QûHq·šx-ëÅÛñn6„÷±,“p¤ÑLXGò¥ããîV‡½¼U=RVÚF’†É^éUé,ùµÄCD—–’°”&I©‡˜Ò·I¯ôQ^wÌ’»’k¾Â£lE—PB±Tû()>&4Ïı™v`=7{{.ú/ØÕºÒ¡IX¢h9Î™»¤ ¼@ù‚ëk×.XÿL¿áæm®ÀÖúÀÎúõ?
ü8x<8Yû»àïkUÆœÕ>ğ5°EÕ™ÀÈrœeW˜zÑøT'¡Øòf÷gÌL41sa#˜@ÈØ›‹‘XWÈŞaRs«B…ôĞXèß!!Z‚[	¿VşXÄ\àNGÌZLMĞˆäÉ3gIu*KlrÀµ²‡Ëe+–À
Óô:j®—ñFg¦N}K%u*.©X55Ÿ¡7Øè&¾–Ä·,Š<éÇ7üx£ÿIÿn?õZzøÁy5>WÈV`.ÏnÙçST‡s91“MÜ*+=Qáïø²Îe
•É$Š•¦ÏÕ†Œ-±í1’MdlD€—TÓ+"ÉeQ6‡ÿËtÕÀ6qáûîÎvÎ¾óÏÙ¾‹/ÎÏc‡&ÿbB“ƒüĞÆü¤2Ld$4šPµ”I-QiIºµµ‰€
h @ÇJH$+Ó[+&Q¡nêĞºV]'4T¶ÑÀ¹ìıÎ¡İ)öwßİå’ç}ßçyŸ7”JÅ±P.A”ö!£Ñ§“‰T*Jƒø#‚et»„x-\J%ÑÆÙèµ«&³TI@»i±›¨Çåıºã­×//i*»­Mİô§W7/i‰Û-ä—¼9’{å¼6ùêËK¼iOQkëÄĞš×²Ş@…÷‰–zí_[ZPßQLû7BÈ¡F€Ÿ6ÂKš"øÙ{jÌ’I—,.!ùc‡¹Cè(ÎyïšŒIº«w&KZè,—u¶”Œ˜0fÖ
Ÿ 	“çÂi±Ø³(I}e¨Ì^IRAÛ$ªTYÔG`N•6âİ†gfÁß—Ùû§—b!RßÂN€èÏ£<4FK·±ÛÜ-t÷zù‘×½„wØ	XÈít‰¡T!dƒÈóâÄ%M›™ê<£ò‰Çwäw½Ô³q7t¢Û#Ú×ÚµÛÚõÎÜA2r|yßá_œ;z;Ì•€}ıö½ê<>gÌ™s|ñ~€waúÊÊÈùT‚ïNxÚ¨f¶Íİì9À0.²#W­“Õf+­\a´6!cür‘§tõğÒ[kµ®ñ\o ¼\¯±×ÜËó9YNâÊ v>^+ÂÜğÿpéõÚı…gÖœ×îk—&^D¾ºù'ë‡^êÙ0x°3‡B¨Y‘g„´?è{gÉÖãÇÎ=ŒñjOĞ]:ó«Ñ2õÉí¥ƒ¥$Ïr}±İÜ@Œ®@Ğõ¨'ã”ŠšÈ&ªÓ–så•Ñ\õÛ=Ç='_ÏÅ…úp¼*Ë5ÙpsÕmvF4ï®YXÎa¹Uİó8Vèb?Á³’pÓÕêhĞW[XÃ‘1ç*õ5–ĞW•q—è„]gÀA.·…ğb5ÏÃ±¶¸MÅc¤Ò”Šq G’†c(aŸTÍDÜ/óšï"~g.æö[ö™‹læÎ¶‚™yÈ[Bÿçô?>=tôF¡«àî­·p#K³_Ï•­×Õè©ìöVquŠA|È×$¤-LÚ	È[RCú*€àN×÷ùÛ•†;¶¦Nî…‹~şI„~sy ™ú>Öşıåƒ]]={†6mÜÕªs—ÉBÌ·ö­Sg‡ÿ„,HúåèƒÅ~µyÁÔ+¹ëä¡£o?rrûX€Sºg7Û§»t‡¹QeÚr€g.23ß0†r¦‹ÙÉÊh‚Q–‚ÊUuoNyà²Ñ`4ÑfÒD´ÙŸ =E…€F¿sìĞúÀïP;6@qÛubOŸ7GûyèsˆÖÜo£ƒ÷¯C:	‚JCõÙ‰jxŸ1VôC·áUÍ¯¶n²öñ´™±±å,9ÌÎ²d#»œ%a¬Ü®VšL@.Š4šÃcgjÀÔĞŒ´“?Ì“ëøüişcæíDQ¸",$9€€,ySÈK<\¸…ƒuó,½A:Ÿ©Å¤™È‹0O%a:c®­ƒ¬Ê`kÜX¯EÎšÑ 0CÓ–æ®Ü?Z¿¢šîÛÒœüö‘…ïhÿŒ5 (vÀ!/©£¯($:Dß~~¿k_h4Â˜\­.’ÿ€›²şAşÊw›VŒ•Ü*n#7jÙÇ)S¬i¡Oõ7{”ÁA~Ğµ[ÙågÒÁc«¥[nk•)&Å
¦Ù¤œT’¾¤ßd4Œ\Ì…XEQ|&¿¢V=Í>çÚá~¶ò™Èû¥È›îÑÈûÊû>n ‹¯ˆœŒŒWEYPe_BP½å‰r}. !^$·†d@-.M$ÜbUj¨½
ÕT¡ê*TU&×Ø‘=d¯6¦Q_á‘oñ`ê‰>7‰Cş ø¥÷SòmÑéh?ŞñnsŞ/‰PPIÉ­òJ”7 ^q™‘HÒ’¬a'Ç’aièÖ°¥]BR«ÓÔ8“‡Ÿ‚å+|òı%S„2{ë‰<YX<<•ùñş‹÷Êı…½GÒ÷j	œláPJiUös#Êï”O£¬°MKÄœbqİŠóa17è{%P0v¥’7A ¤¢vDw¡tQ²Ã®Ñú“NDH]JĞh}›&1A…WqQ…÷Š*¼TT“é„ˆı’¨*áŞkËukB‹«$Uñ'lj—f%r|?6!úq#Š·w°U)lÁ(ÜÌüF?ù¼>úg?Rèlaø‚8üó—a]lŸN°ˆĞÍ3–17äå@ëœA—´d\
xp.¢!\Àş4^Äãtã$ñ[ôãtÀå~\;ÕùÂõ¯®Öî:Ö­~ª¦ÂD¿Í­¾óÍ_fPutÅª°·ºÂírd:üôÂŸÅ•¾2··»-»ûõkã={wö¯†ÿ>%°)¬#š¨îÈ”¡“¦“Ì˜ÍáSBJ¢–Ç—'Hwäåà5f8a9Á~-z6¸#ş|‚ÚTúJâ`œêqö¸7ITJX“è©Ÿ‘2eTe"C¦¬TM"JÅægZRétİ¢¦¥OFò»ö!ÅjkëvÂì÷nñP‘¥'‘;F§ÃWÃŸ‡©p¶_17Æúb±½1:†§³wh ªTjiªƒ»çäáŠÃdÜ9ëb=Ík§P[A‡–ÎLã	j™}:Oa†ìïƒ/â9²pÓ‘©Æƒ¤]ŒC³ã$HÒœı¢~áè'òyTKónIû?™Lğ~Q¡I·‹§ãµ~>™ ı†K±Œœ›8Qô… wßÏœpN~{m¾zEığCmôÊU´ù÷okû9ò9Š|ÇÆ´Ï4ÓñxWt>úô¦@ØÇÄ»şØÜ²¦%Ú4Ü=öZ“áÓËÚŞğ¯^ù÷åÜEuÅñ³»wwD$±m"¤E^&„WQ„"Hk¯$$`ÁR CÒÔŒŒ0C°Œ”0Ş!	)D´˜`¤JhıQÚò2j«?k)ci(ˆ´u„‚yİ~ÏİİÌ²Xÿéoæ3çŞ»÷qî½çs~Zş‘£Ú‚ßm¬l}¿j[ëÉíÛµ¯n«Ò’*›Zº=h^8gIl—^÷wºı¹åc[÷ho&ëÓ{ÈİüÏ•ÈÔŸ¿òjø¯3cG\
uÿªNèÎòX°¶±±¹%BñèÛ	ğ`lÍ 1qÔØØ¸8Î™Ç÷»sˆå6éÃ]ªiŸqœˆúgw§\ó0MÓşAOà[>ct§¯ˆ”…şO£^ ¹N.[Ğ?TAàqĞLS]¦€ÑsTc™<’§)Ï®£‡°àÛ`½™Mğm“5œfq;ÖZ9ú ¼í[¬jZƒr)¾çr_%y|6}ßSP^gfKi“6B¹í	X-ëÙëˆyåş˜ûëø¾22ÓÕ·«*Ÿæ1j¯¼Ç•\Æù¢}˜Vé8Ÿ†q=P/FùèÕ	²3è"ˆz£Ïı!Ú9 ëq÷MjßØGÛ ¿ÒéÚd±~~ ïë¨oûtR|ôˆ1HİïùNğ ^Gã\Zy_æy™İ½}ÕSÌ¦!’ÕĞs”¹—JQO#¤‰
šo\Äì¥ÅÖFÚ†vÒ‚ÿP_ı#J´úÒ0œ_æŸ
æ`ÎCÊf³ò#Èâ%b®'AÖ>êŸêãq¯9èÛÌïçú˜‡3(O±~X?•Ï÷~YËn}}OaÇ¬ÙC½;÷JOcü0—¦ÖqîÁ‘ ßóp¦?¯ƒƒ¬ƒ‡²35W5zµüò‹ Ô5loàI0œû`ıôQö
›aÛdû`Û0+[Âº;{Poa•ûf¾ñÓA7dí¤'\’Ğ—ÏgÛ,¿on¶-¶O*›ÎWv„÷É6å“ëÍMbÔº°-Oò»Ã¼‹XñJ§2#J%l³loäsa[ã÷ÈoÂ•}{MqßH
Æß£l¶èIï,Úä[T†9³­5°ÓÊ'(Ãxƒ2ÌEk±¿_¢ûQø°ûhB(BÉ¸Ë	»9 K;ªåa­çEÎ"J[Ô¹FõŞ"ª™f<g’vÔ¬ÑU¹¢Eœo,ÿ·[m¿ô÷Ìš‹òy3*%ö³–ß„İ ¥Dûğ,èºO+åkûì,Š³ˆ.‚ù"L˜a&"4JÄSçÔíYÖ£Êï–`şÃZã¾~dÇSã|#ÖÒßC| <?äã>;ºÊæ‚¶äIÏ^ƒ’m†ı.¤	Ùïn?¨'\şêaãÁ£Ø?«ø Š{•Úìó(U@şØ³Ï€öØ§´Ë äØÂş]Å¼SèQìíŸı#û8ö‘ìç8öyıƒÒ7~|ÇŸ”®£iî»Ni spıH­±O^Ä=k½#kíQ²Ö8&k­Íò%;_±öÊ
ì;¹-¦F_ÆïÉ‹¥|N½8jö£¹®?+S}±¾Š£ÙÊµï/faŞ78®ò;4*ğîp˜o™ØAßõTİcWv1…2Ø'Š…(£>¿ßa”¨ï“Å'´P$£¼²œî²lZhı†ÇÈ:ÕvÚùÆmæ4Ú»K+i»¹›rø®xúyŒïo>1ô,m±	6\Oe¢{`‡•,WöÄc_“¼?ûAºÛ4°?îxŒ¹…zºç±QEDÑeÃ8ÓzWå„¼Ìü	-	ÅPYè^ø§K”hÃ—¨µvÓÔPX»Pñúc¼ØX™_’Ÿ*ûß)¥Ñˆ7Ô€÷ÅhøOİÌ*Ç[*RçãÈUü~ŒŠgÁş2U>Ñ ‘²jhµİE¢¸·ì%Ÿ¾†òQ#›Ğw,æ ^í“T~Âq*,ßæ÷bG¨«ÆúèÃ:¨üëg ï:*‚/j ¬”†ğÈIã=` ƒª/…`µƒj‹s¤Ös,áv}:‘Ôø-ˆ—ñöÊi´ñSŠs‘?œ§ez*­02`w3ZÂu‘BIÆzÌ¸¢âÏ
3††©~	ˆãgi¢ÈÅøÍ{h¶!Qî
6À1ÎÜGÓÌï Ïšy\ô¡Ó‰&Z«PN•;¹ŸZãŠL`Ä"JWã|(]=Xç*ŸÎ°«ÂX_”ıú²®mzº:^K?µOãTŸ¿ĞhœÓIĞ×‘­“ôbª[õÈÃ#T¨m”ûq®ãŒ÷×E¡V&!
©r äyà ø§BË1÷AÈ×ø£ÿ¾ß_¿xßüğ:×j÷#>”ûıu3†3z
|zÊÕßTÿJ,N“ûc!Å0VJ¶C”¬×£=ãu3‰6‰ùè;™Œtºø¥ùÎ1ìß£w	7ÁIŸìÉïk ÇçÏ¢ßí€û]
¾«Î+İ¯lè,rr[ÒĞí”l„?·§N‰ê<+é.ïĞ^¤Ú÷[ÊglGyãÕƒ÷ÚQóÎóãÙ‡NaF|€ş XG<3ÛXJûzÛº×#“ãœÆ‰LèRß¾nÅQ*£/@½ß?¤{™¶z&%3Ü—ÁÙöapÖû½z1Æd|›¬úd|çšÃçjDx¬¯îÇ³óàı`,‰ßÂı9s&%¥ÿÍßm°Íó%×êxi×›óÿ	¼cà0øıçºì\#Ø*ˆ#ätï ßØ…\õüÇ<NÅD-EDM‰šgÂ!7¿‚¶,”ûA~º¢m$¢QÓ)”àÛ» l_¦gÜ¼²êc±-/¹óõuÆó¸Fd;MCñM+@9ÊoXYÓ!Èõ—ĞÆåB"h^9õ‰ öĞüÔGÄıæÀ9 =›‘Æ4§b|%XÈùÈ5ş‡şoåuşÜ¬„yà[*ç„¾Áÿ7-½ûì@ÿkx÷ß‘ôşK´“î9 ç;ÆøşûÜğ?'qŸŸº\ÿ+erJ[åÑÈeUÎÍù£+U¾Uù¤¦rJWâ<YÎœ;sş
Y¡şç½}
è›Ğ+[éåÅŸoÕShHpß£1èóGèóoøXÄ×KÈ-Kr~3äqÄ®XøÜ×µòdêİË:y1Íó­í|lû˜ö¹Öo5FŞFLà2/€×>×%ø=Õ¥7ŒÅ·JG±û¶cùub´?NÖºç=:¤tÆCïpû¼4˜tTï(Ï½Õz0ïğÕw37ø®êÁ¼Ä«i÷½½í9ùL"Ş›Gàİİ*x§‹ùòÏŞ{õt¾ã¶÷æÖ­¥ôëIm%Á$ƒÕîÿ®>(#ÊÅßBÍ”z…ÒQÿ9ø…ãsd®ûäjm/réËìrZ—£n‹:Õ7Ç%·#{Ú-çç*?Ä™)İKşËzÙ WU\qüäİûîM‚"H %ŠX@&E) ¶JB¤8Pi‹FÇ‘Á©µ¶ƒ(ÊÇĞ †VZ•’€0LÑÆ~ Å´bu¤Z*TH…2`Ñ§ÈÛşÎŞ½ÉãÁÓ)oæ7gï¾½{v÷îó_¾Å)¹†C'Ø
÷¶|kîøŞí‘yõëıÃ|F_ŸeÓ‚Ù,÷¼Ùzßã¹#Ï‰Å…ÁV)Jîµ”`ó±ùÄ÷*¸ƒ˜]‘Üešƒm¶ÍíüWîï—ñÄù™IOîóL1}F²€«ÆlY¡¹BŞ]Ã»‹(b;†'e5ılâıešÂò`“T#¥ˆºÇ5ÃwhûmÖö›‰CRDœïÉÎîÆù*ègsLê®ò…y5È0˜âß ×ÂPşû2LõNÓ÷zûîã‰²Å;#[üMRI/åo”Uy»dU.óÉ«”šğRãÏ–•ùÃ¤šû[5ÏË5_Åy•µOÅe´ÛÆ°‡Ü¦ó¦ïŞÎ–ÇsÎÔv|7W‡šõé~ã÷rKY›2æ¿Kªy^~1mC?C` œ‚#™ş47{=Ì›‘•Ÿ¸gKÎ¯”±ô3ˆr»¶ëd ßÏú[ms59;Ù~ÚÛ±Û5ÎKì‹uiÎ¦…bm7Û}Ó ótñ<:»ºr«FÊ­|¯	P\ şb)Kl4;[Ú ™tù{í]¬ãTt¹=·2±3úWé¬eÿ]YÉ7zÔñ0ûô9][ÿ¸,±c¬…WÙÇFÊX«#­p¶Z0GüZ|)¬—Ç±ÖŸh÷g7·7ıÏeŒ¿Áî™NÌ?Ïu9èÚÍbŞà¸ŸxÆ™Š­]«ã¬ûb™`çˆ¦òjÙ·¬·}Õ Sã¶¹_•òpûõöÎ<ü–A5œ’‚àzôábæ}3ïÎ“…‰O¥DÉYf'|ÊDñDJ|”9±GrÊíŞ2‹õª†ïÃ*æÓ¤h;Û¶N¦;®UsŠùÿeˆËWFe[÷º£Éñ\´3‡àLâc|Ó‚qı+“w9{5Ş™áğ Ã¯ò'³VçRš	ïª½.êÕ^“‰«ï	õjGeBı¨Œ#[»lãÈVß'êû\‚qdë÷êL¨¿ºñË„úqÿÃ8²­sïL¨ïİÆ8ÆgBıøÌqŸ^€?pGıµæOrõ\ìVìì}°™2÷^3Ó=ïvíîjE¦§ãë06äcs†‰­¨/Ó%z'öcî¡ÜˆıFäKßM½ù¶8Ÿ©çÜX_„ß¤=ëØñ:ù³¾Gª>Ò1æ)×~¸óû|4îTWì÷¢öú¿ÎÑ¾÷|+†ãgˆãÍ:·I­èØS[(?i¦ÔKn-×G~›¹'šn0Àı¿°5.Ènî‰Oçh®ÎMˆ¨ÕXkcn•tNËUVcPş©Æ»€Ñø7J Gùª4†Ûû$qßŞ'ßCŸ ,½É#ïò|ˆ>~Î>ì@Üœ/}Õ‡ÿ)z…¾5ïªæğŞ•‰ŠÕ;l®©ù „L	†1¦SÒşÃ½²$˜F<î²íÂ»x¾İñ©B™“»N–„ïó¿'£ÉW¥q}|·5&Ù_ÚÅ¶İ0™’÷;êç£¥ºË8õ^/¬ÙØwË:Ôé=×~w]ÿ°Iäì—àV;fÆ‹½[hs±j']“=²ñô×üÉº]áçÈeAWÎÕYéæ¡/¶ËÂ¼„¬	§ÓN}ıLu]ËÚğK—àéŸ|DºØµ~VfûY×{ÑÒÎ’–„Ã¥k²yÕÈSşnúª‘^É.ÒÍj‡}¶ïÈÆ}lDÏ—µì‰î™º&ÖQ-úæ-öZ Å‡›ZÍió·6MoØuOn•Éş=òÿ´Ó‡6S¸Oj‚}vL³úë&™>Hnİ$£ƒRš,E§•ÒÜîÒ+|Vº©>g²7U¯‘£ƒ^2 ¹V8ã¦”ï³û lqç»Ò¹÷ ÎÅ²¨ŞMêšŸrõwÃCPı¯ÿ™Gåæ“Qÿö¿‡¢öÍ«8k9œ¨ÔIG3üÇÙÏµœ¶Î«­¦?ß:]/«œnmÛfèÏlVÏ0ß¹ MGzò|;;<~æ|¾¡ZÎìut¦¥mÕvÖšãÎpöİkªõ2mš®¾ Í¦_[u¬;g±tõ‚,vJ¬¯/f[ôwÛ¢×/f+Ñ8Ûp©„ªAcëâXûVëtyëı)Ó®@§t:VõûÖ})gn|[è¾S‚&Ó4¥[b$x"G_€ ˆvE"áfÓnnµzWl‹à	Ş{‚üÒÓ4æöL·ÒYaÌOF˜í°Â	Ø;¼Óèåàg¹iD«§YrÇr{?)»A~kğS?¢x¸‡ñ4ßµš]ÂïÍ°slÒ\Ø&{ñƒZÈ}?ñÎiüœ¶¶I‰×=^Çx]˜ÛQû½â1Çş]¿ÿïw¤Ï%m‘ı»˜&åRÍ»­±'w™·á€–9K¸{	Ö4)c^fÇ}„9B89BÏ3mM¬ëGğ7QWáeø§î-= àÇŸÌ}ĞäpÏz•àˆy?kè9ğ^2§ÕRZŸğ»æmöàp5v/ïÜmïHª½>à¬æk|W\ì+Î{“üE, ÜKs}îö¶^‘™çj>3ÉÅàõô#Ä‹NÁ6)÷R29¨ånÛ˜ôsDÁ×|ÇÇòHû™×àÑ:Ûú_¥ã”"…ò0üáÅÔ8½­:vvDêhTß:®8öú(aîºÂÜîà{w´úec[#…h%ªlè(cü9²MÙAõ‡ê{î—ÁèÂ2G1ëRî¯@76È$Ë1ÚÕš3Šj"ûdbĞ[&úñÕÆEâ¤÷whäİhÎ
YÈTûhªUy¬#1Å[Ïåìı[á{Ø‡¤$g6õ å-PDı±À\Ê}°ÂT¨sõ?”’dgúJRVŠi·=²–DDâ­¯>¨O¼N»ù28ÑHİ-cÚæ·h<ıo”mW’8†[%ß+tåRşÛ¹(íÏ‡F÷_ÜfTk›äÇ2:¿Mu%,2õÉ‘¦>ç˜ùår9ßô2àK¦ô>ô¢ÓQœV3ÖñüIâ÷R¥xsƒ²ÃÔ{Oƒ³Éİ24¹BJ‚«d^²›Œã.02èH¾Mú ¥+¢;QJïvwù÷›³|·ùŞ>Æñ¡e«³õÁŸe`Ş|î½¨,†.±MÔ6§ÂæNaoIª·ÚH‘%?2ÿÖ³ëÜğ[²4|-ùŒLu±Hµ–æ’+4¯Sª{'ÙOFÑÙÇŒŠ4¾Ñó0‰Ø ç·Êá*‘üR÷–Ó‚Ú¾Î»J~„’¨fFH‘{÷»5K¿ë’%¬$ú“ò
åz%íÿKòì¯ã|Í%¶¢<èüg¾çÇ9ß6,‘¯)şAÚ)å2ØÛ/çÃ.—ë”Ä,«/ğÜAú…¹ÒÏ¾[yñçÄa)V¼2Ö¸ìügüß¤´Ìû"ÏŞÓrµï·–=mşæÕĞGÃZ6ûà5²Â^6ü·Ÿ½TL»GŸpf? ?œ‘Q'6°ï6Àçvÿ-ˆúCŸ_CÌCOÓf–æÕÀ[Ñ®3U—zõfçÙ/ûØ82¿;cßÅnìÛ|Ø1v’Û¶‰I_/N]Qï6M$TŒÄFíÅ6ñ5qãŞÎç„&mìUJ5qÃ‡øPñÅ!¡%%¾ìñ×	¾¶PÉ©€š"¡P)ñG¥ÖüæİmˆJCT@cëÙ÷İİyfggæfwÕ:§Şù}ïÊeğ5¶“¿ËÖÓ'x­ÅšŠ¶œSï¢ê;× J& Öµ¯S% µÎˆ?c?ƒıë½uIåb'~‘Çpş£Ş:¥Ö Ù§ÇŞğÖ,^3ÕÚ¦~‡X¯¤>…ıßû`¯!ù}¯âwÅoá°‡zæ¼5¡M¼v
¯^ñ'\¹úváßí'i¹ú¢œsµ÷%ÿıòíwÌsïÜ¿Ú{!ÊüèrŞy^¾†1è¢z<o"x§yíªUïò—¾»†èFõÌ¬åï^w0–—ŞóÕ3O='Õ8©ñÚO°¦4üÓw¤¤Ûò'ÈRÏ.ôÓÁÏ/‹=üœVıø[^+º‡¯5ÎŸw~¯QßwêÛá›s/^öí÷ö·\­?·VáŞ¾ˆçà¾òiú¸ÿ¼?ƒºßòùºBµÛ[qiğøfÉèÌÌ‰|Ä£ücW&ónzwæ]¸2•xc½î×ó_úÕ'=B±«c¶-ÚıÿEÍ}F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4Íû‚ATµşB¡C A&µP7Qàñ•cŸ¨šNb+IıİÇ[•éb›ÿÖ+ü\Ò"ãn?/C>èçä#~¤{ŒÃ(i”U¨:‹~nP£¸ÛÏU‹?—8ş˜Ÿ—!Ïûy ù+~öˆ9zŠ,ŠRÿ· ë¢íGì $%@† Ù€½4rµíÃñ.±gÄ¿E›qlüñ^1Ò;±íGIù \Uv€Ëô××2÷#¦i%éŞ£-ªÖ×èyİØÀººE[õñwå¶p×½ÛjÑVìãl†[«J¯yÊŠF"·X]ÛãVG2‘Ì<Š[’éT2İ—H&ÖXÎà µy`ÛöÌµ9>OïŒ÷¯éŞètlé\í¤ú›oOöwt½·Cœ[CVŸ•I÷õÇïïKï°’÷^ñòÖ@ÂÊà\wb ï·¶dú2qÈ‰ş–dÚJâLÚÚšNdÒñ¡5ÿÅáî¦(Ûï¤Õ—~3İºQ¦×WŞ6tø ş{sŞÏRÿ³“Ò_^hîƒô2½Ëß©®Q§J>MS k¶ÈI¶|:¬ŠÚ§.æèÖ®NÏ|x-oş|tôŒ<A=´‡O¸İêğ‰¼}G”ãÚÛ¼Ør3Gww:¸8vê¡µ A!?ë‡À˜4è½
æ€”OÊIwS5CE!g±<†•ÍÆö<˜­?†{9Fı#ehÕÑ|Å|uù£l5È£°BØš`Ló œ’ØN€9 ‘MâÜ$	9)¸fØt*å×hù
…Qû—ò&÷Í—ó¡EQÛ1å(åd€@µC{œŠßé6ßÌ]xg¾²:j¢ü4ú r —Ìbkğ¾TùùEµªúÏº¡ìíq#­^’7ë¢1ôÂgÈq™ ),÷".GÜŠ¸ñÓ²Ÿª¸v>dFGq½vo—5tN;²¿ó°¼CÖSv«½ë»«š¢¸ã²‹„dµ"Î“A7¶f¤Í¿/_qjß>×¬‰•Ê -F©Q”Z••ÙJ¾“®|EUtÜ™/»p›]è–0Úh —\QÂEEÎ¹Q.¥ZœÛ!—Qâ&¹œã7äÚ„øD¾qi¸0#?ÇÖaU).¿Ş›ZëóUÕÑ‚S!×ãlNÄ ä‹ço’Ó(WQôñ²ôcÈÆ0jc©1ŒÔ5†ÙGr?ÎìG™¹›Rrƒ	äjZÕ¸èĞiNV¬ŠNËÈ:tŒ9ƒ®4p´>_Q­ZVç.\ÄÅêòó«£ígåæùê´e&¿¤.šœ‘M|+Ê×5(!åbº•K¼¡X«†ä¬\ŠP³L.wkÂ9'Œ}5‘Ãdˆ‹¢ê$ñ3ñ5Üâ<öUü‰_ôãO½8WEïG!^R±ä,¿Ae=âW4Lˆñ<ÿ°ø¥8­Z!^ÓÔxûıˆÓˆkŸq¯!|ZœÎ# í_u«jÕÍŠçİÕ-~^é'KüdamÔY)ÏÒRTñ2â
ÄgEn@œE¬C,ˆ½€ø±nCü¶Ï‰3jŠ‹ï‰ïÒ­ˆy·Z5!çU˜r*œtÉÛ‹µ„Ïˆ“âÕ£è·ÜÆz}2ß¸"šA}†8&2î²ğB§R1î2şŠBYº "-“n›ªdÜ=c…§Å¸·ëÚì•v³}\FVFš#Ç¥µÒj¶Ú¬ã–cŠƒX@&~¿â ¶md	Ì`ƒq±ß-kË9oâÔ}	Å6ËY/¶)Î[óÒÙ×9kR'¨c/£àa¼°‹İ`x<ÄG2`ìÂj’‚‘‚‘‚‘b####ÅFŠ¯>”Ñ£F/Œ^6zaôÂè…ÑË†jo/Œ^6b0b0b0blÄ`Ä`Ä`ÄØˆÁˆÁˆ±aÃ°aØ0l6l6†Í†Ã†a³a####ÂFFF„†Ã‚a±aÁ°`X0,6,‹†	Ã„a²aÂ0a˜0L6LŸa ŒŒŒŒ%%%%6J0J0Jb×)Yt~ ¥¥¥ÈJJJJ‘•"”"”¢ëîi³Œ€Q ÜÜÜÜ»^Ã@¹99996r0r0r0rlä`ä`äØÈÂÈÂÈÂÈ²‘…‘…‘…‘e#Ëw(ãÚ'å5xØ¸kµbÔ¸‰ãıã^ºÀñ!:ÅñA:Îq=Âq7µqÜEQÇ…çn¸-äÔb	è= 	&À˜AÎÎƒWÁœXgßP
v'‚SÁÙ`ùT°¡@g`"0˜”OJa9¢Š×Q,-tˆ·#Ø^xˆ`ÛÎY»hÅu[±Î®Ã«hµüÑºØdœo2f›Œ©¦¿“^51mQxfí°‹‰ù¢n(5Ûõ[C@%ND„×¨ÙC“h7	ˆ’S‘l'ê…¦‘"5ª H•*U•*zAQÓªãµB×	•"¡«^é­n¥jO½Ò÷fmHUß:ö›oö½ï½7~3Şİ¡ŸÓL«t•†ÅN%)	&NëtbŠíƒ¤ÆÜ™6v_c^â<óén C–	xRÙy’I‚è Lè†ïXõ» HDÅ¤·^»»«&Eévõ§(iÅ<Æ ø½ğŒs ¾g¼ğƒg,³L+İ!¾Ñg°rO¿÷Ø˜¿à[½ xâ±w nyÆÀ¼güÌ2Qz°0ºÎÕ± ¿qÖc7€6ã±! Ó3È†D:X‡¨C õº×[A&Íc“ »ˆl…¸ğ´…$ÅôN †ª0¡?kÔ	S«ıÁ>c‡àş;¶Ç¯ªøE÷é+Âv“_9Ã¼Lùğ|¨Ô‘#>cÛúcö%Ä¢úû‚°¤¯€zæıX¤ğØCÕ—ZgØv•’¬È®±%6Ëné ÷ØÛÅi—:ÒÓ6ß…_¡{ìªî‹)^a0‹ì¢º‹õ%‚¸©ä.V€ŒÙß†úë>îñë)ŸvYÃò_ò¦</gåIY“ä7å~¹GéV:•vå´Q¥E	+’B”ÿè7Ë$°m{Z:ZÂØ‡Å¸SÂ:è‰D‰\#üLÈ–ìB–Úüåmb/«üï‚æÓÈÌM~JËRŞm{.Ë/˜¶/Íò”isyzŞ©Pºá‚–Kû”Ì9>=BÕ£>Ş}ŒäÑz_Púú£u×%±Ş{éXº{ªëâ•\“n±Ş›'-öê°ŸnşM¿ËÇqpÔïÚü£‚ºàÔ¤)šÏÕ¤v×©…W¥ü,êÃ«9h‚»¹hÄ@ š’%*Òà~’E¬QÀK€;ğâÀ‹DIBğ‘¨à…)ò*ûj>WQUÁÑ	Ùœ}¼Â¾¹J"!XšJdQGSÅÄ†D Æ€’d‚Bá½NbT$ã£'½N™8¦Lˆ\!zÂa§g°Áéù?ÛJÖ¤Õ±òÚ^~EË/jùEşÉ½;1ş`YU+ke4¨<”X\¾}qi…—µ•_Órjel¯‰yÍcZ®BöòsNeÏZÉycÖX^[Ê¹Õô%'ó¯\s9—š»„ÁÌ•Î41gĞœÆ\Ì•Á\i+-råïâ¾Ÿv*
Éº—¬JmØÃ‹}q7ÛÛ¹:…º6­õ=ú„´™.?­eyMÉL2ƒ&øŸ¡©ÔuSlm2Ş÷œ>©›:Aİ¥eI£´I6Ÿ˜±y¼pÓÁ­Â­¥ækVÄ&Ì1’¿›ƒ/\—„ÀçU&)6m¥f­\.±+›EBl>\°ùù˜‰,CªÅœº‘†.ºJkkŞ?z	F&AK˜G&5¡‚VN]²´Õ²%KxT(UÏö¿ÿ#<Á?sœtß§ˆûÕÏ/¥êèD€p\EôÎÆÇ!C5®ˆz€VW›úfr3µ¥o%·R- İÙ%ÛÆG©7º"%³Ø(K.¦…ù¾öŞè‰·p`š®Y¤¢^ÿ-6mı¸°ÅzÔ¢_j,H /ÖƒÀJÙË·rİIËÂ)\w'®ş` ~~zendstreamendobj20 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj38 0 obj<</Metadata 43 0 R>>endobj43 0 obj<</Length 5767/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 27.9 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2023-09-25T13:28:08-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2023-09-25T13:28:08-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-09-25T13:28:08-04:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e9ccb478-a5e7-984e-a54c-e534a8c2b689</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Dark Gray (CMYK)</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>11.000000</xmpG:magenta>
                           <xmpG:yellow>7.000000</xmpG:yellow>
                           <xmpG:black>77.999997</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj31 0 obj<</BaseFont/UEAMSO+ArialMT/DescendantFonts 44 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 45 0 R/Type/Font>>endobj32 0 obj<</BaseFont/UEAMSO+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 46 0 R/LastChar 174/Subtype/TrueType/ToUnicode 47 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 0 278 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 611 0 722 722 722 0 667 611 778 722 278 0 722 611 833 722 778 667 778 722 667 611 0 0 944 0 0 611 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 778 556 556 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj33 0 obj<</BaseFont/UEAMSO+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 48 0 R/LastChar 176/Subtype/TrueType/ToUnicode 49 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 0 0 0 0 0 0 667 667 722 722 667 611 778 0 278 500 667 556 833 722 0 667 778 722 667 611 722 0 0 0 667 611 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 400]>>endobj48 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 50 0 R/FontName/UEAMSO+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj49 0 obj<</Filter/FlateDecode/Length 532>>stream
H‰\”ÍŠ£@…÷>E-»Qoİ›€òÓYÌ“™0ZIcyû©ãiz`„$_Ğºçó`™îûC×N.ı9öõ1LîÜvÍnı}¬ƒ;…KÛ%Yîš¶>ÿÍßõµ’4.>>nS¸ºsŸ”¥KÅ“·i|¸§MÓŸÂs’ş›0¶İÅ=ıÙŸ]z¼ÃG¸†nr·^»&œã oÕğ½º—ÎË^M<ßN—¸æß¿Cpùü?£Lİ7á6Tu«î’rµ+ßâ±NB×üw^—\v:×ïÕ˜”9.^,âOä%y	^‘WàyŞ“÷àWò+øCË‚3Ì,2rÎÉ9¸ `!Ø“=XÉ
6²éYÀ³ gÏbCŞDæ
r…¹‚\a® W˜+Èæ
r…¹‚\a® W˜%ÈfÉœµ%oÁìJĞ•°+AWÂ®]yöãÑ§§‡§§§‡§§§‡§§§‡§§§‡§§‡§‡r¦b¦r¦b¦r¦b¦r¦b¦r¦b¦òŞ÷®¼wÅ½+;Wt®ÌUä*suÎeŠ”=(zPö èAÙƒ¢å3£xfŒ:1úüş£¿Áßèoğ7úüş£¿Áßèoğ7úüşÿæç‹Î+!ÃyK·øƒõ¹s°µâÀ}íÛú>qËÎ¯‰y¯b—¶]øz“ıàâ*|’¿ ˜-Üendstreamendobj50 0 obj<</Filter/FlateDecode/Length 33157/Length1 65726>>stream
H‰Œ•	XT×€Ï™÷Şy0€²
Š3ïÍÀ›BUJ£%×ÚÅH¢mÜ‚ ‚ˆ ¨¸&*iPƒî
¸€;®((jDTÜXÜgp:µZ;ÈôğÑôë—/½ßwÎ=çŞs¾ûİÿ½snÚÔéqàéÀAäĞaï÷„¶ab›“šÃW4`€ÛˆØirÛ¶ûr Ÿ:!¹Í÷y 4MHšÿºÄã €öÀ„	q1ã¯Ÿ½_™Í‚BØB[|æ	¦ü’Ófµû÷B®$¥ÄÆ#æ ”fşä˜Y©mûÏs™’'Ç$ÇyÉ!Ì/àƒSS¦¥Ù!àe£}?uj\{ü?˜8U Çea.à ¬z±[ø¶Í\-Ä«Ü•ñ*ûà!ĞvfõgiöüáCúË²­Y¨où{‰á¸/Ğf³±sB¹ı4à™V¶èÉø1»1!h_d³JeùïÁ69^ ÑÁQíäìÒ©³«›»‡§WoŸ®İ|»k´’¬Óûù+†wŞ|/è=ŞşeÏ^!¿
ıõ½ûü&ìÃğ"úöë?`à ßşİïÿğÇ!üäÓaÃÿôçÏFŒ5zÌçQc£c`\ìø¸ø		'%%ONI2uZÚô3gÍóÅ—sçÍOÿê/_g,ÈükÖ7Ù9-ş6wÉÒeËWä­\µz¬[¿ac~Aá¦Í[¶oÛ¾ƒÛ¹k÷’½ûö8x¨ôğ‘²ò£Ç*Ÿ8	§*OW9{®úü…‹—.×@m]ı•«×®ÃÍ[FÓmsğ®áì¢!ìª"„À<´©dÕHÕ.ÎÊ¥pÓ¹y\6·+à.q¯x~(Ÿ)xg„'ÂKâÈ‹|I¢>E61Y“¨™¤9¥©ÖØ´óµkµ?hßH^’F(‘>“FJ£¥Ï¥¹Ò©Rª—ŒÒ3é¥Ô"w–õ²Aî!Ë!r9L—ÈQrŠ<_^.Ô	:·N¯3èzè>Ö×Eé2t+tÅz•ôõîz/}7½¤Ğ¿§¬ÑÇù©ü\ıt
(*ÅYqU<¥»â¯)!J˜’¤¤+J–²PY¦(;•}J™rT©T.(—•›ÊCC˜!ÂĞÏmˆ5Ä&R‚’‚föğ.êV¤³ª¬¡Ö0k¸µ¯u€u¯õ±ÕÖ<îíGo_¼mnñki¶5Ûÿ3ö‡å«@¥SRíæü¹H.›Ãe0j‹¹M\÷šïÄGòYÂ¡FxN@NŒš–tAÑb¤µ$M¥¦EÚtm¾ö…’$Kƒ¥Èvjc¥téT%]“nK/¤W2ÈîŒZ £ÖSîİA-‘QË•ó[©ui§6D7L7šQËí æÆ¨uÕkÛ©EëÇ·R“‚Zdµ\%_ÙŞA­šQ»Á¨õé gHdÔ¢ƒÒ5ï"ÙŠVõF-ÂÚß:ÈZomnzŞJMnI·S³İcõùŒIëG2	°\ËD»æk˜ØV‚Í5Íç…6×ı§,›BñÏ† Xæ<dÕmñ²xXÜ,-.g‹“Emq´ˆ²Î¢²Àû7‚ÆLV0Éh|s§¸qæÓDf—>íÍtvã\€†Ä†Ùe–‹÷‚[V57ä™óÌ…æ óV{~ƒ·yŠy,ó‚Íæ^fÓ Ó@S˜©·)ÔÔËl
0éM¾&O›Œã#ãã]{–±ÊxÜXa,eÖiããã@c?c_£¿QoÔµ÷W7k<d.÷w*X	®×ŠkÄÕm÷¤ÇîrË¥Öù‰ \lk×b]Ÿc]Ãˆ`’.d1½T`]˜œ™„R¡x¸-ÛAË$Ø¡§Ãx‡|G3€º‹}UíŞ.ƒàg†:Dı)Ó¬O«gühµµo·­¨×ıdn¦]ÔYí^ÆÏõ£Ì1ê¨{ÔÿÖaÅ;…9%üO › pQìõy™°r`=lƒÍà
Ùé×°Ã°VB"{OŸÁØ‡ğ
a'œ…*Øã ra<TCœsp	ÎÃ¸ßC<ÔÂe¨İ0š`	\:¨‡xøa"L‚dH‚É)0Ra*Lƒé3`&<‚Y0fÃ0¾„R(€ù0½ò_Áx
G0W¢
9äQ +4ã*\kp-¼…$Ñl¸×ãÜˆùX€¨F'tÆBÜ¯à5nÆ-¸‹°·ávÜ;qîÆ=X‚{qî‡ÂUÌÆ<€ñ–âatÁNxË°3º¢ºC#ÜAôÄr<Š^Øâ1¬ÀãxOâwè>°J°+vÃSX‰¾Ø5¨ÅÓXoà_pî¡„2êPgğ,Ãj<ğ"^B?ôGxk°ë°¯@¾ƒïb Â}x€W)›rh!-¢Åô-åÒZJËh9­ <ZI«ZMk`+­¥u´6ĞFÊ§*¤M´™¶ĞV*âùITLÛh;í ´‹vÓ*¡½´öÓ>‰O¦ƒtˆJé0¡2*§£tŒ*è8 “ô¢J:MUt†ÎÒ9ª¦ót.Ò%ºL5|3ÿ–oám(¨NàA AGA-8Q-ÕQ=]¥ktnĞMºEF2Ñm2S5ÒºK÷è>= ‡ô==bµş„,ô”şFMx¯ã¼‰·Ğèä.ºŠn¢»è!zŠ^bÑ[ô»Š¾bwQ#jEI”E¨wòø7ÍõÜe‘ÆüİgÏîó¼ÏşH¡† @‚¢‚JGzï"*zŠuF±¡ô ‚
xw¢  ¢àœ¨§œb£FTšª(	HHäöææşØ¿vvvæ™Ïì~¿Ò@JŒË19.'ä¤œ’Óò»œ‘?ÜeWéª\µ»â®ºwÍ]wµ®.DUlÛÖ&Û›jÓlºÍ°™˜,¤±}É¾l§ÙWì«vºagÚYv¶cçÚyv¾]`ÚEv±-°…v‰]üÛeÁûš]nWø×ëÿŠ­´«ìjû–ı›ı»ı‡};8
GƒıÁ»Æ¾cßµkí:û]o7Øö}ûıĞn²Ùíf»EšH‚4•fÒ\ZH¢´”VÒZ’¤´•dI‘TI‹D
©[äYêN=¨'õ¢Ş‘)Ô‡î ¾ÔúÓ Hƒh0¡¡4Œ†ÓI£h4¡±4ÆÓ4î¢‰‘¥’.’)Y’-í¤½äÈŸrVJ¤TÎI®äIšOh!-¢ÅT@…´„–Ò2z–Ó
zŞ 7iuTG#QU™º .ªßÔ%U®*T¥ªRÕêŠºª2Uº¦®«Z•å³U >h‚† °@Àªlp…z±ñP¨vĞ©ö*CH€¦ĞšCH„–>£Íóy#Iåª<h£:@[H†H…4H‡È”|é(‡å79"ç¥L.ÈEú² ÚA{È\Èƒá¸‘¾§àYx¦Âóğ¼/ÁË0^Wa:ı3`&í ´‹vÓÚKEôí£Ÿéú•öÓ:H‡è0ıFGè(Ó1:N'è$¢Óô;¡?è,•P)£óTFè"]¢rª ËTIUTMWè*Ì‚Ù‹qTC×0ëÓuªÅØacªã€6ÁÖadÃ–‰™CvØ›asl‰Ø’£\c8[akLÂ6Çñ\ŸpCnÄ¹	'pSnÆÍ¹'rKnÅ­9‰ÛD's
§r§sgr¶ÅdÎævÜs8—ó¸çsG¾oäN|ßŒ)˜Ê·pgîÂ·òm|;wånÜ{pOî%—¤œ{sŸ¨R”£aT¢ïà¾Üûó Èƒx0á¡<Œ‡óÉ£xt4­‰ÆòËãx<ßÉø.Èwó=|/Oâûø~ş?ÀJOæ‡øaş+?Âòcü8?ÁOò~ŠŸ†ù° Â"XPK`),“Ëğ,‡ğ:¼oÂJX«ù©”*©–+P*ïÈyWÖÊ:yOÖËì Wá<”é—õ+zº©gëùz¡.ÔKõ
½Òw€5z^¯7êô&½Eª¿ĞÛôvıƒŞt‘şEÔGôq}Zÿ©Ïé2}.Â%(‡
¸•PÕØ	oÂ›e£¼/H\“ëR+u.€+pjà\‡Z¨ÓV´Ö(Õˆi˜…·`g¼o÷§»aì…}°/Ä¡8Çê–8ïÁûq2>‚OàÓ:ŸÅ|.š†¯âœ…sp.ÀE>#-Áe¸Ü÷Ê7u&®Â·ğm\‹ğCÜŒŸàVü¿Ä¯}³Ù{°Hgã>Ü‡±Oê\<ƒ%X†åX…5Xç{õ>ÆÄ™ú¦±.1	¦…oA­|¢O2mMŠI3&Ë´39º£É3ù¦“oH·ú´ßÍôĞdzš^¦·écî0}M?Óß0Í 3Ø1CÍ03ÜŒ0#Í(3ÚŒ1cıÎ8Ù$ÿ>:Ô¢İÿæcÆ›‰f’yÀ<([8ãBWÏÅ»F®©KtI.Å¥¹—år\¾ëä:»Û]×Çõwƒİp7Úwİ$÷€›ì–£Ñ&ÑuDUÅê˜:®Np]„*„P‡‘CÚBÃPBFÃzaLÆ…ñaı°:©NE*#U‘êÈ•ÈÕHì–=²WŠä'Ù'?Ë/ò«ì—rş€?á,”Èö`SğÌ1ÛU~°%ø$øZ>6ßÈ·Á´`[0Sô½s¨ïPCÔ|µ@¾Ó#ôH=JÖÃôğ°6¬“ ¸¬ÎˆP7Š–|y!ø\üw+Vb%Îív{Ü^WsåP°"8ü;X¨Û‚…ª«zZ-VªP=üSM6SÌSæøV>•­ò™|._È¿äKùJ¶Áwğ=ü ?ÂØ	»`7ì½P?Á>8
ÅpÃ	8	§à4üg¼Î.^ã0#tKİJ·ÖIŞä½8	ïóNá`â•Ş…ñn/·öÇŞÚ7¸¿õŞvâ.Üíí>‰Sğ)¯øQ|×©:M§ë¯ù9œŠÏ{É³½ç™Şó\ïûE©³¼êÅ:[·ÓíuÎÕyºƒÎ÷J+ğ2Vz±¥xÏ{§±^jüïôNÍdoõ!ó°.Ñgı*õ.»z™İ½ôcxOx½éŞpª7œ‰½LÉõ¦“½çl¯øÓÙtÁtL×õº\WàÖ á?ŒW}tTÅ¿óñvÃ’„å#d“ ¼å™T²Y‘PJiX²ÙäKwÓ »!)	¶T$X!áñ¡å Jµ-*(-}ITÚHÕc†P°­Ø@Ô‚‘ôj+°¯¿·	1é=İÙ÷Ş¹wfîÜ¹sçwñ¤+û)Mf‘‹È¼„ç²õ5š—-¾õåŸ‰wö?Dè¬˜úwt‚õ’…ÂŞ¢T*¦½@Á;©…lT–ÍT¢ }'K3;hğ±ÀÓÙ{“ÑXæ2?fŞ(Î ×FJ¢	4‹iocóÌ•TCçåšFó€¿›Ø:3dn7w˜/À+Š·Ì›4œÒì—P·ù¹òù7ò¢Ç3ğœólÇ°ÃäÃ,ë ùc`ö=b‘dæRóKhàrï&I¥ÔÍº¸£×Ó%æbÍÂQö™†ù:¤ÆÑ"ä{€i§²ÙÜ­Ô˜¥f7Å«0ênjÇ	8›§÷Y¢Òk¾`öRåĞ\¬§ƒN².»¹>6S`¥‰4œåô[ä§€_ãË•D%qñ1ó]C“©
ÚîGÏ¿³/p“ã.oÊ YDÉ°Ë,kÓÀòéÀØ=@
ËùsâAJÀŒ“Qê©l¦g1ú9 –#@$=bŸ<(¯Ûn‹]0“±#Yô#äN¯!CpÑ?Ä RıûùbÜ/ÅNù²<mbÕ÷!ßÙF‘}Œby¬Œ}›5°fÖ‚Ó·¸ÿ»ÌgñJ~?nš±B—E(ò!¹¾Åv9Š½ûcì3×ÜDeğ‡õĞşdeğ“`É³t.2yN2Š•[T±5(#fü,ét`–Sì"ûxì»ÜEÀ[fBÑøƒüQÜ‘{q®­“ıÿ·Hp¦¦ŠË¡U‹xå°ø@¦Ë ü\”]Êó¸3*'”^[¢ı‰JxçÆ¾›Ù7ÏÅ(ÖÛku˜P
ö0VOĞ>Š²û½÷K:ƒÌÌ…Èf…l,³˜-c+Ø*XòIdu/Æu?„<«ÀUèœÄgé|°Z_€r¯ç+pÏïàüÏüKaÇ0B¤ˆl1[,õâa±Zì†xwñEñOqÅ”9^NYÒ#gËÅr¥|N^’—”DŸmÛ÷l›ÿüÃş{¡}¡½Ì¾ÿˆıİ„ˆ¡§Mƒ~ìğA@¦í|ŠLCl<	^Lu¢”ÃSùÖÊ×²~‡²Ê6ƒÏ`ó©WfÁÖoòçfˆRVÂ*hŸÜ7šmŒ|Ÿù{º"_ÅÚNbäU¶Dö8¿jK¤vF|:æ|CÜ-=âmz_œgvùSú«t ó¼Â÷‹…ğ‚ã²P	‘[ì¥Cb[K‡y€Èq=a+üx>{q¡’å²	“Ÿ/š&>¤t?÷Ã£ÔJ?dur)m§)¬™.ÑK8•SØx£ÔùhÖA\¾ŒÕMGÆ*”1ô$[$öØ®ò³´’z¤ƒÎ‰ŸCû~H”Ê^¥œ5à¬¥M´Â\O«•<Í–âÚ¾‡2åD·f‘+İø~Q¥1íN÷1ÄY¢-.xÎ<øE"Ä”g'$<¨gü^D±“Ôa«ä´TIfˆ:DòíX9U›/Ñns)=`î /âA‹ÙŒĞÇô`ck¨‰nÇÉ9Çæ)AŞ£M/×ùY^Áwİ_X;“¹èS”C¨*¿!]ş…*h¦¹Õü¼ûNDØİTKß¢°ÊÏ1ÃÑESbóy›MXïy*3÷›ã™ƒÌïÒz•^´+µ{°Ç;õ®¡z^n>,êc°ÃS°‚ÖZ‰ø³Ùç¯ªœå›YøÍ‚ùÓó¦Mıú”ÜÉwOºË›ãÉxç×²2ïĞ&¸Õñ·ß6.#=Í•:6eÌèQ##’“‡;†%ØmŠœQN@FT#+bÈ,mÎ¯U×¢hˆjˆ*š‚Ce5S‡Jú ùÿ’ôõIú$™S- oĞT£»XS;YuYô¶b-¬Wâtiœ~:N'v»ÑA¸ŠUƒEÔ€|¤ADŠ1\Ûp‡_ó×;¼9Ôær8(#Ukjc©…,NğÔ@~§„$(e¤kÅ#M+¶40Df Zg,,Š3Üî°7Ç`ş%Z­AZ‘1Â!|Ãæ7ìñiÔFk5´EmËéÒ·v:©6âI¬Óê¢5!CDÃÖ#=˜·ØH}ì#×WU>ÊjÌÍzÀÕ¨ZU]oQŸ”…sİÖ;ÆèË3ƒ=ˆ©·Âˆ%*fãÃ!ƒmÄ”ªµkU}ë«×VKd™jÓŠ´}Y[“®T¾Úİî;j^ ô€ªW†4·13CG‹Çµ!½|õ¯Ò|jÚP7§Í9²Ï°mÉ#ú‰Ä¤ÁDı /NÅÅ-ª¤|À²ÌÒH›‡0Ô%*4	iXSõªÏ#}IÄğ3ô2ê°#Æ0Dwæ[íVCÉtjª~àÚ•Ï†¶Dû[l™Îkd‘–Ÿ¸ø·hÃã1²³-±û±§Ğ±0^ŸêÍy¤“kZ“SÅæ£…°m4œ?	æw»­ŞÒé£ZTŒue¡¾ºJµíä›ä	<bqºnqRª,Îº[œîÜAA#ÅHÈøphÈ7ØØÿÁ®ïã—Th%eÕ!5 Gúm[R9¤ÖÇÏàõSÆhHdğ~Šgˆ8NY3 lUB‰†ÌÄßwêºN{¼2ŞÂÔ áŒÌé{‡n÷ÿÙ©ÓìµzÅ?_uëWÓÈ÷­ÏR¢^¢. 0®Ê’Êj]wáÁÕú&œÛÿÇSeÈ­úªÂÉÌÄ¿ÓìÊ³p†áƒÉü– ü¯¯©¿:D0£Ÿãgy§7'ˆ@§ëAMê=Úi®«ÕT§¦å'ø	½)¹å8æ±-Fpk¶j`ù8œŠÚ4ÖZÖæc­Õ¡£N"µµ2ÔÎ÷GŠÂ–!¹¿24x÷âG"ì%ÎâğV!àe;‘{¤{d&^WŞUtİğ)tTÙ…k‰šce<¢œ!'ı‡íjnâ8Ã»{/ët½“dK²,ËV‘q°A~©õÑÓ–â„¤˜`Šâ¦PšàtÀuJğÅ„Ğâ6å•bRhêB16È$´a`ğŒ›¶f˜)™!´c(Ã ‡é¸¦Drÿ=a2}ÜÍíííííşûßÿı{s,¹LÇˆšR¥);kyp·é°ö4â(ü…qÜqãĞ.o”N$3i:‘Fõ‰úÄ¬JœÄbTÕÖÔÆD	NÅøã=hX:¸e]ÙœpG³Oâ{X»š¹ÿÇ¦{ŞÍgCÿ1ÿw,e:™N‰C¦™f|˜ÃpïA‡¹§5àC¥¤*÷ztİ®Œö¨ª]¹cé²Lu­X#ÚqóQ8şËNWUe8cùé(ÉlÁÑhéœ²õ[—6|˜}_ÇìÛ»séŸïg®eÿ‘Í+ßÎ^Ã¯Àß‰Œë•Á©¿Sx¡Á\‚,ã’	H¬“¾ğ8ìÜVÃ>¤ ètÙ–Œ'ÇGi:A¨•4M3il˜ñY•±ê˜Ç-Je55µg†>5;^Ã·¾iğ=óM˜w.N‘Uä{€ã#–oYÃ‘Ü S†ñk ƒ_ócoô1:š¤7QECzV%j…EV—xæ’rœêíe÷CÑÖshšå%ÌØDÎÄ“ˆï„÷¼måD2	~JçŒêfßÂ_'‰>úFâ&¯u»ã$5yÍ
¹ãû8L¸ÃÜIpkvCo ‡dî"· ·.˜œ?½FNĞñ4ÍaĞ.ÌŒ&7Òó‹hÔƒcwud—ø„;ÿ‚jœü;oç€E¸ña·dÜAU-p¤&oÙØ³Šåcà;¤°”¯(P*¬U ğÃPÃzØŠ
O‰ÿ;Ò8Œ$²‘n‹ìÊ˜ås:E6$e-ˆ*
+YÛÃ!?³Gùh hÙMBÎ÷ EæÃeÂ¥O^·¾Í‹íd‡s‡~I’ÓKæ¹xæû¾\¸ÈµÌ³Ì÷da‹Ôâ\îzŞÓâûVá:òCq­s½Ş.î—öÒKŞ«äŠxÅù‘îhn›Ã*	WU:0rPqtm”ÆÒ 5=‚:‚_Ë‘øl¦˜‰“­(‰êØájjrQ³&6;?ßò‹áÒ²ˆ‹æÇf×4.•ÄÆ–‘Îµİ/|iÕÈ‘Ëë~Ú×µaCW×Ëæ'ÉæñœãÍ§³“W³Ùì'öŸÅ‡²û>¹ÿ¡«ÆÛÎ¸ò1 x°“ÑI+ÄYªQÕÂo"»É<ş8Hç°Bğl[/³5!Ìt 5yİn¨Ü¶Ğ€¨f
^¶|®)Ll|üŠ`©z•0å‰J‡K ‚ÏÙøG(­QğK4wÀC¢!X_ÇFœù%£%aC¥jˆÂ¹ß3wdÑ¾¿U¼À¿ôÅÅï|e¨™­-\–`mA|ñ—U½.—Ø¨2*†]³”B-è‚Œ¢¬C0ÈŞ¼	*Ìò`ŠX
‘
BÅÔ $TjPqy˜•Ã¨"Í,­gåùÙŒ¼äá„Ši{BË¡djë–Ót‘Æ ›µ±±»ah*N'i,`êh{ñÿÍÆøÌæc³Ù“Y5
ŠÂûâ€t1ïR@úšÒ¤,ÒZ”Úzs½ëUsĞ¼á¿Qx×¯¼ï<ë"…4@‹hŠïMŞE?î@Ë”i(üî@ÀŸğƒZäùœ¤)rôôã6RØÛËV€lwè˜(r[Áx›q-(„(®³£·4“ÕdáI?ù*Æ»OåÈº2eòâ’IÔ§3ÉQÃdÈBÑ®ÍŒj 59¥ESP‡’8ùı¦¦i’H- ^SS]Ô·Eâä˜(ñÒ§µ¤`Ú/ßøä×^Úz÷¹îıidâ«oışÍeÁ'æ&–Ÿ{ùü•-¯Üéúğ/·O,y{ğègfSOŞäó)QÜô 8§Ïk1ÿ{3ªFxÀåaYÕ=(Ëå`€–„r5¬*^¤¿eäI†"ë©`ê3\ÁNdÆëë!‰¤¿ôzÁŒÓóÑÙìbøMÔ|uº]åçOk¹'óŸ§«Ü+ò ®soWwº_-<¦ÊBˆ³yãTT—0Ì‹,,` ~UË‘Š«{ÅÃ{ûÉQä#ÏZe`¥ fªf[shuˆ„¼ŒÉ¡ÍR[ÄÖ¦F!`ñøYö&Ò1Ã›Âuİ¾Üë ‘œ³œŸ©Õ#)ü³SS‚e£È4k<šÌéVf”‘ò$Ã3'„* ÑŠ[›\µùL³là¤Ú‡Õ)ˆ+Q¸4²¸§xOË¦“onŒ-p›Î¶ÔöUÏír÷”Ü~çÅ¡–•+¶vdo]ùİ$~Å{ ı·[7qÿ‚¼¸qùÖmÛB½¿Û½¢ùàÌà»?9—ıçM0Ú@…~Ğ7G¬s‰ò¬ò†Ò¥\R„Üõç<gÇ‘"r’ ;9	)ìCïæ8SQT^âÈ Êƒ-Z§%#‡.hHæSdåYA­¢â*yJ	å\b²+cv†’S¸ÖR%«4\%m.©–:tÂèäTİUˆP"a³o 2z†}CzµŞe{ú¨Ÿ-„ãL^ô&µu'&Fœ99oŸå!dt]wÃ>½©óÍ8HÎeË‹s¥3â_T”`C4ĞÇr+–3®l^W¬H\)À}FÜVÛ&ØvVã˜ó„ÎÀdof9ôú…=ÙjÜ|Œ;óéücÙ#Ô{2-@<–ûK„_Æ.ÎENÂ°>•-49èñL&NçƒUÃHòB¾°wvÅ2¦i,J€D™ó,0ÊM[{u»üº]ÑÎ¢½®·\(W”
ó.¯öy?ç¨*ı cDuÉÓåÒt·ærkº
!b¹˜!–Ö	MM·<øQgu°ğU³BÌ<£™®¦›ènÊS¯$^Œ¼Ôûoº«¸‰ë¿·»Ú•¬•´+[‡ek½¶@>dŒ±¹LLP&BŒ]SC 6ÅlIËQ.ƒ9L0Ã@9RhÄ6u‡£´“zr&!	¥m	tÔB`Ü‡èÿ?IÆtZVûôŞJïøÿïû¿sÇAânÖít±ÑmTÃ[­ÇÿXÒË#¸„PQFØFC*\@WyD‘0âcœGë@m=ÀJbº#¼G’JÀ?ùwsWµµ4MiÊ:ôwéÁÉÒ†-g¨qá¦;x@W(6víßÕZ:ÊÉİz'òÊ´HÏÇ¶´şU[	DÎœç%9´4Æzi6šF+)OS²´ …Z,PªRZ’%A£¤¿‚EŒ)8Es)Aã<Sp®˜Üêş´[y?ÉPXé
a$Ô$ÓÑRĞ1:y´>Õ>I¯ágI³Œsì³ô…ÆE©kŒkS?3~êT%83Š	q²¶ÒÙ€„™ºOOÇWYfá`)ôb%HÏ_3èÙáA;9Ş¿^a¢ Ja7O¢"Qšs0r-
:G¹*]ó]Ë]‚Ë‰c.'NçjçúDE 1ÜÄã1¦ƒ=Æ"†ğA¶« ¸”f¢„äfÇåË ª2©&õ	)ï˜;wlMùS“_äê¬n{ğêG‹\ıõúï[.?VúÚøoì_²ø°0Ñ:'¿$ÿÉ~=szäßŸlÿ’£Ké¡³Ïİ¿:\Ñ¾gÇ‘#p 3€ïœ†ÄBjƒÖ.àÍp¢0Ÿ£‚I¶Ôó<‡GRÊJ4ÏylÆzÓ?H)Ä¾’ãGÁm>]â1ÙËâñà‡êŠKî„Ç+=¨ÆĞ`õ.R‹¢¥’ŒHxQòµÛ‡Íà7EÂã†Ú:øU·×w[š¶Eì‘{í_µĞôÂëès'B&Cºˆäs$šƒm2IÑò#A‡q“óòìéšhÈÒìÍ$c²¡8Á\DÀ†şÓĞNØ`ƒ677Ÿ|ü)¾7}ù~w°t°ôu<r[T\á¢¢^Gr’-DŒ/DŒ.ä*s&¶8‡ÇæÇ>hÜf`'N‹¿t0:s°>Ú_|2˜‹Œ- ~!‚†qÒlçXçXÿ5ùz¾Á”O—‘et©°ĞXg^ /²,vm$h“°Ö¸ÒÜ ¯µlrıI=ŸhÏ ¤´¦ê¼éú@¼Ğı-[—‰æ&2,coísÒõ§MÔÔÎU•@½-¨vl”Øgk§[N¸ëò”‡ñÖ~õ^Kã:8Gó ^Ks°'JyáØŞBlsX´bˆa<ZPGê**¨ß?dpLÎÅ• Ä¤>hé:§vîµÓgnÔÌkÜé¹t)Ò³åÅµ5³×¬¯ª^7blóÄ•[V-?À§dï˜³÷Ë+{«~•Ûµ®ó!¡ôÌæ³tÒì†Õ•3î?,i.}kÅªÃã^sRV|7os”€ş*€P¬ŒÜhq²0¢n•…TeNGu«¹s–f³¦YK­¼ÕšDÊ(e2Ò¢€« Xi2PDã©tBŒD
ØÁ@´1ıdÑËï÷:‰>‹xT;ƒ9¬xª,‹ÿÏ¬Ïõ_Sì;QpğÏsÎ ï§Î)¾*~®s§Ú·Ø³LkòlÔv9y:=7œ×ô=q¤s³ÅÉÈ%r™Xw}Lît]Ô³´Rk%ÙTœ’^,‹Rr."í-"f`dõñ²Úœ‹<İ†4­öæ’T9µ9p¡¯ÚÄT
÷­qÚ%¡:ªˆUÊ'¹!ƒ3‘máN ™ìªÂa¡¤,e,—j[œKgL\V6”ıí¼÷©t~sxÉâ[ûßù’ûàÍ…?o=´tÙ>:QYüòsË¿¨•İå5ÔøÅªìŠ|ù!ò]äØ»§ùÁ»Ot½Ş”9Óög­àF“ÈpĞ"J&N,øb*
	\1èÂépûŒûvÀ ÈŸàX‡:x¸:º»»ùŠîîûº»	÷ğ!†
Ğ¯±ÒêÔjS˜Pü¡-Öø‘%"‡ÌVÁH‰Œ}Tò•jãlÓteß¬üÑp^<£ÜTÌFC-çÊ”Ùæ£Êmù¶å¶Õ$È‚E°òæ“AÀ]EI’¡me‰Óm˜cD—ä$âxûØÇë‚œ¿2iƒQy±«šˆQ¾ä(Ç¢f œ9h—uò’ÄO(>®|³@…vJƒæ2ùŒtEæ›e*ãwÅ&}(qË¥'mµ}öyô´’á‚·NÌ“¬@¸G{Â£®+ax7òĞNynvg‡
ê¸Qéê²vu5¢wÈ–qGÍÇÕ~2õù6ÁÆ¥S`|ÉÃ1‰*èÔ[øòÑBêãÓùÄtŞŸ)J<Wø1÷üå·ìŞw‰ŞÚ9&#µĞpêîÚÍM¥Û;^İ´«Ùv¨¼×!R*ST‰D€˜<c6‹“aŒ¯ÜWå«75˜ÄŸyjMõæÕ†Õf1Óiâİ™9šÓk2%Úµœœìl’êÕàÜÒ4M%F·_”±„‰à+‚…{ÑE<yÑˆÿ.²X‹I˜â¤ş~9!'às2æ…Ÿ’=¹^M§˜„:“(™Åø,4î¶± G"6nğI(ğÄ´¨ÂW*ÿxö¥$|'Ú€„†^¼ šÅ`SŠªEè£6TQ PMïãó¬œ¦Šdî÷é(†ØÅövÎğƒúªê5›§¬8ÛÙJG®şì¸1«öD¾¢ó^ğ?=uÄ¤mM‘Ã©Š—^x«0³sEõ{ÓñTgUÉØùÙ÷öJòğš1~1€Iª~gxÅp¢rñøLn—£Q±Àö÷}°[:)°Ì$µd¡wiğ6“]†·ù7-|›å‚å#rÕ{Û«Zí^ÕëåsÄ,5'UO{ÆR4ÅQ<ÛPã]bßhßÅï´îJ=Hßàª¶&’$âQ’ ÈüKkV#ÿYEŠP!%Q“ùM0)~Û³Ä¯K{Ò\~İH2®Æ˜¬ÍœÆ4W T‚Š>cŠSe‡	ÕÁèê_F?88{¿ÂÁ%ù‘æ8G’‰Nh;72òûoÃ‘Ïw¡OŸûšæ>qºğÜÖCßL›wmíoşÎqƒşuï,}ù“oéä÷şCzµÆFq]áû˜;sgf³Oï®íõ,ö®Å6³`šQIh	˜¸¨¥8f“ˆ¦JƒÊ#¥Ï€Iy%JK@%*„Ôâ´¸<cRÅA‘Ò6AEUJH”„6¨PD¡Á^÷Ü;»¶ˆºŞ¹÷ÌİõÎ=ç~ç;ß¹ğÎ”ı;şµãdá£ç_¼¶¸ça@´b÷¡3Õ®Âs¹‹Î€•ô#[Öq•#µ˜•nDé1¹"¡'))QUiİ3ô>.AïV	zÉ;¡W´óck¨Ÿûg-×¸ÊW¸¢Æc‰QMòÀ j$†¢T-§e)ôÁã)5)QÌf'Ák#Î„–EË¢ Ø	à3jœáÔ|j/şÏ/^ßşôÚEßİqzsá(ÎíøYÃ­?yjQOá]6©\øXá÷o,^YŞØ3£á~~éãIIğú 0Ã? &zÉ‰¨,É¹¦!ªˆ@zÒD\è¨´‚MÚ—èƒ¶a{‰‘ğ*úÿ‘®Ù.€ŠAk•	›o½q1{g6Ôƒ×‘Tñ: Ôí¥Ù¡?ÒMl §pß¡‚·Gdˆ#e3ø £:YéÃvº.ì±‰m’0ïaß)7î)&aá®í³—Ûş¸ı_tÛQıïÜ{7ıëĞ‡äÈp›Ø÷¬á¯ÂVBî¿¹ŸÆ!'Q.ÎZüá ­©A©`I£$‘Éi‹=`¬–%}t°q¦6]cS
~ÕvBäJübõ€ñ'y²ú–‹ÿ'kºjqmeÆ6°!¥ Ï<Ş1šÊ­VşfÑØ¼hGŒy/ø.ÑP ïWªË+ñ
ªz2V:’©Êğ´’©NÇ¼•)õ‡RğåpÈÖànK§p…	È`Hê©ª¡0 Ù”‚Îk±Z²¥—À:ÊãééÀÿ°G´LûúP5JA¤9@’•ÛgöŸ+ì;Ş‹Ûş¼ã™Ã©Çú¾±ùÔ·R3·b²cıµÏ’ûáákÖ¾†9w¯=şDÿëWuµ~qÓCÛö½U¸Õµ¼à<Ş (mQôî	Â ô½3ç4ÉyZ“;O©wçº‰î\vçÊ¤;Çrõk5ÙìEv˜Á)LÙö£#H™ŠÔ†ş†®!´añEDå×M	¿X–ÿ,Áòj	–7ËÕ8–”³íãhgî²¥Çº@ÈäÛW¯iÎ—Ùx œxã”àcóÈßér©^q¬ä	õiòMu›w[@Õ%Ò›hı8á˜JÒ¯ëÃàSÈz±3iˆ™n^HÃ-WbÅ‰
T™y;„íju†”ÎˆJV"ƒË¥lúK1›ûJ\±ò«]„nğ]ÉÂöQŞ•ÎÀtàHXˆçÌìÃÚªÇç?YwªıÍgß<÷Çº¿?wízz}(Şÿ»'ÏF ½ÃVÃ'I'4ç¸>«Ö˜®Î0>o|…n¡ïSmñı èWä‡,
uìåyöå2g†‚§+g¢‹NT¦š¨-(—½\P¬öÂ=/ÎŠ˜+å<ØŒŠõóÎœ8<3Ãõx|€V7tn0ª(63ÂŒÁ·5ôªjˆÍäˆ”˜)ıd–ã¯gx?;ÂÙ¦°¹X3ë5lƒş<¢Q­Ÿlq<¦ıiiøúw[Ät.«¯í/r± ƒ¸ ÿ…„õ		Ë@Ã*`hÜjá- Xc XËA°
=ynf»Û’Š›k½€ˆ×5§Õòš¸å³štaärŸÛ.ƒ|Š€>â69SÄ5¡<Éq¾/
f4§Š°šÁŸÎ)N8'Â|"f$—{µ‹Æ«×ä³HHf~œÂğÖ»N‘sX~™<;‚†o^cÃÉûÃ¿ÚM.].(.j”I€†V:LšdˆÛ¢ ¿Fè=½›w	õ.¡p)ïV;7ESØŞ MÿİØê‡XäâQâ•ÈÒÄ}Ş€äu 0 BW:ay‚âcæ÷PaÂuÓ‡¸NS•¹k÷“>™¸lîÒñ¢'·J¹L…=–PÈà uæÌ` ¤r6ë*wOÚ©Ò$©r¤rTäÈäÈÚª…Ed9…R!êo¬4ä¨•ZE.V%¬ÃÛ6ùåÀ<aˆªD8.~MòGN’%(±Zâx‹u[-…_ş,ÂÂ—Sër@µëL~{YåÎDü<LÊ¹²Î³Åó¥g¾g¾ŸNTÒŞÉ¾¥´CYçı¶o«—›„ñœw†ï!²€Ş¯9¼Õû9Ÿ±›¼Lwi»x7=¨©Aâ÷ùêl'ÜãõÖ3&÷,ö/Æ4Ÿœë†	¼ïóYâœ:ƒ]A İÈ‹1›÷ãÇğè†íx6˜Ø '}Ø„OH?´¬º€è_ea«Ÿ,yÕf¬‹A)!İ½ÙÀ¨qèLoä[b€3Ù•‚½¹˜‡Â`ûK@ç*}ë3²U…	¸w¬%ı5òŒÜEdä¬ìHñÀgu2û½#·ú±
I,nßëKå|“S9o?˜Í9_c³4OLÕ)Åtm‡rªV;ÀGËf4ãT :€«q`7®ÁõÑøtü(f'K–²Û×w|¡í§tè“yÊ;·§+n‹dÜL_%´~æhĞ¥ÔEšxÌ%_¦¢‡J	‹¨ÂºåD£”ë
!ºÆj«*+Õ[&à*1s3	¿“pÎÛ&¶Í6³Ó\ev™Ìä #‘x˜vo‚R)
Ê»{cö¸bÍ¹¥P³Ğ‘²Áˆ¯\n«"O¨D´täÂ«À¯Ü†I2r
Îà8wæåÀıÁ¾y9î4ºfcNvM__ÌF×«ÕÒtÌêœæÃ÷7úB`Vºf%˜aŞ::J·x\êÀNÃ@cpv{Ş¦dàí¡ØFeV×í®bÇ¦ÃIyQs&¯|=LXÂVGX1=IÈTs{0Ã?ny¤¨ayÂN`x'bŞO+äïîCâã)Yrò"kµÁ­WF¥¼là„ •íWšW’JÀí¼ÈÄ­Oíl¿ZømaşŞë{ó6c¾àŠ¾•'ÃÃ‡(~aÃ²D¼"
KG~Ä®²÷PÕá¯9/=šÙ—!ñXs„˜J•ĞÔáªpµ:‰M)û/ãÕÅu…çŞyìÌìÎìÎzwöéõ>g_¼Ø¬Ê(Å$Ô<=--oã€jH*¢\(4i‰’B%D… +€1X¦Rä*q©	IH“TE<ÛZ7‰½î¹³»„?•êÕÜ{öŞ]ïÌ¹ßùÎ÷eµ&v–§Q[À.ğ´jÛ[®mg÷Ò{ØÃôaöWÔËôo©3ô5êšz‹ºå¹åõÙ,•a›XÆ`Ÿ÷Ó®iLBÍh95¯µz[ƒÍUÍ±ùÚR~¹Òá^\Y¹´jYxYt»Ş½EÛ«ÕşêıDóY½È•z>‡T½¯Ïä¯Ë›aYÓjŠ¶¤4¯ÊR\„®ğ³˜¼¡Øx(d§1Y¿Vá%'QQÖ®eõÁç&oC0fÒ2	ô9•Š6ìgöep&¢A¥Y½¦¤4IÜêK¯)û-p)Á¥´—4Ñˆ³g*|É™xò”RçqŒ™İ0¨„_ºv&À<hIî!7á„s„Õz%‡µX”RTİô-Éü§wgş7'NıéÍÂï_?‹šGŞF-g¶MÜ~uë™{¿¸^¸Ÿlì\µî„‘íÍï]õGÔùñu´vèÂï>(üíHqåÏ#ñ…Â‡øpáj²Ég~8ªï¥¢h\8­2rÖWV­ç·V1‚Ãì|æh1Ç8â$eÉ	låÀZœƒ“7úşÌŸ÷G“9…¼¯Læ¥Ù^šaÿ£şJ­¸Ÿw”f²¯·BÛ‚má%ÖÎàÖàNáÇr}¿ø3û‹Òiû ı®|Çî€nVì.E±+v›ààˆ_9§âl¬WTßò*ô‘Cóx¨HÔ¬a/à@æCš|œ#  àÊåÉ]%ÏÁqä‰9#ßß§ãQïÿ[×ÜÿäÓ¶ËÊ–ZB¨fûnz5fÃ+Õwöfåk ;€Ô+OÍ² pIÉgş£J>Kyİ·;g#¡=Ôev<ØÓïË+À¯N¸d=˜w€LuD«àz@˜¤ÏMWU·‹³¨ÕS£§b ˜I'„Ob‘“øĞğ;{şü^{ªcÁäØ•mËª#óÿNî?¶ğÅS…ZvhÑ[=Ç?¨LÄî*t¡iÏiµLì¢ëzæn<@œOçäæŸì{T-vëÉ5ô¦›~‚aÉt>ø]ºÕ² ²¹jN¼%¹„^aé¬\–:X!Ç ï™J0^å@+Ér3¢øáb(Z9H¿ÚB¢”¤ÅqœN&êí¹ØœDsÍÊğÒXGâqëfi‹¼ŞµÎÛcİ#í±?åØïN YJ‡ìGûã?M</³s‡JJ³:¢9š_ĞÒ`(©´ßÉLŸ¦Që ¸¤êÀÁ $T©:”L «²„XLeÉ†ª…PH¥	SŒf#¸J“ˆ¬-¾zu".KV6¬xÇĞ˜C‰xÖ86¨öëvÏBïU©jDoª
£Åh5ÚCDgõŠjò“ä§áÛJ£ôàä?.È2îH“[“È÷ÒşéğLHsùA¶œe;	–íf•Ô‚oÚšU& ö›„öÀ‚_™l8fRà¨cÂÈŞ$Ãy"€±Bä„ (£ë[V4„p]mI-Ô´¹úú:@%0$0!çvyTÆc‚”ğ¥ÖyIúÁ[OmmÉâÎ¦ÂãnÚğ“/~yêşvÈŞwúìÉüLt}ù¾=¾9ñfáË—Ğ‡mG–=Ò=§yCÌóÃlÃ©uÛßX»é§åŸ}zÕ¢ºº-©¦İ»Şí~âAj-è!`EuP—X‚„Sw–qw¿i»ºÄ…®¡ñ 2©ˆ:«I|‰¾(Û®e’/“B¡h Èä/¾ô°ƒt‚ººiÜ&dPl÷Ój#JdFÄQpE¡’9T°R_ß×_’»=9y‡Âİº¨ëº¨Ù—3ËùQ	TĞ€9¦‰oaÚøİöWØ»v‹ÂÊ ¾|\.ëKü@_b¹aLX0hÚ##¬¢°ºXÅ«Õê>•V%-,"±,gE“Å2Še¤ˆèPdJ–¨H‡â:7‘—ßÒaÖmwF—™ˆv@¦ÂÉRªS\˜1»$H9—ªPfõ•µ…oŞ¿ZøzÇ•¹}O}p‘?÷iaüÔQ$İ£ŸÿÃÀ® É}®rdC›/òB#Í4	ƒ“wú(¸;ºãƒ&ƒ@:“7B¶>Ò› `R085&ÍgÄ™Ùˆ6r­ŸqËĞ4Ç[8Zm	!,Z]"8[šhB6*Y¥Ã¹0FœÍÊ! ²bŸ.ˆ¢@c€–<ˆ½º`ÓÅ}"ØH4 KV«-LÑ-ÂÏbŒÉŠ€å*÷İjÌVÕÌ°÷¢$_‰¬†.“ıª¨ÒÇ(Âât›`	¼Õ˜é2‘3ß;5›å¡§°ÄW™Q¯<<Üë€aşYx¨ x¨¼M°1C“c éÇĞLâ°Hí"³çô.Tú9i'+ÔtDAuEó7M¼ı/YÜüÈ÷QğÆÄ%¼•n/´<ùd÷sèõñş‰È)¥¡îÎš§d;ç”	Äì’’›‡æòóZä­.q®l£d	YC6gC¦fOÌš=1L”V> gÏ0c„AdxQÔ*#¹”ˆîhÃˆqÁº˜²sˆä„ûafÈIWUø
²pØ*†l/^Fp_¤?@YjyÇ|›m6è@¿Œ(–{”òI¤vÃícP¬À~ĞÓÇºf9n:Æ)R¸äš¥äMCBL,p¸$™dÚ1<ŒvB.Q—‘5s‰£‘<òFò€¿ÏÀEÍ|BoêHõ#KÄÆÿ^<oü*ãYA¿z>³¶­¯oÜ²¡NÛä]&È|‡JQ¸ZŸ"HBÆ'ù3i)“ÉKõî†@c¦5cHFf³´)³ºöt ı²úkÿiÉ"BˆÔi’p˜©—^ñ½–ºè»œö½›ú‹ûÓ?GE!Ò#RÆN§ÙÄÌV6ƒ°E‰ª<UŞì”L.Ïä§´2ó¦,åWd×ó›²»m½¶Û}é~Vù/×ÕÛÄuÇïİÙw±Ï÷Ë>û|Î9'vœ`—ü°	
ä€&P ü”·Ê¯ĞN¶Š0‚6‰şQÖ…Ú­Œ-P(ÄD¶!şèŠ©€Ôˆ´&İAd%ÉŞ÷9lJl¿;?ùİ{ŸïçÇwrRD6¹4œÔ*BªÿÕ’M%t‰Q*ÖŠÅvqD´·‹â€Èˆ.(pÌ	j^„…½²Ì6‹.Ğ‘•$ü.Œv>qÎX5‚I"¯uQg…Áğ%+äKH	…AíFÃÄ½¬Ú…mÀ|İ‹7OÉ)àÁ-Pr<"…Çt;|~Ù£U$å•uÙ«!ƒKâqó”Ã=KÈ+L–UwVÓG«QµÏ6~Q‹øJÃ—Ù.–6ÙZ–fE@	•Y?I.x–´‡¬HR¨‹³åUÏzÂ¶Ø˜ŒË	ü¶ÿ©„ÖÅúú@9{cµıC½
äÈÑù™lÀ¨&á(L|_ŒÊDÀR‰áN&•É(X.Föy½ªO+,bXNÄ&È/ÄÔ¼v¡¥ãÒ¬7gWnèY‹uûvîòoìŞ¿ïD“ìĞ
.ÚÊ+›–W¼±~İ/‹‚»›ë³gŞ®yª(ÂçÆç¦.Ëø3o7X+æLÜşà»=S«ĞWÅ†\<·tvúåùS¿‡+z/®h+‚LQ›uÙ]RØ^i¯³ÛkÍS&mšFÂ˜al6™ìO¯&Ğèk¤rRÂ‹RÊ÷J %çua´Ñ·1Ği~éêÑzô¿zîi÷ô¯ƒwÌSÏ·—J¥j™½V²ìR“}½'øÈöXvÉ^Ñ†u%×`9äô"ïwóHæ->Í·ñ6Ó´xR£¼ŸŒÁøFû l3I"(<¸CŠîX¥€'¿)	Še#1 ÁDhºá¤vBÍDµh>b(Z<xb¡¼)DŒ¹¡T)<ãßg¡ÂÈT,ü°.Ra	¤çÍšü?vUÑZ3WÂwpH{vs´}­U ^²bŸi¥2¡Bì½8‘åÑ^™*,ˆ28áB€î €EÏıêlëé•køÛß_Ú@'›ºíä[·´_ztpşÁÏŞ¾ùzçróÛ×şÜ}õÖÕ¦‘»L?Ö« zé4M„=)î”Ä#‹j¢6Ses<ç7l<½\ì#»ç\°{N†İs¤Â¯]¿šMœWRğ*/Ëµf9\È4fzfj‹<‹´´'­¡0ï
ÇåãW ;[èõL‹}«k³Ğ&|èúÄqÎù‰Ëåsíu}M3bÁ«Ò&i§ÄHKŒµ£Œ‚‡JãÇ:D¥îP(%I<õìüèa1‡èSA.Ş_˜™ØµBÈ"èÌ&˜&/Şp‡L®–£9&qN˜ÄyåÊs“WF“!F%KşTkÃ¢ÂlÌ(4ÒYµ¬¿õa¬¿•ì“]©.•S½øŸäkŒÛ2¤·)%é†0ı4KrLÍéàÀïz†ÿÕúÍşßŞ2;ô/í;qüG-?A{´O»P9O"zWÇû¹^ÿÓ7ÿøC
3²cv3RÁŒl¶;i›’Âó‚½R­4–Ò‹ÕEÆZú5ûjÇ*5mtš×í7<_é}>u@û§ŞG˜ç3ÍX èÚ îré°0Ñ7…®è:¡^}ÁXê\"¬úØ¿û£‡¢Œ¼ŒÈËf$Ï)¦$ÃûˆŠ(RD–»$+–’VÚLM¨‰,A70G!¦TUX¨ …V!‘N\áÄñõ}ÂRê@GÙâ_æº¸ÛÜgˆæs—GJè4——-E±%¸§ç%›Æ1-•™Û?4t52d²^páõŒg™¦Y%h1ã,`˜sH}Æ3¦jõ•7¶¶\ß~§ôÌPşÉ­Û>øõ÷·¿¿÷¾;Ö˜/˜N‹ëi÷çŸıájÏçW ³¬¢y˜g^ŒÙ"K3)Ã‹3iÊr4ó«™öMÕ|\l¬…0
ğui¬låî)z¹1İ=70İXà^®/4V¸ß¬0¶³Û½ƒô _¦|H4­É½ã3¤CòQ™–e[®áä¨‹ô	¨Ø15ëÄlÀç.cvö`öh–€]—4`Kàÿp¤ÌwD'$O	H˜øêL¤(	ŸÖt°Y™¾„æ¬ğ„äRùã2RY‚#Á#5^S±¹C½ódÜ—f6!¸{õr¥j†25$e\(E,eZÇ(&S‰
JQ¹éOP¨ˆ˜(óÊÅøıß õÖ$¢'wïYu`¨‡^àªZ²ÿ¡%Ú±³ÈÄbïBÅÃşœßqq:¼wæº±Šx0„mö/(	Vê@’^ª—é–¾Y?âú¹ğ‘Š…Sz§nÓá<Šf2˜#0.Ép"/S=6†¥œí*RG<–M‹Ø(†ş‚nµóLyU>­˜a&QH·€&º%`šŒ6Å¤Ñ( âPñÑvãÛlgG©pT6£‘ÁßˆááÁãOI;æ×/¡‹TˆDNj¬'£éNphî—ûûSÙÖçåşjŸíÌ–*+¬ƒcspB’î\Ja¥\C±	»v¡æIkB)¬LT&'OÂ4Á²ªæMx•ÛÛ=İÛ—çVU,|¾«‹y÷@fC²~©û=g}zå'k0#f/`ş‘GM@›¬4ÏÛÕ8Qù:•uõ`œ/Rã…Õü$u_¯.á^ä×ñ¼âÄÂxtZá´hcôPühœ›šTR¯çëCu%‹C‹KÖs«B«JÒñ¶xOônè~á@TÑ|¬÷<}úl±ááˆ“ÈùTñ‘6ª“ê¦pl¥ß²*ì†!9ë
—ÓçMDÎˆßß­!Y³´´Ö¦ÙâøÈéæ8‘5ÈšöTÖ4"kš|‡ÑÈÊÌbá:+k„‚9PôÚ	E¨3|Yê’nK#’Í”j¥ùØèc¤ `+À¯Iü’D´M"Ú&é±ø–È[lŞ8y{Ø/ÿŸÂõÖ`òôzá³“Á¦¤i>- £˜5tVç´Ê„¢’ê'vk:øŠ™[Şú/ÛÕÅq†gvg³{wŞ{í­}~œ9¯i¹¦|Ø±ëÖ—‡ ÅD6øJƒL[^‘â¨)4)¦Jƒ\Ô¨Úb"DQª4ÆœPÔœ”G¥„hšªâ%H
¥TV¹¼l÷ŸÏÆĞú±3;w;w3ß|ßÿ};œ ]ßnğù³¯œÜtpÙ¹¾ßÿ}ïÁîïzcÓÆC­%OºÓ;Õõ¿LÏï¡ô'{¶Ş[qëôÆßÈSÎæß:õö{o‹dÙCˆ|ªV„>wœØpğ£±´,bÚk—Í›å~†C±âtLú‚Y¡¤¨TÑ"¦ásy¦¦6=ÊiSkŒ0ğ/à5" à"XÅÆqôv¼D¼F‡<HxD@ÂE1ÅçrCĞE¼~Tì-o±céÚt¿=hKvŸİoÚÌ–".ò5cÁw„õœœK„	ª¡ ŠN&†,õl¥.>š°Cïx~HHK	-gKtÖ‚‚¹( é¡QDŠ	‡A=;XOC;j@sª/Nı:ğ’ 1SÛš¦j<—hÛÑ`2ˆ0ªÑ`OnK~ıoçæÖ­\ğJ#XÂíÊøÅğiÏæ…;»‡œÜ@ÁKàú4òaæ[¼V¬`>ïå}¼ŸçùE>È5Â+x'ßÊ÷†.ñQnTpğX“d®Ê[(Q•ªæ*„íc}¬ŸåÙ%¦æÙ “K°3pÇ˜ç•¥gØø¾1Ü7fˆOe¨llLÙ˜0ábÏ˜ ‘!öµèïŞØ=!cM7±Dˆqä×t¥Â3j¢2ìÊ\.Çnœ>}7Êªï~²>úÚÈ“´×"gš™â*_a5ÊvE‰éŠ¢1&1%L¨ß”äˆS+4U­4XÔŠ‹+ı®aôš´Âl2ç›²)VT'VdZ˜L0(˜˜)ÍrL&>±(SÇL‚Ü6‹Ã‘7*gMd5²²Ac‹Õ¼læg]¤iÈ°ªPıøú‚55=–Şèİ*ªÖ-#Ny@‹ïDĞ¬X;­CJÃD4 øöÜÈ÷&ÕVÔÕæjÛ=›]?{ööæ½Ù»Xûİ¾wæu¾ÂYoÁ¾˜Òs™¸êy+õYu—‹üÿV†T™ûzªÈXbyÆX‡u€Ê×2–xğyƒ!…ÔD¸2­C8;šœæ"¤ARp 2/ÁˆÊ˜ÂÔ:> P1Zò:ãùŠªTiR­Ö\½^}”7ùçûÛX›Úªµñnö‚²—¿§ş‘ıY½ª^×ş£ŞÖ£!ÃPd™Iªªq®Ã×uWS#š¦ÊŒ¹ŠQÃ€Ët
ÇRQ5KvŒe¸Â6Ê$]ÜU&0Xh[JzÁ ™.‘\ÈŠ„6‘ùÀ8™iÈ}Dœ âO2	¡`œ MH±Ï¹rÖw&bPCë3”Ê‚œ#å-ø…ãÜŒÕ÷(_N±nëhT :À®7Êx=¬bvóÏå´‚¿$KÜñÓ ]mpş¿ÑŞš1ø—Êê¹^VÖ€](«‡æO	lWÖãWhçş—¤RğÄq¢æ*ëÄü€-šV½ê5xçÃæ°é=œjƒÃ&Ì„Î3ªGlø´H¤/ğÔĞ€#şÇá¸÷všmCë&z]¨W´†Ò$Õ€¡ôõë#+è[Föÿ@9qï$íY?Ü!UlY,Îå‹p©C¾^9ª @)ÂFÕ=šÆ6=Ãk§NóÚI.¶ÊM‘R¡ìS.*l>\¹BéT¶*£
57$Ùx1
}œÍ>Bó3¥‰jë¾Ú—MP{kÏé3æItFÑ qí"-ìAíâ•Jyò…Uz7,væÅœrâÎã…ªVƒgJÒ?'~ ™˜^?Vè ƒş’™gúÓ.»Ê®òË±OÊÇÊPBŠé‰$wâ	.ËÉòR5*,…FÕdI±eœqi¯ÛçJ.èXÀíÒ ÃÄæ`ZÕÔÄÄ‹
FÇÄBƒæ6”1°…E˜YîŒ§·BŠ¡ÙŒÏq{ã4ÓÅÇ§‹ãtpÿÏLPLÇ*7ÄtqÁ%,ÎqŸ˜îïáÄq1ŸM¤š¤KÏà^‘*ˆàŸŒü+ûş¡â»PïyäÏ3,Å’Uî1ºñÈÃ
ŒE‰5aäæ„âœnAm^C„y†Òƒ$ºR”iO–}‘puÄŒÓ?:V¨ÑğÖbÈ¯\£X¸÷O?¸bıîŠ-ïÿêõ#Éö¯uş,×ÚñÍm¬úÕ–%K[O¼ytx²ôËUK^=0¼[Ø¸qÁÏ:ü×1Ïõœ›vgÂŠ¬†¥CÖ1ëŠü·ğ <V™ÜF80/XtuÆ¹äŒ:,¡G;‹ª¶ßğ|*}–ƒËD·e¢Û2Çİ–‰$0'á;Ä£Û2ÑmÁımPİ–)ÜÊ¡‰†Î¤ğg¶8‚t%Ây9ƒÔéô9ıNŞa,ÕDmäæP.ô˜÷ÿ—ñá
N0\¬ÀÄ|&ô°k‰YCÙ®û˜?GöÀ(üÜ5>jğ¸³Õ 7tC3dÕªª8-2B§lv¢,üXìˆ{^[wşÛûXFnÊÊ'ÖşšUï~³¹sŞôîáµÒöçW?¶ëÔğIp(dæè56Pô“bºòhÔ+	‘dE‚’kE¯_iF±o–ú„ş¬Ú¦W]®ëi«!Ô`Ïpš­¹¡¹v³Ó®´ó§¬l(k?å¬VVókuhµİál Q®*şÅòÓÊÓÆbß*y™²ÌXå3b¥L‚dDªâ˜}âx4‘r0ûhÕ¬Âè`Nì?vĞ3ˆÀ;X@á*7=U£D³´„&kÓ.‚FˆñÙåÉôTèªˆ/ boéìC|Kß âë±õ‡Øˆp¦r ‘i%é:!®ÙûÈY]©ìP6;KHFM7Aj!Çv‰²Å*ùRe)g¢6‰·„­: D1‘‰¡hæ¿{Ú›o¼|qäæñíG~Ô3 …éäëG.xã‡´œúO}pêì»¼_¨gd9«C¤œ.ÍìôYX_µæZ¬)ÑŸ*_ô%Ë¦G§—}½¬3Ñ›Ğbñ9±9ñ6}±¯=Ö_¡¯ô-·VÇVÆó‰"çó%•_\-¿”MØI–²RÑ¬ÁzœÍ±YŸš7ÊF,3íÒR¡òviÀ$âª3ı/ÙÕÛVu…ï½~ö{÷ú9~ÏvüüìÄqlÇví@â$K[ğ+-K¨:ZV­´,YGIúCmQ*ÊR´¥h$&J[Øhi:ÚIÕÖ‚:Qm-&T$¢
*²!ÄS»$;ç:éB‘ì÷Î³ß}?ÎwÎw¾ÏX)†„’&$œ Û.9^RD¦¯ÌºI,¥²CÖZ
“-i°™5ê9*ˆî£‡é×T©¡%ÚE]çœdc*Ù˜J6¦²B¨—¤ØÌˆ<U#ªã…"Wj×t´Eh¡Ó¸ˆ‰oÇşos{úÅ’ÔÄ’kINÒœ!Õpeˆ¡¡Íš®Yèœ»÷g;Ïõ=zqËŠİæ¡›^upı‘É^÷É§–,yzê…“WuçÜ‰«®ƒ£§ß¿ğş_ÿ]¸x²×õ`h*Úêìò²ËGæ±;ØfİSª,ÙwØ{âûâîb°+ÅÅ–—ÆVWÅVÆ‡âç=—<_ê—#Æ–Ô•í¬E¿ıP_ÁzÙÇú?#Ÿ‡¿´/ÅşËüTñ…¢U^µÂªR 8«¢™ÔÆ9?5ü¥È¯Ä/¤3.Ñó	ıÈ¸²ıL»?,ÿ“ƒSïc®‘*dÊÓK’=Íô;êêEuJUj@ävA3¦e'Gq¡š”½._ÙÏvu|°¶8kJöôß5>Q˜…Ó|@iş÷!ıÔ”d«4ß,T\õùçï=9ùïuìLÿş‰Ú76­?ôæ†GLö2m^'m ê¾ÉÇíº²Ğõ»ÑÑ¿¼wşÃ÷pÂ=Ğ¼¨˜ä¬3¯1H…¦”¢²PYª¬Q75®q_Ğä>âÒ¨W¶<·G£Z2¤A–4ËÂÏ1®³´ŞsÖ ñH"ú¢5L<³D~g ãôwí)L–1£çÛ1H¦¦>ÒÈãìpÅ¶Ó˜¨Ú3£	,ó¢Â xbÿ-½¥û¸åÖ[ç=Š+™WúÏ}5ÛQZ90q³PšúÂu²p£Ër¶(ÉPr.ÿ_”^–\ÜÊwñéCÁ×ëÿìòq+±n¼£şCËc÷2f4QéÖºy·èövëİ¾>­÷‰>oŸŞçÉŒdıÙL:›Óš^!–{Ì<˜L¦‡ÒÏ‰—ô½¹çë}ãAñ[ı@ö`îhæL&œ›Q¢É™ 5¤g‚\ÙNŸƒAj&HÏÕà+œ@¼}…–­Ó…Md*oCuô8{ÍIÚõ˜ü»dwÙ?±ß´?°=~»Æ^g_´•{·Íì“€M%ÔÅk„ª!<İ e=F”QÔù¡p‘JØ+Ì"¥İÕk«YuU¥ªàcà".I€1p‚°RÕà­‰ÒhÚv‚‘b.oÄ¶³#å-v‹Æ±¸ÒNà*[G;,§ôqvÿ[j:KUµŸËÓ<ŞWä±=ñ2ù™>…àòpQ>*oU›ÍW6jb¥¦¡&ÖdPJÓ$RÖ»²äå,µc€€cãC$Ò~IÀ~ùxşÄ4C\q’7*$1è’’gl­}NR ahòi*‡¯»N)‘ğ§şÂ]³4ñ8ha<©4Şho,; m¹ƒb‡Ô¼UVONö†xÊªÏ˜FÀ.OÒ—ˆScÔ}lâ!8¬­HÅH2åÓµ9"FsY.<%FjŒjÔYTYyƒ´/lß¾Ì¢#Ú3Ğßl—©&›É6°–bk[y@@I-²@›YqVö™Ò[ş'·lİÔR÷Ü»/v-øAşÙ¥ÛN®0ëë{·ö…Ã±ï<¿¬÷İm|Lo®úùÀêE7§"uM·oïìØœ«),ŞòPäîî»ÛRUÕA‘n^°µ{ÅË?~û4=õË»_$ùèPƒ©L‘#² ²)¡ºOP	¼à0º]^¿‘$IêÔétJÕnã·­TQ‡Ô=ªB@9íS«§ÔsªGÅa\¥–‡µ¾AÎRË~l:¬^VĞeM†³"Ï´4+«Jõ¬Dhë‘5×™T¿ã 1døñ„Èğfs³qmk¡Pgaş2-f
ø½˜,e†0õÌˆŞ9ÿ§këwì8zìX°‹¿ò²qËêılÕÓT];ùÌÓÏİUÅ=\ö™’»w QÈ¯´Š,ıø´ÍP±¤i-Öi0ì27!M¤9\±ĞND¥W±¤K±˜ KÚNÌ€%éÛºæO,éO,¤wéO,i8-ô'>ÌÇ”EOYÔêŒ"F•hM¢_GÙ#Ñ}ÑÃÑ©¨ÕëøµÁÁ)á	~Æ>38øµÁÁå¹À»r¼¾œ\zÎğŞ¼ÓFïy-ÛĞ\ãß7!0A0ï¥ùåÉ!›(ª>¿yTÍ£¹50"Š#>ÍŒ´!ùüv˜¿°¶¶EB“pšM(xlˆVŒ]¥­8ĞexG¼æÃK–ìš7òÒÈâ_tµ¬g{'>sSÇ’¥»w²ö«Ÿ : ‘ë@GĞËG[xÏ}åÖˆĞ<Ô#ˆ›knÊÜi,?wcáÓQãÓQ(œvø¨±·[Ü”$Ívüî3Û9ØÌ¢†Lwötzg|äğxm‘ä`#u'OÖI6pô‰óX®¡H°ñësHgD;i‹I‡XF—±åÚ}|]Ãzµ^¾‰l¤Ùfmß(†é0û¥ëIu§öÿy?+Ş ûÅIò¶zDœ%gÄ'ä‚øŠ|.®’oE=¼ˆ°È‘Œh]ÄÜíÂE7”JñˆG¾;‡÷ÁW'(‘?Â(ˆäPÌş&å,fEşÊÜnİ°5~Z€ÜÀw´0Z ¥’„2æ´	UÓê¸q.ˆ‹1&!JáAHMcŒzTÁ]„ºuª'5Çqøgü8sÜCnæ†Èá	æĞ¤÷òß°šÆ£öDÏDO42>ÖƒRÕFi>Òe	ZwØİPŞvz¸!‚»å @
pD³M/éY^K›ƒa«µ-ØLéï'×şi¬®&RøêÄäÃJfbÇCëîÙÀvBq@uxq¿ÕPªËÕq‚P™JöñÈAå™öçGtŸ±_€D…ÈLèå?NTò­™<¦‹Ôõø!>İƒ¥›ÿ£ºÚc£8îğÌìİîììcöuöïÎãƒCµÛ˜%NÙB0‹ššbÃµ GD(ÜD€Dy <jşH QEmµ’yøq@T(Eˆ&u *…––†ªĞVnRÕ¡¢®ÏıÍú‰wwvf÷v=û›ï÷}ß“‹ØLìq¢³Au¬+Öåì€@Ÿ°Pœ¢,ˆdHBzxjd
#ìeö¶d§ÃõËŞ)02Ş±í¨*ê­Tyµ ëOƒş	“ê#²®ºrRM8ÑŠÈšª™Ô±+yJŠ&µr¨`«”©4kÖ£e&}È|Dš'ÊBÚ¢ÍáóìÎ2ş¸³Fy’>ål–·(ô„|’÷9ŸÉÃjF³3(cT›^íÔx3P£ó}™î‘ŞÖâCäö½õÉ'Í‘+òÔÛ‘ÛücgHş¯šÒd1c=l­°5Ã–‡­S„m’™<â ›*´JáU¦(ãLE2°^eäG¯‚¥@ßÔ°V3°çÊL³'³¬½$ò8[n¯µ»ìWmf³`Q,ÇØÂÜu.´µ5Ù!ØÅØº)¶1õ‡=xR4
„¥DUÆ(Ô(Ì²mà÷–ãQä€g™¬bÜLÿÒVhZ±'U¼hT1a«Ó3“B¹“eÔƒÇQô^¦ ‚'B¹­›F8=xœRE©ãpnšˆyw,¯01v’‘Ç–nex=ÛÎË“¯j«×ÛÛmb‹‘fEñŠè3\$×Á^|Ç½³*´D‰…C¹\|ì"Érñîe–UÜàÓq1ëì°İ¹ğó	÷Å r§iSL«I¢/–#/í1Òzš¼;z<íd^êAµ<í FñŒâ_[Ë‘úÅqtôÒQ¥‡*·©{¬=¼zã¨’»êÀÕÂ«ğ¢>°‚ğn`«KÇ”ZñÆch99öŸî½üŞs¥ásöèã,I#qhÏY¾írŸã£ip@‚u}ø¢¶¢˜mT"¼"”‚!¡„|â–
R™(UK¸¥pêäáY‘ºÃ'ö5<Ü×]è9uxÊU ˜wnÚï‘oìy€¬¾Fºzÿw˜†ƒı˜ÆÂ*êPŒcMU&²ˆä¡#ç5Ù”vi¨?ÜÁ¼2áËB%üvşVä-º×ü>?=#ŸQŞç*Jü2ÉUcF™Õ€gjÏã74Zã|#Ò¦´iKÍ·ñ¶Gë'yı‚öùkëšô;õ7Æ­[ÌO.MGÍãY°›)z\FÄ@ŒÈA¼€ !qJ«dYR¨ªbYV£	,=70ç†¥© †&é“9áÌ:Î«ÄªBª‡*ã¼*]òt]bª*ID†J@×ku°3ßØ¦W2¾RV·”¡?É;dIÎ“9™–¶‘ÊVˆå|»+,TsCcbZaİ²†?Ê}ÏB+rE´æ¾kCbúœï¤!JÇZ8	è6Ñ¦"(zÌx¹¯‰xkå¾^YêKpˆñ±
ßÏb>®¬ğÕ å+N[nÊ‚P@pêJ…ô4B`‚9~±°÷/¾”šVuüjá{øµë×fşF2¸pw^íìºá‚>ò^ĞVÈÁwU“ş	)Ãÿ)b¤œy\Ò¤T‚;²&»ÃÓZ §‹XIÔdË®—ÅÊ–8	à†²‘<ÎS˜‹X—ò3Ş¼›IÀ‚¤3µõ–h]uJŒ¸S­UëÕÆt}ºÑ`îµµŒ“q-isÚÜ¶Øjgµ»:¶Y~ÖØloñ¶Ä^2^µ_w^w_ñö°CÚ»Ö)û¤÷wö±÷™1bİõFSŒ#ªÄÕRÉ„¿È%¸7ıp~°¹"9×-àJp	Ïu«æÁ€ë@†Uó4¹£ëš,^€RVŠÔ¤N§H*OfõrˆEàåÉ’@›åù–sÚ!NÏîã¸ÍM2q+ŒVÖkõV]Z¤êD‡_¯á2«'™îb„àl€r@İÁ¸5t3aİÌm,‹[ƒaÅEá0(
H‚s<k!µ3Ä°	l¶9…ôÑÛH½?Ï5ŞèŸû}VÙè›e½1ß®ŒùEô Ó€‡ø¸ÕÂã6Ší¾…©¼İ{hZÓ£¥öä¨VXwöz¶rBö¯=…µ_TÛõD}á©ÃVfRr/dFö~çù®gÉšáİ³Û—“î¹¸2qw`8yò+Jü SZúA B\+ŒÎ 3…dÔËÇ>››I3¯¶ZËñ²„¶«‹¬µ¸ƒtĞ§Õ­¸“nU_Ã/ÑWÔ»xˆ$t2B³ªOL¯bEdK¿«'@¯`B.“™*#”±*L@ş]”ÉÊh>‘­4!,¨ªyÖd$yˆaT>E–!„¸Y"n*•ÆMŒÌÀ\aî0?5£¦xn’¸ev"¶ãn„[Ñz4Š$—Q‚[‚6²_voZhZ#¢s3k‰Å2%Ûdİ‚ñ–-4¿h5-ó\Ö0T‚ĞÁjöNÁ“)ÁãÑ£"–0:Û/¢(BşohÃ¹pí)ĞA(n÷'}•–$æìX©–]¬Ä'e%÷‰¥®Ë+*bX™^WËmZZh•ùÅúÍOã¼)QùÍçF¾¹U}œÚ!"?şi¨=tq²«©X}!–'»IV~W/Ûó‚=pİ ŸÅ°9¤ÒÁ‘Ü D Ú/×ºõÓë,‰y¢újô"ê'O¬”wØØ¹ÿÀ¦Öu4Ïíè˜ÛÜùù¦ıû7m:°¿³¹££˜Åbéß¤½8‹ßË÷%ºäå—|¨|è’‹ÊE—œVN»¤[évÉ>eŸKv+»]²MÙæ’a:ì‘µt­GÚi»Gtª{Äs©u®†$~×”îÓ Xo2P“óxQPã®W¶+»éÿÜW}pUÅ?wïŞ{’Àƒ—g†ğ	`Ÿ$*ò‘”Ä$4@£‚%R	k*ÁHBü &AÓ$…&Ì[ÍØÚj;~Nƒ¶ĞfŠ©–:`+1ÜşÎŞ{Z(ÓşÓ7ó›ßî¹{vÏ=çì>KMOˆô‹‹àÙ”•8xj¿uš5=Etı	¡‰¤A¥{ÔKh¿G~^#N‹2—Ez"Ÿ"*8Àšóò£`G°ñ5¥¥¥Z©ûÓ–iá‘éS‘¥‰¦iˆik	‡]2~ÚT]{ÚkÉ_½·»"² evâ’Âó-xj~RäÊS‡³r•§NN%- %ˆ£ÖÑx×z7$Ú¬¶h±ZB¢Ñj‰íÖöxÄz$$V[«Câ®À]	"/çzª\_šCì›¸x¸¬œ¥š-¤jp  ˆ¦õë‰ƒ¿’ãgÆÅÅ³»â×	¡G.K¦áš¦­TŞBhDNg±«UÂ>êùÔãõSi)ü¦-¥§…,ÓJÎÈ˜–Ó.<8lÜ’ñéú‡^CşúÚÂ”9WçoqÃ5ñDâV°¸äL`H€ø×x,y,ó/åê'Ïîï¹'H8tû`<k ÖÌs¹tsÎî?ûPĞ™'æŸnº"1#Šñ}S®¥00ÏJß5
h±¶™ŠD­gèC)Kî£5Û„şàVÖÅø|àO@( »²ùÀ@÷1öÖÅ«yÅk©(0Œî7
ì¬Wc´Óİ@Úòí5gĞ*ôwAï5I4Ç@§Æl¢ZÈŸÅ÷åÕ£ß€öRè¥ºí>V%1&ä)˜g«»ßdı eÈµöGØË70g6P5€g9ßlÖÚ©Rk·ñLåX3ËY.ÏÅ<›ğ=z£Ğ/G{0ì0ÁıÀ±PíèUğ$ì¿ĞÙ7ĞN÷ò£{‚ı®M½áØ˜¬ù3`¤˜aŸ ÷‰±ÍræéiT.† Å[´J~4øëãéÄûéÀrå¢¯ÁÎ<ã íà>0_a­İ#Ÿ¥zı4MÇ·‡Ììcü=ø‚&‰¿Ğs4m@|ÍÂü:Ìùg+è6¬?œ&O¨ª ¶a­¿z~bß ¿çºk}Åù ı<`Î¥¸íÁú“Øç|îZÁ¹{c–2 OTÀŞ9&Y‡õ1×h7Ï35bLüz,0ÛàAÅ™|{ó$&0˜œ àz ƒµ	ëê*^3›*>F;|ÛTÌ:{¨SçéäLƒ;¯3ÂÜG%.Fğœœ/³°åyonÎ)U|—¨¸ÿŒ÷É1eäì¢9lƒÊAÄ–Çœw°™ó¡FäS%xâ¸œc–íó˜ıÂ±¦|‚œp9³×T•#`h¤ëå{¾ˆò½´sŞnŞ‰šROsåwh®şİ)OÑ,=…&©a?Û"ºhQ Òp–·¢ÿŒkV§¶ÒhÃ>›áÏNz>-•âZÙ©F³}Ò ­Ãh«v/öCks¾13b¿ı§ò+8d4£f6ÛŸ¶ılçœ°º´T`¸Ç¿ ”cã´Ú@‰ö²•OA“è4p¿Ì¢ë,š&Ûp>aÔyääùÆGôš^E[d§ı;­ŒÊD'UXaºCÔ ¦a-qˆÊ<?xuL]sşXòØ‹W?sÍwcjØDş½íâ¸‹/€3ˆ£Ädß\ŸÕı€T8ñjŸÆgíoõâÓ§%¾øŒóÇ¥ŸÕİ‚úîå)ìØâíŸë#×8®‘\ç¸Îxãı£ÿ˜hBs~‹ŠÜ¼¾ÖE6lüØÍ}Ôaœw¡m›³í=æ{¯>ĞŞkNAûCÀ°÷`ßFïÔÅö9÷>MñîRGN}½{ÔH£Un=Û¥êÍçô´ºG”}}Ìı´ÁèÆ¹£*{ëİ„?aw‰¼>ßAÛ°$}3òr`)ûDÑ ¾øNÔ«ág¾‹ª¨\?Œ÷ë¦Ñ u_dR!lïP2Ü©Ì,3
©Ñì¢)2µ¶VğYñ>Ø>ûÀ:Š„Q':i²ü1Æ„é*Œ«W>È¢=*.X·*øÂZNb6cx¾¥“E]ìR¾Púx‹p³/0§¦Eê=ÑE?4ò©9Ô`•Qşiòb/æØ½|¶zƒÕ}]MK_•¨M•¨9¤â¿ÈîÖ›±ŸQ×½>j¦AF|X¢ö>K:5v3çŞD×qŒ˜Õ¨Ãü¨¦Çä8ºÅ,¡*ÈªÔI¬»²G‘¿©Èİ-ĞæÖmÂÚ[ gİL~ËğóÅÊ¢Y¦Ş¤làw
Ö×ORƒM•ˆãÕğÃ&š€æGã5Àdªÿ°‹m”,è°6BÒ÷Y.Òè}¬Ğ—Èæ;ô¹‘¾%hŠ>¹;€&È÷«_ÒN½?Ë7i§|™¶q_†hŒŞ‚ıÀÛ’åïĞ–‹÷Ñ¯¥"~%}[ÓZıyÄŞoé*y7ÎzÆãˆ“QĞÿóºĞQ‘^€Üª@ûK{Sk°r.MPz1P¶zğÙ,r°«lœ)ìåööÂÖ¨±Oí“ç…‘;)?F;|n¡¨¢f ^ünÖçÓ÷´½v+ü:Û‡¹±}™®­&Êtú)°íñàŸû>ŞnétØ„¹‚_äÿqe0CVÔ¿ñ¾Å‚×¹˜<Æ»õ‚şK¸k í´İÊğ‡Ÿ3°^†¼Áne ³æJ° =òk çëCO/Ñ(ì¿_Ê¦üRcü˜»Gï<ÀW_Äğpf÷n¸bÛ®8ßÀ2åßÏ(ìÄõÓÙGÀÚ!
êëƒ úĞyşôÎ	ò(¹ïü+Ä>÷Ëı}ÿ¹^ª/^¤âXxq‡í4“!31ğ÷4“a¾o¯÷îË=—@Õw°MˆÁäŞ}óVJfˆQ°u0ë ç€hÿÔ€Ç*ıxšÃàÜeˆø¿D¿§Ó-Œ¿f°_õÎwï|¼sñŸìË’oÓ<ğuàà<p¶Ç±9ëÏ[¿Ì«%ãËÔ5çÿ;oíÀÿëµ4B¬AÀ<‚wH&Ş‘xŸ,¡r¢Ô’¯&?Bºüd¸½Ï¥ ñh€ìğsDİgĞ^y§[È!Tï¾+“ û‰«pçËsô»Mtö4°ßÑïnV¢ı7 ÷y÷ÀÁµÿ	ôÿÂùŞSŒşÀ«èw¡°í'Áağx „~ƒß#½ş‡ş×ùâÿ?.—ñfY;‡[Áëıÿ!.›½ó¼ûÿkxç)6Üÿ½Ùñş3}Œw_Ë?Y/÷àªª+¯{¹ †GÒIR;RL›13¶RiÁH"4&<JÅÇ%…*XÑ±µŠ[K‘"*Å -|ÎĞÖ÷íT:ê¨è upT5æ~kŸ}nnNH2(wæ›u÷>ûıXë·‹ß>=½qË~æ‹ñ£v4åQª£UËª~6úÑZó~3:–~EÊËx²ª_U;«~Åjû-oÆÓÈ¸Î5ã²q£Ø·f>“µĞ¾mí…”ùÂ9!Ú…ï)å|àmtŸBúhhŠ‰^&v•ëvâw`_"={ ‰i‰oíâc{‰iG:}¸1òkÄÔZËœİå'œb9CIÇâÃ¥·Øıµcy71º8NÓtç²?‘Z%íPÒº´‹è%İ›Î=ÜtZwv:¥K’tš.ßÓg/Ñ3URU uï}[xuhÿdé{\¸o6Íı´ü@µ¡ëñèÿh0£¢ÛÉ»ºä+©-Ù"µ¤âfş#lN¿aÿœ¹EÄ9µ“¾tï%Sv†%×ÛyNŸ[ÕçF²fÆŞªã—áT‡É^ë’¾_wˆºúÎõfE¼]Ò€½Ú“åØBº”t)¾¸,€ß+áÿØ>Ø>ø÷iĞŒ/Ÿê?µ‹M™‰|«÷.“	øù…ŞnÚ|7zŸ¾ÀËKix”´;¯'†áûJê.%]­“ûhçQê/Ó|BœN<Ìjì ß&YRö,ï¹Ãí+ãhg¨÷®”Y;Òo“ó4^#¨CÌ#ï{Øjcß•“¼Ù2ÆĞŞh5î&ÎÈêœ2yÜ"{›eímíÓ*k³ÏÈÚ’œÔ—\#+ƒVYé®‘ëÉ[ş^Ö5Ò¢m$qUcbò1•	›˜¿€t•µuÉœÓšÀŒo¶L&.¯/î7©WRO,ı„ùÓ·µ7mCŒ¿rÌÃÃL÷§kä´F/ÆVæÙy!æ7ÉlÆ9F×Ô¬íl™æ^Í»Ocºö¿û9Ç»ì§Ç’ôÅº´w§…mÂÿé0A÷Ù 2HÏ•9K1ş^³_gèùı¸Ã¥ºÿÑv]Ã”w¤ÒÛœ!§Âùª„›g-wt!w…3è­@3µÊe£¦ŞE¦Ş¸ Æ0®fúiŞë@nè zÏk”›¬—îŸSmÇ.r^ ¯QRjÖïRÆ´œ}>=$RÅ:ê¼+¼jòõ|ì?ü–ôP3wkÍZ¥^)ï:#šÊ!Â·÷TÕW¬›->"õáXÎk_©÷·ÉP÷bôË?ğuÇ°wÙ×R¹Ş}GõN‘Ü’S2õÑ®Ì>,J]q>$ÿuìm¤[d–óªœÃz]ÁÍÌ»Íğ<Z¸/¿¶ÌUœÖÌwøş&Ì´ÿÇÿÉ%’6ZeC”‹Ş6çú®“œó(}¬c,ôãöçş¥ Îù–jÛÏxo:w¬3§§¡®ÚÓ¯ö»il~UòÕÖ¥!¿îãè®\wãè.Xò‡qt×îñiÈ?¾‡ñMJCş¤ÃGwë<4ùC{Ç”4äOIÿÄ;6ÿ4oÓÍØ×l¼ß‹ŒåôåŸä?ï‹¨Ù¦_³åş«àNøê,ø¼heZ°ÿƒ0­ƒüsØcÄü’~¢ğ}hŠûÒºùÇâ¾¶Ïü¶¸~û;Ş¢tş[ğ~ÜŸé[}ïìñ°Ú–_jûİ=¿¢£¼~×9šz[;ˆ\øß‡`:È?=ı+¼ÏÀ³öÿ±v=tÎh[~A¾ôVËrõ‡«ÃV³¯”ÉÆç¾Ü)VAœÙhü]„ï-µA?tÈİR§ºA}¸?×”_æçˆM‚>A+½ğ¶øŞSRéï‘9ŞBç>Œ.¿¥ïòsm[ı¶j÷&9¦jÃoj,œ„Ïméó Ñ/ı)Sæ}Àxï”¼Ù–ú3¤¯úópé[™Ë=r…¥,.Y ;ƒëni&^	æÈ(ÿ:™¼mƒ’õBXÛ7#d!¿•¸û¾ŒË¶ ë^‘©¬Ù“¾ëJùºg(½<+—gï¿ªÉfÌŒæy5è14“‰×¿`Mrf<S4~zˆç^+âï'vŸ!Õaíu¢,ÍVÈºà óè«Fu]aíGº­2,ü¥œä·È0¿‘=ªA7¿Ç:Ÿ-}‹oß^ ¡?+jC»İãÍ3zq ·I*Œv vlÒF«¬ò¯•åœ‰i]“è¨‚¦ğÍ7&}æƒÕøY˜¿µEzÃ¬;ù½r©ñË9;è.Ö),—”]–èÙp§L]ìin”ÿLÖe4„OÈÀp¼T¨>C£ëhŒö¿@‹6È0Îşéö¾ÿô.·wü2ò_…Íñ}Ôû¥ùæn’×¾Úæÿ
®‚ùñwı]ÿoß·o¾]—oçFËY6Gõ¨å­ó9®X§=këÎ¶ ëÍù©ïÕ¦ôgwVï0gdPA'z²«]—¤ÑyoqGo§îq$::m)»rul6T{¿µ÷êYS­—¶]İíN¿éØø%6ÖÕ7¤ì9ÖKôuo¶ ¿;Ù(²é£z½7Û$Y£;­oÁ¢AkóK‹lĞåıTlÍˆku¬ê÷‰ª¯½uhÑĞs§×q:Ó¤¸·Éù‡" ’(áE±:¿[‚?PJ†¤‰>Uóïb¢»,û,ë7#¢x·¥‰>5èÛíwÓ/”	Ÿ‹1ú¿X	¹Á%4ö*C	÷[–%D‘’¬{²Éº0·÷™÷¼Â˜“şm»ßt¿é¾©y÷4öb¸“{ ±rÈq³?†OcÔ?Qv%`]ƒMğ¼e…Â]©âŞpçr ¸N—spoSÅ¦õ.*Ê.¬ˆïo¤cdæ¡Ö'œŸ¿ğ„xü69Ïj¯=Ì£ŸúwÅú¾¡Ù©rñM2D}qWïùHïŸÒÜYóEœ›J½ÄIŸòüË¤Şy!º×_ŒOø8zÖ¿- ôµÄòœe]¬ı¢¿adÖy”lÇ>PoÛc-C—ÂıVo«]“ÿ ÎïWâ{İÏ™G›TªnğÆJ¥Ñ/ó¥*İ}|G/0‡¥îyršÆ÷h+ô‡êsDyobcú±.SİE÷»F–x¬¨&2ûô41@Ë?mêWY¿X­}¹âÇÿ+Cœ}”ãõ–jşƒ²Xu‘Ë‹Â?‹s1²Ó¢»«°,ŸÃBÆÛ$ó%2Üm–ZçôN9ù—ÀÅü¯À–ÂLX—ËI&¿sò%åÁõH¿ˆõ%µÎ–å1ú=S'9çaÉ¡‰s´—ÛmêÄ’ËüËô•sëhr/%Eá–Ûÿßo ŞNíeöÅm™oI™lGÿ#©ïÓ,õÁ ¸)ÚáŸíÈì•ÑŞ,Àöƒ“Ùë]öı :êe`µ¢µ¤Ÿw¶ÉÅİ+«£î	`­¿Eæû?–á~;úàÎÁÛ2Ú?(wùc¤:˜JÛ,z–N}Û5{—F_qîœİÑ®ÌFÆRD0CÊ³OÉxöP¸’Xg`3&	gZ2ªŞ6ÅŠŒw‡kïÚÿÙ/Ø(33{>Œ‰}g7¶œo×Y×vê3gÀáé;ó(Ğ:l“„67>Ìã³Î(U¥j%Š)­hš¶1h%BZĞ‘ÃF5•[((Z‘„µMÛÔQ„”ÒF¹şgv¡BP£ªJ¤¹Õï{Ìkçff¿™‘çÜqèa|Ç‹€‹œ³Ö­¨›#¾=ØÍrı1•8ç8q‡z£•ßCbCê,w¿áåXO?kË=¢jæYş’¸×fêùäÌ_FA·î—œ{iæ!ğ°íş ÷˜Yv1³Cp•?$ø_û­4Ã3Ì…=÷zóv¹fn½ÛiÀÓ€r‚UT¥=)ê:s}3ßÛL^wLşîu›p7uƒ7÷ù~º] ×[Åõ>şÓBÁ•ÿ}3?k\^oWÖôş_Fœ‘a_ñ>“9ÿ9ğ-Ä×]e2È;è×Ñ&àÛNáº„ÊØØGAÄ¯ ç1¬=œûöè3ˆM"6"Î¿'öwÿû&Úı—8—jÿE,ÃYÑm_Ü“‹úâœ¸·DÄ¾¬iÔ&b­ˆ©rÏÀYTÜÓo:EláG©¿çÄ vZB"iùˆèc£ÔÒæUnLi¤ñ¼ÿåÛš/sTÆ¤<'fi„öÒ"aÿuâU‰6Ù‰_ü”ƒø9”¹ÌEğ
ã[8ä öœ÷wË½éŸNœ”±qZØâîâŞŸ|âD¼ˆŞì¼ä-÷|@_Ö7;ºuö¸u®/¿ŠZ</bìÄÜ‰=ùyªÌº‡&\¹wÕ‰ñÏú£¼¯,F¾8ƒüçœ/ö<±OÊyÂµáLôWb¼xNS‹˜Û¬ˆ½ãtœºJ·;È}ZŒãŸp.ËÁ¾ûEùÄ8´_ˆuzÑí§¸ŸLÂ:}ôÊİïò]îò]ƒh¶ç)Ú¥uá,TK‹İışĞU÷Û]±ÎœˆKUÿÏ`U-»Š02y ±‘!¢oB_“Ô×ˆÆ¯$Ê9@tK/QŞ"ğQş7ğ·PîÖ¢Sx˜¨ø¢‰Xy“Îâ³ÁŞu[+Qà‡¼3¸ÈÀ	¯m—c÷08T •óˆªÑÏÔ	a?¨5¯eêqLï-7fú9¢zŒ×L´=»œhÎ¢y3ˆ"¨=FÔøs¢ùgˆõ}~=Ñ¼ÿkˆšÊˆîBŸ–á¿/Ç©·ãµò.¢»ÿF´*‡huŠhÍD_y›¨ó÷ŸLb«?İ¬ÅšîÚ¯P(
…B¡P(
…B¡P(
…B¡P(
…B¡P(
…B¡P(
…B¡ø„Ãˆr§Ó;4‡~Hãˆ“ŸB´’È³ÎSBYğ‰òèg‰ßz)…=†à1r~ÓY¹kk”Çîumì.×öÂŞèÚãè>ö0J2ÏxÑ&;ïÚŒ|©ksÊãk][CzÊµ=°·¹¶ö³®şğh7¦Z<3`µÒ:ŠA7Q‚z@Š¤^™2^¶HË5È‰R7ƒV ­õSÔ'½t¥7Av¢dvuEÙ¸,ÓR²½N”y :I– µ£/¢ÕÙ¢S¯^x»A-°:¤ç¼¹©!Ù‚!Û^'ûjĞığ6"7%{+J×ì6Âµµ3ŒÖu1£)Ñ“H=Ø3æ'’½‰dG*è©1¢İİÆŠx×ºTŸ±"ÖKnŠuÖ´-Œ6µ4WG“ñî¦Öò¤2â}F‡‘JvtÆèHn0koø>#Şc¤×ÖOÅ:–TG*†Ê=¡DÒH 'iÜŸØØ“JÆc}5ÿÇùm£…(Û„‘n¦ê«f»	o¥»0®İr?ªäÇÍûÔ®.7NP¦‚vĞ‡üR«öÙAs¢~òVIç×*íêı V¡•Ø³õHZ»}° 0ì‹~N3BR	°Œ µkA¤û!· ì#à$ğ"e®` œ9Z‰°İ­Ğ&¡î$DŸVLc 4Ò!C ´ƒ~0 ¼²œHI€-`¼-s"Z±½½}/¶•jp}wXºûåû¤;x÷½nZîèKœb³œbS§9É5®¸ÃÑSÂ–Ğ9¹áÃÑ"­²ï…dü—äcŒtÚ©Ò>À5¯›Ñ
ËÍğÀˆæ!¦qa"õÌaÙ¹ùáhÏğ1* ÿ¿åäğ·óòÃÑ¥üí#@ãğ¼Î_§-ü¼sÈ0 FÀ	0¼ü<×ğœãçÈÇ_¥h í` Œ€10¿
éç¯ˆı@Ja7 Î_ôó—ñ·^†ôñ³°Îò³èÚoíú™áƒÒ¨¹†>Å5Šos‚¢pš¿d_ªÄŠ21ÓXQÃZÍ£:­Ì2UOkí9q=Íÿ0hTë;£µüíØé ıÀ ËÀĞ¼°ÎÀ:CØv‚} «Ò~g¨DÀ2ÍOÚxMšŸ°ÍF=ZÄ_äÏS1Fü7Ø¬„>ÎHıkş+©B¡ñ#vP§èäêø¡ıĞ!ägñ_–è™h>ÁØé!Ğ šA;è^>ÂËìN½ Ó±lBI›Ş”ú'ôt6EÖës> !„9k.,ˆcÀäsÇ÷à
a>¾–æ×ƒ%„ùÕ­°„0»7ÁÂì\KsU;,!ÌæVXişÔsåz}ófD}|3Fi3Fi3Fi3yøfñĞ%èÛ÷íª*ŒØ“‘êÊ*İbÖ!f­`ÖÓÌŠ1ë!fmeÖf­fV5³Ì
2+Â¬av'†Âb‘ı×¸3#™uŒY?eV³LfMaV9³VIóR{IT¥ŒŠzî<D/Åˆ–bÍ—"&Œ@ éEPÈ(s
O

]6XÕàø5³Â‰èb>ŠŠ£˜†Qzx0A£XF£hdø @;8Æ@xQºï—Ò lcÀ+»38%Ü.î•¹nÅS†§”—FJüµ±Ö`¾ kf‚¼ŠŠ‘ò³óÓ,÷À»¹ÿx7—ÆGÇóÇy?•`"¶¹ºß¾T¢§Ù¶9¬GÙw)èÁªc3ÉdS ï¤>éO§@¶ĞÓp*Û¶+QÍg›wèC,OÔ: _
¼¡¿Hs˜ë¿3Òfë§‘²ç€~*ğˆ~4”ÎFÊ!3Í †şÍxùü6Dq|&)µÓRš–ªDÄ]¹AÀğc…
a	JMjoVø@hò„¥"qArÂm«r¨Dµb/+qà/@HHc*UI¹pî_Ñ?ràŞ;)ˆ"1ÊÌ¿ïgæÍŒÇöÄhO»©¿ß—èŞ|Ğ7Ğìêÿh%ı©&…V(<öáÊšÔWÎÕô¿¡?[[Ó-úÜÕ—´Çúíºmvõ?`,¬^„Á^ĞdP3#;|ëÒuë’òZñ”{ÊåšrI™WteNI+3ê´šTO©'Õ1UUGÕ5¦u¦Û?°[73šD3:‚åˆ¬'cXâ_zT‘»Dœ»1·R¤®øÔ$îš!¾VÌ.»_'Ì"Ó.q«Eq“¹]¥¿"rÌJù‘Pú¯ˆ½ìRRõº´®­´˜^öz„Ò©­Wi´ç·^qNR³Ï—RKÓ…©?ÿ²)QÉRê‡úœxíV<ñn‹kXéÏqWü_1ê^~¡Ÿ»GÑp¯/Ğ/Î
úã›s·KJô8Ø1‡’SáÃŒ1ÔLÈ½	¹,´np‰ÉJ.›HHn„"ø,,HæŒA|ÉøgŒï™ı,0Ù¬df7É¾dög7‘‰h M"ô,Ñ$¢Ñ³yx„\í!²-#Åé£…ÌÄÁ€™8 †ınj£;yŞ¬;-Ói˜NrCüû|=%6×#hr?×Xk®£]m	n¶lÑ4m#È×‘ë(çM; u§êu«eÈ[yÇ\µùN©¼˜û!Öö0Öbù˜ÎÊØÙ"Æ*å‘s(—0Vcå0VÉ*ÉXDîñ²¨¤È—ë¡İ‰Á~m¤çyq6ù¬ 7o~>µ‘ŞƒÓÊ[2Î¸8iÅd”.ß¹|%x¦P:îÉHJmäçÓ{ôm$%Á=e	kwüI9OìğçCW»ƒ–ÌÿUÍÖªí·	qÅÅŠ+–î×¼@QÀÛÀ)‰[ßø¸Óí
WÀyñøDßmô%øóıïDvŸ‚ÍØÇje(ü9áq‘q«1xTk0×zÍÛƒ³~|ô)£ş hØŒ‘ğšàœ¹İ‰jÑZ´#¶„&ş`I†	‹W¬ÍØ· –\\endstreamendobj46 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 51 0 R/FontName/UEAMSO+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj47 0 obj<</Filter/FlateDecode/Length 472>>stream
H‰\“Íjã0…÷~
-ÛE±ãH÷6`iÒBóÃdæ[Img‘·Ÿ{|JÆè3²¿c¤|»ßíûnrùÏ44‡8¹S×·)^‡[j¢;Æs×g‹Òµ]3}ŞÍÿÍ¥³Üî×)^öıiÈªÊå¿lò:¥»{Ø´Ã1>fùÔÆÔõg÷ğg{xtùá6ñûÉn½vm<YĞ·zü^_¢ËçeOûÖæ»éşdkş=ñû>FWÎ÷Ê4C¯cİÄT÷ç˜U…]kW½ÙµÎbßş7<—OÍ{²ªÄÃEaƒñ3ù¼"¯À[òüJ~5^nf¶Áøl/­übfŒKr	^’—à@`!XÉ
¦‡§‡!¿€éæáæwä˜nn}úzxzxzxOö`º¸vè.Ìäs9ÂA0G#ì.è.ì.è.Ìä»º»º»º»º»º»º»º+»+º+=JO…§ÒSá©ôTx*=JO…§ÒSá©ôTx*¿âû¬_x®<zÚ€ú¹#±eíd¹¯óĞÜR²£0¿ù`÷w}ü:¡ã0:[…_öW€ õqìˆendstreamendobj51 0 obj<</Filter/FlateDecode/Length 28083/Length1 57786>>stream
H‰Œ•	XW€«¦»«aägºg '‘ã*ËFCÆcİÃHÔİÄ#"ˆ‚Šg¢’ºÔà…·à…·(*jDTP¹¼gğŒ:®&®ŸYw€Éàc³ß~ù²o¾ª÷ê½ª~ışyU6uz,¸B:p1lÄ;½¡­™™DÅ$G§fóeÏ 0ÀãÓ˜irÛ²ç
 qt\êÄä6»+ó'&Íë><ñm i@ÿ»ñ±Ñnx¾ıs
‰gmşÑS˜
ˆON›Õn¯¾’”Í_;‰Ù7’£g¥¶­WõgJ_’[Ìlö~bjÊ´4{ \¨>ïXOÛî_ıˆ½opÜÕqÀIX+ôa§ğkë¹ZˆSy:	*È«o„@û)˜5€…:;âG ûÙ›„ú–±†ûÃív;Û×(”:vi`ë†ŞŒa7&í“¬W©>ÿİØ"Ç$:9«5.®ÜÜ=<½¼}:ûvéÚÍ¯»V'Ézƒ€b|ãÍo½İó^¿éİ'ø·!¿{·o¿÷Bßû ¼ÿ‡üû!øãŸş<ô£a1ò/ıäÓQ£ÇŒı,r\T4Œ™71~RBbRòä”Ô)S§¥MŸ1sÖì9Ÿ1wŞüô/ÿöUÆ‚…Ïü:+{Ñâ%ßä,]¶|ÅÊÜU«×¬…õ6nÊË/Ø¼eë¶Â¢í;vr»vïÙ»oÿƒ‡—9Zzìø‰²“§NÃ™ò³çÎ_¨¬ºxéruÔÖÕ_¹zí:Ü¼e2ß¶4 ïÆÌ*B0ÌC»JVRíæü¹a\
7›Çeq‹¸|î2÷Šwå‡ñ/áœğDxIùIÔ"É.&k´‰Ú3ÚJ­]7_·N÷ƒîµä#i¥AÒPéi”4FúLš+”Ê¥zÉ$=—^J-²›lrO¹—,÷“Cå0y )§Èóåò!½ ÷Òûêz£¾§ş#ıH}¤>C¿R_dPÈàfğ4øº$CÃ[†!†hC¬¿Êßİ_¯€¢R\wÅ[é¢tW” %X	U’”t%CÉT)Ë•|e—²_)U+åÊE¥Z¹©<4†Ã£Œ1Æ8c¢1%()hfOßÂn…z›Êbµ…ÙúÛÚöÙÛìMã›?h~ÑÜÔâßÒdorÜ3vÃòT Ò«F«Š¹ .‚KãæpŒÚn3WÃıÈwâ#øLa©P#|O@FMGz
§(1BŒZ’¶\Û¢]º.O÷B©‹$KC¤ˆvjã¤té°T!]“nK/¤Wì²{2jŒZo¹oµF-GÎk¥Ö¹ÚPııF-§ƒš£ÖÕ k§e˜ĞJMşjÔr”<eGµJFí£Ö¯ƒZ¬1Q‹
JcÔ|eÚ´¶wµpÛ Û`[½­©)²9¬•šÜ’î f¿Çòó9“:VŞgÒÃ‘p-“šgu¥%°-›jšª„|Ö×ı'-Ÿ… <çŸ°ÎxÈ²Ûêcõ²zXİ¬®V«Æª¶:[E+Y+gUYá‰ã?‚ÆLXõjÌh|}§¨qæÓ6.yÚ—é¬Æ¹ 	³K­—î5.±®n(jÈµäZ
,Ù –mø_ËË8fõ²„[úXÌƒÍƒÌ¡æ¾æss/s³Áìgö6£é™Éjzdz`ºëˆ2U˜NšÊL%ltÖ´Õ´Ç4Èô¡©¿)Àd0éMºûkO4¶‹óóÊX
®×‰kÅ5mç¤ÇæzËµÖå‰ \LkÕbUŸcœËˆd’.d2½L8Â¼]˜„Px¤-ÚIÇ¤—So§	NyÎ ugÇ¬Ú³]Ã¯4u°z8Ó¬N«gül¶µn·Í¨×ÿbìB‡¨3Û­Œ_Ûëg‘cÕ‘ãÑÿ‡hÇ(Nª‰ÿ6C,à"!ÂBXÙ°¶Ãp‡,†ô+XßÃ°VA&"û>‡°ş	/à%À.8°ÆCäÀ¨„X8à2TÁE¸ßAÔB5Ô@1L„g°®@ÔC<<+|	0	!’`2äA
LT˜
Ó`:¤Á˜	`ÌÙğ9Ì…/ òa>Ìc_ù/á	<…£˜‹«P…ò(€šp5®Áµ¸š¡	Et;®Ç¸7aæ£3ªQƒ.X€›áüˆ[p+nÃB,Âí¸wâ.ÜÅ¸÷â>Üà_p³0â!<Œ%x]±ÅRtCwô@Oh„;è…Şx£vÆExËğ$ÂÓø-úbØ{±+vÃ3X~Øµ¨Ã³X¯áßpî¡„2êÑ€çğ<^ÀJ¬Â‹x	/£? ‚F¬Æ¬Å:¬Ç+PŠoà›Øá><À«”EÙ´ˆÓú†rh)-£å´‚VR.­¢ÕB ­¡µ°ÖÑzÚ@iåQ>ĞfÚB[iò	|"ÑvÚA;ií¦bÚC{ií§tOâ“é¦:BG©”Ñq:Aet’NÑiú–ÎP9¥
:GçéUR]¤Kt™ª©†oâ›ùŞ.€€‚Jà^DÁIpÔ‚†j©êé*]£ëtƒnÒ-2‘™n“…¨‘îĞ]ºG÷é=¤ïèËõ'd¥§ôz†×ğ:ŞÀ›xMOÑ]ô=E/Ñ[ô;‹¾b±«è'vµ¢N”DYÔ‹—Æ[ã£qû‰æúî²Hã şî³¿g÷yŞg„é	¤¡¨`A¤wBQQÑCô¬ 3Š…¢ˆJK¨Ò¼;PQqNÔSO±Ò‘.%tH Ô$$@n½›ûcÿÚÙÙ™g>³ûıÊA9$%rXÈQ9&Çå„œt—]…«tUîŠ«v5îª»æ®»ÚhUQ°­lk›lSlªM³é6Ãfb²4”FöU;ŞN°í$ûš}İN¶oØ)öMû–}ÛNµÓìt;ÃÎ´E¶ØÎ²³ƒÁA;'ØmçÚyv¾½øWl‘]l—Øwíßìßí?ì{Á`o°/8àà~»Ô¾o—Ùåv…ıÀ®´«ìjû¡ıÈ~l×ØOì§ö3»VK¼4‘¦’ Í$QšKi)IÒJZK²¤Hª¤EŠ"ÅÔ)òİIé.êB]#c¨u§Ô“zQoêC}©õ§4
i¦!4”î¦at§{é>ºŸFDfKºdH¦dI¶´‘¶’#§ä´”J™œ‘\É“|šJÓh:Í ™TDÅ4‹fÓšKóh>½Ch!-‰êh$ŠA¢*WçÔyõ‡º .ªKªBUª*uEU«LU£®ªkêºÊòÙ* 4ACX `U68ˆB¨1qPê«6Ğ ª¶*Acˆ‡&Ğ $BsŸÑŞöy#Iåª<h¥ò¡5$C
¤B¤CdJ´“}ò‡ì—³R.çä<ıYm -ä@.äA>@;¸n¤Ÿéx^„qğ¼¯À«0&ÀD˜¯Ñ¯ğ:L¦ßhm¤M´™¶ĞVÚFÛéwÚA;ií¦=´—öÑ´ŸĞA:D%t˜ĞQ:FÇé¤ÓTJet†ÎR9£ót.Ò%ºLTIUt…ªá˜‚1K5tã°]£ëX`ClDµ°bÀÆÏš#ŒlØ21sÈÂ›`SLÀf˜ˆÍ9Êu¸.Ç`l‰IØŠc9ëq}nÀ¹7æxnÂM9›q"7çÜ’“¸UÔp2§p*§q:gp&gakLælnÃm9‡s9ó¹€Ûñ|#·ç›øfLÁT¾…;pG¾•oãÛùîÄwrg¾‹»È¹È]¹[ÔF)ÊÑ0*QÇİ¹÷ä^Ü›ûp_îÇıy äBÄƒyF£u¢u£1|7ã{x8ßË÷ñı<‚àù!Éó#üÅÊ%ÍñãüW~‚Ÿä§øi~†Ÿå1<–Ÿƒ©0¦Ã˜	EP³`6Ì‘Ë0æÁ|xÀBX‹a	?/R)UrÊä}Y*Ëd¹¬d¥¬Â|©†³P®Çë‰ú5=YOÑSõt]¬gëùz‘ï Kõ
½R¯Öé5z­şB­¿Óëõ/z#œÓ[õ½Gï×%ú˜>¥Ïèr}ÎÃ¸—à2T@%Ta{¼	o–Õò¡|$5rU®Éu©u\j¨«p®C­´Ò µ@™FLÃ,¼;à­x»?İ	;cì†=°ÀÁ8L7ÇûğA|Gãø>§Sñ|Ùç¢	8	_Ç7ğM|§áŸ‘fáœç{åB‰‹ñ]|—ã*ü?ÃÏq~‰ßà÷¾Ùü†›q«ÎÆí¸÷áA<¢sñ–b9^ÄJ¬ÁZß{¬ÏğuM¬©géRošùÔÂ'ú$ÓÚ¤˜4“a²L“£Û™<S`Úû†t«OûLgMæ.ÓÅt5İLwÓÃô4½LoÓÇô5ıL3À4…fl†˜¡æn3ÌïÜ#käÓÿÏG‡Z´ûß|Ìp3ÂŒ4£Ì£²Ö3.tu\œkèš¸D—äR\šËpY.Ç¸ö®ƒ»İuvİ\/×Ïº¡n¸áFºQn´{\DGãÕ~u@T‡T‰:ÌµaªBFBMhC
9C	]ë„uÃ˜06Œë…õÕu4R©ŒTE®Dª#5²I6ËÙ*Ûd»ü.;d§ì’İ²NÂ)8¥²>X|ošõª X||¯ŸŸ?ÈÁ„à»`²îã{ç ß¡ú«©jšü¤éÁzˆªêÂğzX+ApY% n-ø6òrğ•øïV¬ÄH¬Ûä6»-n+¼%{ƒùÁ™àßÁÒ HİLWw¨çÔLU¤ŠÕóÁ?Õ8a3ÆŒ5ÏÃò…¬“/å+ùZş%ßÈ·òü?Ã/ğ+ü`#l‚Í°¶Â6Øà ‚8Gà(ƒãpÂëìè5ÄB¤›ëº¥Nò&Â‘ø°wÚûa¯ô~x¹=±ööÖ~Àõø£÷¶7â&o÷Yƒc½â'ñ)|Z§ê4®3¼æq¾ä%Oñ'{Ïoyß¯èLåUÏÔÙºn«st®ÎÓùºÀ+½„—±Â‹-Ã3xÖ;ñRãş¼Ó;M4£½ÕÇÌãºTŸö«Ì»¼ÃË¼ÓK?„%xØëM÷†S½áLìbrL®7ì=g{Å·˜¦#¦cºn§oĞõ%\$üw-")AÂø® ¨®+|Î}wD”õPû–'Ä² ÑFED]aµTQ³‹šî"tÀØHª1Õ&ÁßÁyÒFã$ÕØÔÖø—Ÿ‹Úˆ¦c'“h­ÕXcMâÑÈµZ£ûú½‰t&¾·?çŞsï=ÿçCd]¼÷T[mœı/®¢wéÛúm{v¡²ş*=vómJ¢[¨ Ó’t5ûÛ¨o_¢4•Ö£íO½hM@œÌªçÖBë
¢h³µ——Y;€Uú-pğ™dN“°~*õ+Ú%
Z¿¥Xª£Î4’¦p/
£b9M7ÀÃ‹´ñ3Ö-Pí	ÿ{òh,µ[w(“êåÇ™NBE€Öl«šúQ™Âc¶>§
¢³x<y¸I'7ªü•ô2'kôú‹Ç‹YZã=Pš@ÓQÿ?M&:‹¹;;Î8Z¬_Y—ÉI=h xª¦+<”'Š-2Şm¥´>€¼öÛ$gÈ­‘1Ö«Öû”H{Qã¿Ë‡C¿¹»Ôú½õÅƒŸÁĞÈ$Ğ)GOsÊ¿èQkÕÒx*å#¨ÊuÔÚø4j‰çÄsÚIigÛ§èw¤`‘ıt€B7ÿDÍ	*ÿ˜Ë3ß :©ÇµÚí”d¹ú6(:Z€èz'ÚgÎ˜‹yÏCÏò*ŸJ\7e¬\.¿•w‘ó‘o­IÖêM)ôt=µĞí¢ñÿWúıÖuúz®B£®¡:J“EX/¶ˆ7‘Öj‡åP™/—ÇäYÄÃê˜pLäÎë‘#oFNX{­ğ®8?ƒ
¡Ñ¥ğŠ-ôº±Q~JlÿÁù#¹Œ•ù¼Š×¡:‚îã*¤¤è›&F
¨Î¿€–EoÓ-È v8+>_‹šCKC<‰;QiÚß´/¥KfÈr°œ,ËĞÁ;a›c§ã}Gâ¦ÂYãü
5õŠØ£w3ï~¡HUDEvÃwcáI‹¡‰Mè6ß†. Ç<
|+üVHAïôøÁ…\ÄùQÉ•¼ŒëË^æèôŞ‚õdšğˆ±¢T„E%ê·:T{ğîG.;-Îˆfp¤Èƒµ	Z™6C{2,ĞÓV@³kµÚqí¤vYûJk†Õ’d?ù”\,_‘[åyäçx7ãlrœpÜqÜq
gŠ³srÊ6ç…gÌ°˜bô	§b®ÇÖ Ìç:İ÷ˆdÄ`?±Cô”µÜŒ‰¾,)’{`‡RDÅu£E`—®6¼%ŠdÙÃŞéôJ…ıø å#TëÉó´‹Ï‰óòÏbºØ'Ë­Ú…›v"­ïŠœO{D˜.6jÄ—x]‚¿ÿ’Öñã<Ÿvr3çò³<œké”è¥•ò
Ê³6Éx·8 ¥²‚£><‚ÎÑ•È&ÙE>ƒüÔHëaÑ7èsŞN·Ùa]CvÓÂÈ2õğ÷•dg½Yˆ³ZÄc22È\çqÚÃN¢˜áÎÑr1µĞéŠc?<*™ôr¤Zn’_XÃ­lD¢Œ¶!îªh"æ¼ä Æöh&"=¹d¢º˜Ê¨‚EÖ[k)k£µÜZdÍ£°÷6úÛü"¢;òè¼ÏÓ'¼q8îÁr~ß© &ºÊ½9‡ šq3í@]uÈqÌ9Ú^AàÑàÍq`6 «t“ca›dÊ¢GÀoxĞ\ÔR§Pbv òx~›$óqÊ2ho#âù b£yb&¢3,8	ÍıXœS=ÿ«_‡—ónÌT kgÒ×»+çˆ çÅIë‘µšÀÓ9úÚ¶¢|e!/øx:ÎºIR(£bn€Ş¡È¬>í(ôİŸ]”ÏiüGì!B»R_áø‚eE&Y9¢Z;ˆ;ÆÂük¸½Ri?	. Ç]JäÉ442<œdM*ş{”‹WD¥U§=™KÑvØÄ+Æø¼c§zÇŒ•72wDÎğ¡ühÈà‡ÌÎòdşpÀCéı4·şƒ~}û¤¦$÷Nê•Ø³G÷n®„®]â;ÇuŠq:¤&˜²üFaHW!%3Œñã³í±ÆDø¾‰Ò1UØqÒCÑezÇ•^¬üÙÿ­ô¶®ô¶¯d—GyÙYºßĞÕ1Ÿ¡7rYI ğ¯}FPWÍQxb^…» v»±A÷÷®òéŠCº_.¬2ı!kèW`TÆegQC\g€©$£¦“FsIşÜA±]À”J1|~•løl”–îW¨â’€ß—êv³³Ì6Êù*Á]BQ2ÊY b¢dôj[Z­7d5™õ.*yâ+ŒŠğÌ€ÒÂA›F7èúTÒâ‹½¿âğîºû±©šéï]­ÛCÓ¬ÓUSIà~¬ÛşqöŠôÂYÒõPbQ©jbe0 x%Hê¶$¶T­òU~{&4GWŒ|£Êœ‚iRLES¹w¥¤x÷Yç)Å¯›S†[I5‚a_Ÿ†dNY´;Ù«'wÄdg5¸ºµ*¶¡kBßå~ ²…¢Ëm¨hJ»fÙæÈ˜ ‡PúlœÈ”cÿTæ9;Ëğ»T,R­:„LW®=oïWt—¡›7`4_ë8n›q¦»nÚ~ÒîjÀßƒ•Ç£23m‰)€MÁãèèxhvÖÂF1Ì¨qéøƒú¨ºsAın·màÕ^*Ç@-)	´u*OİEŞA !Ót“8ÍÆ,¹‡iß2àÉ{—%ªØŒöO‚«WU®â^@W¶â‹J¢’²€î7Cmº-šÚaÔŠÏiÇµAªGA@KmHÕ¢X8åÌöÅö ¯d:>Î¨SW(N`½P¹Bã[ƒqn÷÷îiŒ‰½oS£ÕbïŠş}·­K•ëé8ÙaÜ»xS¿2CM-3Í¸¸B$ Ó,4ôB3d†­%å†î2Ì}b«ØjÖøC÷Úhí_ª
ëƒ¢Šsá¬‚ò^UÒàåU¥ÿc»Z`›ºÎğ9çŞs_¶ãëëø'Ä×Iœ›Cœ¸õmB…÷+i/P
„Á´DXË‹TÊc¥*Æ¨D¦•] ¡(I¡ĞŠÑÂTM¬ÕŠ¶IERÕ¥‚, ßì?†VEÂ×÷œë‡ÎùşïÿÎwşÓº°_EHß6waÁ¤qICKK%",.Ø¦EÔp‚`KûHÚp#Ê[RDŞÂ¨@¨E¸S¸ÉPú‘?¦¥²©éê`ª9›BixV‡¡—¹B®04vüa;;lPtéüY¨ĞjkYI?A*šläEœoqD’1’U¤I§q	’†‘ßŠ|Ç¾_ç<áûÈ^×ÁÕlF3“Ì¨”N«)æÂ&.-'Õª»¦¶ŠO¾æó’åïïëz~şæ³ÛÛ¨.µfİÀ·oBI®œ¶.Y¾ş£uhÿ
†¤9$S©PÚH›²=”'Ê’Šà­©‚ˆs˜NHwè~;C£­jdh2Ù«‚q?ÉU'	WåÕ<ù"á3iBÑŠígö¾ÕĞtÔšÕóŞ½Ï;¾ÆÆc?³Šï]ºeZ÷’«Ä¬<L¿#K6Aûp±Q(¼ëlŠ²—‹eND:J £ö¶õşĞn6_ÍÂÜÍ™Á,vÕ#W}ı¸„;äÉ±¢¦¦¶t.ˆv´ÖÎ›B¶á‚^[£¯+Z:Í·š£0‡Ê©C
)ÿÁøü÷ãgÙèãUÏ]ì$fİ àh…ğ¡Àdj‰…\„:^‘»9B„r¬Ó%´[úøH._L©!”Î¤a$7Œ„á¾ÀÆ‚³¢ƒõÃw¾yµ[è(‚èe#*¨yî$UU-9Á?¡À ó<+GDAöº‘QL2Èµ×9ûÈ®õ÷™uF‰)E8ˆ@¨H•CªW÷o ä©*VôƒƒËLtÍ­~l†e’˜¼ªf¯›11‰ÌX¤U*kª“å¥%‚®)«ÏÃ¢ p¹5‚gùÃ/¿°zg¡eÙpáõÛ¸ø'G[bY kC­ı—]ÇMœİ±a£Şûmöù§×§µZZ.\ÂJG8L ‹
~ª‰#—¹¶>)D ûFÎr¤:)ĞÀ§ËÆÌPüÍhå£4¢Œµ×¡Zš¶¯B«Èrn])µ)_pÎifKŠSd™e5¯˜¥µ ó¼N…|JI1£TØ¶À¨¤&'ğr>eä	"¡<‘d÷ù¨<gØ‚8w²íÄî#e†”qBî”‰<@ÊÿuŠimÑóßÉ¦`Èl4ÛıÙéO/Ÿt¬øM§š3. ;•ÅR[i<¶uã¹­q?ëD5•ÚzîÜq4Î]xBNÊ$ŠµÀrj:f›Ót¬|³q#VÄ+#05|\àëØ«·CØ+âàÂ!7ÇÑ3Ö{Ù“/YçÉD\½x7[½t`ø×DÏ^a.·˜_
Ì»AòcĞe#ıó(^™÷bô:?ÄórÈ#‘1¡°WzfxHÂÓí!O~iIXsKz~#RX±Fè„ó_S¤¢ÛíÀd¯lK‚şv¡DÜˆÏŒ/‰¯‰wÆwÆ»â’OÄI<¿DGº;á&î>òjoå¸9ÈbŞÙ¬šíC±vXÈf&ç£ìvÕ5ÛaëéG‘ÎQõ˜¤'ÀºÎãîz¸ş„Q÷÷\9«ãŠ¼˜Èt‡Æ¦V¯7ç
aWÕøÚ¦çŠòRğÃå¥{È´¿ÙÚúÂâ-;Í?¬Ÿf]³8òÁÛÑ/hš6æÒa¬uÅæ/]¤£İ·¸íh¬âÔ¯–nwH„?o½Må?š4O¦Ù~ëEÙnNox6Ê|æ¹‘t8l ıÓ˜¾EŞ¿İ{ ıNøPş”ûÔö?NË{Ä1:´·ƒvÈ[¨$ºEŸÏíó&Q.LÅİG÷Ê¸¿ÚhÏ€³Îlá+pò ˆQîò's½z2Ûğù+y)ÏÈÓ’yM‹x†;?éìÃ£D«T8ç­¼ùèÊHá"OE—ˆbPLˆly;z7=ÌK;ó“Ä ä$;3Û¯ÆXÏLfØ4ML¾TG.…tŸ×GË™M¸ToÕø>ƒÖÇ_Yÿ±¶á8‰‡–·ş8¸şÍ¿}Ôµş0)|æ››øuÜŠ†wXtlòÚÍ_ZßZ_~µ‡1·œğP¨í4(/JaARœ İ`®Tæø0làŠ¶!8ğ4qdŠ‚lØĞ	‡áà¼¬cfç@¨ÍşCµåÂJ5¦S•ª§ 2}Dl…ušÛ<¡‡÷n>=|“\Éê\¸g½{×j¿è÷úÍ€^Fk4 hXÔ¥„tFú\âÇJ;%"IèA2àO3`-Íæ !İ–°Û£ø•Çá7|^cà‡o/—ÉN$Ë²o0lïeÃ˜]
š<šÔaİO®+n*/®—ÖÛ_‘6Û_ñm.”ŸP¨ù´Âˆ+â"ÅÒÛ3ü\¹Õ¶Šÿ¿Á¿.p2ï¤ú¡ã¼ú™zCÍãŠiĞêaËAöU
²Æd¨5Ípc7Ó ›i0ê­trPßè‹áë
m>	ê:!—$JHIAE—‚JPI(œÂ´Útà-²àÕÁL{ÎEh$™q1Om¥r6“%®¹@—%e¤:©ÕÖTéüCezT”Y[Í¥É&Ó:ğÎuëğÑ³ı¯ı»pÕë_Á#\ûâ”ùn#)¼›íkİş>nûä^¶xêµ‹µ?İ8tÛºoİŸš€8™ƒFsú|ÓË<U8"+a^ëæ0Ç!RH¥(I N*éÂßE«ëU£ÄpÌt,qüŸëjâºÂ3÷ÎÌ}ÌîìÃ³O{ñc¯kËjl´“š8¡$Åi€6®¬´†b£€íD“c·(%QlÄ*MÕ†¦pãBâ44­ÔPñhEåZ¬ª®øA)vÜsgm0Y{î]íŞsÎw¿ó}¸ÅİåFª÷¨[q#=WìQ æ\·<L›o5NiL§‘À jîà;xÅ9rÓWğ:‰ûïÈeh™\f_ÊRG²¡GïÔ£ÙíÓn€Ço!&,½äœƒ¡d*¥
~).qf+m†R’j©«Ô.uLUÕ&µE½¡*]*ğ	ÂEø2héÃÒ˜„GK‰ ÎÁ“"mRLsóT(iG0¶n†İŠıí–ËÔ‘;õ°~Èí'"·ò[V”j²ßÏ¹ŠV€Âg”«Œ2N‡åVÑLB4,Z;‡ÖÎ9ƒVÎ1Ã "56&é:%Dô÷ªOP˜,?qˆİÏü4M|ïAŞ#ráıİO{ò='T-ÁM<\¡lóqn¨¸¡ŞZz‹±6×Í±¸îNA]şx”& «‹¶.Õ­±"¥Z‚íQú´ŒrXUÈÚ¯”qå–
*drlhñ3)&>nJ´¥üeÜûq?àñ>‹ùÇø¾ÇñRşŒ6ƒ+Z×:xĞ&Ç‡üzZ·ò<zZ™ïÂà2ÓJ\÷§a'ç†<‘Ül„r3¬pfXäÌSëyi)'.dg„¦**^ş‰¯ôœüföª·wØ®³[Ğ³¸·ş¯ıTr?ğà/ÔC`­–ZÑUD D¾&QE‚;˜™{mÁÉ™g„<•‰ƒßÀ~ø½1õĞİåÿ<d¦E %.¶t—ÒR+pú€²-V°$ÅãKjRN6§fë½‚JxƒºÊşÍAëp‡
/+äÅè%Îæ	jV^dxjWŞcù16Âo±;<x@ÙÃğOÙY~]R.°Ëü:WşÁşÅİm¬¿v+¯³İ|"kôÑekæ[Q‡B–¡Ê2¶‚¯¦«ÙNÂ|‘BK”«áiƒ`äR4Æx E•#9ØX…(ÎT!IÍp%A´yÁ(®¢î”.'JE-#‘ÒÅ ¯öY^q£SÎø‡KT`7]+›+d£jÿü„x‘?<YcÍ…_‰+”±$VLŒ~+‰Ü"øìRrÁ¡b„²1,»‡@E)#à™A|§1G¡†gSj’Xd;•ééíP…Óz\w¡aôuËŒ`ÁBÉ‚ER²PÈEø·à8ïÍÖ‰Š
oí¼µÑˆ7Ûšm­†½ á…÷Z+lŞëœ¼Üa›¡˜§Ôq^ NÑãB
7:‡Q*$8 @j±¾·äßÉ\&ò){Â¾b_µÿ‚8ŒÇïÔ+¯İí`ª˜§XômùÏ–Á°F#8D?ğdWçJ0¬[ÌV9D„“„QL"˜A¾ WX+"b%©}î@°ÄÒWéM:nÑ»t”ÑGu”ëõ”M}©sæ††K>ÔøŒ~ æ:ÂtK€'‡I…Nª®ŞU)‚‡åp$úÃ˜Å 4ÃÈè	&PãXŒ
‡êœU]Çõ*Ú¥W9-V¦h*â$¶°Rw‚lÉĞ£ôÖÎàÏè_)ãy4…kèÓôm|€fğ =Œ?¢zÎº-¬J!k¡cİÆ,÷¼d
ÅÅ@Ì*x³×bE•)ô,ÎêúYqx‚"BÂ‡È#(AjĞB²Yäyôa&Ê'O¡ÇÈ ù5ùºŒÆÑuò%Ò¨Œ|“´“òÒD7Ù\1ı‘¦¡°Vr 8DöõÉq´FÎ³/f  æâÏïÔãS÷–I@CkA]eä‘ò¥w­oíU÷Ò>WŸ¡P™ÔCÂ‰p;kó“6_{ [é¥½®nc§¿×ì	ô„zÂİQñ¢ÔŒ†Q’7×Í"s	&¹,q/çtŸ³bM±–XW,Óâ±1ó&2’ì‘
¡ê¢æ»‡
:?¹/~$n¤ôDzBbc+¸›x¡nrò[’M!nÀÌ€ĞY[—üÍºŞ!y™¼Óî´OÛ'íNyÁ?¹zåÄ‰1t~¬¯åhÅ{“=`ï·_Şü¥=99yïö]‘¡½oÃ)yh³J4õ¤y2ŒWåuêù}%nÃò½B½z$
á	u“s€ÂCXÁÂØü©øÔ˜×3“å¶}9×÷@ÆÂ($\«Ãø`(¦l[qqAhS®ígòßdã™Îƒ/ì]¹áìÇïn­ûîUu$Xtep×ğz_ {Qù½İTùÂ£«šİÜ©ëFmÔ5 •!ÚÖÛU4 ˜û‚ûBZ»w[¨-ŞÍ»oÙ›Oµ+‰æ›1³(RòƒĞ+}Y’×’f€XG´cVGüG¤××í÷“ıßûäxğÓà… oqşßz²¿"u€‘Ÿ”—~()s‚³‰9A"a•€øM£'•>={.C"c_
Ë–Ÿg¬´´0’@+ËeÿT6ı9´”[åMå-å]å™r-^~£•&2.Ùã*tÍwa—@Ë×¾ŠÈëµ,(c)}s¢Â›µ79İ"ˆrÜ
*®Æ’`ˆ@RÚ´‹“|&ÑJMá( ¬ÜâÒÄâ º`c×Æ:Ë8±gĞ>dï»äår½ÜYUfTW;öÅXÕßnlx{deå_ÌbòjZ~Sn–×É?±[íş÷l²ê>|Õ¾{/@Ô½ŸH*T(T¦Hºm½VíYîYM6è\Ù/LñqããÕxˆù"£Ş¨÷êe>Ó0=¦w‘±Èó¸g‹Ñáıœëí¬=²5ÖÃz"İ1MæòÆãã§ÆÏÕˆ»]¦Ûíò¸îP°$ÏkÊMfÆD¦)Å‹Ò‰Bƒ;e%$·¤áùüDF;¬jç4EÛÕR,Ç‹ç£â¢ÀL<Ï©S:q³ñ¾`|`Í~nn4@%Ê>§Y Ô“ÒI0ú?ÕåÛÔuÇñ{Î}ù¾¿í{mƒíkçC’kB 4·²<Èkƒ,3E*	„iÊCLŒIŒĞm¡´e¥-kµAÇ…¶¢š !4¡¦AÛZ¡•®„è¦T¡Tììw®Maqîùùœ{$ßûûıÎï÷ùº£tÖu§óA¾ë/áÿ~8ræôºm›Æs¿¿0¼jm_ı§nªïhŠ»ÆèxïÉƒ…Î}§£Ùıt{¼ç±–52K8©eö*ód9úÀ\:åœ/=[ÎğnŞëwû½d/Û[º™û©²¹ôcù‚.§ÅÕöÕ±´¾Qîsmˆö—n(ß¿•]:a©9sbÍ^U3ºb]úéØiŠé;b;ôË±Ë:—ç)ñX\¯S½UlU–Ç–é›”^}«ò³Ø.åéØ!ñ5åõ˜@^ábœ®Šªâ‹ñ1]Täï˜jÄ À œÀ½Túƒâ2ˆ‚ó=4Õ„HÃhÖ"F2Q'Z‡ö ? #èoÈ†¾dL­ÎÁ fş<!psÖü¦Ûoø[ù’b­ÎŒãˆ;ZÑMg>€êüó…jÔú½£”¹(İF¢×îølrÂ²òv&y%o‡“Wà å›Š…Ú1ğG0üˆN9oÿ=æ®‹{ÀÀìİ1™}`¹ê”ˆ«N´®"²ö…i—aM©är×%şK Ğ»X\¬¤b)ğc³²,Ö¨ßˆ‰T&](’î„Ï—/ù%Ö'e,| vyÎëñû+³8İ-(¢ØùÜóKWS_®Û¹ıæÈƒü|î_îmÛv4W–/BGŞÿÉ³³ÔÛ¹¹èbèù§¶vÍAWÅ’î­ü{ßWï)CO¤buF¢²ïÇ§ùùg?BˆäW9t‹)8Ã<5lê•BSÅv
ƒÂˆ°Gà9ÄâCc²	~¿Æl'$„æ›"ÇGPµœ"˜:i{'Ä#xf°jË¾YˆJWÏQQ©oƒó•­‡aEïò+…nQo	hé©¨ ïR®ÙkgÎÌÌ|ó<OQü3D YÓ•¤“\Dª‘ŠC’©-6@Œƒ¥²cj
øëš)haCTaïÏ(2cIÖ§}aƒ‰ÀÀ°s²Fy…2*!ğ×Åkòá®xGfÏ±ïŠçäO¨‚>¸ ß ş#‡™?³‡ÅƒòIfœ=)NÈï0Bc+Åˆ¼y‘İ'şF¶å#~Ì†ì
Gª¿=šGL¾ ŞGÉ#ïÏ“ÿ~ÓKtÀz2“8šB<À¾`±>¬oà±3ÃF&g«Æ9@ıÉÙjó‡4%G(ã¢<D‘cÙjIôH’(p<±	›M`$Y.ˆøZ¦0bdš%^°q6gY`åå”Nˆo%Ğÿ$ª2ÅwJ:eV5S9Áí§*kÕRSÛ²-Íjj6h‡°^ı–õ…õôğï´FÊI$@ÛÃàÿMe-	0Tà?2e¢(êşwG‰lE½¹?¡Ê‹H†º.£y¹ı¹³¹ÏrôÍ{Chúf2Èy}ÊÒ}S?{k¢¨ÇÈU8š2†äF¾$’Š4)1I‘ 5¢yÎ„.Ti‚Á|‚hº!¯•LZƒÕ­™^L0„sóXL'X£I\lañ	ğ/Ç6ÙdI„„ ‚VPS€ŞI¯ƒßù®…PÙÄ{oŞïKpµ;2_'ÉW" O]µÆé‚¤*H /ŒVyÕ£ğğ#Î”‰š¸N´pƒh;7‚l8-5xö¿s¦$²=åPv>Ã?ûùa¼ßÍOà“¼Æ~>ğ¸ªÀñüÓxD|NšÁ·ø"è}yL'¡C™dÈ48Ì(êõÑ8»šYpï"ı’è·f®ŞÓïÀ[5Ï~ÁT0P:U†Ì¼f±aŸÖl
5'>u\r
ÕFõûÅ}ê†âÑâÔµCÚTğœöNPæ8ÅëãT_	WæM«[ğ(>ÄMpg9ùmãcÇ«8Ë•¸™¬0âf¬5lÄïÅq¼1LŞ°Ê^d,#*ì	ß3áp9ª¡LXÍ;|uÔ9¢fĞC@3¢“xóÃËŠXN’îYn[v”ÃÓôHsÛÊ„R%=W> ã¹P¯d$›vŸ!k2ÖA&şº
·¦,ú¸]ò£ÿãş?íWkú-0ß0ô«¡éL>ÌÖìJB=…’ "Ñêb‹$óù;VFCééû"1²06VÅ×Çq&™&¼¤í|™ÊvSÍ…€
íñù£3rzÌê9µkó¸ˆ­{=„a1…zg“çßÿëd+LänHnz5óê©î}/üceç@ë*´váxmÏò•+jş¼âw{Ó»ŞÊM>û«•¡ZÕÖØ8öÔv·†‘P×Š%¹ó®ê@Iı’îêâÚx/¸|'dÃ^K¥„¨W¦(×ìŒ¹@ª«~'ˆ]İ\·Øíë¤Cwx.Å,Q–¸SÁL«Òê^ÜËÿVe;$Jƒ Œ±¼‡ÄÂ-IE”èÚ´Á9h£ÓÅE“¨Ì”Ñ 5BÎT¸!ïï¡ú¶élıÕvP/yílİPo15Ê,ë1¥>®OìóõúCl´'$vÔ	®s_ƒÃJ¼nèËß*µH}rìL.—ZsÔtÍ[3¿øå†ŞQöDöÖŞÜµÜİÜ­Ü'kÒûñ¼ƒƒÿã+¤ç®†wo€“ R—Í®¢´+íÛXÔïê÷mlU_Æ/Ëgg9.®s×m×İ×½3œ{‘{‘·ÅÕâk¤å~™_ìªõÕè-ì–¢ìhÑ.õu×k¾)×qŸ`·24h;áòö…¬¨s¥ Y”ˆ¡Dğ™Ë)Q&l¥LØGÕì<=…[?È*ŠR•
ù¢D;ìÈ®ù¨GÕzò®l#°•i›N‚HÚº¹›½L‚Í3øÔ¢™|V-¬eIÒ¥©Èüîª¢<ÃûíÿÏíŞíİíŞ^H.9“ÜærÄ#Ü…8¸‰‘Ÿ‚ õ1ÁHj	V¥Ú@F"?ƒ©•Bˆ¬µt A ‘RÆÌt:R:g(N‹MÌÀ´©ä6}¿½ÔqšÌŞ»?ßî÷}ïû¼Ïû¼Õö5å;‹;º7?Ö´FCşØÍ?^µ¯!}ôü§ägÓ—.ÛóÖ™şëã¿;"ˆF*?Œ{eà»UyÜ¼`Uy3lFÌxshÙĞ¸%¡9“JºfjÉàªÁµ@kî¿	£ÆR$NqC(Ä@T‘##Åí&
vcì„ù`ÑÃ©;;ìË!Æ©Ï-yåX‘;Ø±Ã›CÛ’	‡kòô&¦Ô0ú_¨Ğ«ìÛu¿i>eß¶Ï>‹‚Yo¼áéUÛ{×~w[ÿŠ2A+(ø3Ò3ŞùÖ7×½şÚ©Ca¿u°_°â'
Ñ/†	äI£T»_è“÷zŞ`‹§…ÓòPÏûÑ<ò¶Q\zC>É,xO¼àúHü‹ë÷…,º5B³5éÖÎjïk”æ !”v¬ KşÄ‚¶ËÛ¤´)¤bxq)9œ’D	/Ç•${O4gcU9k:Ör€K	,»Õë7§%¯İ]&qDÅµˆâ¡ÖĞúĞÁr‡yKv'Ááy6Œa·`Pİ„ä¡nù«ÂŸ6¬~€‚ÌÕÎNg!ï…EÀ/^òæ©ÛÁÉ¡7ó²Ây€ŞZ¼èÁ 6Çâç².œv„Gæ
fĞgzÅ/)xRO¯Xà,Gœdâ) gh'@ì$°xé¶@â% æ1Æ	*ìH|_NÑÈ/‘1ãêQûÚsÈÿá(ò²Y‹zvÕÜf“Ú¸|e*…Ğƒñ¾C'ö\,Äì÷ì3İ;ç¡ï?½¹¾şqÌ$À? Ô‰!kúUÒ%5C÷OŸ5HMWI¿WWŸ›ğ(>DxH¿À»%Ô*MH¤„!²HuëhBG:¾yà»7àÓ¬Ï/
‰4¿˜oâ)¾ÂW[URB´%+¾éo%ôs:©cL€|ÑƒÃd‘‹Pê8H’ñùÁ+„iÒÒ•ÊÂ‘†ŸÚénøË×!_Âér¦8‡´„V
ôZjô×îbãã‘ú9³k>øÀé§#M[{—–½ë©]²ğÒø)j¾“ûöºÍQq´Èzô©¢mE¤×%wVo•{ªéTJ–RÓP‚LPª'ë©îŒ?S¾<ºBõ˜û–zËç%'ôY‰©ĞØê+¦Şpeâ.¨Ù’K–*]²©è­JvAëe”á8ád€tEu@r\rålEe.JËs¶:™KA›âşVN±ÛÄF«°Ã%3‚leTŠ˜t„`° `w5ª
²D"Qö§İaŸ›yşñŒz²W&‹Uöæ†œD¬ÿ„³8gòA_GXâƒã=“%®Ëá-w‡¿£|mtM¬#Îâ*`ôÀdİ¯
Ë8PVı
YZBÁç¿Ëe?Bu|QÅòuß(÷É›Î}Ôı(Bgßƒ¸9§wÛÿúÛø–¶µ»¶·¯ŞÒhŞ§…Âzué#œØıg$¡‚_¿4şÀoßù^jx—BnyóåC¯¼>ğ28ë§ ×3Àë:1hÅÜ¨Õâ@zæ¢¹ê_ÑÀ1:SF>¬¶«ˆlŸ_õú(?‰ÜØ©E'ˆ¢_AôKb„¬’²äQM€à7CHô{Ê’/ÙiÜ0Èë2D×Ú‚±º¡!-Hçßµ!–úVo8Ë_åú3èqFÁ§G^ñNÕ „©”“N¹cñ)úÕö3«úÙ#%Kf7®KØ# >=8¯sûîì²úpsMÃ­ÙÏ`Ó€í!À)EpÄSÃ„ +K«bÚš²G8&œ.
×¦Xh6pƒ¡X`h
ª˜E\$>7[@±ËÑ"ÉAÍt°.KÒA>¿¯»ûH;éI1¼£œHÜóáEÃñ"
Ú#(HŸD´=~{¹ı1DhD¨V(ÿ&¨‰KÇe5í4¹İÁª$Gy(k
kØ£âYñ‚ğñcQ\
])s†ĞÈ~›’eN
—éQzœşœeq‹ø5l7ı<}€îgúØ>®‹i/£cL%[ÉUòqy!½A“
¢À‹Œ(P,-14»$$‰çDJ%zˆüUÀÄùÚbq«eRŠ Ã‚ƒ®ô3y‰÷ôŒuQ¸;%r‘„È’m|·ç]>5™MÔÄ…A!œ$&Ò.b(j¬qFœºÑ|Ôl¿„³ÿd¾ÚÏ1ô¤ıãì#èÒûL}7šK‡	|Å±dš²‡9Æœc.2×¦˜ic63pƒ-Q É¨"&£Fé¯E-§D.FÌ;_6Â\›‚İ¬h¢YÃDŞn¹ 
¹4Vw%©$Ÿ4’¥äıüıFC©«„ŠG—
mÑèÁèkìaî—®ì	×±èÅè'Q…ˆÆ£Mğàlôr”Z…É4\÷8.LsE¸lŠ\Ø©4çQUsJaaÄznOÄ«ZÍ5m*Z@"-wÁ”HQ!Ü[_ˆÚ
Q!Ü{»<1±â$Ó!B[k¬Û„¡¦UG
23iZ3g'ãæûæe“r›ÅfIf‰9Íœ0i3Xñ÷Ôd•£ÄX+ScPï¡$A“šº›º'}Ó£@7‚?7ÄpYB1_XÃıQÀé’º“ÊæT¾›Õ›µóÜš½Ó_]ùÄ«ÛEæ’Yí÷Ú#¡ôŒºö*{„ìysÙC-k]Ù°/›![_¹75oç^›$4OmìİŸ‡˜íÁl1Ó‰ƒ–Áù¾f¾§‡hÑò4ğî«†u¨Må™uIHUEtÂ¡6MÀGşµ‰RÄ¥`ÿÊ²ëÃ¹Ğ¨r_e8ÇS_#¹\bLªÜğW(Íq±GÊ–ÔÎÿaˆ‚ÙùaKßâb2tdõ}M½ƒv1é»¾½÷Ìk‚~íƒÊĞíüÜš÷O4Âñ_¾«¶‰ë¿w÷îÎï>û|öÙç@âKâ8qB±²æèBøiR ”tÊQ>ÆX)ÙÄÈªi¥"º²UIÑ4‰ŒMkJ²5Ù‡”µh¬ë¦Uk‘›¶hJCE 5Îşïœt¬Ófß»¿ïCşÿßÿı>wƒä2wCàôˆ¡\§o{`{¨3<È‰CAu‚^áş$ü™^Q¯×Åšï¼çmî·â›_©Â!ÏóâQïw»P1Y‰"Éê‰ŒrQoı‡=É™¼œh_b?ºÏ·4û¾0ÁŒúpW ¥CZ(h€Á+—<Às[NÌŸ½SÙ·>x){÷.<}àÀÀÀ§9û,È^şğvöÍ£#ß>;2Âò=™ı„|}àOÎ8+V68=Åg´L mâ7jMÑûQÊ<î’o™“îG=°ô³!Eñåy—ü¬¿ÌëÍ‹û|®QQ>éh[o5ÀBúfşËÓºÜÄøyÚ|
è0XI–ó¢©eVåßYŸÄbÍ>?‰¹ìG“;NµÁ‡^Ü³ó¹cOì=KÛ¾+û—ì|v.{µ¹cşüäØ^;ÿİsĞıñunî#NbPÀÔ‹·
{„C_¥ïğ~Î{P'2ÍSTî”º rj›Ê©Üa§L’ ¿yN”ˆúh5=H	µÑÏé\·şŒşªşNtŠcŞÍŸãàaÌáˆ¿qççDhïí<×iÍÉP¨twfU®½¨eÔÜÚ2š~ôñ¯É«VCbnO,HE?fıéıM=­ÿÔš-U$>¸¿)ıÏk/doCÕĞÏ>È±œ{Ã™ıb‘§Ôô›ECú1X:PN%£ÙàôŸi“ŞË±÷‹îis¶X¦uh»µeP?oOªÒÚ"§¸)¾×Şï×ûcö×‹i]|Ø¬lÒÚòšcÛ’]\¯SÓ±´.JK¢,øi,¬•ª¶mIÅ¶Sñ%µÏøJğËe‡Ê–Ÿ	”ÛãEÚ|Ê|!ürù÷ËG+D3rbE©“_*á¿‚ä¯ñÄÚKN•p%NxYªÄª`è`ê¶Wàê
\U+–Çª}ØWƒch™İnÉñÕ€—’}¬äÚ‚Bí½µˆ É^ßB9*uÒ"Æ"á¸]kmÃæ.¼ÏœÃ269bÅl.ĞT.auLšJ»…­æ€&_—¾]½ÑId/¼Íwl"7ÛÓcË‹Y<=VPœ‹#–;Q8Ù¯áZ»ÙÒ¾m_²ß³Å˜­j„XhQÓ£¦îÇÌÊF¼h İØ.I±ÙYÜ‡p5vp;&=øÅ<Â>ˆz0qï„àNŒVDp7™%K!äÀ«C5¦ï5x©é¤ëR¦“\CIğŞ<³Àì6Ÿ2‰Ùa9€Şyn·,n1ùŞä®—Í$Yx'¹ÈnÌ“²bä.væU/|ºº\[[¼ğ–C½1/ÔáƒŸhÕP3ìô¢š
İ|MÉ¸ÖÃó€‡’+úÓ@u¥ĞtàÍû	9»4ÀàâÕØÒ<ñd]‰Ü˜ıág¾víıkï%²wıİ;ª.Ìã_vî¸óáÕy\•ÜÒ‘È¯*ş–‡¶¿|âç/\ùĞÃ¡¢åÁü=›Z½ô‡QØE7¸o	¯ 'üÎ)+D`İä²¼zï&og	¢0
"SØÔ9‡y*É’fåÎCæ°9jò=0M™¼	õb3ÈCAQbĞéUZ%W!p‰İ€ÌÄ&Â|ÜÔ;‚Æ9ãUƒï1ß4Ş1f>£Ğ¨6ˆ±ú†—ÄDËhàÄÀ‰Id,L­îÌ9Ü;]¾;®ÃxÄ…[g@Føkn;k¸55YÑâPRQº&]âçRJóK7…w~uóÓ…>û,¶H|:»í¹d~ôZyÍ£ëVàßO¿û½ìóPŸo Êl%qĞgó1ÿ^ÿi§bDlàü-\‹ÿ:'¹ÎÇO”’ƒ†!S1`ÄƒAÄ ÒrUB/Àÿ?*z>–<ëÁÿm€ró	uĞK‹nšinÚµµì”¤şûö_ØŒ#[7|±GÎuìüì…ÓÜp6<½{MÛ¡<–òT@=y*8ê…„U•’Ø ²ÁÃ0ƒÙ53…V}êÁ"¯x<²ª€cãtŞ¢–l£Jå²¢ÂŞuBË
S2E”T®¤P½Òh’Æe¬©î»j¦F‹HF°ŒI&3QGWL™RÃ"œÓŒÆç'RŠV UkF4Ó´|r£Ü&d‚«vÂeÒHÚO~ÊUƒ@;âä©i„BxQ/AoEXs%Ã­·º€©º"¬Ûİôw7võ)§zÃ_p·v‹íSøÄp,`ÖÖÕÖÀ€¼İ†K]oŠ^ßop,Õ›ÿÛ×…*+¹å¹šRğ«¡¦*Wê¬„ÊÊHädI Qâ–¿`I].ûUUOòI±HÉğq¿Aâ‡Dêe™öU¬‡*„„*2Q£È"!Á 9¨ªE(AJ…JšKÕ•¨Nxˆ6£õÜzaƒ´‘F}ä°ĞGûäÃj?:Nú…ãô¸Ü¯^EWÉá
½*_Qo¢›dF˜¡7åõ>ºOæ„{Ò½/Ï©•ÂÄÂ»Ö§H:±pÍd©K×‹D†À‘zÖS¯Ã¬80,.±ƒbf×ÁÄ¹ş4'ŠÃ"E— ƒ([tæ	¢2<tW~ü……­c¢LaŞì¬â‘ZOñ*â0QyAV$ê=’$„°şPeh$Wy½œšÂ³–b/*„š?‰ø:ˆÇŞñBÑ.Mb+§U¬Hë¼Ÿ·"óá\ Üò7.z_ƒû‡àğ»#ò»ÿúåÀÛÅp`Ä\q´d|ï¢–„ïì+Ê~™ØçsDÓM/‘€Ë"L±ş
°ÿ‹ñjmê:ãçœû²¯¯í;¶ã(€óÀqãBv›†âBy,ĞR	Ìm†@¼Ô-NHÕÒQFE¢Â€¶°L£°0ª:…´:i›(…Œ1èL¨KW$¨hQ£¢¢äz¿smX:õYşï;{Îùç;ß)Úl¡9gSç{ç¨Çx×øöx|lëçøşSöîÈx™†“ÛbÜîÄk!å¬Èº•t^RnÚ%‹’/æÉ!¹–Ä,3h3ı%íPÔ +5t’2ÎRºmwå»Šu¼TÊÔ¨8I­ç¨§DËOÔùb³ºL|^}‘®Wßw)'ÕKâ z_µ¢¢XU¯ËÔˆ8E.Z=¢_¤ÎQ×¨½âqq@­
¤=æÊãñâò1Ó+	–¥¢ªˆÜˆ bµ\<2!š(gNoIT2k.cVI¶Ù²İ7m”³	ºmA"å"É’„\ÕbµÚˆÔÏ?*G¬ 	›eù\û^û»`x3‹Øx³ë&Ô…œ8@*ˆH–ÿ7¤pòoùõä°É‘òLtE±Yš§Â›×´yb^–£ÜW	/2ş¾€Os‚’‡î‘L¥Ú(/"Ô´+åVÕèc]ô§é,£›v½—?eÅL0i‰aù„Î4óØá0çÁªnís…$êæ¢çiÎ¨ÅkwF^È¼¼hcüpCL–dY´Û²Îˆ[İL„á9ãnA*ÙO# :íå	x*<-á&·™k£œ&\c£1.$òüÑÜ ´4aefQÆk.'‰‚š(×"Ş>¹eïêpãˆ%«#æY‚¶Úõ[×ğêK–gbj×\æ@)½k*sŒ’³è¸ê'áª?*êädÖJß|OĞi¿f3±’Ò_&öœ)nİíGáÊ›"q7C…Ó£¨gæjÎ"Å!•–òë°ÖAÃÆ]ZltÕ¯_´á©§çø§V/}Öå`ßŞg'’K'åÚÛ›¹ö‹ğ~ú'´¯ÓÆ>×€H‘g¦•zNT¥(jQÙzWeµ¶'Õ'µ&ÚÄVÑUlƒËò¹xQûF¼¢‰j¹Ø£|ÈÖQé|äëV´\ë1“§®u›¸©j 8CÃ}V5¢;³©>§‰ñ<×wêÎ€³Â™pnpÊÎ|èş/x1—b‰Úvşhƒ[X1‡¢ùx†Âà?şbĞğbÈyñå/şLK†Ûô[H.RmÃIŞr«n(ÜÆCàÈík(‡8¥©Œ—Ÿ€9.&Ö¼(uµTU,Ü–aæìÃÑ0ešŠ!Pmq›®v3Î5“H5­©•©ºĞC•šH¡§ˆşziyåSF—ğscõ¶zì_t µ\ ì«3Æ£¿Sî ¸¥ï¤¥ï¤ËÄIÆ‘©§¾ÄKñ±½ô€rÀÚë”â®oM¾0727Ê<e¯{…^éÛ;öÃáÏÂ–‚/EÖG…•cº¢»#Â
÷
ÏÊ|¡Æ»8ºÂ'Ô¸âùñ±Â#Ñ8«qÑ°P9)ŞPS[›ZßPÔŠ|Hï$´²ª*¶!@‡ò:-¶Çyækß¢‡CBŸ‡„Ğì*Ş¢N©l­ÜX¹½R¬ìgÁ„ZĞ¹/©ü†úz?(ÜØ`ô¼ŸÛ©ù§={‚ÎÊÜ?#ÃÉ:İ'9;„P„„7òø“éÌ‰—£¤º/Ï>bÃqšép0}%†[#óK‘d’V‰.O.‹‹JXuÔUâ+™'×%FªJ\ÕQVBs"U¾±h’¯×çõùŠKñ¾(ÎÉ1ÓÅ(çÙíÓtõ…sÆÎ³gç.ĞÕï1şİûZòûZ¼¿×øÌPŞş²`Ş’Éí+Ç‡Š­‘–¿OkXÜ®ßÖ*±µ^º|ÚØ>À?=G×œ ­§wí1.ïë1÷ï§%=ûhhÏ÷†0)‘U‰¦õNGáDmÑşM¯6Gé?¼µÅEÕ>‚˜²IX)tIg‘“úH*áUÅåu;5ªÅ|7ÜıtlÂêrâÆl7^+–]D&J	QÛµ$‡ìîÍÛæ°ûìA­Å¿â“¼°>Œ¼¹nH¿¦ğHÔÙ¦>2<”4~ÏãâñUƒgƒ¬D~À¿e\¯]\;&ë¤—Àw4›¼°r`İÖÖÀÚ‚eÏ×^Ş’a¹«„f!%4åx%¡få©lÊ Ü°ÅˆÓE]¼vßğÅp“k£äˆ–#Ğ*´o´´&jıì±cyo¿ÀeJşÿBÁê²R
aŠGó¬‰ú3‚ĞÍFˆúË:×.˜Á:¥“[·%è€$Ôÿå×'‘Ø¶²_ínxÎYwÛâ·şÛwµn§§ÄÖ×ïİ»?¢‹ÇÌ©ù <nÌ!õ:¹wïŞ:İlı³WËÙ&Ïâ éÎ‘V±¸€éÊÒ,!‹éuòSô­ê…1¤@ü#Y€ñ¨·ƒ¾ÁâéŒ_ì"@#– ‹²xxß 1Çs|“^%«•ód2Ö"À.àgÀ›ÒB²}¿‘ãd)oÇZ[0G1øß¢ı-ù Ù¾ıÍ|¬Iù÷É,ô?
şia:­l%
Úø´{±şë|Ï A¬ß.¶§‡À—aî™èßº t~v¿y&•cÊÊeìâ<ôó
Úw ó€×€%Ğÿ¾ßC}+xöeÕ ‡HHÆÔ±Éäè¬_Ÿ•›˜rC‡2aÿæ~øşF{âr}œ.ÚÛÿbëĞN¦	Ó~\f;ğ;O¦B/—Kú"}‡~wr}Hâ2Ri!éƒØç©t£^Ô™h'TÜM~!Ü‚úÈ:yéA;a•À0Ï¾&ùòxRı5aşEÀrÌyÊô‡e|é¯AÇ‰_àåÕNZ€ÕX{à¸nPŸ»6aì}~ ×MÀ*è hãûÃúå\ç°ûºĞ8€±W°Îl¬9ÎdÏØ•tàûæ¢æ:;d(€şÕĞé!àÏÀ_ùÀô³,Ì¹LêòóÀîo@çc°¾Šñªé¯ğî›Ü?şÃ}µgqUñ³»ww¿D¦¡0€P(¥%441Bªğa…V­	¤Iä%)M°CÇLq†€™AÂÓğlH e¨E$0…RLP¿>ÆPhZµ|uŠN	5ß`eHFš®¿swïçvCPû;ó›sÏ}{îy-Û†İ¨lõQ–İ»ƒò…µ¾Ï<…õ³€şÀg?Íö1sY?sÙfÙ_ôŞl[l3š*›^¨ìşß“m*@·Ø1šÆ2¨sa[š²ßaß¥L­¾J¦j+N•l³loš²^ØÖØÙ'|:5p×LßG2±~°²uØ¢¦ZIú6UcÏbg#ì4AyâåYoR½tî÷[ôá>"våGb”·ÌÇÚí!ZÅpãÆœõsQ]Äi§ÒkÜ¼KÄÛ®“çl2Ş°ëÌ2ÕîBÃ0bŞSFpìfûoæ»v• }ŞK‰ûlbŸpF60DSô¿¬ FFî3ª"#nõvˆZE"Jãí(1š(úRzş"ç!w+±£‘ õx¯Ÿ¹}i˜u±g™ï"? ¼?è÷vô)›Û’¦Ú^Ã”m†ã.¨Ú~W4 §|œšaqnàø¬òb4°Ş³Wy!iŸoĞĞÚ>Cv:2dŸnØ.Ã”sÇw•[à§c½¾?ÇGq#9ÎqîÓóÃ4°~+bÇ_Un¢™¾_g Ù@ö8êÇ‘ëˆl…uŞ‘îDÙ`—Îv¹Ç](9/Ë¸wF2§Æ¼XÆş¤s)ë‰ó¢Î£ö=TâÇ³j5ç«<Z¬â 9Káh.ö}“ó*û¡µ~}b¿r±—~$š©²§Y/zıâQÊã˜(JÑF?b:ÁªTãâ•Š´÷‚ÖĞíK¥Î«¼F6©¾3Ş÷Ù3éYØ]–XM¿°Ñt~+¾‡9Fç·‡Ïˆ¬ .Á†›©Z´ãÎ1Ü±QÑeO¼ö°lçû¹Ğ—l÷ã9 ¯±wÒ_Û”.bJG[•C¼§sRÕ„¿£jû9ZI¥êÈ½ˆOm4ÀE,Qg¢ïG¢JïBåë‹ğl¬ˆ*ì>òeÿû¥´ÚáC	øÃÀX_êo'¨¾T¡ôãÑµì?V‚ú²à~…ªHÀÆ_ %N­sb°»8rAï–À]Ò×ĞŞ(êdæNÆÄg£šªO8OEåŸØ_Ü¥»Qœ9,ƒªÿp®õwÈ»™*K&Eô¼3„²‘¹h|Åƒâ—eÀ:ª¯·G¡Øc÷›OĞ1HaIƒ}Aü
¾WC“¬_Rª(AıpÊÍ,ZeåÁî. gX´Œy‘I#¬ô]ë²Ê?«ìT«æõC?KSÅ¬Ñ<ñÍ³$ÚéÀVØ#ÖÙGh¦ı8ê¬9ØÇ‡™‹5)4ÕY‹v–ÜÏóÔ—e?†XJ9j] JV–yw@æ­¸ÕOa,/ÚAyYÖ¤œ¾Œ×’Oİ“÷Å:5ço4	zzîÑ«ÓÌõTì2O¡Q™±MÖC¯SBx8È‹2£˜
QFµ £@Ïq`pø§C+±÷+ ‡ù¿€aş±ã/ ¿>ĞcAğ9×êB´Èú oçĞ8†™‰˜ùé15¿–F‹g‡³e=Ã*¥T†se¸Ê0›Ñ_Œu!ŞAÏŠE˜[@VO2]ø²zŒï¨ß´ßàı Âş5Šóóg‘ïV€÷]<©ô¿‹îW6t5¹+_3ÒãCÙxî0<(}ÖÒíúĞ_¡úCï[Ée‡ûÑş:Cóáwí‰Ç¾óƒĞv áæP”!>À| Ì#DÛXfW>ynw(¤ÑĞÓQYš»òNoÊb˜‹ÁWa¼…îe$ùBÊ`ğ\t;Œ]×3ÌfÊ°
0V æO`ô:õjÅx­Z¯ŞGÛyø}°–ÄëˆG¡f.¤aôÙ°ß†ût,¹Öœodw·çÿà;ÇFàŸë9°sƒ`«@oBM÷êƒ¨UŸÇ?æ	ZOt¥‚¨ã¢ÎÇ‡ƒ; ¯í{@/éè›ŠlÔñ!Ú‹1vhv‰ôŒ_Wö?Ù[{e¿ßpo=¯kGµÓ‘ë­ïXÔ ı +ëxthæÄº ¨:ËAGƒŸ
À:ÿ~€¼ß98@ÎN”1YX_”r=rÿĞÿ-íæÿãF)d\ ü@Õœ7üqÃT¿g4ü¯¡ß¿'ªÿ%ºP_¨ù3ÿ>×ıÇÑïù‰Vàc±Z^AMéª:µ¬ª¹¹~ô©ª·ãª4TMéSè“åèÅµ3×¯ ;ÔŞÛçizr+¹t	ÄV3“ úù@Ü£1ç/ç_ˆ=iÈ¯m¨-+ä}s<ÈÈ]iˆ¹0Ê6Ğ&ğƒËRtNÓ±µKŒíšÓ>Wşfsä-äÔ|óCĞı%>ÂãY>îb„sñÍ¢§Ü}Ë¹¼›ÌÓŸ•×y^#eå0Ü(äv­KÃu@O|OuîÍòáº#Àb\g\ñáºDóatïj{^=3 ş¦ò»›üô›b‘|Oû«–!ìÇIóyg9}˜¬©±—F d ëüÿ®ah#ÊŸp~‹tRNä å€ÿ5ğ/æÈ^î“ëŒ—QKÿ›CÎÕ•à]Ñ¤æN÷1£'{Û-×çª>„Î”ì•x‹VÊ î O%ßÿ8û˜…ÌËÿ¹ÖG²{µuWvGñŸ·„ÿ÷À§OC,è¢ÁvŒjĞ^š
šŠø>ø!bv‘İ(¯8‡ÕœÙ+§(q¾Ä¶h‘8#÷#¦ÏµÓñ«±„6qî\¬İµ«Ñšæ~LÛ°Ï¬ßÀ9ÀMG¼DEÎ$Œ¾µœ‡y˜û8t;Ó<MƒçïÄXºOG9pò•“¡rÌmèë'÷:Cã"—Fã0öU`–Õ½w«µkÍoĞA«ƒŠTŒı¤î£-)´%‚û¤ÓN÷Ë´S,¡Í©ã©
ÿoUà7r¾Òyº¿ªÛ¨İö¹ƒh:ß{ßíÓB}çpM äËE\'wÏÕë"B7¸#UßØSmƒ}Æ£€V %|çfklò(­ğsü“Éœ_LßÁ>Ùhg*İÖÒı"C·Måjäl»öé¥dW:Ë¢Ï‚^®tWéÚ˜¬ìæ•³ôñû
U]0‰Á{åéö*Jk¨ÀÜ'_OÎAÍÄv$ŞR6»†åd°}ù6·ÙÜ}úp[œ¤Íx£•>Ê`§{X·"Aë”ŒuÀ«°cIĞUËßJB¶ˆ:œÅ€¾X5bš²Ïş¾m—éÛb¯²™;pÿ%ëF€u·6šëãiÄ3ø”¦JW	è}å«;¢¦²ê`·ĞU‹úêÍÒs#©Ğ]{}¶Ss§ĞNĞJéÎÔ‡kpïÉX[NæEÊad³)Ğ† ‹(G 2Gì!ã4Û:A‹¡¯*àÇÀÜçƒç©¹ûé1#æ>c(Æ İş¢×V}Ç}\ò±' Ì“§óÎŠıÿÃ~ùWU\qü¼û3	&ü”¤„DK€‰PÊÏ!I‡
Ø !	2P‘´…ÑÒÒ©©†™ ’éP@‚…ú£ÒPZÔh-ÚØB[±2P-…Ô‚ò£PÁ§µHŞö{v÷æ=nò’aÊvfa>9g÷îİİ·w÷œïZ˜×‡jNvìÕxç^`úUÎ¬Õµ”„Á»lG†A=ÛÁat}VÔ³-ƒúâæ‘¬]²y$«õCnÀ<’õ;(êu2¿aP?ã:æ‘lóÃ >¿“y”†A}ixˆO?¿Æõ—œ?‘«WÂî…»ì{¯X Ëu»…qøŸ¨ù
˜6ÈÇâ"Ø
fÅá±D¦z'GÜ?
ûU5¿{Y-ÑcÆÑs}¼”Pæ¹cìØ)5óˆ5*#¶èöô¸ÏªyÇúÁ.Wíù9ÿFùŞ³qŸ@oåß6;Ï=Ö »ÒL±õZîPã¶â(úƒı¼&è î‰#®à\b±åX+cnõIÈURcÀÿÇ;³q&Ò }¤±nà.ï“ˆûò>ùô	´‚$yä(ÊG?Æ>Ì@Ü¬¦¡<†óô
úæ¼ËšÃ>J³©5È\]Äù mÍõÆcNSúÏöS­7ñTİe»ùQştÇCTéù´"eÕúïâ¹MS‘¯J‚úànëı@w8ul·ñ47õW¨¯†–Ê¢<?†*°fcƒ±ÛÖa7ßsåwçõß	'ºúEp»œ3æÛ6[æbÖN¼&‡¨óÎùëÖÓ‰Pº×çê*õS¡/öSMªE›ıùhÇc=Éº®míì”é¡áî#”)×úiZêÇº~ZZ[ä‡ZõswãwÕÓç úª§\7“úKípLö­lĞÇNè™ôöDVX×:ªMß¼…=-Ğ6†ş=l9w&ü~iô†\ww/Íqî§/;W´>Ù`Nş1ª÷É=0Oê¯É4Ï¹õyšê5Q‰[>JR²(×šú³>ó`o²^Cör©À}‚pÆE	¾Ï!ØAƒ>ß•úÌ½vëØQ¦êåÙD]ë]¿¬Uê9?«•ßzIõ/Ÿ­Rí[9Vá¬Ep¢b—4­à?úÌ~Â~Â:o”š¾½Õº~¨ukç6¤?“Y>ÃøÎŸKĞÃJO¶·¥°‚2Îçk9q8ĞÑa‹¶õRÛI+.h{RÛ?ğ^c­¶	ººC›L¿Æu¬>gUºú±$vn ¯»²mú;‰mÓë]ÙJ!8NÖ_K>kĞÀê8vSÜj]¿?…mtZ³Ö±¬ß§aİ×âÌ•vï;ÆkQ¯%Ñ"FûÈÑàå ]‘¿GDı=qËwÅÎğÖã½õÈ/E4e`¢¥>æü¸BìM \ûÀ;"¢vãlQhõ‹Ü±AŞOÊ:Â«Ç¸õ§ã!Šû‡0_DÎwÍN~ïİ+cçÂN9Œq RÅ8â+çŠ´-L°îÁ:ë‚ßvV~¯`ÎÁøºßÿõ;¢ÏÚÎHş]Ds£~wgsw'Ş'ÙÇY:¡ï%°¢…	Íyœ÷üFàÏQğyFÛ¨¦ëúø+Ç(Íëàep÷–=À`Æ	ïƒ.óYd¼3â]º8ÉçÀ~Q|Ì°–êh}üûÄÛØƒ'ı°‡ñÎ"yGbíug5ã;£c_^ê›È_ˆğs9×§4`oâÏk´àZÍ'fë¼ıâE/o•Û1šãíÂİö&Ä¤?‹3ÆªÖÒlPÚO¼~£ÖYÖ?—ˆ=‚røã1FõZo³]ªˆUõñy±×Æ]—ğÛîÁ÷î.õËfÌm3eCóÔ²^9¢;MsVĞ:hÊÖ¬äYXF£¡Ë4yX—r§ºñ4Í–œG»]âS†5‘üN§i–—O³œ÷ â«Œ‹ˆ“öß@ï^„æ¬ <ëÅÚ‡û`=ÈºÈ>uDL±wàålÿ¶BáØ°«¨0²µ~ÈAıÍ°‚•ğ‡À>î»uı·©Ğíƒ¾\øLÚíWVb)¬·v.Æ@½õ{´«¦ÑVu·40MÃm^ÆãgÅ²]¡ucÜNiv¶öKğì8HáşÕÏ‚6Åñ6î?ijÚ&hªŞ`ht‹Dcä<å8åÔß4àKÆø>ô‚ÖQ8­b&Ø†òeëUªbì˜s@4Ú[¶îAçÖQ¡×—¾ïö§¸yİ‘‡ï¤¡ˆ?ĞÒêNã»İBg™¸ŠïVmÃ<Ş“ìÕ¶ÑûH­Æ½*S§ÀZ» l¤BæNÂŞ¢«·]J‘¹ˆóYt®ÿuZëo‡–ÜNwéXÄZ‹sIOÎëğÇñŞq‡Q1zBöÅJã>³øüVé3\å¬¡§xoi-ÈíwÛ}é;°c­MX‡I”£ß½LßÕk8ıns±FÀàOdà72	ÏoHÙÙ†óµ±eüQíËø35×|[¿¦0N3Ú1å4Ú> ^wNu]özĞHÆZ‚ò¦Ê4ÌO¡aòİÊ®ËÖ)Êcì2¬qYû2ÆŸÌ´ıî.ÊöVÄû­mO'ûı§Åk¬¡9úØÇÀ6|{YàÙqì¥<´{ÄºŒ3{ùáS¨b8âáiì»Ÿ‚Oäş{Lõ}>1zm–p`Ì±ÚuëR»Q4qœc­(õ ô¿+ÎGŒ)ïe“i–Œµˆ©˜KkQ¾§É”&ñ8ÎpŠ\¦4@g¬P^rŠKì[+pÖÁ¿Ï§©8Å1Èwæ£îŠŠY2frlãsˆxeOóPş‡1ÈzØ¯ªyXç¨g¡NÁ9'ö$ç&;-Õ¯õ!ÆÏwyn+)‡Ï Úu¥—´¾4fS¸Ü•.D›C‰„ŸÛïã”SòÍ(hšVÌ«/kù¶{×2Ä9Û»UŞWdÜÁ·ÌnÓùœó8Oòwâïµ†z"¦d·»Ø´˜¿­[O¹œ»°N¿Gì|…ÌÓ¼ge¬ŒĞİrÄ8½ï<©kø~Çw‡âÍ„»_p—ë«÷ÖPü¶Èƒ5îKTªóı+è;¦yŠáy«ˆK\ÿÂ.ù^—Öˆë¤¦=8µıywB‘Ô)Rî ‰Ò°çºy`"mÒAÔKÖõ½3@3QæJ¢¾'ˆúOGâ|¾OœÏ$g úÌm@À˜7£ŸüsDƒÁšˆ†‚a·`n·`=‡ÿœ¨`+ÑˆZ¢‘5ŠQX«[Q?ãi$‹¹[N49d"´ÙäÊÿ?¦LıìS„u.:e0ƒÁ`0ƒÁ`0ƒÁ`0ƒÁ`0ƒÁ`0ƒÁ`øŒ!JCQšHëÉ#‹zĞHª ò®X¯“‹2QíÁ_›øß"ù—}ŸQŠú7&’¯}›zGæjßÿ€ö=ø«µïÓİ‘:´Œ8©Ügä’ö#4Äš«}‹2¬ÕÚ·Q¿Vûü}Ú÷àÿEû˜%è9Ê¥B…ÿ_‚WNé>Ø¯ÑbúXNÑYS‚ÒRøü÷ÔWÉ#ğä¿Ô–ol“ÇÇï¹~œ”Ä!„ŒwƒS'îC¨éÈóĞBµUQ<HªL]…SâBDj[‰SVhIÚ©R	*¤ë&­«ÖShcîÔY‚â®«TmêbmšJ'MõöjTôÅŞNÙ÷ÎÖ´›ÔNÓ¤%úŞ÷»ßçw÷ÜÏvÉ0ş9„¶cà³dT?%áID?‡r‘.êC`Uì€²:ß b…hK“gşƒ¹¨¬)±ÂõáiOjtA£6 Ÿ*#§ĞÚ¡3û¸« Gñ4†Ş¬­Šnÿ™°£Ñ‡Dïñ¤èN§ÒÙç3IñHz$“È¥SíÂ‡†ÏŠCÉÑäÈsÉÁö¾n÷á6wdh`8²?=<Øİûåšt]Š‘L>;0rB¤Ÿù·Ã‹¡”È¢¯/5”MŠÃÙlpj°#="ÒèGÓc©ìÈPr´ı¸İ}ä b»±ğ=¤íŸ6?Bö#×0bº1¾âaÁ‡õæ9æ¿õ{(«×Y	‘OÈ¿ø»Ş;áÖ³kdÂ…R@9ˆ‡]óÌzÛ)À›´Ëæ6{~¥ˆÊ×wéöÈì‰E6K]h•}ªyÖsµµïÚ[ñµK¥Ûl²¹»XDI Zë.@ÓĞäÃ„fÉgĞ
ÄØUvIäÈp‰n»‚›ÍA¹­@³¿‚w¹BîU[j0«Ë^íj5üeMmd—APZĞ4-C«Hå4´1Ô.¡ï¡ì»(-n¹uìm2Qöc0Â‘ıG¥×æM/°Öv\‹ıÄ!Jò¬›!Š´¯{P„?.#ê%|Ü«k°-ÄŸÃ¤Ïa"ç0d¥¡ŸHÅŸóÖ6«ôß“5š;-£•ŠgµØq¬Âw‰Á’,E¶ÎÎÀ·ÀÂ7ÃŸfƒ¤^ÏÓñ–=ñºŞÅÖ‘èvY3>çœ=Ê6:lL6TÆ“;Â6ŞøÖ¢C¬tÂıÌ”6ÌÑ‹ÿªW{Ÿšß«ÒZgßb¯0“4!jQëyà«ÃÎÖé7éõjëí)w5ëÅköbY8æh`•S:QJ"‘»†`›H3úN°Ídü Û¢ı§ì"9ÿ‰×º‰Øšú¾JŠá÷UÖ>¯¾Á.ºµlzóì<6à¼|Êkİc·•í QˆbÇQ×‡~µIìÚ$vj;5‰IMâôv=gÓÁN‘;I¦ iÔÕ±Z'± óº²}‡=Ï¾ÆZ°0Ö–Ò@ë¯¶AÍ¬E6®Õa-Şê»ëÅ9EN‡e½õ-vz…õ«<àµlT@Fâ¸Şbë+[°YmÉ-¶	¡f3Û"×ñ¼Ëñ¬2'ı5-©E¢¿§PÛM—ñ¬ü7Uÿ¸ê¿­øJ‘–*
ú;åewı3’¡"Ó¨Qº@?ÀåÏéiAÍ‚~JçIü6áóğ]ğ_Èû?âZğ`˜û[²¾Y½,ı@¶uT+<X­¬ßX­46Ûnş’¾O6!Å'ğíğ÷i‘l…/Á[àEš%ÁoĞİd/üçUÿ]TGœ¾Go’=pO6¨)ä¥©lNú”½+Iå)ŞÁé»t–l@è;²uZ¯z­Ûy`ùz…fåfŞèÖÑ‹F¿ñWåÈmå¤‘^’1•dJ.
>O§è”Ós‚NÄ™aÑ`4a"(""&f„kÑó¸@¦)>¿ôÊ§r )zVÖÄòîßğNê½(™@™ÓµÊŒ®”Ö?z¿Ğµ.ú
é(rœÆ¡	è%ü`›¢§ ÓĞĞ‹º%A'q›d@d@d@d4‘‘‘‘ÑDF>)""""¡‰ˆˆˆ„&Ô| šˆƒˆƒˆƒˆk""""®‰8ˆ8ˆ¸&„£	„ÂáhÂá€p4ÕDDDDTQQQM„ !4!@„Ğ„ !@MX ,K„ÂÒ„¥÷gRDDDDYeeeeM”A”A”éÉë¬ä~¤¤¤¤‘’FJ@J@JÕWÏêÅ 86g qhRllllQ³E}¼Æ ÅæAäAäAä5‘‘‘‘×DDD^9999Mä@ä@ä@ä4‘ÓwRÄW?”_ykèKF¿ßµtÂØ©}œÜÕ~†ÜÖş"¹®ı2£ı4yYû)Ó~’´jG>íYÂı†ä±€ÛŒ+ :¥¡ihZ‚L][†>ƒVèngkMÀì1§Í9sÉ\5g–Mğõø¦}s¾%ßª9_ÙG…»‘Öë{W¹ Ëq”÷ |‰ ìÒµ.Ú‰q;qÏîÆ'ítÖ|.î…å°±6æÂÆ…°áÖÒÇŒ}Ó	£˜¸Ñï¬nİÇoC±ÖĞ>ÜLçoŞ]ÏeëC¼`,Vl§Ó¿]‡f —¡dC(qİF|¿³µšr
A÷CBAš›ñ±qß™§õÆŒ÷a=©Uã„v€[¡(¬ C=°÷dèiîÖ7IHı*2n`çfás’ßA÷;»&ùìªä°§d¨ö¤}Ìİz£ğ…öVı0Ş[ù!ÉŸ@Ø·$ß	k“¡VÆ@Aôî4úÉx°Jm¯Œ´Mò½°­’?¬¢ı$¤6Şğ‘ˆŞ*H9ó0¡{óFáÜÇ?çoğ»Àÿ‚…ÅñøTj`ËÁ‚ñ„SÇ#o#ØåÒ­Sñø~¸^õ¼ò|&x–¿…\Fğ&“·óó‘‚Í¯aŞgõ’¿,
tÖYË'x”g#wø(ÿ&à‡øSA´Kş¾¨¦I¾môÓÙ›<„ßÀ[%,XĞS<ÈŸçñ‡Å¢Z_²§’7YT+@ìÊè`}ÃÁ‚:ã}±‚±Æ	›_˜Sæ“æ~s¯¹ÍÜjn17›MşF¿åoğ¯ö×ùı~Ÿ¿ÆOıÄßTX);mÇ¶Ég)óÕ¨²F×-ªJ(ÉßI¯ß$‚(<³ ´TúË¦Á"aqV7Hh‚hÚta»ëÁ½´¥‡İÚmCÒl²»íõĞDcjzòŒ—¦ñ4‰&&Mø'úø7xÅ÷fùQ#7fŞÌû¾yßäÍ,ËtL ¯	»0£¬Rƒ]ïcOd¿ËR‹†7¶ÙI¥lÖ Æ–Ê^ÈF+ÔİdÙ`¡õ7¦Gé¼LøØ¢dËlÑ.ºNclv@rzkJœY‰Î+Qevuæå+mDSéµò°Dowãì«Q6Ù÷¸Å–°Ó[ûPwÌ¶0%Dt­-L¢±ÌvğH˜Ò7Ñ<Ò, ıâ48Í“@#Ñ mL%"Òà÷DEì‘ÏKÃtà%Ñ /!iÎK‡#œ¤ÈónD]óD‘sR„ÜpÎMŠÜâÀ‰¹š—Ns–$RYÔ”D¾°'<P"”L‚S(ü¯ã”‹±ì’êQòJkè“ğ9s‹}ÎÜ"päÿ,UU¦Íœ[ëèUI¯Hzj…}>>ˆ²÷{¢èÕ\DHWööĞîV™+U5V“4ÑËuFÀ„s’æ‘¾ezbUkäŠ9]ÚÕ¬¦²b–şÒú4Ğ2WF[Á`&j)¥p	aµJ¨UB-¥¨p-ıÏıºéÕZÛñmS˜Ã®Ä’–:?}´Šº½œŒÖbWAB/É„l±{’Ê"PÊ”2%„à9ChÜS=(Z[NÆ®èeš÷Œ¤’~j	’–ß0X²¼mâQaÅİÑ{fcáp”è‡|aìğ
ŸÛLb,Î¨âº®+Û„ìiÙ`Ï7`%¡HU4|Ïú¾@€û¼ñq½Õ½P†EPå°'S2XÃ­+$ÔïÖC^œæB|éíOxƒ¿ƒ
÷8á¤‘Íñ[ÄIóQ
ï/N3›÷-\WÑ6’K Ğ,ÀT´)ßg2Ğ9OgÎõT=S/Üïp&.ğUÚÈ^ˆ#ÛıD@×± Ù°,ÔûÖxçÂuìÈ²%Û”çëßdÓ~Ò‰µ{QmŞéoˆï·{A`'|u·?ÍíMâ Ë'ùAüÑ ı` Ú@¯Àendstreamendobj44 0 obj[52 0 R]endobj45 0 obj<</Filter/FlateDecode/Length 446>>stream
H‰\“Û¢@@ßùŠ~œy˜Ğ@_ÆÄ ®‰{Éºû­C2iñÁ¿ß¦q’%ÑäØTÕ©²+­÷ÛıĞÏ"ıåÇöàfqê‡Î»ëxó­Gwî‡$ËE×·óƒâw{i¦$Á‡ûuv—ıp“õZ¤¿ÃáuöwñRuãÑ½&éOß9ßgñò·>¼Šôp›¦OwqÃ,¤(KÑ¹SHô½™~4'Òö¶ïÂy?ßßBÌ×î“yä™vìÜujZç›áì’µO)Ö»ğ”‰ºÿÎ•!ìxj?_/ÂëRæ²Œ´Ş¡ZA;¨”IheĞ·H¹Š¤2È@d!QAQ!„GÚD*¨ ¨Pà©ñ,4”CTĞT(¨ ©PPAS¡ØBU$…§ÁS‘ÓS‘ÓS‘ÓS½CZAª 1OÃ<.Å<óÔtkèV3OÃ<C›‘v“°LBcm±ÖX[¬5ÖkµÅZcm±ÖX[¬5ÖkµÖ™](×uü²U©ª Å›GæÙq-¿~‰]o¶‹S.e/ëãV.×6l—xîD{ó>¬C\Á¸Ëôƒ{né4N"D-ŸäŸ  ã%ì­endstreamendobj52 0 obj<</BaseFont/UEAMSO+ArialMT/CIDSystemInfo 53 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 54 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278 333 278]36[667]38 39 722 44[278]46[667]48[833]51[667]53[722 667 611]60[667 611]68 69 556 70[500]71 72 556 73[278]74 75 556 76[222]79[222 833]81 83 556 85[333 500 278 556 500 722]91 92 500 191 192 500 380[604]402[354]404[604]3032[83]]>>endobj53 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj54 0 obj<</Ascent 1006/CIDSet 55 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 56 0 R/FontName/UEAMSO+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj55 0 obj<</Filter/FlateDecode/Length 41>>stream
H‰š y€›k:ÿÏï?€±+à``ĞÀ.3
H  `Jendstreamendobj56 0 obj<</Filter/FlateDecode/Length 23030/Length1 52254>>stream
H‰\UxMWş×ŞûÜyŠ$—Ö¹d*7)‚zN„›AêÆxÜK®$ê*mTPU¢·^õ©!U£ŠjõÄ„AéèsÌ§D1EgÆ«:´_=f¾OÍ÷Ì:‰æ¬ïœ½öÚë½Ö^gÖÌŠbğ$:/è”Æg?¿‰ÏÎÒ·ÔpN*/™Ú¸w–Úµ’)³'6¼ˆd¿[
Ÿ:té ?š™,eB#~:”NUyo_t;9eúÄ ¬X¹¨îÉûÓSƒ•å÷ÌÇóGŸœj¥wëÈûÎ€ê\>3tïü` ˆùR.¡•Ğ¥Õh]ÙË6«ü“D‹(MÄ8”°u©ÖATzY´‰-_˜ëÕ‘İº£ˆäQWg&íÌY–ÅvR´lëPÚ>$ñëÒ¶ I¥ °.ó{Å^#eÖûÜ^Å÷Ì¿çŞlÅ{T†÷ğG|L7Xê}ìE!ÙX*¬F5Í”—‘Ï 1}5%Yuè„\‡8Â¼£0ûĞš­ï0‹ä	–Z„8´GŒÀt,£¡VÆàœZˆŠi(§,¿µÜZe½…ÍØ+Yw¹².Ld8b]ÓN[C:K¼†u8G«šìâŒâÊï•o`&jäXEV‰õ{àÆsìƒB.ĞAáaí!\¦Dª’^Ö²É2­O™«-Æ¢5ØGİi pkc¬\ëZ³JÖº;±›aàkŠÕnXoY7„4æxêp”ÊÈİ‘~œ1³Ô½ød:>ÄŸpŒúHL×bµ-K{Ş:‰–è‚‘ìí–üİóæËÏU5 M9/¯ÚÙÆg¸@.êDÃé)ÑQLäLD±Å.Å(ã|¯eígÉC»E¬¨—›ÔvuÛñhä¼Õ”+’‚×ñ>¢8T§gèEúŠ¾^1^¼..ÊÕj›:îrÔã0Ë°·¨õ¤<ú5•RUÓ«´Ğ1º"ú‹Bñ´¸.Kåy@`(PÏ¨…ÚbíÇ•ˆ?òiäËÈ-+ÃZŒ<î‡ìıkØÀ‘íE=Î0œÃEÒ(†š2èä¦‘4‡a-£ßÑVÚFulå]¤ïè_t“n08Dáí1S<'V‹õ¢á˜øAüG&ÈöÒ#»Ë¾²HNg¯ªåJ†]ò‚r©zeq3´5Ú›ÚVm»ö±vÃë|1
Q_ÜÙt7õîÙ"K"k";#uÖ´âº8íĞ—½2Læz¯á{'(–sç¢TÊ¤¡œ™ñ4™fP%gò%ª¡Í¾ï ıœ¥St}m|~BtÄp†q"$fˆ•b•¨_‰Ÿ¤SÆÈf²•L•åX’³äl¹FšòùwyQş(ï0X*ZµSíUŠò¨j¼ªPÔeuY£Ö¾uD;¦:;ö8şé|Ò™éáÌsu®pîvŒ
pw~‚]øxè¼\ }r–‹®*IG¹ŸÇ£Xæ
îT±•–ˆ¹T':h•>¢Ã•Â¹ş\¼)~}d.¡L]µ9Zªwxé«>ÁUµŸc;Êš+±4O\wÄb'Aôb›ŸÉÎÊ#ãkyœj#şª¢)®Š-rwÁ•©ùá–ë±CÎ ¹Ø%|@ôí¨¥ÜÇÃè…”Aÿ–¤Æ]ÔC~ƒ…xZœÆU¾ÇKğ*V%X®T…Ëx›oEGmš#ÕÑŠş,ÊTX<BujG×‹:ÔZâ%+k×ÅT ^Eã¬|—½¯;d®º¡åS)ß€¹XŒÖÌÖüê8•@ÒSHæA»U2C¹yÏSeÏ´İ|»÷ñè/s™’È3”ûb$Oˆ†µ<'wPßñQ<Å¢ÎQ(ö DkJ<uxäc´õ6ÖY%˜f­B:Ïƒj«Š5nÅ·X­´(2åxŒoÎYªåˆz-ÇJaqFˆ5×—³L‰øao2yÖ‡Õ) ŸµÔúw÷ã<a×a~…Kå5¶0HD×È0QkåÈr÷ò¬-V;ŠF©5Ãù_¹Ù©!èôpM:ÎñÎAHä[³d(RÆyXÁYÈâlUğüy9Ë;²°V¿Ì_öíÓ»WÏİ»uÍèÒ¹ÓéiÔÿ"%¹ƒÑŞ­·{ìÑ¶m\I‰	­[µ|¤EóøfMãbc¢›D9š’‚æ3rº™0UŠ1hPº½7‚L>@˜:“ræ1õ@›ş0gsNú?Î¬FÎ¬ûœ¯÷Eßô4İgèæ‘lCßC£óüŒ/Ë6ŠtójÛ€¯lÀãw»Y@÷%–fë&tŸ™óliØÈfuµ1Ñ^ÃŠNOCmt£1Œ™	Fy-%dR"|½k¢âØ)ÓedûÌ$#ÛöÀ”É¾`±9"ÏïËnãv¥§™ähL0a0›yXàm0c:¼¦³ÁŒ^fGƒWôÚ´ƒá¥{â1!à‰-6Šƒcü¦Ù6š{Øn¶™ğü¥ÄÿmYy¯¿úÁÓ62ìK,Óím8\­›¿Íó?xê¶¿EE¬ƒeErN œÃ¦—r‡èlM,*ò›´ˆMêv$vTñ…ŸM	LÖÍ&Æ £4<9À¥q…MäÏvït¹²öZçáòéáB¿á6ûµ1Š‚Ùmk["œ?û÷IYzÒÃ'éiµñÍ[Û´Ù=$6îA$tÿ¬k`·±!ù÷3K¶GÆ`nSŸ¨³'~ƒcêiB=Ø“Ùø)"–2‹¹"efo ßÛ¦Ûò¦–oèá›à0®şğ0%xâH¿	µûä~«ñùÏ¸éñ˜©©v‹ü—ñªêªâ÷ã}íÛ·»w7Ùd“°ÉÛlóQ–4›„lØ˜×FRm†BJ6²5€X¦ZM°S§õª³Ğ1Ø…%­Vii‡…l˜M‡3:Ôv„ÒQ@,N—F`R„fã¹o7´ñ§oß»çœ{ßÛ{Ş9¿ó{÷ÊmSğñ¦İPµì±$ñûû™Â‡º ¶"ÍÕ~Ÿ'xwÒ@Áˆo[İ“±u´±è2ª‘8éã##în>²maäöã}~@ra w\)¿}:X^ÎÊ-Íqœ÷†7gÆ;Öø;V÷öè+c}ÙØv¬]deÆ›neµxN[-"YQs@¹şöÍÜèÑâBœ’	ê/$ePiö`½=Îú>•i#ªÏ÷1JÎÏğ§LñácY7ãÍÅöŠEö"÷´‡áSÙ±¶7SÔ2~:+ ñhmOo‹£n¨Ì28“óMüŠÅY¿ğ—éÊš‹n,Êê88:«–µÑÅbí~½=ÖÛœß¶Ñ¯3l”L’ÉXÿÊ¾à$çÇvÅÛ÷D V[p3A÷õã]«x×šŞQØœè»Öö#˜´õİá$mk{>š=³$"Uˆ`sy+Â¦Éùœ>g4>yètâCD·.LÀg	}3½šô‰o"†ZµÂsÉ
cIFí
HÃ)´?ˆ(£:¥ôeçO÷xl6:7›b³)Ôn×Öà(.'ÎúåËƒ’?7ÃøÜşØÙ;¾ıñŠ Ò«Çñl¿òöÜ­×#±}¯ş*]’ÖÍ¿ÙĞ*I%#•aä²pÔƒƒL ƒôA;à!ÁéåFÂá0•	›ÍTŞ5ªJºö;±¿ìÊú€ãüÌñ#g}E9ü‚yğ¥cdn;J[*Ø>ŞÛyöeçñßÆG÷Åzß¸5÷ö•ôÕ´^¾”>‹¿»­Q!¨‡¥$î2Ê1‚UF*¡` ©Inş,¬Ü¾
ë!HÀõ¹Ÿ€'×£×/°T˜…Q+oYŠÍ¥°Óª­	6İ¹’\ÑØ¸üøt×ººP#Ø]ŞY°ás0ïİ8I&@—ı¤Ÿ’NÜ	Sú)ûá†¡ÿ)O`»e—Pugª¶ÀK6øÜw“;qrd„çxšà=Ee†‡pgÃ aÆ‡ÓËÙhâ”Ê856==‹3ØÍ!1{NÙñCÇ±İ Éù«‰¬r2 qåºÑ4©Û¢ñV4ÛjVÃR¶XúØ.:È~/şVš`3ÌªˆØ*u±-Ö8»¦]³]³[M°	v
ËQ4›]‘dY]=€¦1šFº‘.k¹0D(å}nŞGuAË…§,Å¢¨KTJ’~Ã‚í²µBÆ°al5\š6Ëôş.Øzœè €…$Æ†µK›ÏitPÃ·™C>)“ïÈÛd"?í8uÚÌŞ@\pzR,UXÀR)äi¦Z/„yVS;Å»o±©wyLÉSr†B;ÙÔ”}jj§˜‘ ¿¸uMG¼
6!8¨"ÁîÍßh‚#‚·˜€ü8ˆıÔGs|´¼B’)	ş‰ôüõğÜ3ÏÁÿŞß^º$(İlÇãéO’^¼oôëOíæYşâü?ÅÇ ’¼èÍ‘Mäa/ÁÉùwV«Ôñ{Çø<×tTgÛ«ÖG½ÛĞ÷¼ƒè€x˜¾`¥	Ûïl¯£Şk^§İåuz½t©Té\ºD/¹×ö@î:÷[Ä/y¿áÚí:@÷Û,9„N9ÿlÏõs!Ëe… àì±ÊÌ9aTU†˜a¡(§X£EÅ‚…•;îCå:Æ¸°$¿\W°¢qo”‚âMë9z¯¢©U ÀÎÔuÁÖ”3Š
3@¼çK‚¿ôÒPïº#X'äËååşR‰¸s]yÁºF!1Ù’şÍÅTúô3GpÛä_ğ²'‚“O¿øõ\Úñ³¿RûŞ­_ã¯¼qw=ÿ‡ª¡>Ÿ~oï«éË±qÀ8z0Şw@ì.Õz	nS–x‹=NVì@
¸lÁ%§‹Î)È¢rş±xÌ}·	ıÂ/Ó1g5ó.û¬IT¦ÂïåfÂÄqrşıÆ„¶ÊKE‹W¬çU˜Á@4<Îê¼*ÁâWmMÛãF#-’IA¤O¡‡HVUSm*•Üy¹y9yT*¢ù>ì²CãQ–øpêô!ˆb °í8túêòÿ\î\b'ş2_]ãòÆÆ†zàE¿ïYüŸÃ½ß<úµUOìş~ú(í}¡veç¿¼ê•ôkâ˜Ûû™é“S¿L§_ÜP÷JcíÊË¿¸ôşÒbxë ÃíGŠ^Á°€&" a¸©¥Ş”ÁúŒ¬ªÉÈÊ;3Ò_–‘ŞâŒôšÒXjcõº8()Õ~ ŒGB5lkºĞ94ƒD—ƒˆš·[Í {²w!ğW?k°ƒ˜ñ¼p*ò‘`ÃŠäØ6 ‰hd`kx.[† ğu+Ğ¡3è<1ÉKŞq`å~xG+NÅ´tyH±4W¨R£z¯ºî §©ü˜z†dp`˜©÷1ñ%á_Š¨
¸A8%@ÍyÃâòÕS7P<ÃZÈÅ{‡ÁV²RàÒkÊ‰aWï?k´Àœee-Š¥  E’dìÑT‘
‚.ª¹¢–¢Ë°¤¤ªH$&²UAŠJ‰V IÒl8jD<$ÆÅ	ñ¼(ˆ÷)¼ÏZ#cX/.S9IvšUÿ˜@¾¹ ä«@ÖVâ´™mj.:òLÁ‡/†BÃ/W¨š§§Ì)€K°šô MM"aş­¦ÈQ‰¯u¸13¬9y¼fŒ|P$fwÖ+ÌÎê-\S`eæ˜üa]Ãi)…¸-+	ü*-
hÎÏ5/$ñ°Z]!¥47$¹!æ‘2Pİ¡À‡G„ÿ1Ø NÔØ‡á”û&É[XÛOœGs³3â¯ÖØ(®+<÷Îcç=³c{Ÿf½kï®½6‹müb±ÕŒ(°1(ÇŞ†ŠŞ	
4¢hÒ¤´" ¦•?JšºŒeZ‰F–Jš´ÔŠ¤¢Y¦MÿH‚wİsîîR´^Ï½gæÎÎÎ=ç;ßùÎD.E?Èıjæ½ùI^ 7â8ÉÔØtê-lEDjèBÙ4¼¬”TÁ€÷úÌ­CKwpY´t^á•Íäd…ªš„1ÑlŒƒîÃ»4pób1Z_–¢5SˆV#¼ùØ €¾zÕ~ÿı«^Ç›+øˆüëVyXvHläÙ(°Qd£Œ1®A‹2şæ%Œ<5ïÕ}•’,‘İªĞJŠDªN«ÅQç9bjœ,ªâÆñiÌ`¹B×søj½kpì‡8©Ä•ì±Á½L7Â˜®ë*l&{/â„İCµär–…}úQı¸R_®/·ø”0æšù~aŸñ´9lÈåŒÑn®¢=üb+÷‹Lõ=ÍŸôœ”Ïñ?÷HµL³I¤cTÖ£I”Á”õ5Öâ‚ĞeEÕ€…LÓÆ8mr;Ô™ ç8ƒ4¿%FAJ7»ª®¨QW?¤m6iVè8È¤wÔÚc{œ®¿7‰‡E 6znÔÛ	LD™í
@Q`
ìĞİ“©,èpƒ}ß'*Ókø “%04¼'?~Ãé³w ƒ×Aâ]gê£ç¼ku,çŒÙ//˜*^…ÔÁÓ¿ŒÅ2æÜXÆ³#cÎï`æ¥4\M“¤ôdph”âó·w˜·ÆKjˆ÷‰“ş&_°<BÄ+ùõoæ7ŠwnÿpÙêŸğ3_/Ş½Ó&üíN´P‹…dŠÁ¸·Ü¹[¼;ËiİSŞo÷—špş ÖfNv’²Šø–í":§İ0EECşCã–ãBav™}^"³àıU™•å•ö`Ï{¡.cQ"c¥™d¹Ba€,¡±˜ì»5•¦Nôî:Ñ÷Yşüä»¿şYvEóóùcâ„élÛ}%ŸËı’'/x®Â@ErªÌx!ÀU“7æh&qÚ+®zLŞ]rŠå=lŒC}`tA™f†^2´’áŒÏŞuB­0>Z]ÛêÅó9µ­vq¶Š3¬8:'YX‡ûíâŒëîr0fwewt­6P¹»òIåis¿uD}ÁzÕxİ·>6oY6ğAÔk•{½–×Ò'Lc!Ÿ*9^ÛĞÅ€¢øü¡`Ä%;ˆN÷û¹X5‹g `Y¦Iš¯I¨\1TR)TÖËjÜ‡$á¥l4¾'~8ÎÇ«ÿoŒ¥bŒÿ[yÕ`ÁZYªXä^H-ã†àT å¦T1Ö°Ö•iÊ! R‡Íy"T.Ãı\QW¸ªìZË^èub–A–S&”œP0ã…ªäÀaº•Ê]]Çİºƒ™4ßçÃÔš¿¬†ŸGN5Zˆ­šØz|ò½¿ÿsoİº³Óo¯{|C:ÖówræÈÉ•¯Í7‰«®ííúœD|åŞü i~şÅš'·—oéØÿà¶£Ø7ÌŞş	}C­pk7ó›…!ş)AHÔ¶ñ™ÊoòË=+æ,©Z_Z»–ïóÌÙPw¬Ì¬Áı/‰’‘,µ%£†…¢psÁH”ŒdÉ¨E}¶­:#§q¾6ÑnµÖ,N,i|8º¾f]b—¶ÃØi>V¾%°_;`°Ú{ãC‰£üqí˜qÜzÉ>.qÂ8i¬ˆkY:–tÂÉ’L‘$Ç¥B0¿9Émä2ÒûÃÇÂ4œğéHm‚$DŸˆÜQè\#i%ññ¬i€F.GqÊ,4Ÿ>a7ˆ›†&Æ WËIà©Dñj¸&‰‘p:ä"ì^úÔÇ¥YgÄ*ºM¢d5ÙDöWˆDÆÉy·,?‰?oÜ­$¹IÏ~rÑ4éº¾šßK…æÃHÒAy‹KN	äbÙbYş-Ì…`óæ~èlï ºÖ•È`÷Ú+4îÓ¸#€1v¬LPM\vğŠIv°¬#B[æ»ƒxm2ÙÖÚŞŞ¨,ö`å~Ÿàg • CK\6¹vğ‰_¬]=Ğ™ßõĞö­ß»ıã³_'¬‘×ÏŸÉ, İxøÀÑ;?ı]ş‹Óäûñ—6,Z¼dkÿ;g·<ñÛG·¿÷¬ùı<Û¿ª¥eg]ç¥}{ÿ4ôÔ?©MP&€=Ü1×iÎßEA§C£Qã„\–¢„6ò„ûaÔ lâjŒä"7Ü.‰×%’˜)‘B¾ 1ğ‰òØéû2pg—›ÊŞD2(PsSÌk‹UÄ¼´,?G8‹ÆÈÈ×_àÛJÀáKámu²cš^èykÔñ£Œ¿åš`Axdİ Sşº`u08I!%×«¦°l“¶iI‚(ğ¼${IR$^QuìF£ªV®‚.ä%…ÇDòáU>JI9¥DÒ5‰€£ˆ6Nƒ®¢ª
OÁmæ8¸Š®¬qÕÃ*ˆ0rÉ54MrüšUôeJ)^QáÊK¼êjÌyzÑa7Š.¤1Ã|;¶	´¹
ı +L7ÑO L¦™F#Nfx^Cƒ|)¢*aÖ°999lÃĞsŞ
¤ÈEYWtabvšãg§ÉÔ'ˆKÂøTaJèŠ>ºDªì»‹×˜—´¤GñÒÎÜ»ÿ"±ÕK}›TŞÈ]¦»ùŞüÒgz…¼93šûF)˜:Ï¢¤_pLÌQËğ¶.#ÊË^•5…ùÄÔ9Ó ZD—e1"Qî\×¹I‚‰vŞÀÇ„Š*Èªš„­N%_©D¡®«uZe+Á#<
³€‘.Ã«ğ1â‘¨¦FtèÓ®Kğ^¸?ÌyšdW¦r·ş (ÆI8QzˆˆKÈîŞi "d6Ô«éÁ.{Êá”xty3L£„|ùg¢§íÉIò$vFĞÁ0_ÒêX†b[`†V3Bİi#íˆlâ‰U¤è¿W/›ù£šy§?w‘ãÑî‘‘ÏÖ ÓîÙ…Já\×AÓî\ÅPêƒF¨>eÔ×ƒœ®è/¬_^Ÿ5²õ;Œíõ›šÿaºÚƒ›8îğíîNÒ½¥ÓN>ùü,)ø!lÆàãa±æa	J„—I 9Â´L)¦ĞÎ? ©I!´PZC (ÜÖÃLÓ0ö4ÀL<Ğ0İ’“ZlwweÆzì×ŞÛı~ßã·«ø v(p\ğE‘É#K ~â,pÌ8=gü>ÚetGÿæ»uÎĞ@.Ò?‘ÓãÁeºåf4²tË‹KV9ªâ³³â‹œKb«œkc›ùñáŸObÊÄ¤rI(©—ç«ş×Š7“Åf‰X#îÛÅ‘n;Äû"%ò¨ÀE$¼¨æE´°O–™f‘G’ 2’?E“ÒÏ“'Îù¨¦ÉhR KGmÄ]nR\ñ2yÁ`’„óCHªGò®Í¡»!â¼îƒ›Çƒ‡øàà&R)8Â…Æ4)t|Å#6Q$å•uÑU(ï!€zã”¡{¶[˜,­ê¬"W*=ÛTôõ°¿ $t™éfH‹©aHFÄá
S™ñãTÅ£‡apfDœ°d´8SVù,ûf }ÄdXNÈKÆÒR¬z(Ößl¥/V30Ô§ Œ4:?“5Ï*lœˆÂØS`ñÅˆLÙ6“‰ø§"AvÂF¦Ø]4ŸOÕôÂ"ŠaE¨5èApUıú…–K3ßšU±®w5HÔîŞ¶5xÊ¿¾gÏîM²K/¸dêË»6,-síš_w4×ıfçœísTQ„Âîõ/L^’ñgŞ©·—½8~ËƒovN®·¢¦m,™•~eîäïÀŠŞ+Ú‚Š AĞf4/…è
º–¦k¬SiYfÂœfn´ö[Ì$oµVhĞ)gJxIJi¯Zœok¤õÚú@§õ9ß«÷ÿğŞÕï_o[#–‘G—H%j)]#ÙtƒÔD¯¢{ƒƒ2/ûDÔ•“aÛgŠœ?ÔÃ™³¹4×Æ9,¡ÅáåüxŒì4ã?À5„Ã>*8¸‹İ±KÜÛ@I¸ø¶¸&ÉN SÈap
< Ô€¹€ÈQÑÂÁS;ˆÊàR2úkàA¥p©Àÿ;‹*OÕĞÒÀÖ*Z¹3'>Ÿ¬qU´V7ÊCğ Ïnâ\_
ª—¬ØgZ‰L~¡’P`Ú€-•LD(6¸«‚¥^øÕÙÖÓË;2öğ×¸´L6ÿtóÉ6m>I_z´oî¾OŞ¾?|ã=ğîåæw®şµçÊU¨«M#w¨¨Wğòi{RÜ&‰6ÑDl$(Âá19Öo:8 úX'Ú=‹wÏòh÷¬ŒvÏâ
¿zíJ6Mu¥ÊÑ»¬4ÇéâeN÷N×xèioZ?D¢
Gå£Ş)îr-ÕBoâ7
mÂ1ş#×9÷G<¯ñ»ø/IJ,xMÚ m“(	@‰±·–è¡Òğ±ö‡‰ÛÄÂEHG<{F>zHtb}*Èûq1º6 ÀÆ ÙY“ Æd¶éu³ÀbkX’Ñ$Ö&±X^Ù²œd×hê¨dÉŸj­_PXùF:+—´>Œ´â½C²+U%rª¾pv„¸-:â6¡$=((~›rTõéàıßõÿ·õ«=¿½iuÛ^Ş}âè[~vêwƒ pŸäö÷sÖ½ñçÏnüéddÄìÈH2²Ù>ê&BXH
3ºB­0“İóÕæjòuz¥k…š6;­kôuï-£ßÛ¯Ş×ÿcôcæi– ºÖwÙñdH¯M"+„z²V¨Sg›‹İ‹„ÕB?ó/m<eà£DN– #9V! %)ÎŸ DX‘Â²Ü£ Y±•´Ò¦@j¢šÈTñ æ(Ø´UU‚	ï~§ÂWDtâğúf©‚òû4„ò¶'t™íf¿`GX‚h.K±¹¸ä°N³¹ÙRÄ°a[b±û°Fn²é9¦¥2CÏ“®ZF™¬aVŞÏx–IAšU -†bœr¨ÏxFU®ìÚv}SËµéwKÎåÜ´ùƒ_wËû»~±÷›#í€úñ¼©¤8XGz>ıäWz?íB˜ÕCÍ…<óAÌØºE˜>˜IStÊÕÌ­¤ÖÑ\+9§¹ Ş6ØóÑ(h¢ÏˆçszP}p”y&eæTOc`ª9Ï³Ô˜o.ó¼Xfna¶ø“ı2¡IĞõ&-­mÔ(Í”öË‡eR–9¦›%.’'PÅ©Y'd<w²ã€²G·èº¸hiù?:RÍwEÆ%O	@XğêL¸(‰¾í©Èf-`i	9ÄÚ¡qÉ1¤òCÊÄHe	fbŒ4ŒDêyMLÅ‡úæÈ°çzŒû®F¤„°3‹õar¥ª‡2Õ8e"¸@
[(È´QL&å„¢²ùÂäa¥^½¿wá«áû@½yˆàé÷‡;Wìê%çñ•‹ö|ï8X¤9,(ö<ˆÿ}ø‰œ×qq8°kúšcPE¼Â6ú3B‚«º€d”¥†ml4ñ?Î€N†Ã@çXÉ S xÉtS½Š!Üí*PG¼¶C;Šü@Xç™²Ê$ú¶c¦•ÜO ÃF41lÒd´ÙˆâF£ ‡ˆ¶8ØºTtD6£áÁ?±áÁÁàÇ8†ñ—ÀE"ŸxÜÄXO2FÜÀĞ< ¤²­	ÌËU
<Ûé[mUVË8aB’]Ba¤±qÛ·ƒäIkB)¬HT$'N€4²†TÍ—ğ*¶·{;67,Í©,Ÿ?£»›:¸7³.Y·Øó».½|ïÓUÓ†çQÿ†ŒÈ%Ævšãh5Î…Õ®Ve\A#çŠÔxa7A}‘«S±/qk¸A÷#Ÿ8¾0™R8%ÒÙ?g'äO(®‰×quùµÅó¯eWä¯(NÇÛâ½‘;ù÷
ïG]c|çÉÓg£¦—ÅN"ç¥ØGÚˆN¢‡€±•ü¾]N›¦ä®-0y·æK„î°ßß£Y·õ´Ş¦;âğÈÉæ8–5Ëšş­¬éXÖtÿ¢‘•54‹A×YYû?İÕÅuEçÍ¼™73»;³Ÿ™Y¯í]ögÓüâ¸ñ–OL!Ø’ˆ(2i18µ¡4M‰iIˆK‹ UZLb-jqÀB@“Æj UøPšş5Qœ9²*dÑÀÚ}÷í.^hkÙ;ofÇowî¹çÜs,0s¡é­7Šs‘Pì]÷e÷€{ÌCîZwtŒ1îÀÖİÜ…°“›i››i›;P6©cÈ[Y}¼İÒR¸ôàH%Ï ğg5À˜6:”,Ë´2²„²†ÏèœUUaø˜	õæ‰İsÇÔò™[vÚ.´±÷ÚğóW_}û…C«¯uÿîŸ?=´åÅ#¿~aÓ‘ÅãåMK§õîB5×÷#ôÊşm÷šï\ŞtT˜xµÿİ‹ï½ÿ$ËNnÒ©åCß8Í™´ñıV¥ ±…Ùë8®fgœ˜]ª¶•–lh†Oç.>UÑâ$Y1µrŒ ~‚L6cÌ$À@JÙ«  ,(aŞÀ}ôêHâH>—(@xÿ$Ô–Ô›ÀE«rje¯9lò­f·Ùk™Øä}qÆ×¤N¿Ã0}.L;ç‡jLPa‘´K3¶R†æp–¡_dü Ç3ZòÌrÖûëdÍE5šj Rä9Dv™ª`MÆNG;]’ËwIZ9eÊK³l;GIÊ*2.Ñ4ıFÔ`0J~£³okÿÆßÌëÛ°vÁ«5ÔşkOªçõô
ş`çæE»·¤K9¹“Eß¢®ÏÁ]J.'Sá	Hé&½¤ŸaâàHˆ´’mä@öÒ2F”¡ËyHÂVÄI¢„É9| wã^Üo`©cÃa|…aœñÊü3ø~İ0«VàS1S6œS6&j†D
Ô×ËW¯Vd¬vˆøƒ–oo+óVUøZ•}}}øÖåËwı8q÷oĞ—/Ñ—iì™?9)²A–§}¥’+«2ÇÉS2ÇHœ“qÚ¾n1$DÜ@_†E!$¶ŠÛÄ1ÓîPx!Ó0°k?UÊê§¶•Ïï;ãİS”×=¬
Y}—³â)]Œ1Aáî×‚«ÇÖŠQÊÁXß¹ñRŸxæ‹'²œ”Tƒ£è§9'K°½|*» ¬øKr¾ê¬ŒãA<H>¶>‹‰#aŞ’ÃQbÃD¢Å…’$Ê¤hA@W®ÄQW¼;ÎÇ-«Àï2™´™ûvªÌúà!éùÍ¤jğÌjÌJ@x•sƒYW„RIÍwQm¼¿]mGÏ?O°]±.ÈŒ<½:š!{Pƒéù=¶qö39¾"GW8™‚qµ\íøŸ:›¸,êqÃÄÌ2ú^næŞNúµ3P0=ã±ø)´éÄ„º|Îå½ô`^LåÇÁtıìÕ³>£Y†1måùÔ¨Öthèñ5Ÿ7áÓŒ ò8ı9âg­Å×?•™VxÉĞŸÍå|!8X~¨yã¾ĞÖó¿øÕ‰hãã­?é[ÜôäöjœØ[¿bÕâ3ÇN¦KøŸ¯[Q½·'½?¾iÓ‚Ÿı(ı×œ†FûÅD[’^Q¼üı”ş‰ğï°0â•(7‡“5´a¾«£ıúû†=fã°ìsùLÕp$™NÅéÒ\1›é¶Í4\eê­2õVï«·ÊH FØPa¦Ş*Sozşï *SoÔ¥5•Ñ_µŞÒ€’ÛÃ6ßjwÛ½v¿m¯ğ›Œ›#}†‘aŞÿpå!7òg™ØŸô<<ê-}$Õ6)eám&ê\¥?CÔz®×«º)D‘‡"Hz‚¦¥ r+,È·Ãø¦-ÄP}·€¸ó×W\ +}×ÎY'ö›İ:¿|Kz=ÿòó-_Ûs1ı6d‘Y4‹”P\ ­=é·áI¼”‰Œdn äzXØ‡Ğê¤9ò³Òù›ÒY®Ô«=Õf•=[Ÿç™gÎ¶ÅFò”ò¤Ì§ì±…4é-³ÉşòIt.ŸV–ië„Õâje¦X…ØaPÉğÅ‚ÌKY8À51/å`áĞ¡g¯÷±È –`8°Ë ‚7¯œì@œCw„iğ˜2@5®¢	]»bœæíatÖ¾…_I²¬eúÃ™á$İä€ç¦@D¡ #GJj$•ÊÃ¢ä•ZÈ3'É"qY%®"¥–pp‹WŸFAãüÌdqù&kVÏÎ]Cææ[»F‡Nï|ùø‰Çy/*Ù½qôãô¥[ßCÅÈyñÂÅ«ç.œ§_¨st@ôpÅhUr·¦Iÿª>OÇµáŞ0
?¢E‹ÊıåE3ŠZÃ]a¹ÚªÎµæ—ÈË´F«1Ø,¯ÕÖè-ÖÚ`øCßuûzÁ‡Åƒ¾Áâá±°Åez™¿
WëOà¹úRıSõVÑ¨®.&AåÍB—Ê¹±+
Ò•¤²RÙ¦à0ƒ0ÌàThIª ¤bgÏAÇÙâs†¥ T ×¢Pl¥y+ø
OœãúêBİ¨#Bµ¨†2˜sLScÄÔ±Al‰€Ì€»•-¤ÁÆT")®(ª›f£ñ”™b=}{pÜ6§Ú(ŠFà#Ğ‘KÁàäÚ¼9Q5ı>r‰!ä¡×ÙS½ç[;¯4oØ¼ôµGC7=Ü±ş­Ñ5â;?\¸ğ•±ıoŞİõduú®Ğséì….œÿ3héJÅ÷)†÷Aò±/{‘QWâ™x~w`‰2‘‰Ók''ÈHeÅçRÚ%#9ö"/1ş¿'½ï*î$<I“XË?0»2¶Tb=/gl©§îìÙÒA=u»}ÖªCm(›HÓ9ıƒN×–³P«v”ÊMŸLtPIÚñÆãkj—-|ÆŒÇ–ûŠqâ`ÛœêÃ%uµ+ÛÓ„*ÔİŞ¢U˜,XÉÍ8â‹T“¹dVìÙÈêÈ‹d7ù~ì÷è¤ßNbØÖäy“şd‰Aş×Ë‘b7Ê¤QiTµFg³ÜLš•fµYkvö%úJÜ%‰XIì‘©±¥Êµ)ÑTÚíˆm‹ıXy]ÛSºoÒŞÉ=Ê/µ7KzJO$Î%ÌÒœç‰äÑÜ"–[°{ J‘Ü"š[Är‹¢ScOzŠ§/•Kâš‚Â	?V-*€Ğ	L‚â‡µ†ÀŠÀ±Àå€ä„ßp(ğZ€¼C±ñÓ¾øÙÕÅqÆgæö5³ï½ã6>?Î6·ûŒqBêE$‚„‚Ë£®PÛ€H(¤*Ğ@ŠI”¦‘ô!ÒT*¡ŠZl0¤i-5ò¨·šĞ¢Z*MŠ¥4¢üQjÜï›³]ÒÚ»³³s;;³ßã÷û}?#¼šÀÇ=QæÑÊõ(£¨(É•nwü¥s6Tn­d•3t·!Å3äà”lş8Š£ƒ•Š9fU–fë2Q<]jÆéM˜¤™t¹Å¼Ê$1F2yœ™Éã¬Œ‡_•IJ>dëOéuE˜:PÑ>R¤E\g‘<ğ5²ƒ3 sıN*fåRÕÅÒÆæ¡fÖÑ¼¿™5{”Ò:’.++rù²•D°ƒÀN”ÁMäë\™ê®Ü›ÇÇ\äã<®é:¸ kIòªù¡(àÉÜ˜	ß½sÙdÒÁéÁåñå’Œqhg¸ìõ5ªêÛ´7•54Àƒ¼@°Ã1Ÿ*ótÔp×ÌZ51»Ş÷/îÅ´;Ÿ#¼QÏQõ.hf&à¶Ú©Í‘šZÛ2f‰mlàB•©ò*‘ÑCø¿ÜP\¾8p€ÜPX¹tÇÛ’e¨i¨o˜ÃZKóÚÊP9&Y?‘šÉÊ´RßqÊ}æÉ½»[/½}¬sáüâ‹«ö½¹ÎïµØ²÷Ñd²)wğ×GÖly{ßÑû*{ü‘ûï«Mš<°|ñÆªpÉ“›Ó+7¬l«­¨Œ‹º–…{7¬;şğë˜§uŸ±¢zŒ¤È‡çˆ€¬­/qôìBèìÏ@õgÙ‚ÆHÒã¡+€$b¦ëÕj‹NèÆüú}¿ş]]!ÀÑ¯è½ú>¢k:Òb•^¦Ùù¬1K/+ÿÉ:_/kµ2û#Ë@O›eı¢Ÿg’4×·éÊ! ú1PbŞÕª¡‹ ï·´xïb†…Ú¯¾Õ¯mmñÛ ÉjıšyÙ/.øêÖÙˆ‡3|ÜûÂ#¯²¯=Gõ­·Ÿnü¥e³³²’,UêaõÎs$¶áP#²|<Yrq·-A¢ÆiOZ44Ì}0iIÒ)®Y©ŠSR§4@J8h”„ïÔ´NI%œBx—J8%K›*aí1‘¢C)šZ••'Šàì§Y¶#ûJ¶7;‘U²VO§„çùå
Ÿ">M\®Ì®Êñı’/¸TÁœÉ:qyæsÅ'$×ØÿË]`´{Ç‚2sÈ$Ê*c»6ÓtC3T$¯båˆmø9‚‚·X< s«[¥kÀ9-><&Ä<ìÇ:ö^üÊO:=³ßô·­XqøŞşö/ùFgëì{ã§Ÿ¿{ñŠU/bí·.ƒwÀE±kàA¯÷1¶hõÚ(¥DÕQ¹¡R¦Öaø©Má•aïÊ0„²n5w¶U¥¤Æoˆï¶ßÎ¡ )Ø0@ºÓp¥“WxâÃˆÏ¬.‘Fh¤Âá5…IBw—£ï4Î)‘<4®5‹4òzÑNZÅ²X¬¡kX—±–o¢›ØcßMvÑ]l±›ï=´‡={F?d<ËDòÅëäUñ&9«÷‰wÉoÅerQ|Bş*n‘b6|H“¤h$õ¢Mt’Hp5
’%B¥Ô§Éoçğ=øéÅXä¢‘Š¶À1)œĞ*r”©ªe‚Ûš®„`8‡Ãá4utHWæ¢6¡F‹ç‚Äa’ 6"@²cTÓª6YÔª1¢(âû9ãƒ47©ûU¦B/âyÑóú0šÆ²™ñîñîlzìj7JT.; u{Ô9aÏ¾·zæ¤ñÒ$A{ßY^‘î®jÚO¦æµÅ[(ıùí­¿ºZ¨J‡Ÿœ»½M©?¸yûêo±C!êYˆ@©,GÇ9€d-ªk’¨´I5{¡ß²%Å^‹Lìùy«üÃP¿ãÉ€Z±çGò^ø1J,PCTsÁ¶¥aBY>eŠP|7şĞùÀ:ÃÃŞ¥aïB8ŒÑ‡FÆ™¤L†d`‚•Y‚=ä¯÷û1?/ı781*!P™êø;¼ªºäUT6 \­ª+)šÅãZgU!ŠfrÓ1Äc	½ÂÈ™•P+ô¢:%ÒªßcÜëÜ[¬Eú2c©¹È]ì?¬wWé_76{´oëß4Îiçİ3Á?µ[¼ÑôI£İà4ºASb>ivOGcG¬ô5öšùSk€œÑÎ;ï(—´ø5åšû÷à†ö/^aj¸cK¶lÙº²&Ã6'W	ˆoèFAw³©U°'.EmˆR6D_QV6MÄ5aúõ"ôW++Å«¿×Ö¾P ÑeÇü×ÔİRÖ6…7àÀ{ï*ş—Ù\”ˆ©* –®r!Ó²„çû€ïKO«$ Íò`´I¸Nş7¾näu?BUO¨ªî€Ÿ¶“°mÇ€*7F¦u:S£z ®o9¶Ü^ 8nº©¸®ã‘¸éÙt£½ÃŞoÇìAz"ùNA·‹§ƒìËïôévÿ)Ÿùxgz*İ¨î€äŠAr 7ã77II”Yv£»;ºL²îôÇÓ™åMşÃ§ÓÉ¬óeÛ³ìÎ„ûü¢²ÇñŞÒoØÇsioÕªµıvŞÊ³_NŒ‚¦%ÎÄH?™ëæˆQ:ò¯kioidœ11Ò§Ï¥r zÕÒŞ–ëäèhŸ/0:SÂ‹Î€„wZœÒçâO‘ùì|y¥é—OÏKÉyşÄèi‘Wò Ø ‹6È·]8´“ÙpB‚÷ÅÛá‹º¦ÊD„ÔŠPJ@‘xO!¨ÔÆbtéí7ÎŸìPZN;Şzß™_Üîãä¬?ÀüàªÿÛ6~ôıa¶éÖe¶wàß Ò¸ÀCÿ ¤ñèŸ'yh†KMMa\cšéJEî6…2(ı”ä7 nM¦]CşùR¦}û²ò²qÌù¾;¤iCúû.w£d{6ç3ì¬×Jï1ĞÃ¦Ñ<¬té]æZç=*šgÙ õùó;ïrì"ÿ½ı'ïo"˜J.ó?¬WilT×>oíßó›{Æ3ìƒÁÜ¡n™Â–°8a!eqCDYäC eiÅÖ”J
(PpÀ…D¦‹ ùùLÚJ¤¥@K N£ÊPÅÄóú7oŒ¤J©jë›s·wï¹ç~çœ{52óõ°•£[—t•D?y½"|„/˜€0Ä"šzZU%—ÛãTÕ£È®|:ò¹_Ğu¿áÃ¥Bôû$Íğªº¨{3tÆ#¥ä	y$ÑÆ/øK5)¨i’×ã‘$QÅK@ÓÈ;ÕÌ	ş5ZÂ«ÏW=kR^d†)ušºN•ÔñáT^±´FLL…-'ä¯¶ªu™d\a\3:Úÿ^wŸ9WÔ9l­û‘ñbõu½Ém³4óÁÔ­vW;¤hÎÇ“>¶·/Ô…I	àúÑ’¤Á1ŞJ
‰’¤'Kf3Nmİr*GQp*9õT¡šºğRzçå_Š,=öIúuaó¥?L&–	é¯ÆUŒ®¼“ÖºÎkÓuØWIú1ép¤Hø·Ã‘¸7¨K>)ÑMÕ§R¦^ìKiÅW"ƒË‹.…ÏELœv;mDé1AçM,‰%Ë‚5úa¯”ò§p ÅeÃşqi³À6ûùúiıü#´şáy;ó}efY`|A­Y¨-6‡^TWú_Ì_\zÙÿJşsK`Sp‡w¿ï=ãTşÉàï?‚·ü]ÆWA+ö@–Q_,*ëcô—tIt«oë‡3¨sxT¥ëšX‰›C$”šŞ *º†`Xêó}>oÀ45Í§ò3bâàXkLŒµˆ£ŞÕa‹T°Eœ™ò2S¦ø„ÙjŠf‹0ú¸.$è‘¨—»lk¥Šµ
mª&MÓ,MÔ0âØ`¶G5G‹W#0Âx]Ëñ\‰PlW#ÆÕºåíEa£İ.Q˜YF¹Á$ÈpyC©&›?ˆzyˆ6aD›S¤Y×Ég]zÆš õéñª¤7Q•Ìƒ—½Jæ'BI‡=ˆ4¸Ã€>~|Ç­âÿ»W¤*Üƒ×¿=°z|a~_Å—^ò»Kå‰^åWšÓÏ=Ô§buÍ°ô¢_e}¢õz\.ëÚùüúÕ+Åú;];a¯7’W>¦E(.ÄR¸}şˆ×Y&Ì-Är)fšùù²,©E!/nÚÑhQ*Db±xæÉ…+MÜà»J<sÂõ%®ñcõ©ş><~o[q)^Ôë5ïä¦2ÓœÊC)RdÉîQ”Z¬«ö}	…Ïí»ÄÏ>NâGÏ×İ¥Ú])/O-EX=ÍNbÎ«b²Ñ‘ÉXxÚU£xµnŠq;óî°Û'ÛFµ½ŒìPœc»ÏígH^®ºò\F”pÛˆ
¸e­__ÉÏÀáÃFT-tõíPC!~
Ã+CŞ'öìÙøã§fÆ†¬sş¼PÓÜÜ,ıtó¢İûwx&¾ğÈæ¯¿'ßüè£;!¹/®—¢m÷†Œİ…xj []òºÃáB
‘üauÇæ|‘‚bÓ§"‘°ıŞc“‡óØDán“‡m“‡Ùäm“‡[ÃVX
E{˜<ˆ«ÉÿÉêEÿÅêøÏ1<ç ì8Œ3ĞN ßÜì%÷›|f®Á•“cq‹¢£´Iî-u’Ÿğˆ†„‚Ô;A˜sDaBUCAv¬áÃúöŸ]zae:}üD:½òÂÒºw\Ü¾½mÁ;RçŠ+Ğ&ˆ'>^ñè¼#ó¶_¼¸q¹Qx_œ.m'‘ ¥Äéé!Ò–ôóúİusVë¿w{gç—G¿!™º"¾:ñƒÉ_>¡WßrGİvÏŞ+ı°ü½¼ìµÎÃ]‹rk¨z0¿ \ßMO¡‡ê<Ü¹ÊÈ™—È?\ušÄd7ˆŸĞ<¹BÀWœ~¨ÔĞl¡‰æˆh5CŠSJ>D+0ö êAäo1~ğ ¨Šœ¶ÉÀ|`×1ö7ü-æXÆóØ²æ¸{ÑR¥ÆêÂzÛ”³ô4°å½òÚ¯&i	êûğ]«LTÅcğÍ6õ í@û›è
m»!g£şÊsñ]…Sö¸¶R„% ¢½?æÙìì·Ÿô[!7X—±—ZÌ9Ø€5¦A&aL r4Ğ$œ¥ÂYk/ú!©ë7q;0Æ‘ã1ÏËè…ïú ŞˆrôP!u (QRÒ{ƒ±ÿÇ3ûÎÒ3¼çî=AG§û‘ÑqRO`Í÷ŞbÒºéé¡[.s0Aª¤uõ@xL<GKäGI€½v*×Hb€wl§OïÈi
êôœ¡4Ó.®“m4X]ò›´Gê o¡o•ºûX{ƒÌâm,~Nª¥´üƒù×»1çu›i&ÖY)_³9´Ø‚µş™µÛõõ8×éXëkö|?‡sY<Çú`ıÁls>w¡&ÄØ«3—öBØ;s’¿áï1W©ÃÃ½w%íÅ˜­°ë_!e Ä:daóÌúÎ` q`pØÔ#I@Ö&¬+Ù|g˜›6?Àå,lİlÎfö°Û>ÏŒÏ¼åÌÅë”¨‡¨ŞA	ÏÉşÂœ….¿ÎÎÍ>ÅœÉJ›ßõ6ï¿à}2§º%|O¾IãXÛÁ­¬d¿ƒÎìÛÄY´rxÜÈœeı²’íÂ\³mŸpdu½VØ>‰ĞÙÛázcVfmÑ-Ÿ¡}˜óIubÊ/ÿ€ÆK¯ÓùK#õ§AJÚ°Œ="Ş¤éîÓT‰³œŠúÎ¹ƒájUNcŸaÏ6úlº\nr› (­Ï>TŠkìò}2ÂéLKFÏ¾oÚş¿@¼¨DÌ<hİPÚ,ûyƒ}ÂuS¨ Š³íGuÀ w¹°Ã]/´¸f‘¡u KåTRT%ŸÆù„çáhŸ¥\¦Vi+rY›õ'a­Ûhƒ+DóÅmˆiXK¼HrYİÃ¹\.ee–¯¹’c¾Ã©^*üï¼ƒ«n·À£Iàd„sÇg;? F2|µ:»ùù!ırs–Ÿ9<­Ïá§–ËË\içÄ÷¬ŸBMÙıs|äÇ1’ãÇ™ìø\ÙãûWÄà1Çás4Çñë„ƒ‰Ğñoï#ã¼·,u¬õ¶Úlí—Lk¿:å?Šõ6öıBwNm¥|Ú?›K3íäËæQ¥’–8ñlŸoşE?±óh­ŸG=Lk•;8wÄ@[ß=ÂĞ»^~6ßE[°ˆÔD;0—mbŸQ˜óÂ¸/×àªª+ ¯{Ï>÷&L€ÄğÒ!Š¼â@e¤$"I(¢±%b[„¶X_E”GÂË¡"´âğ4eŠ¶"‚Z§ø¨´Ó´ƒ´µeÀ†ÜÓoí{Nr9!DĞşéùf½îŞg¯³öŞk­­9ÑY†Ÿ5-–ÙÎGÔ:ö:imóE”aû>«#§ªT[&ÏÅNH¾)!Ö¾&ºVúj®}Ú}Ò*-‡8qHú™è“#ô[k}P(ì¾Ğ±S)¨ğE|²ÄÙ³£é£ï[gÇJßÏ[_ØñÔ"º‡Õ¼3–#·Úzâ„<ë–Hgh]|–¬‹•pærd#ïøãJÔÆåÚ|½Lnã|U›ªˆ9b÷ÿD¯ÖÙÄ÷<@\g>Ú$íÜYøpªıö!&c+õü8ÕÒM÷HlqXë‰e²Àô”›bSe1ºÅ.q’y¢›ÃùíËÙÏø.~Üæ^Çh-£5‚—x¡´Í²u€X´Na~ç¸¬sFHûø[iËğÃ\éÅ–Ö¢±s²4µå©¶gú,JbuYI¹ÒÉ’Ÿª>z¼Ë-D<Í¡¯šÇäû¦Tò~œİÖÒËü³zFV9™RnöË*³SiÛ´•Îf¾+µ¥êÊÕGß¥½B&šAŒ¯’é¦\îu^aïıQ2ÌÖšqîì“<ÆŸä½>‘£2Ñ)ålÍãùŒ÷¢ö³slõÊ3LzÙq)X[B6GGòU#XSìÕçsìÅÖz;ÏcŸıN}/ã´Y%ƒğÓa¸*)c£‹e¬şIntn–#½üZbXjÛô<½MÙñ|-ò×ğr²MíÖ_>‚¹¼ûuä½(Ñ" İXoÿ¥¢óœOŸŠÛÁ«9§½\‘S^îŸ0ß óM¯Fa/PbJvü~Évº£ïÌ¸PÛíÀyÚ&yxÿiÎ¦Á¯oŠS¿1Xäå_‚Ã)ò
•~n¸dÛ.Ö÷Q¸İú÷Ÿ’“ÜCrYä=ï0²4òd9÷±v/Úmë„~©Õ‡Ö½"êó°>Ü¯ksíè)O%ØõûáI¬˜úC¸¶O+±=ü·§qÛlh†‰r³RmbvoÜİ"İ•h¶æêÎÔ·#@ûÚñ­d¨¢gW‰nå¾õÿ÷—›”¿P¿:+“ÿë¬Kx}°¯ĞáÈnÈÈqÈL=³ásÖ±ä|}Bg£oSïü‚³³öÂ›ÿë¹"Â^…,ˆ¦) <D}r›Ì©#–œíë‰Cã‘ï£#{'®†V<·Fw7ò‘ÚÓ<Ï@(‰5d­_W¶G·İ›æ¿o\r|í["_œ‚—“ãk«á<ÿÈçµF¾\AÿO7ù›äÿuå´ï‡]´OĞ¾&ğ¼™ƒ¼ÚBÆ/W´itıÚåùï_VR³LÆÎ.Èä#á;Ä—–Áz6#Ãw`ı›“®—h,“~àÎt„ºosêİçBwœ@²‰TL‰WGMÙRëh­eµ~¶õ£/íıÍÖ±Ì+’HìI×úUkg­_‘úşÊ˜kí)Á®;­]~ŞH­‘S²² ƒ/§ÒçL´»w€Ø“Éş>Íİèy…öePšÄ;HîÊ$×í&îF¾C»òtÓ‚ØÚ(Æ6“Ó¾îöÅæÈKÈ©ù>å!šÒ\ï3\	çâ‹¥¹Ü}É¹¼‰š§¿j;Èóéƒ%_‰z5J¸.mT4Ón®Î½Øv¸î¸èv¨.	ÚaıŞ{A=“+¹õ„ÎİÅ¢w³­¡ölŸãúóæ·ñÑM©zø9ô9âõ¿×	ÈQŞ“èf¦•ü´—$Ÿö6 o&ş¬ĞÿÏF‹D?÷êh?N;Ë¼cûNğ©hn?‡÷­Öç¶>Äg6.Qû¥Ü mà˜¬µŞ!™ûÃ(YWï¹f¢wÚ€PØ¬ì/?†—hgÒÎ$gÇZ·eÏóÈâûX˜B,ãîõêbÙ>#ø¯ØüD†ç§›C¼ó¨÷1}šIHf¼¥T’;g“C»ğÿrÆVÑÎA¶‹_!ÏóŒ_¨9 v’<XF>L×ÜÁ¼¥²¦Ò÷sRrZÈŞ“gJ¶/ûºµòÍW±ŞŒ!ç¡»ÙÃÊ£ÒÏL’!PÀûi®q6±G>f,ù'š-»œÑ²Ë¼(3xßæŒjY“¾WÖ¤UHqÚ£²<V-ËÕ2İêø²:ÖS*õA^Õœ<SLEâlÎŸF;×—EÁ7‡kkß$E^~.uŞ`\Z1¹ô$ßÏÜjksµ9~Tğùyx>õQ´Úû]RÊ÷ü}Î/•IØY >µ¾$c™Üû4§ëüë‘ïÉfø>ÛÌ…_êšª…‚Ú„ç2¦ëli«ûÊî¥$%îq»^ÃuÍÜVœáL]ïUõåúG¥½ùØCj§Âşjó•èÎètÎ
{Ğ,¥fª–9>ôõÖÛq÷ØqCbã  »¦0Oµw¬™Û€wÌ”ÈşÒõ‹f{¯"gDßf®’iıw/6-bï¤ÉÅúİíLôº?ÇëÒÎ³ßîKë«BÆer¯Óo¤¦rz‹ğ_šsƒÖWøÍïß!ÅñBök)v·HóCê—×ˆuY»¬k¦ÌvHgs½LvZK…)öDN ©Ô•è§è?DşŒv¥LŒ¾/wà¯Yp,à»k-û©€óò#Ÿ»”huäJşÿ|Ûî”|F7P¶[‚wTËúèçÚèSÌ]$ÑÌ±[˜ÇÉâü…`Ìw}zøó5eœ±s¹1cUö	ƒ^åUa|}nô*‹Â /:MõkÊ¦ôİÂ ïö5ØÑÔ{»†Aßõöƒ~äEØÑ”ŸóÂ Ï»€£Ã ¶ƒøÄ=6ñ&wÓ‘øùş8r’İ—xƒgîŞ¿ıßïç°†SPäCÌóÊéS‰ü;¬‡±$ö!;ŠıóxKá(MÎ¥c¿JÎmñçLlI¯{É·7¥¸>IÎgçÖØ[ƒì
+ışUş¼›“¶'–6ô×ÿõí¸ÍxÜÊÿ]ãHlKâıùK8{á-ÿ¹³ïıæú®†¸ _˜•²Hã¡æêxµˆÍÙË(s“«lAÙhãGì$ù±VÔ!ÏH‘ÖÃİ»lÿ…n¹I¨O¨l½ğWqÍiï~,åfºq¶S%Ş2‡Y&·é»5nkÍáÌ—›aŒæ0â¦æÂ‘ÄÜÊŒ­¶~É¢O¶ùö>-»¹³U¹¤…ÆóxoÚKø–uò€û°<”6MvÇş…­‡d
ùªK¬\ºË°àn›&énKê_¶ˆÈäôè«É»ŸÈôJêºßË|ö`îz?Ä%½®•^Ï%Xû³=a”µ{©ÃŒéI=FÍdóõíø¤ÂÚ3Zó§yAŒ3KÄıŒÜ=\zÄÓ©½úHUz;Yûœïˆ1WO­ëê}ß×©–nñ»¥Ÿ[)İÜÖ¨'uó1ü<^2Ilßı_öË=8ªêã¿{Ï½»$6	$$)Iî$@ ÁåÑ–‡fÈ4 „
­eRvCB–n::`Åªã 
Tè ¡ÅIœV"3¡/
¶CiGÚ?ÚQşQG©Å)´£ò¸ışÎ9wÙ$$™ªuêô&óÙßyüÎ¹÷Çï|Op5í•îUh·ıV‹Ô‹¹VHí€³+e½>Ğ3öÚ5QÑW×x:*¥)l9ÇŞ3RßËçgêûµMÓrÜQ^kåS¹µİÑÏêw
æÓ!ønóôl°‡jƒöGÔø5Øu—<jş’rƒ¨€õY0(uİz>£í¡EhÖş\½ß¿x/-Ğ{<‰ò?ƒ£j?òşâr¹7Qv}·._î1UÏuîf•¾~Iõ/ëîWş×±İí6“õ¨æ…¼‡8é:UêQ¥­{Û”®—ë§fHÛGdycä¥ô°§'ûÛ]°-^:ïìÑhë€€§£ûZø>ò€²R²=¨í¼ÖXëõµ)]=€H¿¦éXµÏ<«tõÃ}ì·µçéë¡lJ÷²®«óÙ)½>”]NRwj|ñÔ³º<'ÍúİŸÒ­œZÇ²~¯e}míƒ^wLàûX½YÎˆô[ÀIÂ[{£uş€@;0¬´/îeïü Â}VsQóCFDŒµ£/îe	ßİnAà9<›¬QHı?
bË•6Àgá @e0ÁKšm®Ëxãî£7.ø¶·ğİ-©wö¯ûı¤óøIçåÓúîÁŞ=ìÉ7gÌ-ßó#¹¬àøß<M ãú
è ¯jv1Ø+EØ·ÿQ¬'Ş¦ß:xwSFçy/2(»`Ú¸#½« ·Ÿ`T­¿`™'û*5iíõ&¾#‹ã;£cßØŒÅ´_Æ‚åTÊ±ç.ïó)ÖÏ©¹·æs°n
yoàœ´á?ÂNRù[÷û>Ä„÷İÓöfh€gmÕœÑìSÚÏ=;Só×è8ìátp·-aØÏkµŞf›PÜx[•ß|//öŠğW©uƒUE…R¿ÄèP(.¢zßğ¨h¢0Ÿb´ôë¹ˆò¬×aY—ÅâPÚş.§­V#Æ	°&’ót
g ûŸ’í‹t\ÏÏëÇÿB¥æEø¡íå>ì—è>ÖE7
»ëb	|—¸ÏÀ.Ô| Úğ¾Ë)fn¥É¢™Bæ9è|”Ä‘.€Í+À°‰îåW±N>‚?ò¿ƒµ)Bæ‡ší
®7ª)bş”"ĞÄô§üÎË6Š EŒ_ÈgED5úƒŸ‰›’€¢ù:@ıÃh×‚şŒ‹ª/YçùdÜô±ß£šÌfª	äÇÜn;ìvïĞlk%Àœfé˜ë³úşÀ:ê÷ £å>ü«f­bÄ;T+Ùív‹2 ­ıcŠÙsh²}úà¯Xh¶ı/zÖ¾‹Æã;J¼–f¾Û5[íî5¬»ó¼{Ö8„wI#p7ågüš`	ûƒ<kv X£QG„5M«·¥Èpïz¯IœGa× ‹”Öú"ÚfòŞCº^±©Xé8¾CİÀh¹¼2Ñf‰ŞÃK°öóÚÒZMİ£æù^ë~Å,r»ÍÅT¢Û~SİKİÀS ıîÁ=f&c\qŸfÒòİÌ§·¤Öt0é9ıó˜Ï¦×ÜvÒŒuü˜•4Qìæ¶j®‡Êê©Œ1ÇâE·ÈoÆ½nî†Ü¶dè¼ùaäz+ëŸÇ7ÍgRß=T>kxë-µ¦úşv—5rÎ•À÷<ò?;_0¹.êk½ö˜¸{;‰;è"«b8bc;• ~•XÛ±ö ûU”‡ØTÍ±qşŸúü{ı^e]*
ÿ9–A+êşù´Û³ÎGÜ[Ä±ÏFk9¦Ê3Z”ïiˆ7-æšj^S1È8/!EbbG5Ş±ZZ™6'ê˜RMæT|Ë.…ÈqÏÈ˜”­b– ô÷2Ç3œ¿*^‹"¿Ì×T2_‡Çğ.…°N(øÌ¹qXM©8)c!â4§ùî¢ïO9¼/ÂCé%­-;úØW<;”.Ôm:t›şş+©Á:‹u²sÇgòoh‚}7İ–ºwMåñ·ß’÷•…¨grSçó™Çç¤œ'ÌQ#4ÑE2úŞ¬óÔÀskWQ.Ÿ]§Sàµ4»J!ÏiÇ·¡Ë2qî~]>1ıçc^ÑïÉ÷“B¬Óm©»Ÿw—óîD³¬çé€X-4…êóşDÚıö ÃëLE\šøp«jq§12Ù öÓC\QØPc›ú\©ÈxRñ…î›dTŸD”û'áÖşäã;F®˜ÂÙD_*"s´êÕ©Â”#şAÛÛÇ}“2ÌéŒq9Æ`Ò9¢Š§•8Ñ¦âš†sr¦ä«_&š½èÎ‰ÂÃ|şW¨ŞB4÷o>>ÿ?Ì[ø_"¢Ùããããããããããããããããããããããããããããããããããããããããó9ç¨Ïg„A”5şA³é9
’IÃ©’–Y-V1ÙÈeÓOğ+ˆÿÖÊ_N©9ƒÔßtc¬NÊ6Vè´…ô ½Q§ƒtñ<+ƒû4.è´A£ÍZ6)ÛlÖiò¤N[H?©Ó¤ê4ŞÇ<M‡É¡MÁÿ¤–QEaë(Nm I÷ÒY2¹ÒüÛ„ò˜ô¨@M˜ZñïĞR”­Aû$µË\6
ïMøÀ3ŒtmÙ7&}š@RöÏzØ­CYœš?Æ»p¯m²GÕ®¹rüt‡j’9õä6”VÊÙw‹|W‡V#·µIù¶ì]qØ	M™2ÃYÖuêâmñä½¢ÎÜxbC<Ñ”ŒÅÛ*œpk«³4¶¦%Ùî,¶G›¢‘ŠÆùáº†úòp"ÖÔZ·l°œ4N¬İir’‰¦Ht}SboğyN¬ÍI¢®±-–ŒFœ†dS2ŠÆm‘ÊxÂ‰£&á¬olK&bÑöŠÏp~i>|ë0ÒõT6Ûux*{¯Á¸¶Ê9ÌóãÖ}nW×qZ&Æw+(=wBL À:Ë‹K‹2QÜ9«´êe1¦+7?”,ìøJùëà7`Ñ*Q‚òáøİ¶€c œšYë€8Ø.p(£;Òáá2Qˆ¶…ˆ$9b].TŠßJPV'À^~\›Ax_ÖT‰Q;§âİGun“¦kmkHf›Tö[÷Èl×7V([·DÙy‹”ÛLåvÇ4U\Q­lÙ$esoma›™:)Fâ#GâÅ7à×0E9†A¥´OäÓ‹À]R%r»ÆííÂ&ªÔ=)ŒÎ¬¡p¦éš—(—JÍ¿›ï©š3^u±QTQøŞ»kwJ-»­XV;İ™ívGé Å‚.PìÎ.»Ù‡VZÉNmh¡4A1d[š˜ˆC"‰D¥FTL¬ñÁ‰qvÖÔiKRL£†ŠbüÁêÏƒ>˜Š*Oëwïn‹DLœé÷sÏùîÏœ¹;3e¿–×´'¶±È;Ààa?àü}Odó¼æà80Ì ç ‚Íã¼Œó»Düì;ÒÄ~`˜ û`ßòç½`îÇÆ¾Ø7¸¬oÀ~vŞEvKûÂ‰mlŞRv”hÙYY_vjëZ]ö¹suv”†;5íi$íd§Ñ‰Ş­¸ ³ùÅe?T]y=±–}Il o2p P.` 8 TÀ» ï±€ç×À. •Íç€d-` ]€Ä>s0ËÎ;ZRIÔ±OÙGd%*ş	^FÜc
û1û@Ø³°!Ø9ö¡RH¢
y‚>Ø lò7±÷MµJ1QÃfP;ÜÄN *Øktö(µdšÌIJ‡ü"ì›ä‰*†¶På¤mºh\×˜¡MNÚ±àqÒz'íñÃğ8i„ÇIÛó(<NZo?<NZg<Ë^{¯é%Ö¹ª	?E•FQ¥QTi”xÙ(?ÉU/_Û«Ns3*vÂĞW5+ÖµNSk;µŞ ÖµQë0µ6Sk'µtjÉÔ
QË Ö4İ€RXÔx÷ºæF#H­9j½M­µ4jE©ÕD-•Æ—…Ö	“¦à?:ØûÚñôñ³0*Æã™0>EË€Hm,‰oqÛXh—Úk6µîOle³è8‹Û0K.^Ü Yl£Y2‹üà8Ğœ€"Pu#>&Ønâ@?ğ$° Tˆå, Œì//ñ±°–ò¢;y‹ÍâlÄfa£! ôÀVÏ˜Lı!Ú*†XŒÔÕáóª¶FªqiõÄŸÕıYM*•ì#¸Ï—í˜sµAqéË6­$n¥/‘»n$Ân 9Ñ¾‡È·ëñÕu
¶Õ‘w ›ßÑV+St9ï5¡\•R~‘]÷gyZùZu½ÔQ¾BäÔ„ò¥|T9ÛâJˆœÖ\
3¥
é¤¼Ay{NH#qÂQq3¡<!w(ûd‘*%væĞ2üÊv­WÙŠñRònÅÈaÌ	%.ïT6—T÷ğ>ÊZ,A/¹ÍXì*YL	‰Š¹t¯±ÚwÜ—õuúîõµúVûÂ>Å×à«÷­j¥€´\ºYZ&IR…ä•˜D¤nqŞĞ	nİŠŠ 7^Î^ágşÁÌzTbd±oñdX¦;I3ö™A’Ù­ÚtG\ºìÁ^û¦H’Úµ’éIÚôŒë+n·czÆöu=œÍSzÌDÔfO»”ôd]Zä¡#õví–ì$¡´æÈsõÜŞyä9Ó$Áºƒñ`¼¶½fãı©Ğ@™õkGğ:¿Á>éÎÚo5˜v+wŠfÆ~±[íËNÒßéoéÔ$½Â™ô´ÓßÓÛyÜÓ2ÍŒKwQéè°c®„3×U
•t'Jº(úC×Ät••$*tÑÊJ¡óR®ËçšÒ©|S“Ğ¬TINhr+Õjæ¢ĞD£BSg‘9¡™«³¸ÆnY†$$	½ÈB"ÓÛ…dÇ5IKYrtIrTÌä¡×4rIS=¿¨©‡Fÿ¿ÇPR×i¡ÍìKEÒ‘ô0`?spoĞ¶v«j~Ğä	Õöh»÷r»kÈ6#C){0’Róm}7H÷ñt[$•'}él¾ÏJ9mF[:²+e:ºÖÇ®›ëèÒ\ë»n0Xl=Ÿ«#vƒtŒ§;ø\1>WŒÏÕatˆ¹ˆØã]Ù¼D’æ–¾’-°ªeØ¯õa3Y8Ğ.6o[8x¨~
_+'I•nÚ7G’v5ÀSw%îJğ~S<µa9<Ô®Ÿ¢'Ë© Â5‘$Ñ‡Gr#$˜~$UúËá@hx„¼Äzî¿äÒ¶±+•&$c7wgìøƒ½Ù¼Ï‡è ¿${Ób¬ª*íÏ”‚kÜÄƒÏ’Ç6óXeeYøïû?R¶[ø¯ÀbÓj„(şù0=v(ÓÃğ(èéÅµöõf§ğ-Å_9˜£:Í-Q^¶®“R›ğk^ÄğHÙ+×b¸lK=Ñ%·X’¥ƒK_ªØ°®ÿ-À °‚Cµendstreamendobj19 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj36 0 obj<</Length 15073>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 126.1038 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 36.5 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.8067 714.5277 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.006 Tw 1.8 0 Td
[(Ch)0.5 (an)0.5 (g)0.5 (es i)0.5 (n)0.5 ( th)0.5 (e el)0.5 (ectri)0.5 (cal)0.5 ( acti)0.5 (vi)0.5 (ty o)0.6 (f yo)0.5 (u)0.5 (r heart cal)0.5 (l)0.5 (ed)0.5 ( Q)0.5 (T)74.7 (c p)0.5 (ro)0.5 (l)0.5 (o)0.5 (n)0.5 (g)0.5 (ati)0.5 (o)0.5 (n)0.5 (.)]TJ
/C2_0 1 Tf
0.023 Tw 32.062 0 Td
[<0BD80003>6.1 <0026004800550057>0.5 <0044004C00510003>6.2 <0046004B00440051004A004800560003>6.2 <0046004400510003>6.2 <005200460046005800550003>6.2 <004C00510003>6.2 <0057>0.6 <004B00480003>6.2 <0048004F004800460057>0.5 <0055004C00460044004F>-23.1 <0003>]TJ
/TT0 1 Tf
-0.015 Tc 0.03 Tw -32.062 -1.115 Td
[(acti)-0.6 (vity of you)-0.6 (r h)-0.6 (ea)-0.6 (rt d)-0.6 (u)-0.6 (rin)-0.6 (g tre)-0.6 (atme)-0.6 (n)-0.6 (t w)-0.6 (ith KR)-0.6 (AZA)73.9 (TI a)-0.6 (nd)-0.6 ( can)-0.6 ( b)-0.6 (e see)-0.6 (n o)-0.6 (n a test cal)-0.6 (l)-0.6 (ed)-0.6 ( an)-0.6 ( e)-0.6 (le)-0.6 (ctro)-0.6 (cardi)-0.6 (og)-0.6 (ram \(ECG or)-15.1 ( )]TJ
-0.02 Tc 0.001 Tw 0 -1.115 Td
[(EKG\).)0.5 ( QT)111.3 (c prolongation can increase your risk for irregular heartbeats that)0.5 ( can be life-threatening, such as torsades de)-20.2 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(point)0.6 (es,)0.5 ( and can lead t)0.5 (o sudden deat)0.5 (h.)-22.9 ( )]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.331 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.013 Tw 1.8 0 Td
[(Y)91.7 (ou should not take KRAZA)74.1 (TI if you have congenital long QT)18.2 ( syndrome or if you currently have QT)111 (c prolongation.)-17.9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.115 Td
(See)Tj
/Span<</ActualText<FEFF00A0>>> BDC 
( )Tj
EMC 
/TT1 1 Tf
[(\223Before taking KRAZA)74.2 (TI, tell your healthcare provider about all of your medical conditions, \including)-16.8 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(i)0.5 (f yo)0.5 (u)0.5 (:\224)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
3.322 0 Td
( )Tj
EMC 
/Span<</ActualText<FEFF0009>>> BDC 
-2.941 -1.295 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.331 0 Td
<0192>Tj
/TT0 1 Tf
-0.016 Tc 0.022 Tw 1.35 0 Td
[(Y)92 (our healthcare provider should )0.5 (monitor the electrical )0.5 (activity of your heart and )0.5 (the )0.5 (levels of )0.5 (body salts )0.5 (in your)-16 ( )]TJ
-0.018 Tc 0.012 Tw 0 -1.115 Td
[(blood \(electrolytes\) especially potassium and magnesium before startin\g and during treatment with KRAZA)74.4 (TI if)-17.9 ( )]TJ
-0.019 Tc 0.009 Tw 0 -1.115 Td
[(you have heart failure, a slow heart rate, abnormal levels of electrolyt\es in your blood, or if you take a medicine)-19.1 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(t)0.5 (hat)0.5 ( can prolong t)0.5 (he Q)0.5 (T)18.6 ( int)0.5 (erval of)0.5 ( your heart)0.5 (beat)0.5 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.019 -1.259 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.331 0 Td
<0192>Tj
/TT1 1 Tf
-0.013 Tc 0.038 Tw 1.35 0 Td
[(T)74.4 (ell your healthcare )0.5 (provider if you )0.5 (feel dizzy)74.1 (, lightheaded, or )0.5 (faint, or )0.5 (if you )0.5 (get abnormal )0.5 (heartbeats)-13.1 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(d)0.5 (u)0.5 (ri)0.5 (n)0.5 (g)0.5 ( treatmen)0.5 (t w)0.5 (i)0.5 (th)0.5 ( KRAZ)0.6 (A)74.3 (T)0.5 (I)0.5 (.)]TJ
/C2_0 1 Tf
-0.047 Tc 0.047 Tw 14.373 0 Td
[<0BD8>-0.8 <0003>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-18.793 -1.637 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.01 Tc 0.051 Tw 1.8 0 Td
[(Li)0.5 (ver p)0.5 (robl)0.5 (ems.)]TJ
/C2_0 1 Tf
0.01 Tw 7.344 0 Td
[<0BD80003>4.1 <0024004500510052005500500044004F0003>-51 <004F004C0059004800550003>-51 <0045004F0052005200470003>-51 <0057004800560057>0.5 <0003>-51 <0055004800560058004F005700560003>-51 <0044005500480003>-51 <0046005200500050005200510003>-51 <005A004C0057004B0003>-51 <002E00350024003D0024>74.5 <0037>0.5 <002C0003>-51 <0044005100470003>-51 <0046004400510003>-51 <00560052005000480057004C0050004800560003>-51 <004500480003>-51 <00560048005900480055004800110003>-32.9 <003C>92.1 <005200580055>-10 <0003>]TJ
/TT0 1 Tf
-0.023 Tc -0.02 Tw -7.344 -1.115 Td
[(healt)0.6 (hcare )0.6 (provider )0.6 (should )0.6 (do )0.7 (blood )0.6 (t)0.5 (est)0.5 (s )0.7 (bef)0.5 (ore )0.6 (st)0.5 (art)0.5 (ing )0.7 (and )0.6 (during )0.6 (t)0.5 (reat)0.6 (ment)0.5 ( )0.6 (wit)0.5 (h )0.6 (KRAZ)0.5 (A)74.5 (T)0.6 (I)0.5 ( )0.6 (t)0.5 (o )0.7 (check )0.6 (your )0.6 (liver )0.7 (f)0.5 (unct)0.5 (ion.)-22.9 ( )]TJ
-0.014 Tw 0 -1.115 Td
[(T)111.3 (ell your healt)0.5 (hcare provider right)0.5 ( away if)0.5 ( you develop any signs or sympt)0.5 (oms of)0.5 ( liver )0.5 (problems,)0.5 ( including:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.617 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.014 Tc 0.033 Tw 1.8 0 Td
[(your skin or the white part of )0.5 (your eyes turns)-14 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.08 Td
(yellow \(jaundice\))Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 1.08 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(nausea or vomit)0.5 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.296 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(bleeding or bruising)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.296 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(loss of)0.5 ( appet)0.5 (it)0.6 (e)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.296 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.021 Tc 1.8 0 Td
[(pain, aching or tenderness on the right side of)-20.8 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.08 Td
[(your st)0.5 (omach area \(abdomen\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 2.469 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(dark or \223t)0.5 (ea-colored\224 urine)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.419 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(light)0.5 (-colored st)0.5 (ools \(bowel movement)0.6 (s\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.419 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(t)0.5 (iredness or weakness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.019 -1.763 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.026 Tc -0.028 Tw 1.8 0 Td
[(L)0.5 (u)0.6 (n)0.6 (g)0.5 ( o)0.6 (r b)0.6 (reath)0.5 (i)0.6 (n)0.5 (g)0.6 ( p)0.6 (ro)0.5 (b)0.6 (l)0.5 (ems.)]TJ
/C2_0 1 Tf
0.026 Tw 12.815 0 Td
[<0BD80003>28.3 <002E00350024003D>0.6 <0024>74.6 <0037>0.6 <002C>0.5 <0003>28.3 <00500044005C0003>28.3 <004600440058005600480003>28.3 <004C005100C000440050005000440057>0.6 <004C005200510003>28.4 <00520049>0.6 <0003>28.3 <0057>0.6 <004B00480003>28.4 <004F00580051004A00560003>28.3 <0057>0.6 <004B00440057>0.5 <0003>28.4 <0046004400510003>28.4 <004F0048004400470003>28.3 <0057>0.6 <00520003>28.4 <0047004800440057>0.5 <004B0011>0.5 <0003>46.4 <0037>111.4 <0048004F004F0003>28.3 <005C0052005800550003>28.3 <004B00480044004F0057>0.6 <004B0046004400550048>-26.1 <0003>]TJ
/TT0 1 Tf
-0.023 Tc -0.014 Tw -12.815 -1.115 Td
[(provider or get)0.5 ( emergency medical help right)0.5 ( away if)0.5 ( you have new )0.5 (or worsening short)0.6 (ness of)0.5 ( breat)0.5 (h,)0.5 ( cough,)0.5 ( or f)0.5 (ever)55.5 (.)]TJ
/TT1 1 Tf
-1.8 -1.817 Td
[(T)0.5 (h)0.5 (e mo)0.5 (st co)0.6 (mmo)0.5 (n)0.5 ( si)0.5 (d)0.5 (e effects o)0.5 (f KRAZ)0.5 (A)74.3 (T)0.6 (I)0.5 ( w)0.5 (h)0.5 (en)0.5 ( u)0.5 (sed)0.5 ( al)0.5 (o)0.5 (n)0.5 (e fo)0.5 (r NSCL)0.5 (C i)0.5 (n)0.5 (cl)0.6 (u)0.5 (d)0.5 (e:)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 36.393 0 Td
<0BD8>Tj
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-34.012 -1.595 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(kidney problems)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(vomit)0.5 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(decreased appet)0.5 (it)0.5 (e)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(t)0.5 (rouble breat)0.6 (hing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(muscle and bone pain)Tj
/TT1 1 Tf
-3.6 -1.741 Td
[(T)0.5 (h)0.5 (e mo)0.5 (st co)0.6 (mmo)0.5 (n)0.5 ( si)0.5 (d)0.5 (e effects o)0.5 (f KRAZ)0.5 (A)74.3 (T)0.6 (I)0.5 ( w)0.5 (h)0.5 (en)0.5 ( u)0.5 (sed)0.5 ( i)0.5 (n)0.5 ( co)0.5 (mb)0.5 (i)0.5 (n)0.5 (ati)0.5 (o)0.5 (n)0.5 ( w)0.5 (i)0.5 (th)0.5 ( cetu)0.5 (xi)0.6 (mab)0.5 ( fo)0.5 (r CRC i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (e:)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 46.56 0 Td
<0BD8>Tj
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-44.179 -1.595 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(skin rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(st)0.5 (omach pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(decreased appet)0.5 (it)0.5 (e)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(vomit)0.5 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(low red blood cell count)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(muscle and bone pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(dizziness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(const)0.5 (ipat)0.5 (ion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.319 -1.376 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(dry skin)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.881 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(nerve damage in t)0.5 (he arms and legs)]TJ
-0.016 Tc 0.023 Tw -28.7 -1.579 Td
[(Certain abnormal blood test results are common during treatment with KRA\ZA)74.2 (TI, when used alone or in combination with)-16.1 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(cet)0.5 (uximab.)0.5 ( )18.5 (Y)92.2 (our healt)0.5 (hcare provider will monit)0.5 (or you f)0.5 (or abnormal blood t)0.5 (est)0.5 (s and t)0.5 (reat)0.5 ( you if)0.6 ( needed.)]TJ
-0.012 Tc 0.044 Tw 0 -1.583 Td
[(KRAZA)74.1 (TI )0.7 (may )0.7 (cause )0.7 (fertility )0.7 (problems )0.7 (in )0.7 (males )0.6 (and )0.7 (females, )0.7 (which )0.7 (may )0.7 (af)18.1 (fect )0.7 (your )0.7 (ability )0.7 (to )0.7 (have )0.6 (children. )18.8 (T)110.9 (alk )0.7 (to )0.7 (your)-12 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(healt)0.6 (hcare provider if)0.5 ( t)0.5 (his is a concern f)0.5 (or you.)]TJ
0 -1.583 Td
[(T)0.5 (hese are not)0.5 ( all of)0.5 ( t)0.5 (he possible side ef)18.6 (f)0.5 (ect)0.5 (s of)0.5 ( KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 (.)]TJ
0 -1.403 Td
[(Call your doct)0.5 (or f)0.5 (or medical advice about)0.5 ( side ef)18.6 (f)0.5 (ect)0.5 (s.)0.5 ( )18.5 (Y)92.2 (ou may report)0.5 ( side ef)18.5 (f)0.5 (ect)0.5 (s t)0.5 (o F)0.5 (DA)55.5 ( at)0.5 ( 1)60.2 (-)-39.7 (800)-39.8 (-F)0.5 (DA)-39.7 (-)60.3 (1088.)]TJ
/TT1 1 Tf
0 -2.447 Td
[(Ho)0.5 (w)0.5 ( sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( I)0.5 ( sto)0.5 (re KRAZ)0.5 (A)74.4 (T)0.5 (I)0.6 (?)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.403 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(St)0.6 (ore KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( at)0.5 ( room t)0.5 (emperat)0.5 (ure bet)0.5 (ween 68\260)0.5 (F)0.5 ( t)0.6 (o 77\260)0.5 (F)0.5 ( \(20\260)0.5 (C t)0.5 (o 25\260)0.5 (C\).)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.331 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(KRAZ)0.5 (A)74.5 (T)0.5 (I)0.6 ( comes in a child-resist)0.5 (ant)0.5 ( cont)0.5 (ainer)55.6 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.331 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.022 Tc 1.8 0 Td
[(KRAZA)74.1 (TI comes with a desiccant \(drying agent\) in the container to keep the \medicine dry)74 (. Do not remove the desiccant)-21.9 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.115 Td
[(f)0.5 (rom t)0.5 (he cont)0.5 (ainer af)0.5 (t)0.5 (er opening.)0.5 ( Do not)0.5 ( eat)0.5 ( or swallow t)0.5 (he desiccant)0.5 (.)]TJ
/TT1 1 Tf
-1.8 -1.331 Td
[(Keep KRAZ)0.5 (A)74.3 (T)0.6 (I )0.5 (an)0.5 (d)0.5 ( al)0.5 (l)0.5 ( med)0.5 (i)0.5 (ci)0.5 (n)0.5 (es o)0.5 (u)0.5 (t o)0.5 (f th)0.5 (e reach)0.5 ( o)0.6 (f ch)0.5 (i)0.5 (l)0.5 (d)0.5 (ren)0.5 (.)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 27.581 0 Td
<0BD8>Tj
ET
4 M 
36.5 36.5 539 694.808 re
S
endstreamendobj30 0 obj<</Length 12624>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 668.4985 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 488.9016 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 361.4938 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 159.5877 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc -0.014 Tw 10 0 0 10 251.2311 714.5277 Tm
[(P)74.6 (A)74.4 (T)0.5 (I)0.5 (ENT)0.5 ( I)0.5 (NF)0.5 (O)0.5 (RMA)74.4 (T)0.5 (I)0.5 (O)0.5 (N)]TJ
0.023 Tw 9.5 0 0 10 253.7224 700.7913 Tm
[(KRAZ)0.5 (A)74.4 (T)0.5 (I)]TJ
0 Tc 0 Tw 6.65 0 0 5.6 293.1533 704.2053 Tm
(\256)Tj
-0.023 Tc -0.014 Tw 9.5 0 0 10 297.8979 700.7913 Tm
[( \(krah)0.5 ( zah)0.5 ( tee\))]TJ
0 Tc 0 Tw 6.356 0 Td
( )Tj
-0.023 Tc 0.023 Tw -8.081 -1.14 Td
[(\(ad)0.5 (ag)0.5 (rasi)0.5 (b)0.5 (\))]TJ
0 Tc 0 Tw 5.157 0 Td
( )Tj
-0.023 Tc 0.023 Tw -4.222 -1.14 Td
[(T)74.7 (ab)0.5 (l)0.5 (ets)]TJ
-0.014 Tw 10 0 0 10 46 653.282 Tm
[(W)0.5 (h)0.5 (at i)0.5 (s KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (?)]TJ
/TT1 1 Tf
0 -1.608 Td
[(KRAZ)0.5 (A)74.5 (T)0.5 (I)0.6 ( is a prescript)0.5 (ion medicine used in adult)0.5 (s:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.428 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(alone t)0.5 (o t)0.5 (reat)0.5 ( non-small cell lung cancer \(NSCLC\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(t)0.5 (hat)0.5 ( has spread t)0.5 (o ot)0.5 (her part)0.5 (s of)0.5 ( t)0.5 (he body or cannot)0.5 ( be removed by surgery)74.5 (,)0.6 ( )]TJ
/TT0 1 Tf
0.023 Tw [(an)0.5 (d)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(whose t)0.5 (umor has an abnormal )]TJ
/TT2 1 Tf
0.023 Tw (KRAS )Tj
/TT1 1 Tf
-0.014 Tw 15.877 0 Td
[(G)0.5 (12C gene,)0.5 ( )]TJ
/TT0 1 Tf
0.023 Tw [(an)0.5 (d)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-17.096 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(who have received at)0.6 ( least)0.5 ( one prior t)0.5 (reat)0.5 (ment)0.5 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.019 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(in combinat)0.6 (ion wit)0.5 (h a medicine called cet)0.5 (uximab t)0.5 (o t)0.5 (reat)0.5 ( colon or rect)0.5 (al cancer \(CRC\))-23 ( )]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(t)0.5 (hat)0.5 ( has spread t)0.5 (o ot)0.5 (her part)0.5 (s of)0.5 ( t)0.5 (he body or cannot)0.5 ( be removed by surgery)74.5 (,)0.6 ( )]TJ
/TT0 1 Tf
0.023 Tw [(an)0.5 (d)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(whose t)0.5 (umor has an abnormal )]TJ
/TT2 1 Tf
0.023 Tw (KRAS )Tj
/TT1 1 Tf
-0.014 Tw 15.877 0 Td
[(G)0.5 (12C gene,)0.5 ( )]TJ
/TT0 1 Tf
0.023 Tw [(an)0.5 (d)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-17.096 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(who have previously received cert)0.5 (ain chemot)0.6 (herapy medicines.)]TJ
-3.6 -1.536 Td
[(Y)92.1 (our healt)0.5 (hcare provider will perf)0.5 (orm a t)0.5 (est)0.5 ( t)0.5 (o make sure t)0.6 (hat)0.5 ( KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( is right)0.5 ( f)0.5 (or you.)]TJ
0 -1.428 Td
[(I)0.5 (t)0.5 ( is not)0.5 ( known if)0.5 ( KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( is saf)0.5 (e and ef)18.6 (f)0.5 (ect)0.5 (ive in children.)]TJ
/TT0 1 Tf
0 -2.472 Td
[(Befo)0.5 (re taki)0.5 (n)0.5 (g)0.5 ( KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (,)0.5 ( tel)0.5 (l)0.5 ( yo)0.5 (u)0.5 (r h)0.5 (eal)0.6 (th)0.5 (care p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er ab)0.5 (o)0.5 (u)0.5 (t al)0.5 (l)0.5 ( of yo)0.5 (u)0.5 (r med)0.5 (i)0.5 (cal)0.5 ( co)0.5 (n)0.5 (d)0.5 (i)0.5 (ti)0.5 (o)0.5 (n)0.5 (s,)0.5 ( i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 ( i)0.5 (f yo)0.5 (u)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.428 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(have any heart)0.5 ( problems,)0.5 ( including heart)0.5 ( f)0.5 (ailure and congenit)0.5 (al long Q)0.5 (T)18.6 ( syndrome.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(have liver problems.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(are pregnant)0.5 ( or plan t)0.5 (o become pregnant)0.6 (.)0.5 ( I)0.5 (t)0.5 ( is not)0.6 ( known if)0.5 ( KRAZ)0.6 (A)74.5 (T)0.5 (I)0.5 ( can harm your unborn baby)74.6 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.018 Tw 1.8 0 Td
[(are )0.5 (breast)0.5 (f)0.5 (eeding )0.5 (or )0.5 (plan )0.6 (t)0.5 (o )0.6 (breast)0.5 (f)0.5 (eed.)0.5 ( )0.5 (I)0.5 (t)0.5 ( )0.6 (is )0.5 (not)0.5 ( )0.6 (known )0.6 (if)0.5 ( )0.6 (KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( )0.6 (passes )0.6 (int)0.5 (o )0.5 (your )0.5 (breast)0.5 (milk.)0.5 ( )0.5 (Do )0.5 (not)0.5 ( )0.5 (breast)0.5 (f)0.5 (eed )0.6 (during)-23.1 ( )]TJ
-0.014 Tw 0 -1.14 Td
[(t)0.5 (reat)0.5 (ment)0.5 ( and f)0.5 (or 1 week af)0.6 (t)0.5 (er your last)0.5 ( dose of)0.5 ( KRAZ)0.5 (A)74.5 (T)0.5 (I)0.5 (.)]TJ
/TT0 1 Tf
-0.018 Tc 0.012 Tw -1.8 -1.356 Td
[(T)74.5 (ell your healthcare provider about all the medicines you take,)]TJ
/C2_0 1 Tf
0.018 Tw [<0BD80003>-11.7 <004C00510046004F00580047004C0051004A0003>-11.7 <005300550048005600460055004C00530057004C005200510003>-11.6 <0044005100470003>-11.7 <005200590048005500100057004B0048001000460052005800510057004800550003>-11.7 <005000480047004C0046004C005100480056000F>-17.8 <0003>]TJ
/TT1 1 Tf
0.011 Tw 0 -1.14 Td
[(vitamins, and herbal supplements. KRAZA)74.5 (TI can af)18.5 (fect the way other medicines work, and other medicines can af)18.4 (fect how)-18.2 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(KRAZ)0.5 (A)74.5 (T)0.5 (I)0.6 ( works.)]TJ
/TT0 1 Tf
0 -2.472 Td
[(Ho)0.5 (w)0.5 ( sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( I)0.5 ( take KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (?)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.428 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.022 Tc 1.8 0 Td
[(T)111.1 (ake KRAZA)74.3 (TI exactly as your healthcare provider tells you to take it. Do not chan\ge your dose or stop taking KRAZA)74.4 (TI)-21.9 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(unless your healt)0.5 (hcare provider t)0.5 (ells you t)0.5 (o.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.011 Tc 0.046 Tw 1.8 0 Td
[(Y)92 (our healthcare provider may change your dose, or temporarily or permanen\tly stop treatment with KRAZA)74.5 (TI if you)-11.2 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(develop cert)0.5 (ain side ef)18.6 (f)0.5 (ect)0.5 (s.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.011 Tc 0.049 Tw 1.8 0 Td
[(For colon or rectal cancer)55 (, you will also receive cetuximab through )0.5 (a vein in your arm \(intravenously\) given by )0.5 (your)-11 ( )]TJ
-0.02 Tc 0.003 Tw 0 -1.14 Td
[(healthcare provider)55.1 (. )18 (Y)91.8 (our healthcare provider will permanently or temporarily stop your treatm\ent with cetuximab if your)-20 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(t)0.5 (reat)0.5 (ment)0.5 ( wit)0.5 (h KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( is permanent)0.5 (ly or t)0.5 (emporarily st)0.5 (opped.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(T)111.4 (ake your prescribed dose of)0.5 ( KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( 2 t)0.5 (imes each day)74.6 (,)0.5 ( at)0.5 ( about)0.5 ( t)0.5 (he same t)0.6 (ime each day)74.6 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(T)111.4 (ake KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( eit)0.5 (her wit)0.5 (h f)0.5 (ood or wit)0.5 (hout)0.5 ( f)0.5 (ood.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(Swallow KRAZ)0.5 (A)74.5 (T)0.5 (I)0.6 ( t)0.6 (ablet)0.5 (s whole.)0.5 ( Do not)0.5 ( chew)55.3 (,)0.5 ( crush or split)0.5 ( t)0.5 (ablet)0.5 (s.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
[(I)0.5 (f)0.5 ( you vomit)0.5 ( af)0.5 (t)0.5 (er t)0.5 (aking a dose of)0.5 ( KRAZ)0.5 (A)74.5 (T)0.5 (I)0.5 (,)0.6 ( do not)0.5 ( t)0.5 (ake an ext)0.5 (ra dose.)0.5 ( )18.5 (T)111.3 (ake your next)0.5 ( dose at)0.5 ( your next)0.5 ( scheduled t)0.5 (ime.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.32 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.019 Tc 0.009 Tw 1.8 0 Td
[(If you miss a dose of KRAZA)74.1 (TI, take the dose as soon as you remember)54.9 (. If it has been more than 4 hours, do not take)-19.1 ( )]TJ
0 Tc 0 Tw 50.2 0 Td
( )Tj
-0.02 Tc 0.005 Tw -50.2 -1.14 Td
[(the )0.5 (dose. )18.5 (T)110.7 (ake your )0.5 (next )0.5 (dose )0.5 (of )0.5 (KRAZA)73.9 (TI )0.5 (at your )0.5 (next )0.5 (scheduled )0.5 (time. )0.5 (Do )0.5 (not )0.5 (take )0.5 (2 )0.5 (doses )0.5 (at the )0.5 (same )0.5 (time )0.5 (to )0.5 (make)-20.2 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(up f)0.5 (or a missed dose.)]TJ
/TT0 1 Tf
-1.8 -2.292 Td
[(W)0.5 (h)0.5 (at are p)0.5 (o)0.5 (ssi)0.5 (b)0.5 (l)0.5 (e si)0.5 (d)0.5 (e effects o)0.5 (f KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (?)]TJ
0 -1.32 Td
[(KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 ( can)0.5 ( cau)0.5 (se seri)0.5 (o)0.5 (u)0.5 (s si)0.6 (de effects,)0.5 ( i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.428 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.026 Tc -0.028 Tw 1.8 0 Td
(Stomach and intestinal \(gastrointestinal\) problems.)Tj
/C2_0 1 Tf
0.026 Tw [<0BD80003>28.1 <003600570052005000440046004B0003>28.1 <0044005100470003>28 <004C00510057004800560057004C00510044004F0003>28.1 <0056004C004700480003>28.1 <00480049>18.3 <004900480046005700560003>28.1 <004C00510046004F00580047004C0051004A0003>28.1 <005100440058005600480044000F0003>28.1 <0047004C004400550055004B00480044000F0003>28 <00520055>-26 <0003>]TJ
/TT1 1 Tf
-0.023 Tc -0.011 Tw 0 -1.14 Td
[(vomit)0.5 (ing,)0.5 ( are )0.5 (common )0.5 (wit)0.5 (h KRAZ)0.5 (A)74.6 (T)0.5 (I)0.5 ( but)0.5 ( can )0.5 (also )0.5 (somet)0.5 (imes be severe.)0.5 ( KRAZ)0.5 (A)74.5 (T)0.5 (I)0.5 ( )0.5 (can also cause serious st)0.5 (omach and)-23.2 ( )]TJ
/C2_0 1 Tf
0.023 Tw 0 -1.14 Td
[<004C00510057>0.5 <004800560057>0.5 <004C00510044004F0003>14.4 <0056004C004700480003>14.4 <00480049>18.6 <0049>0.5 <004800460057>0.5 <00560003>14.4 <005600580046004B0003>14.4 <004400560003>14.4 <0045004F004800480047004C0051004A000F>0.5 <0003>14.4 <0052004500560057>0.5 <0055005800460057>0.5 <004C00520051000F>0.5 <0003>14.4 <004C005100C000440050005000440057>0.5 <004C005200510003>14.5 <00520049>0.6 <0003>14.4 <0057>0.5 <004B00480003>14.4 <00460052004F005200510003>14.4 <000B00460052004F004C0057>0.5 <004C0056000C000F>0.5 <0003>14.4 <0044005100470003>14.4 <00510044005500550052005A004C0051004A0003>14.4 <000B00560057>0.5 <0048005100520056004C0056000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT0 1 Tf
-0.026 Tc -0.028 Tw 1.8 0 Td
[(Call your healthcare provider if you develop any of the signs or symptom\s of stomach or intestinal problems)-26.1 ( )]TJ
-0.023 Tc -0.014 Tw 0 -1.14 Td
[(l)0.5 (i)0.5 (sted)0.5 ( ab)0.5 (o)0.5 (ve d)0.5 (u)0.5 (ri)0.6 (ng)0.6 ( treatmen)0.5 (t w)0.5 (i)0.5 (th)0.5 ( KRAZ)0.5 (A)74.4 (T)0.5 (I)0.5 (.)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 20.1 0 Td
<0BD8>Tj
/TT1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-21.319 -1.356 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<017C>Tj
/TT1 1 Tf
-0.009 Tc 0.059 Tw 1.8 0 Td
[(Y)91.7 (our )0.7 (healthcare )0.7 (provider )0.7 (may )0.6 (prescribe )0.7 (an )0.6 (antidiarrheal )0.7 (medicine )0.7 (or )0.7 (anti-nausea )0.6 (medicine, )0.7 (or )0.7 (other )0.6 (treatment,)-8.8 ( )]TJ
0 Tc 0 Tw 48.4 0 Td
( )Tj
-0.023 Tc -0.014 Tw -48.4 -1.14 Td
(as needed.)Tj
ET
4 M 
36.5 36.5 539 694.808 re
S
endstreamendobj34 0 obj<</BaseFont/UEAMSO+Arial-ItalicMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 57 0 R/LastChar 83/Subtype/TrueType/ToUnicode 58 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 722 667]>>endobj57 0 obj<</Ascent 998/CapHeight 716/Descent -325/Flags 96/FontBBox[-517 -325 1379 998]/FontFamily(Arial)/FontFile2 59 0 R/FontName/UEAMSO+Arial-ItalicMT/FontStretch/Normal/FontWeight 400/ItalicAngle -12/StemV 92/Type/FontDescriptor/XHeight 519>>endobj58 0 obj<</Filter/FlateDecode/Length 250>>stream
H‰\PÁjÃ0½û+tlÅIºŞL`íäĞn,Û8¶’Û(Î!?Å)L`¿'¤'?K^š—Æ»ò‚i1Aï¼%œÂL¡ÃÁyQV`I÷,ßfÔQH·Ë”pl|„R ?¸8%Z`÷lC‡{!ßÈ"9?ÀîëÒîA¶sŒ?8¢OP@]ƒÅ]u¼éAfÙ¡±\wi9°æ¯ãs‰UÎËÍŒ	§¨’ö
UpÔ ^9jŞş«Ÿ6U×›oMBUkoQ0õTfÎÀü¼ñ3óS•9óãÆyö}Êú
/_03»ÏË¶WÃÎãc©1D`ÕzÄ¯  X x€endstreamendobj59 0 obj<</Filter/FlateDecode/Length 12664/Length1 31133>>stream
H‰Œ•	XW€«ºŞ@ˆ(ˆÎtÏ@Ñ¸ÆUcÔƒˆJ¢Æˆˆ ""‰×]£ÆÅ¨ˆ(
ŞïÁ;"*¢ x÷8à™Q\¯¸^Cfòøø²ß~ù²ïûªºê½ª×İÿ÷ª^Râ¤(¨³ ´_ÿÚ@Õ0s	Œ‹HL|Y€ş u"''ÉUËn. šğè„ÑqU¾g4÷G}cğú Ïr?iLTÄ¨+K^Ìx>´Ã'ªâ¥D®üÆÄ%M­öSš…ÆÆGF@»õ ‚r@\ÄÔ„ªõñ¸’ÇGÄEåd\Çı0 6#!~b’Cï² ñºs=!1ª:>ñ€Ë&h>¦€DMº¦-è±Iå3Œ.A´à!j„Ú.L­ÀÊ –`j7ŠÎü!İdnÉ
M‰}¶uíŒ{ —ò}™I“ë|0®…ªxğäü¸…>\\ª7qn&Î˜ÿ|‘˜ÆÅUÔÖª]§n=7÷ú<6òònìÓ¤©N/É£¯ŸbjöAó¶ü[«Zÿ½MÛv·ÿ¤CÇNŸúÖùó€.]»uêÜ³Wï>!}û…~ñeÿ¿ôõà°!C‡##GEE36f\lÜøø„	‰“&M2uÚôo¾1sÖì9ÿø.yî¼Îÿ~ÁÂE?,şWÊ’—.[º"me:¬ÎX³63kİú7mŞ²uÛO´}ÇÎ]»÷ìİ·ÿÀÁìC9¹‡=vüÄI8•w:ÿÌÙsç/\,*†K—K®\½vnŞRÍ·-¥Àêìæ?Úˆÿª+4‚™èda°°ƒ|©ÅÓ$šIheÑEzÍê²~l¦æŒæ±æ•.F7NwJW sègéWé_èßI%(…Hƒ¤ÁÒi˜4CÚ/åI%’*=“^IvÙM6Ê&¹•ÜZn'w’ıåÎrwy¸/Ï’—ÉCƒ—Áh0Zú†’Ë[Œ‚ÑÅèfô064ú%csã‡Æ`c„1ÊWğu÷5( JÅ]ñT¼•¦ŠŸÒRi§ø+±Êl%Y™¯,R–*YÊve¯’«Qò”B¥H¹©<4ù›L]Má¦HS´iœ)¾elË)­¼6ûl6Ø[{›¿­³­‹­»­Ÿİ×QápT¡Lƒ&ì$?
¥$šNÉœËbZOÅô†Õc¡l¾f‰¦Xó\œK¬.Og×ƒ~¶>SÿRÉ[’¥`)´šËi¶tPÊ—®I·¥—ÒkdÎ¥çÒFîXÃ%†sI‘3+¹4ªæbèoÂ¹¤Ôp©Ï¹46ê«¹„GUr‘ÿ„Kh—%SÙVÃ¥€s¹Á¹tªáeŠá\Â[&q.^›eÚt¶œK€­›-È.;¹8îñ’Q¸ˆ\&rá,ûX§xmÙ[T•QEqÅùòX€òåO ¬ î§ñgokOkk µ›µ«µ‹5Àú¹õ3«¿õSkGkk{ëÇÎÌ²¹\–sI.{wgKÙ”Gµ¹m½Åõ‚² ¥1¥ÓÊr­±wN”-¶~Rº¥4Õ’jYgY`ÙäÌ/õ²L°ğ¯²´¶XÚZüÌAæ@³¿¹£¹½¹­¹µ¹¹Ùhnbö4£úT-W­êõ®3KÍW«ÇÔlnV7ª»Ô@µ«ÚEõSªAÕß)º=ôö@uèÈƒ#÷hñ²YíºÊ5İu¥kZ-™°²·xò¾QÌûOgŞ[MÎ~«‰qvYM:×Oy¿óvIvM¯b#Vj×Š*[Ã_Q/ò-ò®*†ÿa6¬RWÎˆóş47Á)bbµ7ş¯Şõ‡Ì 1¸ÆîşÄ›şgŠ`=$Ã\¡Rá!ÌƒÅ°2`+l wXÀ¡}Ká9¼€`ÌGä÷Ú3XÛàWx	¯`l‡³;`$DB
Œ‚ˆ‚3p.Ây(„ğDÃ%(‚bØ	£á),+pJ`<‚røb`,Œƒ8ˆ…ñ	ñ0 &Â$H‚É0¬0¦Ã4øfÀ·Y0fòÛv<†'ƒ©¸$d¨T`®Ät\¿]ĞEpàjÌÀ5¸31µXkc\‡ëá5¼Á¸7áfÜ‚[qş„ÛqîÄ]¸÷à^Üoá*.À…¸àAÌÆCXëaæ¢ºc}ô€2¸ƒĞãlÈ;ö"<ŠÇğ8À“ø3z¡7ì‚İØ}ğæalŠ:ÔãiÌ‡wğîÂ=”PFñÅsX€ç±/àEôE?TĞ„EXŒ—ğ2–àÈÅfø6ÇpàU:A'ég:Eytšòé¥sT@ç©.ğ»áñ¿‰.Ñe*¡+t•®ÑuºA7é©d¦Û‚]p…J©ŒîĞ]ºG÷é=¤_ÈJè1!•Óú7=¥gôœ^ĞKú•^Ñè5½¡·ôŞ“*è7²“ƒC&0bŒi˜¥Ğú‘–Ò2ZN©´‚Òh%¥Ó*ZM´†Ö2W&2-«Íêğû«scî¬>ó`˜'kÈ1/æÍ3Ö„5e:¦g“™™/óÃkxoàM¼…ªÌ‚XÌz²^¬7ëÃBX_~~Á¾dıÙ 6}Å±¯Åb/±·(¾ßŠïÄ÷¢M¬í¢CÚeÚåÚTí
mšv¥6]»J»Z›¡]£]«ÍÔf±Á,ŒaCÙ06œ`á,‚rÄ>b;È²Ù!–ÃrÙav„ıéúÏ¢Øâ ~Î™™³³Jè"WJBè$TéU:ˆA¥«€ $tB‡Ğ¥£  HŒ ÒK¨*¡†-ôv½y÷xıpw}ŞïóìÌœİ™ÿoô^½Oÿ¢Õ¿éıú€>¨éÃúˆ>ªéãğ'dè®ÓôI}JŸÖgôY}Nÿ®ÿĞêó:]_Ğá\„KpÎÃ}I_ÖWôU¡¯éëú†¾©oéL}[ßÑYú®¾§ïÛöÛÑv²mÛÕv³İmÛÓ~h{Ùl¸ímû¨ UÁD(iÆšqf¼™ ¬™h&™ÉfŠ‰2SÍ43İÌ03Í,3ÛÌ1sM´™gbL¬™/Y¹Ğ,2‹Í³TU´Û¾¶ŸıÄ~j?³ıí ]r•«]cÚAv°Ùo˜ƒæÈãˆ9j™ãæ„I3'Í)IÜ3æ¬ùÃ]ç®wãDğ1>ÁËøŸás|‰¯ğ5¾Ác%üÿƒ9èÃÊb )ÒdˆÉ!+¶Ìƒ!äGy)ùS å§T
Q V¡ÂT«b5*JÅ¨8• ’ô•¢·©´X)ZTP«c*‹5©•§ ª@ÁT‘Ş¥JvˆjŸÙçö…Ë®ãZ×59T™B¨
U¥jTjPMªEµ)”ÂŒÏx4–ÆÑxš@iM¦)ESiMg 4“‘‰k6Ìì°e—ó°çå|ìÏœŸpA.Ä\˜‹pQI™â\‚Kò[\Šßæñ;\†Ër9.ÏA\ƒ¹"¿Ë•¸2‡p®ÊÕhÍVqjWç*^%pM®¥6ªMj³JäÚÊa\GmQ[¹.×ãúÜ€ò{Üˆs~_}¯¶©T’Ú®vpSnÆÍ¹…Ú©’UŠú‘[r+nÍm¸-·ãöÜ?àÜ‰;sîÊİ¸;÷àü¡»?âpîÍ}øcîËıøÙSvó§ü÷ç<ñ`ÂCùsş‚¿äa<\íQ?ñşŠGò(şšGóàHËãx¼›Çõã	<ÑwÜî&w³›È“x2Oá(ÊÓx:Ïà™<‹góËÑ<cÜ-îV÷{wÇò|^Ày/æ%¼”¿áe¼œWğJ^Å«y¯uóò·ü¯ãõÇ8x#oâÍœÈ[hÅP,Í§´ÑbZBKİ|ô-£å´‚VÒ*ZMkh-ouıİ 7¿}éşèîÂ+x3ğ^ÇNm'Ô	sê8uzN}§ÓĞyÏiä4vš8ï;MfNs§…ÓÒiå´vÚàM¼%>Ÿ+'µ·í›eïÚ{ö¾}`ÚlûÈ>¶O(‹îÒ=ºooBl§9ê/¬Éû1vÀN8`oAü
3é=¤Ç”MpÆØLzFÏé½¤'ôÔÖ²µm(¼À;6ÌÖÁ0[×Ö£_TAHµõmÛP”ĞÒæwG¸_Ñ\û–ÃCø6ÀBl±ØGã\ˆ‹pìÂñ¶‘JU?«}tÈ·éö‚½h/ÙËöŠ½j3è0¡£tŒÓ	J£“tŠNÓ:KçäDWüï;Jè (àİ‘;+÷×7ØËÎıÏ7Ì»A¹’Kşçşß•
û Zf/-	ò£EDŠBæÊ¼ïÁ1ÆÜ)"+&Y?áÏ4z‰ ŠŠöC5TŞiQÈÌEiĞx±Xü 84Mì–T<ïecüRÎ’%¡t†•éWM13Ò‘3®+I£v2îPÂ 5t€pS‚Œõ \Â`ÓÔË€w 1t‘#EJëáÆRúšâÔÓÍ[áI/ò$AĞB\3\F=VÈ<‰:
‰2U1½Ê÷Ô÷Æ‹“™W€ZĞš‹u&ÃñÒÈ„×ØP%êª†KŠôŠx;eÌ¥ ´‘ÖºA_qĞ$©ØjH¢õ*ÚwÀ÷Jt+Q!2ê0¨'óï%µJƒ‹â“â"ˆ
Ø
»à`ñÏ_²§Ö•ı+^)£‚¥…ÊI)Y]<‘Ğ·ÙÏöÚzƒ¼o­·Ï».5-ÁĞN} ŸÌjŒèk*Ì’·µJÚjX+ßR
ì‚İ°Gd—×Å†¯DI5°>6Àø9Fˆ©’EO§ğ,õ¦~´Òä$ÛKú54“SÚH}Ö¾:¾h_’ï¤çïm÷{¼©fi©yy©hô[NébÈåÒcb®«¤í‘ä¼,š|-¶sÅdb®r"¤É†Pìˆ°ÄQ‰QƒóÅ‡«Dw;d4{Ea1K’é©TFÊ,9 éQæŸ,è@i¦ì[(™R¥¦ß).Q¦¬º7ª€
”VF²¶•j£ÂÕ0¡"ÕD•(õ<®®ı­  ¬+ëizƒŞ&Ù_¿1~’³‹Ì2“i2$Ê®;Hö³]|ÁQN'g€3Ñ™äD9)lY»¶ËêH’™şßEá¢às¸®b¼
¤DìH	â`U†ª•xÆ´…ÙÔ€~ÀöTD=“Õ=
«Mø\¼"Éš•t~©²’¢i(Eè ì¡7é%2Qtâ);·Ô	ÒÛh99}rf¢âô5Ç)NŞÂÙCÖ°Kóå½ÇBµ‚ÚØ:÷İĞ#‘}İeˆ¬“\oFÑw8VeQ^è9”õÍ(Àùa
î ê8Ş’•—*ßK[ô_Æ«>¶©ëŠßûîûğósìgÇ±ÄIŞË‹—Äùp>\ââØƒ"BÃ°P'„Ú©´Vı -Ó‚¬ëJµı±nBš@t]Ç3I''´(Ú"­ª„„´iÕÆ¤ñm#bemƒÄ;×	)Ù¤i~ÏçsÏ¹ïû;ç~1<§÷›pB¿Éì@[™ãè'ìî·°ë¸ŸƒüCìu²™<§€KÿuŸ¹ «&ÜßB>A{ğÛ0û¯0:ÚÌB?"ã?£)|”=@ÆÀË—‡¹ğ34I6±Úˆ¦ÈºŒÏ“ßa]`_ÂÏãÓùÄâºÇŸcN²\ëÏºôG¸1\ÍÏ0_ Îü§dÇÒü.[
óò(ÌŞ#€„Ş‡öïÂŠqY€À||òµÖ6fyV®-h/¾3æ8 ÔëP?Scî¨B-úiÎäçÑ:üö<¬3±'c=ˆ®ïtu¶‡ÛZ[šCMzıººÚ` F«V•ªÊ
yY©Ïë)q»œ²Ã^d“¬¢Eà9ˆ*F	-™QÌ`ÆdƒÚ¦MTÖ†¡bø±ŠŒ©@Ur­©d
fÊZËX>ó–±eËØª%–•(Š66(	M1¯ôjJïHÿ^-­˜ó~kgƒ¡U…JÂ7Ö«˜8£$Ìä‹cF"ÓßËJÖ¸ßoml@Y«¬œéÕÆ³Ø»Æ›èÎ2ÈR^™eZoÂ,Õz©&	$†GÍm©Do¹ª¦Lß§˜HÛh:ô‚	Šº1ù¸)ºQÒá “J¶aÖ8•“ÑHF·j£Ã{R&NÓ>œ:ôÛkz_¹áûR„»â©‰ÇµåÄHø*T4Œ	Å<3z\«RšNÃ7 -HfŒ$t}Š¢è#Ô}:”åAí×´&ó¬bŠÚFmÌx6)3L´ıeõbYYl:•%c0¥©fO¹–îõgİÈØşòdiL)]«ilÈÊÎe4³vÇ
c+zœÙ¿ª+psÊõm_…S´Í¦²OOR¤‹’ı]ÈØ×fğKcheBšb<cÈİ´¶7¹€¬)Æ=a×æo¯­^©áò=DYš«	úG¼©ëf}=Í!7äöÆ†sL‡6.+P |h[
š¥»C€¹ªÒ¨ÌÅĞæ±Ô²¬ ‘ò‹(ÒÓ&“¡šÙGš’Tsì‘fµyFƒô‚M¡Ó\}²§81ÖmbÏÿPï_Ö÷=¥õìJ)	#³‚mßàiYßµª[áÌâxŠ”3+SN
ZÈÄ=«ÆTHÙL6 /_ÈäÑœ`T,Ô`%iÊ™MË4mUÕÿ³Q.ÿ7ÚªP|ÙlÅM³[_+¯_#¯qÏfp˜2}ƒ»ÃºF—„uÇ0’š’42Æp.lDSdÍ˜fÎ2gñDæQDsù™“åfòT1†»![´1«áÙ>ñÔ®Ô´Œrb0u.œñÌÆtº®Ø?ôÕ,ƒ/á&8S
LçEÄ±9Ü4EU Ì‡•ZxêDp|RÜ}Ù§Ë÷£‹Ñ~y!ºu1Šz€—iiVª3 #=TÈìÃ‡ ……-5ÿìfwàt, ;:KZx¸KZ,'Zm,o±Ûlp¡tp¢lû3
¸X)ØÜ‚`cl,[I7¥]pÀOdÛŒhQ9>‡/Åì‚À²„ ‹í=Çñ7|z©¼€|=Q™>àWOt;½g$2Ñ¤O¼67ÑäÓ_“çt§+wB¶Ïqss*ÈÑ	y®¥YÃmÅQ	VI°–Ö‘[w/eñÂ_qş<¢ZZ3ÜÌ¿’øÜÒ.æ	<~íío~ Y¾P¥ç	ı#¶ÓpUá*ÈËrE‹ÕÊÂ•F’*†ı[ÉYİgx¾R´¸Á”çèfF¸"›U$DâX¦3RE@.‡;cEEG0Æ²… (ÉiÜ‰|zhHá~ù&Ä#ªCTàº¼ìb™ØÚ¤s0h:v”Ü
\›¢‚l‰fy&>˜ŠI¼Ïæ‹
’Ë_Ù%g˜÷¹êÂ"%Puı"”H/üÒ-Íxé2ÅÖ¹|a¬§Ûp`†±†1Ù[çN?v/îÄ¿¶”^º2ÊÍ,n`~¹øşÃ2·–î-Õ@^À)qŸj^TƒîÄ^WÙ® ì”p‘İ.É.—Ãã«ñ–û<Å"W(öÔx½+ø¹J»ä+—C"{°JryÅo{Ê3>Õã))AZZ¹âuÔ9ìvd©©½ŞW‘ˆ±è ËÒ‡±ª^á›!ãA,#ïwã>X€¼xë¼şŠ|6$€‡€ÿxÊ"š\ºLS__DQW$•oÈŸC2ÚÀÍNÑæ–QF®å0Ñ(Í6ú§ĞézV[ÁO7Ïy¼/d\°6Ô4R¬¶vn`ÚÃ ¨ÜÆøÅGÏıeéÁ¶u{ºÆ¯Œln{áÆ‰÷°ã£È¡7û»÷^ªæf8lò¶¶>òº±t;ßùz_hñRÏIıßÚ{ºÀBoåoqOs¿óÖï§QCşúd‘3\!ù€±QÈ¿ÑôÆ:¦ƒí°t©DìÀ,U†A©*@J¡Æw$â(’êšxO{EÄ"¸¢Âƒq»Öè!|c»ˆ_E9¼>VT[¯¸š]ŒÃ5îb\9¦m²K¬oÉågcVèªå×õe?åêº°âoö3!ÿUÿu?ñç˜““‘O ò½¡ÃúÂâ‚>/ß:<¿0zæ{æpg$$ßoPP—‘Ô‡Ğ-Š;·ÇÓÖÚÑ®Ò'Øîèh+ ,áÚ&F«ø7ÅŠ=«U×¼5ËôO5§[ZÿôAÏ¾½Gï|òş!ü±ä<½ûLº·ksøW?nûÚ÷òèì?—à.õoÖË=¸êâŠãç÷¼7ÒÊC£XEPÔR,Ì“€<*d*”Ã;¤ <HA¬H´…V¡Á·)µC ¥
Ôj€qÃc¦¬(A@icØ~ÎŞû»\.´ÒNÿøÎwûÛ=»{ö¼¶INÿ9·=6¢{~Ş°^­º.)ğÇaS6ÌÊnØ©åÍwäô¸i`nÿï4+*lÕşÑa÷m¹gH"äÊ²VoŞ<´aÇÄ/‹Û"ş·ÿ¼Aùõğàğº}õ£dÅêğ‰,Æëëtª·ÜrAUİ¾/û5Èâ…Kd½Ú8R~
åî.'Û/—¡àîX3©ŠäYg–ã»U²Ò­2¼fRë¯uŒmGßPx²›o3ş¿Üù<ŒƒÁ\°|–€_1~’ÎU)”;~¼¹Ü™]¬wgP-¯€´ùdp˜Ï>ª¥Hçú"İèˆ¬~a•”Ğ_ÆÿWé ¿Æ÷0Úó˜gh¿IûTl#ÈŞ@û(ı7"ç›àyö=ÛÛÄØr3Í­rZ#³tcrx,Í8=G{íwªåf§ÚÄù_H;—õo±ãË¥‡UgèDç÷V]ò]A»’}<í‹©§Mv“V¼¦ÆğB\ï®0wpş¥‰s=7gN‰ı'÷t6{Ö|0§÷v*2ğŠ—ã4†]@'w»ŒóÀıÁr»".NSôTÂøe25.f%û|>XÍ<¾S(—^şòï„äñï'á"9N¿¸íÀ?å÷n­ü:¼V^Å¾Š‘¿¬@ædkeróo°r>oÑ~èÚ×EzRİàKcsd:zÿJıù»ÁN§Ú‰a~ëOQë½;Eõ‡Ó—1ÃÁUôßkQ.ĞÕËÜëqì{7²f'ípĞi–AI»MA÷ÁÚYV÷U²l[À{èl.èAû6°
tá;ÎÚM±£ë¬½b3j›Ö>°µ½+k³‰3°6f}Æ	˜)rƒeá
y ,ËsHıEmV÷ÉVÛR›‰ØÚ÷Yƒœ\=§ÚTŠÕ÷DÆ§|ÛŠXıNm_Ùí"yÊ^äªÍª½E¬z±ûÇÕ'R|ú¬†ı]n¹FÆ%m½"âH)'ÅVß/ÊjÚ#ı‰RêıLºû;¤Ì=%«‚<îrŒ™¦gsË}ñ¢q²ßK2x±"VãŒ6Ê'VŸ5ò$<Á¯q¯ökœ Xn>
ÄÙ,w§ÙöYœ	gcâŸ²"ıßÛÿ¿Àİ,—‘´?jŒá<óÕ'b‡¶ EÄô¿*@ëøõÎâøg]¬¿4
EN„ê]¤ è"7Qtwö³‰"×Òß?Ø/“¼9ÒÁ?,?r*È5Nv,›°H.ÓµÜ2S¡òáñivt†ÍeÚRÄ‘½f²Æü¤MYV{Ö|6›½øï"ÍŸm~ F[X{5÷¤ìs‹”Â·Föy¦šê4û¬E~ÓL»Ìd›[ˆï‘ŸªoDç×ø¨1Nc¤Æ97ßiÏäÓó©Ùªl®ìâo—’¤oÿ, #øwûü+~û€Æ2Öz7ì##Â7ä.ï
)KX¯V†…9r9çş$•S‡˜Úd>½1Ê¥ª'ş×Fy4h+qÏ¶I±7Û¤Í£ìMógø;©/á­—˜{TıĞúàé®÷à”Eş|óçxÊ[ƒ¾é÷‹e†ı'ÒÑ;f¶û¥ææDoAeşBsĞ;ˆíéÜ!f\ğ<v²”<kŸî?ü“|èsÆ`™Íùó¢x¬wŸe>íåü›ä-cšÉ‡ÁV=:hoÏt§[i~ª²bEf­ÿ‘Œ^¦Ø9SÍá¤>ŠÒuamXuÌpÍÙ‚·ù7BŞ‹–âX)ëNc—Ò§kÍáşo€l¶Ú|]A~k#eŞ§ØÖXk‹£ƒéæo4ò°WßÍ4»ƒ©ğ( g·LÜÇl½„/PŸi=±€<.•ûÃ·ä~ÿ¹?8ÀøöÒÙ;Šù´Í¡dÜîî…ô.ÃÕ¾µL¢‰õ0»Ã§ízİí´N)—½cRì®•ÎÄ’¾ñ*le¬àWg³ T& “áÏ’¨OÀÙÿ¾ÿ·{ä8ínÌñ¶òïuîlœ?]šùEæï^;ì¢1yşm)rNJ¯¡¼äo%V¯“‡ø^ï_$Ë¼UóVË*Ûÿ–´tNš/ÜwÌ11y¬£ÙáÏ–'ü¡’ãıA^ğŞ5Ÿa3ÎæR]cŞGï}Àz…s û,’§Â_Hä?®ãÀxä_ªğ{˜÷í¼4Ø½FÈØ³ÛKÚx=%_÷K»÷ûe¯©}Î¦NÒ=czn+—y:Æœ·–˜½àÚŸê›Æ—œö¦qeît©æ…p1o'±ïNj–&RÌ"õ]ÁZÆ€kéë@›û3y´³èãO½_FÒÏóúºù—ã+‰8õ }£ù¿~î¹~3ßmàj‘¯€¨¿~LóA!×íKìÇüFò¾ZÈœÏùÎ¡½œGÁÓà!æìçÿwA/¾§€»Ô¶Ïªkşï|î|v¾œ–ÇòğÃC™9é¼9ºÏ¯áÌÜİÿ×qZšÁ	=DçHË¥ÿ1gFŒˆ¶é 6w"FuÔ¸¬±Qã±GI¶u@".~¬9E<¡±Xã!±øMâátxR²İOö…=kß»ë‰BŸÊÃ¶Ø-k¼¶íˆ«å™´Úe`XhÇt°5óD{şnä‘şÓZkï¤ü2–eß‡¹è¢4ª?ô[s¹™ZÚ´êâğSòJ1zÚ­{0‡m~)’Ì)ÖœK^ßLMs|óŒ}G’wÈ»ìã5ûn‘Óõ±Ñ¼”C»1:ø’5¦P»İêM—è£òõ=áõ&®‰*ïbyçŠsĞ/, †Ÿ+¹ô•Åæb/öİ89º_|ñä9j­ÑÂT­–<s¦mÚı‰y^óLúºÑ¼x!wz\üT}ö5>–Ì÷¹I~ğÜu\Ú{#ÓöÎ|÷™Ş4³&Uk–ÀøŠERÇ™{‰ÖâÚÿ;ŸŒ|„ölk7åV§İ´’}Š	A¥LÖ:ÊÖG@Ş4ùFßVí-F±WóÊT¾§F²°¯æiyü-pŒvÌŸ!m©Æ%q6ĞÈÎY–¨)Â ƒÕwµäª4AgÙª70É/dN¡tåşv¹·›<wèKÛlrĞİõà
d|Ÿœhk4ÆíÀÎwÀûü+e¡µÏá€ûÛøŞ
ªÁM ¥ÕUSÖhB]6*Që¸Ls]Ï[hÏx7ã´vœ#cc@µŒ† ¯Uøærj"WWóİ€¯ıyr‘{Ÿ(äKSél’p%ø¶û¤øËwyï˜]N6õv$ëng#Xéî‘ı Æ¾X©àßPZƒ«Ğ×Bô4®Cã©ïûñ]—Äsih\PÉÛtç¿Ø/û ¯ª2?÷õ·,ø”šÈÊ[	‹†‚A ‹&!Š¼[$+ ¬â.°‹#/°“šEØL
æ/Î
¸ä 0)ŠX¤¤ÙJ¨$Œ¥‹9€‰é 5¹¿Óç9÷Şm½°»ZşÑww>¿ç¼İsÎ=÷9ç|yR†¹÷¡åÁ2úèŞ4´½.Â<ƒİ/£¥ïMQ’†gÕöKC¹Úiâò³ÒP®vxÊ‡Ÿ`-µki-•÷LCyÏÏ`-õÛ-åİZ™ß¨4”úóhi»§¡¼{+ó¸*åW¥çÁ¹}k¤ÇòªÕ7ÇÚı~l',ZŞÔ“F‡‰jÌQÛ½(§ÁeğgWİ¹Ş€wis<h®¼jÅCĞ Ãà‹”Ÿ‹EËåocæQ>«uªíÊ¡'L‹93z¾‘ç;“Fóå7^EÇæ¯‹ÇÓç÷Ã%äÑ˜2ôÍØSÉ3–©$}R¤}óÿÂöŒû;ÍEëòÚ7ï×Ø…|èã€.Œ»©'v1hVCæsä_æ`˜«y®$_æûôj¿=Èy<&Gs'ËBµöÜÕ3w‰ùc³»ê1{6Èd/4‡|Cœ6-}’lñWÊ±p—9>D,2UT»?ŠíãŸiU­`õÂ_ˆÿvÉÁ‡ôWAl9V.t_“Ët-c¡_ôŞÕñ¼;¨¿CNÓ;ÌÆºQL¸¨ğF}ZÊÂœ·¤_n”“Œ¾e6q×çBòsĞ-k¤s°@J
úKIø'«FzÛLcXëœì‘]M÷_GÉ­Mláy¼à.ÊWQÿ¼L+.ç\½;ó¿KÆN´Ïb=K£Äú|Ä7ùèÊxÎ‹¬F#¾UÍdµS/ößWì|¦Úû3ÑŠ—·ü»d^î\™ÜO»Í²ÕjÈD×©iµwd®¯¼œ'›XãıhÈåáïeXĞQº$VõF¢KŸ1{Iï`¡9â×˜}ô5Š»«w¢O›úxÍ°;í!ÙŸÖ5‰j¦)¬VmÒ¾Éû`õşlzÿØ§7–J©wÖ™÷Vm¶ñœr_`Ì»~#UäVÊÈ°û}§ <›»îSÀ¸ÛrûÌ‘ğ7f_ÁYøc­µz;:8 ¦à°”ğı~Í÷™G×Äd2‹4{-ÿ+ÒŞÄv†òü£”mq."_A~&yâ5BúÍøüØÂ|#:#tç‰óì-aÏ‰îµùÑy Ä¨ÎÆf1Có3¨Ö²fZmR¤'S¶™®×÷OÙkSù‰Ÿ4–Ó=ŒLnÒÃ‰<ÎšFüöı$Î»Ìy&,Ñ³‰N[ÚÕ1e»F6¯>\ª~œ¶MººÛVlÙ´Ïû1}mŞKÙA‰¾nËÆú»*¶±»Y‹õØ‡±³Rºı¶cÉ‰œ3Ä‚‰Í-u„ºU‰mŠ›l¬Ë›â§”µßÄúÇªX¿—jçßM¼×
êwJ¸D¶Áf¶A±úş„çÈ¨Ë=,µ°#±şlÎñV—ñÜ2©+è"µ°£™­WşœÏ‘%PçÿTjaG3[o©Šâƒ4áJÆ]É¸ç3ŞùÌw7óİÍsªÿ[5ĞwÜQpº}Ç½[e¾Ü¤2N!Ï<È8Z{@IÖ=YÇd]’÷kšs2~ÜïÿúıÙœù­ĞÖwù¬Ş»µ¹7]rƒj’ØßÈß>>g]7æ½D^„…áûØ÷Ñ,œO´İÓĞ’ÅçÖ\oº¼i»'¦á8?¸Ç´Äyİ‹
ãnÿÊØì+‹pzŸh}rŒƒÿ-ÌÇêZ}^rqLv7ß[µÄ2=ãã³¯¤]¡LÉ-•~öm¸w_Ñ8Õß)×Çz¯ôÎÁûtQ½ä÷1kô¼B™é–š.AgÂ³fi0Aæ*Ìïœ˜11Å°‘ó//ÀÖd+sº=Bz*^_ó$l§şY–¯Â7ı:Òª–Kãò‘Í¯MÎ^Ï˜=ÁvóÕ¾#Ã¬fšö™-çy»d„êæÿ²7F:Q7Ø»Gºªşğ7A•Õƒƒ±Å¼ÿ‡¬ÅÙ¬Ëbo½-«°õWĞ×åÜ-—c;Ësö;UIQp1Ö³Ñ¹ØKÇ‚oúûÍ?¼şuMÑ>Úzp¯ê"ï™<!Wxkd¾¥VÆ‘µŞd¾3Ræ»Éß®Ì÷+±»á9ø'mN‘»¼Å¤×Á—å5o©<ÉatnÜëîå{BV¹ß“K¨¯óÎŒpÇà‹cdŠ×Ujó=ÜÛ©7r‰;Û‹úWd)vlvJGçnYK_Ë¼íœ}äV÷€<ïİ)^±ôrß•W½Ìe±Üçu@çó†s‡ÙDû´»Æ+6[ió]¯9D›ÓiSü½<DÖÜó$‡Vß| WCñõ1æu£Ü€æùË46ğ}?ÂGŞv_â[à z÷ÄÖ­¬3ÁŞG‚o‰ós
(×¿àMûüX4éáÜhY”;M×AÊí9ğŒ\Ë÷¹g‡øf'ıN~­Ÿ9n¬Ã&ÑU{õ9ö¨î¡ÕÚ§Z¿Mjì¨šÌ¨îîî‘îé}©z‰;»X…{Ãlƒ³ññÕŠŞõÔ=İ­æ¨×o\-Axkh÷ßÆ×†ú‹åÜfıÕKd€j|úÛºŸ£:s„~+µ_ï3P}Rïõøî.Õgcn´wÃ6³ı~‹½Ä<ç3ª»ùß1½v²È}UÖÁï<yPıÅ©•åN­9¬~ã¾,[ğQp]Ì(çu>‹‘¯á/¸7S‘†Rw®©Ä·±.cñ©G`½û”\ŒŸ4à[WP7Ğ»˜3b®TÁlüæëî*¹Òò.l—>Ìa+kK,k~…PÃ·®ÄÏOÁ§ûÓg1~Øt7Õ™ÑÏ9ÅwÂwNoënkK´u‡·ÕŞ[-˜Oæs+s{›4ß¿aãĞB«)Ë©ïÀ|/¤>ÒXz.éY†µZ«ÔÔx¡)Kk7b!{ßãã/ùufë3VÁ
 f0½áKøåÁ(.É_“û‘tã¬iŸ}]é¿?sz'^·~ê¯øÚÅMú<ÑÛ‰¹É¯—‰^1Ó@©¤ÿFúî}Ö±M^}yH´mò„3ñ“áş¸e¼8eª32222222222222222222222222222222222222>1H»½ò–R	Ä•S¥ŸLq‡º£Åç_ädy˜_OôïFû«éœ<FÎ‘èo€Ó=N{ÒÉ™§}Òq:$]§s2ÙYAKÇo§}:Çâ´#½İkã´+'»?ŒÓåËã´OzgœI‰ÓÌÇë$¤H.bş/"5^fÈtìh©”
¨–y2Ë–”›CZË(/·-úRs©Ìä¿HÆRvÏWK•ÍMÇN§õ-üN£å¥¤ËyVÛ–Û6ePmû›F››±sä&Ê*åúÿb.Úk…í1zn¹rr:z‘Œ#UfsÑÈ”ö³=Ù¾gØ¹ÉTrs©­¶³ÕÖ}7]P\|QÑøÓ‹FWVTVÏ›5½¨¤rÎ¬SW6±mQŸY›ì:‰ã¦‰K”¾¦*xm'uJC?¨×®İ¯mê6N*µ&1ÅÂÄÈv«"¤–KU*,Bê¡¢ĞtcKaíJ´W®zâĞCO-¨¾˜7³nšJEê$fóşÏï½ßÌíŒb)[ÉgBr´PÇòÇß¨”å±\9W:™›M$¢£©¤-å³…à¾J¶Ÿò$ä|YÎÊ•Rv:÷V¶ô¦\|ı7!çgä
Ö&fò•Ü´œªd+9œ<3=X,ÉE¬”ä©â‰™J)Ÿ+‡şÃCŸ 	dGñõ'‰²ê
É>~ Œ§°>ÎçÇW_à×àÉçıäÿöª²šæmıÍäyÌXº.\ÂŸUX¨nVMa¡æ^f¾*²ğËZ‡'|&Ú%Ì“kh7Ğî£ÙÉjí(š§ÏW?fü|õ(wµƒ‡Ãï1`4Ìcu¯åÛ]–wl³üĞ0ãæj‰S,«…·Y±“?·Û»…9Üã}®¨ƒh´3hvl>W[ÛoMst³i³µgúÂ7„Y$fqŞ,ßâ¬ÚeO²-)
÷£#ô®ö×3\rpäÚÙªŞeİ¹Şàzë ××$×"WÎÓğùŸ{øÜ¥wU	PÔ n j€ª@ëÔAÕÍğ‰IêÈfÉ» Œ6,ï z@{×¿‚hş8ŒP\—8¨@$ÒÛ‹Ççé’T“^ùê¯s®?Ï¹ˆÃ¤‘ªÿ DtiØY»-hÑìU	¾ÆÙ2	‘…ËUø#hÒWªğ;˜­Âo`
T]¿Âø®ÃO°¾ñ_†:R«`‚iGês¿)\V;áCÃÍİSP€™—
èT'Lá¤Iÿ$¤e“u9(ó.{ —Y†ã~“ÒePáò©a6u6A	BÀÛ¬v/X{{¹eØˆÍå]0ár¸#úw¢¾ êó¢~ZÔ£¢¾]Ô·ˆú‹¢>$êƒ¢®ˆúQï»%ä––:¤vI’Ú$»$HDê6›·U…à™u·¹™k³3µóÏn)
ûŸ+PI û‰±Æ¦	Z*F5ãæÑ^“ŸS>“¶4òÅ¨áÑˆ6ó/)š)6ÇŒE3ÄC¯¦—(ı(ƒYCxß¤d<mÒu,u¶ÏğìJ×ñT×=ßÇ|óìùL†ôœŒx#][wÇ#ÇZª<^å‘¡z§§œ®‰ğ²ˆa
C…:½ıÆ-•6.õgŒ0ûĞìÏhÆ§)ùHºNé•D¼N¯2—I×mº˜cy[ Éhx4œÃk¿È¸Eæ“n‘ãHDºÅ9;µ8çğÚY\L|œóõÈpëéUÆù™C®÷6YÏ¹õ½·WqK_"¾äó=X«Á™†µ–±ƒ# ˆ Gğ«*pd÷C$ØBB+Hˆw²Ñ‡XŒK~À¸X'å‰F.¦(‰<»+‡ÒK‰ev±|ûíüÜ]ëv~Ñ× ßÚî§’1Ú}1Ãé‹‘HÄ«¸wĞÁ¶£S"£·xO÷5ì„.pºÓ®V)FY	o/+=éÎVÉ{zû@_ƒ.´JnLwaUû¬TNà ŞD>¾òWn-_!šáOiFäğdzI†z,ÁÜĞƒœÓ™0›7­d“;XÒf[WrGÄ·±œĞ$ĞÜBF)ãV°Ñê7X)sUş` ï%‚“endstreamendobj29 0 obj<</Length 3422>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 726.248 cm
0 0 m
39.882 0 l
S
Q
q 1 0 0 1 36 684.238 cm
0 0 m
119.21 0 l
S
Q
q 1 0 0 1 36 642.228 cm
0 0 m
48.445 0 l
S
Q
q 1 0 0 1 36 600.218 cm
0 0 m
36.383 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.248 Tm
[(Hepa)-9.7 (totoxicity)]TJ
0.003 Tc 0.1 Tw 0 -1.539 Td
[(Advise pa)-9.8 (tients tha)-9.8 (t KRAZA)55.2 (TI can cause hepa)-9.8 (totoxicity and to immedia)-9.8 (tely contact)3 ( )]TJ
-0.009 Tc 0.039 Tw 0 -1.044 Td
[(their healthcare provider for signs or symptoms of liver d)-9.7 (ysfunction )]TJ
/T1_1 1 Tf
0.002 Tw [([see W)18.3 (arnings )-37.2 (and)-9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(Precautio)Tj
0 Tw (ns \(5.3\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.017 Tc 0 -1.625 Td
(Interstitial Lung Disease \(ILD\)/Pneumonitis)Tj
-0.013 Tc 0.019 Tw 0 -1.539 Td
[(Advise pa)-9.6 (tients tha)-9.6 (t KRAZA)55.4 (TI can cause ILD/pneumonitis and to contact their healthcare)-13 ( )]TJ
-0.004 Tc 0.063 Tw 0 -1.044 Td
[(p)0.5 (ro)0.5 (v)0.5 (i)0.5 (de)0.5 (r)0.5 ( i)0.5 (m)0.5 (m)0.5 (ed)0.5 (i)0.5 (a)-9.5 (te)0.5 (l)0.5 (y f)0.5 (o)0.5 (r n)0.5 (ew)0.5 ( o)0.5 (r w)0.5 (or)0.5 (s)0.5 (e)0.5 (ni)0.5 (n)0.5 (g r)0.5 (es)0.5 (p)0.5 (ir)0.5 (a)-9.5 (t)0.5 (or)-17.5 (y)0.5 ( sy)0.5 (m)0.5 (pt)0.5 (o)0.5 (m)0.5 (s )]TJ
/T1_1 1 Tf
0.026 Tw [([)0.5 (se)0.5 (e)0.5 ( W)18.4 (a)0.5 (r)0.5 (ni)0.5 (n)0.5 (gs)0.5 ( )-37.2 (an)0.5 (d)-4 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(Precautio)Tj
0 Tw (ns \(5.4\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.017 Tc 0 -1.625 Td
(Drug Interactions)Tj
0 Tc 0.086 Tw 0 -1.539 Td
[(Advise pa)-10 (tients to inform their healthcare providers of all concomitant medica)-9.9 (tions,)37 ( )]TJ
-0.012 Tc 0.026 Tw 0 -1.044 Td
[(inc)20.1 (luding prescription medicines,)37 ( over)37.1 (-the-counter drugs,)37.1 ( vitamins,)37.1 ( and herbal products)-12 ( )]TJ
/T1_1 1 Tf
-0.017 Tc 0 Tw 0 -1.044 Td
([see Drug Interactio)Tj
(ns \(7.1\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.017 Tc 0 -1.625 Td
(Missed Dose)Tj
0 Tc 0.085 Tw 0 -1.539 Td
[(If a dose of KRAZA)55.1 (TI is missed by grea)-9.9 (ter than 4 hours,)37.1 ( resume dosing a)-9.9 (t the next )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(scheduled time )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
ET
q 1 0 0 1 324 726.248 cm
0 0 m
26.074 0 l
S
Q
q 1 0 0 1 324 692.5881 cm
0 0 m
24.239 0 l
S
Q
BT
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.248 Tm
[(Lacta)-9.8 (tion)]TJ
-0.015 Tc 0.012 Tw 0 -1.539 Td
[(Advise women not to breastfeed during trea)-9.7 (tment with KRAZA)55.2 (TI and for 1 week after the)-14.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(last dose )Tj
/T1_1 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.2\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.017 Tc 0.017 Tw 0 -1.625 Td
(Infertility)Tj
0 Tw 0 -1.539 Td
[(Inform pa)-9.8 (tients tha)-9.8 (t KRAZA)55.2 (TI may cause infertility )]TJ
/T1_1 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.3\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.012 Tc 0 -4.207 Td
(Distributed by:)Tj
0 -1.417 Td
[(Bristol-Myers Squibb Compan)-9.7 (y)]TJ
0 Tc 11.119 0 Td
( )Tj
-0.012 Tc -11.119 -1.125 Td
[(Princeton,)37.3 ( NJ 08543 USA)]TJ
0 -1.687 Td
[(KRAZA)55.2 (TI and the KRAZA)55.2 (TI logo are trademarks of Mira)-9.8 (ti )37.2 (Thera)-9.8 (peutics,)37.2 ( Inc.,)25 ( )]TJ
0 Tc 26.731 0 Td
( )Tj
-0.012 Tc -26.731 -1.125 Td
[(a Bristol Myers Squibb compan)-9.8 (y)55.2 (.)25 ( )]TJ
ET
endstreamendobj27 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 518/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 20 0 R>>/Font<</T1_0 60 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 748.9131 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
[(KRAZA)74.3 (TI)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 69.8846 752.2021 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 74.3179 750.2881 Tm
( \(adagrasib\))Tj
ET
q 1 0 0 1 324 748.8025 cm
0 0 m
252 0 l
S
Q
BT
0.008 Tw 8 0 0 8 493.1 750.1775 Tm
[(KRAZA)74.3 (TI)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 526.9847 752.0915 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 531.4179 750.1775 Tm
( \(adagrasib\))Tj
ET
endstreamendobj60 0 obj<</BaseFont/VMKSGM+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 61 0 R/LastChar 174/Subtype/Type1/ToUnicode 62 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 685 0 0 0 0 0 0 0 295 0 722 0 0 0 0 0 0 722 0 611 0 0 0 0 0 648 0 0 0 0 0 0 574 611 0 611 0 0 611 0 258 0 0 0 0 0 0 0 0 389 537 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj61 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/A/I/K/R/T/Z/a/b/d/g/i/r/s/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 63 0 R/FontName/VMKSGM+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj62 0 obj<</Filter/FlateDecode/Length 309>>stream
H‰\‘Ínƒ0Çïy
ÛCÅGYh%„D»Mâ°í 1ÒQ Ş~N\uÒ"ÿÿí`;:×µˆŞİ¤\ Œv8OW§:¼F$)èA-·Søª±µ"¢àfkÓO¢( ú ç¼¸6•:ÜŠèÍitƒ¹ÀæëÜl!j®ÖşàˆfÊ4ö”è¥µ¯íˆ…°]­É?,ëbşŸ«EHÃ9áŸQ“ÆÙ¶
]k.(Š˜V	Å3­R ÑÿüIÎa]¯¾['ŠÔ‹ã˜ñùàùÈ|$Î’Àdˆù>÷'æñC˜qÆœy®˜+bÉy¤Ï#Y/½^²^z½Ì™sÏü–ôoå¬Ï½>ß3ï‰«§Àd|±·ª|Ù4¸÷T]£v††>úïS¶“Šò[ü
0 îG”éendstreamendobj63 0 obj<</Filter/FlateDecode/Length 1549/Subtype/Type1C>>stream
H‰lT}PSGDúDÁD“gD[$Á¢hü ªÒÚh$	Bb“H¿ªu¬(¨EÛ‚¥ŠZ;(uÔÑQPÑÁGgtZ¿ÁÚV©ö‹~°7ôB«gz7sw»·¿ßîŞŞË0,Ë™3#=+eÆ+Ó¤ÂbÉcÏµfHË¤éÙYÛ«“l~½¬eåòàãÑñôòÓ\¥,ô—ÇhL‡1~=Ù¹´Äe_œïãÆMÇq1}£y´hŠ‰1‰I6ç"IÌ*q{¤"·˜êÈuº–:]Vd‹“
Å>°[tInÉUìW>I´»E«èqYmR‘ÕµDtæ‰Óí§§d©$N¦,Q´ØNy]’M´;DO¾$¾•%Î¤ìhuØÄìçèÌ¼<{®Ô§,²–ˆ4¦Ñ¹’Ëc¥³“Ò¸Ä‚e.»ÛfÏõØ÷3r‡µHúŸ(œ.ÑN3(¤ô·$ı·R´hZTtrV¶_ˆmRCË3jÆÀ¼ÌŒfÌÌf<3‰™ÌLe¦1iL“ÍìgÂèÙ2ÌL¦Œ¹À ÊNa?g[Øßòš‚b“¢Añ[`V`h77É?5±tŒlRl”7öÎôm$°[L€íJè"(âyü‚¯Rå#–¾5$ •‰|Nğ¯Ğ/q±\2)~:ÜËƒ¦÷:3ò0Gi0¦	M÷p°Ô$	"í`“¢Àx†ê»ıÀ@L¾ƒ°“	£4“¦q0D‡jr‡&4i0:I(ê8ø¦¶Ì,§yÙõ½™Šõá`&Á¬„İ¤éGpw¯E‰cÈœ"Tp§gnjmq¯ÅË^£âZ8{-h$ô¾¨…RòÃCX‚7”Cğ’<ê¡A‰óÖc£Ñ¨êÃPu ¼œ‡ëÁHÚê
?ÒoŸ]–¼ËDeç±òÎ§6|½ìfÂî 
U[ı—;5ÀÄu>€9Éõ£EÉ“¥¢©zL$\m±Ü,x)1x)3 Âw# €}x3DÈs¨Å^ùÅŞpùº7„È¼lQB¨ïµúKåã}%ÒªÇñí ÃêÁ 0ğ§ä˜/¾oFÅÛ‹ªÎŸ;¶óäİÉíMåûjƒ0ãOáâ¶†=ÍÚ¦ë2fÅo‰]­7¯1;1X3ôÎ›?_¾Zsú”_^^ºµtÛŠ ˆ$«k7œ>­=*ÅĞ½‘„ırqĞ{:nUOTtö@º7¬™:^K7ò+›ÃAKøÆ«ªÙ/{niEÌ†Y¨èˆLOwÏÉ×—AˆÜß7_“7!..¯íÛGÚ:;Lˆ}ÔŸÍ†Håñ”•VÓ€Ueäì’ÌıZ€êõ|#»…ôF]mÙwñ®‚”Áá5ç¸WÍy÷Ûï×ßízt`|œÃy!¨.tEõ„¥Äï‚–oç’ÏÈÕÒ€Û“ËT_ÚçîMÑâğäPƒ†«¨†èÖÖıÍõ)$©|ñ´9?=¿ZC	ª+¡ß[İZXw "ïëqÇ÷B¬³ıÆí†ëwÕ%Æ%å&Çë9‘¹Úû+³-ô	´„ƒA®¦©S÷9Í%„ÛGm†šúŠØĞw|=B¬"|İÃÃ7ÿ¨©-ÛX¥ã« BÅ×mY·¦b­6yª%í}á¿z‚ZzWW=¦ÕgST:õSò[ DjPŸ„ÁOâŒİ¥ß5¾ò¬æÄéêÏX™½UG+ü»Ã¢R‹
$vŒˆ¹ç¸W¢ï^viåBMÎÜ‹²æ~ÖºIÇÉ)¥wáÓ+p¥ã.ûI7ê€˜`»ŸÀS—C*„´§ÂHX^L…¸€öT^]w8ı\@úz¢Çşôc™ˆ<†b4q „ÂDBIè€”s¤S”Bº²uÛ™·5g2èĞD:Ò„ëäè™õ–yùëçë“WZÓk©Á‚jx}3šİ;|·«Uÿ*?‚ı•¿Vú~ü8¸G†~=†„€agÈKå!œeVø[€ r<8­endstreamendobj23 0 obj<</BaseFont/UEAMSO+HelveticaNeueLTStd-Cn/Encoding 64 0 R/FirstChar 26/FontDescriptor 65 0 R/LastChar 215/Subtype/Type1/ToUnicode 66 0 R/Type/Font/Widths[564 240 497 497 463 463 240 0 0 0 0 759 0 0 241 241 352 0 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 600 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 556 519 500 463 519 462 722 0 462 463 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 259 0 259 0 0 0 0 0 0 0 0 482 482 0 0 0 0 0 0 0 0 0 0 0 407 407 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 600]>>endobj24 0 obj<</BaseFont/UEAMSO+HelveticaNeueLTStd-CnO/Encoding 67 0 R/FirstChar 31/FontDescriptor 68 0 R/LastChar 122/Subtype/Type1/ToUnicode 69 0 R/Type/Font/Widths[463 240 0 0 0 0 0 0 0 241 241 0 0 240 352 240 0 480 480 480 480 480 480 480 480 480 0 240 0 0 0 0 0 0 500 0 519 556 463 444 0 0 204 0 500 0 704 556 0 481 0 519 500 463 519 462 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 0 204 722 463 444 463 0 296 407 259 463 406 0 406 406 389]>>endobj67 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/f_i]/Type/Encoding>>endobj68 0 obj<</Ascent 932/CapHeight 714/CharSet(/f_i/space/parenleft/parenright/comma/hyphen/period/zero/one/two/three/four/five/six/seven/eight/colon/A/C/D/E/F/I/K/M/N/P/R/S/T/U/V/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/l/m/n/o/p/r/s/t/u/v/x/y/z)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 70 0 R/FontName/UEAMSO+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj69 0 obj<</Filter/FlateDecode/Length 499>>stream
H‰\“Ín£0…÷<…—í¢âÏ÷:•Rš´RÓV“™ àd&€²ÈÛ'j¥A>„}Ï9¶oºÙmwC?›ô3ŒíŞÏæØ]ğ—ñZoşÔI^˜®oçû×òlÏÍ”¤qòşv™ıy7Ç¤ªLú3ş¼ÌáfÖİxğIú:úád~oö&İ_§é¯?ûa6™©kÓùc,ô£™Ş›³7é2íi×Åÿı|{Šs¾GüºMŞËwN3íØùËÔ´>4ÃÉ'U¯ÚToñª?tÿı—§íŸ&$Uşg™j¼Ÿë¤*²å;¾"¯È+ğ3y³!oÀ[òüJ~\²N‰:eNÎÁ¹ —älÉ,d+YÁìÀôVÂ[¹&¯#[jYhYÖ·¨oYß¢¾e}‹ú–õ-ê[f´Èh_È/`f´Èh™Ñ"£0£ £0— —PW +Ôè
uºB]®0— —ĞƒÀƒĞƒÀƒĞƒÀƒ2£"£RW¡«ÔUè*uºJ]…®ê}¿ÁÔUè*×S±JËyPîµb¯•tñÀuP¬ƒŞÏP<p•ãš8¬‰£7oŞ¼9zsğæèÍÁ›£7o~ü8úqğã¸×ñ…Ã}?Å8æ±ÍWµ×bû,-»ô:¦üWWOãdâ,ÜÉ? Mõòendstreamendobj70 0 obj<</Filter/FlateDecode/Length 3955/Subtype/Type1C>>stream
H‰tTkPWíf¦/£Â Lš…´¦{ÑDp‚ñEˆ
Š0¨ø'ĞâÑ™‚‚ÂêF¡V D]¥6µ¢A]YWcB SL@ÇˆFV,@}ßleïk²[µû£«ï×÷sÏ=ıË2j/†eÙ×ÍŒŸgXğF¢¼.G¶›2óåMrrªÁ5>Á¼À½"XÉ*Aêm>^Ê(§ãñ_¿ˆå?eÁˆïFúgù3*JÅ¨Ù vìêS‚eCÕ”½Æ.EÅÅE†K##'JñY–÷dÉg³ËëmR’9Óbİ`±írV„¿näØ$«l“­9î¿ê‘L6É(Ù­Æ,y½Ñú¾dY-%›Ì{ŞYJ ,”m¢¼V9K2™%ûYZaˆRv³]2š³¤Ô_ÑV¯6eÊëyÕôßèLÙj7Ò·…ÒX¥µ›¬&[–)Ón²˜m/ÉÍÆõòÿPa±J&z‚u”Şl“åß¦g¯/1bÂ,Cª»ˆ–²äÕu‹e˜!,ãëÅŒĞ0Ã3Ì3aÂ&‚e¢FÏ1“f
ÃLc˜·5Ì<5cP3K½Ø=ó–Ûî$&™ÙËÜ`º)—İÈaÁ+×ëœŠW•ªšÔ&õ~õ7ÜH.;À]åZˆ/YI‘;ŞñŞö®×xkb4…šóšûCÔCÊ†rCÓ†^&KÖéâ3×'Ó§ŞWë+û6j‡k7i¯ø±~á~²_µ_Ëğ	ğnÑåéB”½]{	ìÇ›<NƒbºJø5îÂuĞÛEÒ=c˜†´&Ê5Ş=Bw¥E‹Í8)çE@.ûÀ©‚îtı0 £M¨_‹Ë1¦yÍ_IŒŞcNALL¨ƒ7Á‚4¿a!õª“yğƒ€Ÿ!ºô§`bÄ$¯YN¾ÂÑpÌŒY‹’ñMdÑµõ³_ÁXUs@-ÙmÛ‘¹5WŞôáŠ£U·Ëîiã&­…N¶«ú¡‡½¤ÜÉá^2ˆmoŠ}Bö»WV4(mìÏmpºMğ`¸Y0îsŞ>S)hĞŠY¹VÄ)ÙfLƒ Ã"kNC0006öL‡½Ÿ£‘9£!ìsQ[U•£Tß=i"WA¢RÍÃ9W5÷À¸4n±†LÚµ[£­*r*×¬’Ñ©R–;y¼A*/>w±†µvİ¾qã(0šïJÿ :Œğõ‘øªE|L¾,>°ÂÒ¤ù[Å-SW¬J\6{YàøÙQÔ(’çŒpªaWmğÿ±¶wÛu÷àğˆ×İ¿@W/‰ÍÑÇš¸q‰0yKKıaQO
wpë>²ádH`äÃàOŠºË•½™W§—iöy;+.×}Ú¤Ñİ»W¾­Cü]|,ún¤j®ıéÄ£.ávéâ9â;ù‹fÄíLw(r.Û ,S)aJ#¿ÌÂŸ8L$3ò›§pPB²q:µä4Lç~"eî-Ò«ÈÜ¤AñO ÂÉ6·ÃÇí*xòwöpåû¯\ûVh?7u³˜Ÿ‰êaü®3ÅT|Ê¶=(ÂB[A'EûË¢‡¿–§å­É÷9ÀÈÁ>OSü0¸Á}¤4ø·vÀÎÎŒv¢|©|Áëúj~
£0N@c
Ú1fˆ!ë6â»&@`GŒªu
U¯êD?aê¢ÅsÅBrèïœ®ïLq-¼C…[ÇÒn±[xÒ\v¦£[èş8*~‹¿eU”^Ğõéww4—¶‰ËÉ£ä¨`ªââá.ÑGM™3:)x	zeKš^R¯×ÃğÛÀ6ö7?ºrµìÇ@Wè øßàïhÿ¤BÓ_Ûç„%|ÄGPzô?€¦ëˆXÕcùfÊÉ»Õç/–İÑèz€Km@µ€êØ$$6qËôÏVÖ›5º¾HË’…9áîWÿı‘e‰bRAæÒ¹ÂœÍW‹‡Ï^®§ÊQv-äT\¬kZ+“iÅæ­LârëTˆ Á%wÖV¨@¯Œáÿ7d\û_µçh[¤9 ÷yQ®ÿN¥Tww'Me¤qğ)Á4î	ÉHçp(ÑuK;¦{9L%Ú[¥ÇÁ>ï„¦nššğèœÕ!’€ÚRxâ¾éSKGZ¡óĞ¬ÉùâÒñU­8VÀ¥ñhÀDY¤O C€È{0„3¢öi‘Ci¤é+éQAí@ U	Ñ›0_3‹øŠe)Fb¸0ŒIàa´0ÏŠ°ôüˆF+½#ˆ¶È	%N°;Ù›J…êf€2ÂÓaÉß „ƒ
OQA.ƒSîÂÅm>µ í?0I´ı¿ÅX\•3ËŞ„<K!œÚ£÷ø¨åÀ3:£<ôÌ\ƒ==ÏÁŸr½Ç*ÑPW¹0‚ÍøŒ+$ÍğÌƒÂ"E]Î€ºÃÿ6d;ó3w;£ÛpËM4 æö‘ãÿTs´¨õ4X¹wÅP¢;ƒå®:J·I©s×Ô@:Î-Ğÿ¦Ò®ÛàQè§´Pd¿«…ß—z)Pçê¢@d•.	Ñ~F]¸î€*ê~Nç ßÃuz§ğ}ŞA4¿ÆZÔÍpq$ğÏHÛ‰4šúğÜ¹s…`Úßä€OşÊ¨îâè»)nCÃÈ…k»Â
ÄÍ¨ÚµfÏâCùAı$¯tGeé½JĞ–|k»:ÿ ½ÏWÖ¶–;54ÍÜ±O,¶¸7ê#­g3fæ‹´Â‹–ÑÔêÁÖkì€æÕ¿(¯ö *®3îõº+ZJÖ…ÖC]©Ï‘
´J®J¨&JE	¢Á^!Hx¹¼4h€ä"…HyBÂµ
Ç&¤D)Ah¯ÑŞÊC ¼«	é`'Õï0‡4ıÎ…gÚ?Ú?vf÷ìÙs¾óıß·´ÖÊ`Wô³'ÌËÙy¥*~¬ş‹°`‹­)»z&ëGúËÑ•ØÏ£Şw7òì>ä,m=û–Y^…Ã=e­ÍwÉPYà¶4ƒ¤ikô‚4LM¦­eØi&€ŸxÒ] O‘‘o¬®‚é•Éª‘qõ—!£3µ<+,çÆô˜æ`ª—Ïäk’BÖ“	-ÿ¬šµz;÷¡›(pıv^ Ç¶ÙÂ† gPÍÌ4tŠNsBY.Ø2Uí{”*8›?í ël‹R$™qGœ‹Ğ:s9KÀUªé€à ²DóC)>ğf™ëh¸rÁ û0ª‰z‘¾À"‚îB)¬CÚ1oã´Î¨j¢¢º‰7¢Ş(¬A3­ò{æùÔ´pœ#¼!ñS½pÓ|£Ãéx_ZiS¾ğEÌ7Ú\Ÿ€íŸK-ğ],ç*ò/ŒÜ'm5±3”SÁgOî:Á,#ü\Ò‘À”mÉŸ)òq{ıG—•<QÒ¾ÙœÛ@*«óß*PJ:„7Ïdegãç*«Î)]Ğ*´Wşi[²;€YW ’ÅÉR‹ºw?Ù—Ñx½X)úğBåûåW«»u«T“o;İd‚M˜`ÇZÈÃ°ü RşºêÊ£	Ò—·™-‰Sp¥°îäùS0¿Z‘´ÌUÊı¢Ô‚9ÈCßnm'`}ìÀû—5°c[EöÅÅÒô8Íj–Œ/“@mT™ÆA;¬¦¯ĞErgI.,ä¹ùEæÌ–¢çy‡]r;K°p¸BÑˆ¾iÑ[·“Õõ°üN©®|ZÛJşTøb`†òtğ½£^ƒ±ïÄØaI]ã`™8ã°"‘Ç¹Á‰¸gâ°B­é>Y#`§‘¿?\ˆ0Ç l.¼¦0÷—k˜ iokn®0'±ë7CG°Ñ¨Â]2†Ôpzåüß
:Ì#wówø¤)Y±Â]/YwQ€…ï”Â
Ş+ıÇ™VwÂOşXŒg
=«q#+kÁzW­ tÒ(#ˆ&U?|®î·§hÖ!L¯³XÒ%\.¬Ô_"Mb©IØ+n9òÒ–×•4oÁS«èm„Å&º®İ×dÓ42ÚZ©zh¼<—ù	á®.DSªÑ
e.9ÒßàP»ì&JİZOLÅÙÇš}	³÷d?e«b°…ŠfÁ…|ÒVw­3¡õ¤{áo¤nÂ.3$²¢¥ ÏÀ–¦‚œkÀ>t¤6^äBã9*º~B}qŠB_Ùgï]#=é;V±Õ ÖBWIõc¶ŒòŠ	‰ù!¼ĞPCò?&U¡îÀ@¤|S>(‰•“ßÍá~2ƒ›»†›ß§€®_MH×ºæ"*¿UÓDn?Á}—ñ÷;©Ü<]³‡îyõ×Ñ£Ô‹@¸‰VO¶Y?!]şNéğı
·gW@:ÑFÕ_F!kL=‚|eÑEÌœ	8İšÓcC&Ø1gÂœv2;|¯À*#»¢ -ŞQğjš&g×0‹x¯°5¿$VÌ9	1ÑM<8pªô1iÀ,e°ª½8öÀ¬åÅñ¼¨ÛŒZ>÷èë*…=‡İÔø1d¢ŸoŠıˆ€bÂ¿/«Zÿ‰^IÄ×/4ôÿ+ä#ÆÏ4˜ƒğ;CYÉ67 ¤zÜÆ+z? uçßÌ)T¤’ƒ‚TŸ:#ï$ñ9zä@_áfy?+p6×G!}`?ı‘ÜU\ó˜qÚphM¢’ÀÔ]':;»´Úí¼¥Å‘Íg>ıs	ÒÎ?#ØE¦†o`ÕTªí­ö©Ú[µ»¸¤Ë¢»¬SWGn…{¦rUe™èZ£jò¾öSƒ<'‡Vÿò(ù]u~Şo”ÒÛBNfföë$äò«ç•¿ÂWÂ.<'Ñ .<X³ÉÄ'Ûô!Ş´Ò˜×pOñ|%˜l-¾u¥PáĞˆ[f¬ï´„åà@Z;ßmià‡:EÙŸûèNm°¦¶Xöœm'E(Fn›«ßÌóæª÷<¯zû±©ø$	Š’U4WĞ ³£¬İ ÖBD'‹À;Wh€@(âõJa~~àgşí0N/MVåR¶dÈÇƒ„Ø”Ä„0’”òV^º‚‡ÏÑë³äá%ã]ìUß£·ù÷{Ì{kg÷öÀ^ÔŞ¤ª£jXFÃdHÙÀÌÏxáæÃN‰ĞK—•ŞXY	QÆÁÉİ&›~úªÔûÚ(3Qò…KÒxª~:XÏüõ°R/B­nT7s£páÉòéàrUl#Sº™/Šı £  à]KËšü|ËÒĞ%4Dş·  ßÀçendstreamendobj64 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[26/Delta/uni00A0/lessequal/greaterequal/fi/fl]/Type/Encoding>>endobj65 0 obj<</Ascent 932/CapHeight 714/CharSet(/Delta/uni00A0/lessequal/greaterequal/fi/fl/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/Y/Z/bracke\tleft/bracketright/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/braceleft/braceright/dagger/daggerdbl/quotedblleft/quotedblright/bullet/degree/multiply)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 71 0 R/FontName/UEAMSO+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj66 0 obj<</Filter/FlateDecode/Length 633>>stream
H‰\ÔİÚ0àû<…/w/Vx<C$„ÄOWâ¢?*í°‰ÙF*!
á‚·¯Ú•Š9&vòeäL¹İïö}7¹òÇxiqr§®oÇx½ÜÆ&º·øŞõÅ¼rm×LQşmÎÇ¡(ÓâÃı:Åó¾?]ŠåÒ•?ÓÉë4ŞİÓº½¼Åç¢ü>¶qìúw÷ô{{xvåá6ã9ö“›¹ÕÊµñ”.ôõ8|;£+ó²—}›ÎwÓı%­ùœñë>DWåñœ˜æÒÆëplâxìßc±œ¥ÏÊ-_ÓgUÄ¾ıï|]qÙÛ©ùs‹å|&Ï|-«”7È³õy›rUişÇ¿ä9ªé[cüú9Ş¦q5Ëã
×¨3ÖUærÍŒõÕšy¼eÎ×Ù1ïyÏtH™÷K‡béy/{ù9ó¹b®=³Gf<“§ÍÃæ•Y‘Ùiö0{š=Ìf³gÍÒ!eú=ü~¿§ßÃ/t
œB§À)t
œB§À)t
œB§À)t
œB§À)t
œB§À)t
œB§À)t
œB§d'ë,¨s`êèğúüş  ?Àèğúüş  9Àh0šÌÎ §Ò 0(
ƒÒ 0(yÿ*yÿª>ö+2
ƒ²†Š*=y+=
Ò£ğ(k˜÷¼Ò¦Ùöx?PC}¼¨¡±††ı¿Ñoğı¿Ñoğı¿Ñoğı¿Ñoğı¿Ñoğı¿Ñl0/pÍŠïìÂ˜a«}Îs<c-Ì˜_ÎyÃçÚ`ít@ãyt´ Ô)İGknã˜Z[n§¹§¡›u}üè¸Ãepi¾Å? »{G¼endstreamendobj71 0 obj<</Filter/FlateDecode/Length 5229/Subtype/Type1C>>stream
H‰lT}TWŸ!Ì‰Í0,FÍLAV>(‚µ"¢Š¢‰
µõ#&!h@DVÔºâá@×o­k×£²§Ø"Ú¢¸|XJ]Y‚®Y@DÊâ¨A®®Õ½ƒ/{ÎN`Ï¶çlÿx÷İûîÇ»÷÷î}8æî†á8>uõ¢„eÚ´É\n!g5êuË¹.u•ÖjK4¹Á…Iî;F±(ûİw±„àæ-ÄL¼=Åo™#Å0‰ya¾˜?.Å}r¹V]É¨V'¨s9‹…ÛZ ËÍ2s:+gåó·›YÙV62.NÊF©ÕQl‚!Çj‹-V.ÏÂ¦˜ôùæ-ùfÑÇÎ&äæ²—ƒ…ÕpÎ\è:ü_¾¬ÑÂêX«YgàòtæÍl~¦¨3¸ÜMœ9‹3³ÍúÍy:‹>ÛhâLlÂâP–Û¦Ï-°¹Üb6×¨çLÎÀZ³ÍùYÙlªÑ”o-ŞÂ‰Ì&³Î\Ì.ÎÛ”ÊêL6OWÌŠYš¹,£ÅU5šX=g¶êÄ=§Àl´Œz«1ßd	HÒ®r™É¸LLDÇD°qn˜—ó÷Åæ¸aó0l[aFËÃ±-8fÅ°";ƒaÕ¾O‚­s!»[õã4¾ß‰_Á¿ÅûÜBİV»]¨$K$Ÿ¹ËÜ¸·jb)a%×ˆ>Ò‡ÜJ¶K=¤3¤K¥W¥ıÒW¬GšçñqAã6Œkñò¬ôü£gŸL*ÓÈJdgd²ãõãoxa^é^½ìò%òòÏä=Şã¼§xx×x¿:áÂ„¿O\0qÛÄº‰}Š÷kÇÍ”’*¤¾¦şåí“áSésÉÇA«è•ôïèCtıâÓŠFa¸i`£¤Â](Yá,'¡
µÑh"`ˆD,j¡Á%8JäúQæ!Q&…fÚÅ!—$G‡åp²ô&Tß\ç"Šëvğ´C€‹RÍ°HÓÚòÖşşªÖÖÖ*m\\¹VËvN¡ÿJBûH&±ˆ¤ÿ­şªÙµ4È9^¾Üé@2$Û|,d5 „ §¿¬“‹yÍ.|ç[„3 •#ëéPä›f¢h%ŠjF1Ï­ºA&@@BŒ"ªaÖC˜¤úÉÈI3J¥ŸƒoÌ„h%D¥CLĞªÈ.ğ
D1JaB³æ —_ pµ4¢_Ğ-		š½Z°c|Xc¦ıŸöiµñÏ€¸TĞÆn"@–&«x‹w9$]¾õR¿»({»êcéàÙwz”"Du ìïÅoB¹ä&ì§¡¼•“?óq¼EÓÁÂ‘íEø.h’ì*¥m$ìÙN¤ò’R›ğÈ†_æa/OJiĞü”i‘¶Í=Š4 e	ïhP À ;€üEUÈ^€0„í… QÉKN
Õ·Ò`¡LÔİN¡š†Îê’ªÉH“Rw÷Ç•EıÖC^RÑ+|kÇëyØÌK„%½4ú<Òpñj]ÍËG~î\û0åí­@‰Õ4­)U<y¥
À{.¤,ÿ s£f­jåZbîâ„Hä§ØÑRà’mo!œµ)êøyü×à{†Oæ©î2H†AúÉ_IEã—oMg¨†²9›»;˜èİdîQ440¥ã	Ğ/2šŞ?©ª”RõX×©¯Úï)ß éèWšXä%^ß|xpèÎ¹5KTT¶0gõ|•zéªâí'¾hØBµB']‰úP2‡Qü Ä÷Ùß¸ÙÒÑ‡mŞ‹_áÁÊKÚ`€îÙGü¾®ùÏ«ã>H,AîÁa¥CµªhRs10¦·ü $qà½>.Î6©öW^•½èîXÍí ±)¾äÁÄ'òÔJ„/éšR˜Šân²¢|­„õüî¼©0iÙSäıÁÆ5[K™ı­díAX*J¸U³~#>x7İuêÉ3ÑüÙ©È„Kd4C	Ñ–']Ìèó:{ñËÂtÉeÁIÃ}2)R¬ØàoBn¿a=^ÇaZL¸xıÛÖÁº&¿9§Õ}Í;lŠZ>…‡å"¡^×B:^< ¢ëÁcè¹şû˜‹*jø^õ×{”@&Ù;rOJAdüëî™TÔë˜|ıŠP%5-ı—êµÉ)¦—.Éo´u^üSC½FRç
ú‡šöşşšÔØØœÔ¸¸œöT£·kìğĞ…R¢'¥á&PÓ9'ĞTˆİ°B•Š-ï	ù-öGSÑ¤Ûjğîı¦åü	¦RKf}‚!¤á´œëmŒ8#İôüâ¨0Ñ<¬øqw÷¹Ç<Cóç¢æ3£Ãcó'Ò®	tV¹âÏT¿8ÎĞ0føãñB¼A¨’4€…ªP	a“:çCº .ë:‘ÿ6PÙşk×-ÚÙœU$:ë>Æüc¨‚â–è'n)Ra>JwŠ‹*6o†^¼ª(RìS÷÷ø:ÈÈ `Ù„2‰V¬''IµÑ•äSô‚@«HùÙ
;œ¶A™]ÑÆƒÙ‘ä{+†è7äıv.$isj8ƒÆ“Ñ‰4¬!!¤ÿ{˜Æ:£O3ât	Ÿ×ut(‰¬W¡|’O¤ÿAÖnL@n³wg2AbğR»ğÜ®¸á€#Yê5$‹ÛÌòÁìd$/¥øjq'ÅMÎP¯OšSÉ8H`÷-ïGA“Ñ‡9âÏ•Œ’/ -l`¨!P·À˜|ˆ‘ßª°v¼“‡ÿĞ]5PQ\WØu™7ÄÔe¨¬‘j 
#Ø‘hƒˆkEDE@cPªÆø~Eñ .›-	QƒHƒD±Š¨Y%Á(u›ã
t+Å&­QïìyË9½³ FÏÉ9œ3¼}{ß~÷Î÷}÷>5;¼yİƒ"¨W.ºYìB ÑQèI ”né"¢1Ú`Ş²©ZP¹Şò¯mô,ìr-Gş³9¢IÀzö<ùzŞ?µÍ×…V¨JOoá¸Fy›\ÊŸ(Ú	‘tÅcü‹ki4ÌG³²}q¾í h"\î‹ÌÒM‘àÇrAïPªyº×ØsxîÌbQs
ôÛÀœ…@À€»[[5S˜CRíĞÚoGFš+2©YCx©!DµÍê—¥ª”àUtS‘NãßN_ğV}‹Ğ¤[ÀN9÷
<Gû€=9v‘»Oû™Û„n—Ca\`Æj¤?2øO0ÚC_—56zÆáŸÂJ<Å­WÕj—ƒìêV„âf"0yÀ±ãÃáÆ˜Ü}‰Ğ±ÎvÆ€¹Á%¾T1!S¾
£‘Ä˜m™KA „['_5±ã¼ÊÀH%1®ÌyËÀÒ|ùC	Æ¹X¦Â×Pƒd8âXÇ?fN-2'	’ja2`ÎZXD“ÄH7Ğü•ú¢©†mÅÇ3•5yXñf…U©ø–>W-šAE`ä+hˆ1F¤séŞs"1"(~ùŸÄß=ƒC~ó5¾±)ÒÂ4X÷=¼ç;ôãO»pª´êˆ÷ŸŸ›Q¸éAœ´sZF¼¨o]ÏhªÙ7VxÏ¥ÕlEQ÷pßÀó„“ÍŸ/ß§jÓê’%òF= ™¥Ûíº^šßìj[}!¦Ä5{ÿß‡ª»m¾ÀÌBSèV%‹û¤»ay‚Œ	b(ÑŠöˆ}zäØ#û¸+Ü59^ş˜CÌ×t´–ê7P½È]¡ £©¾3â“¢î&åw~×)†Ô8ÂïÂÈ¸+°ŸöÒ_Á2ßo?­ï¸kRuš+²ÄÃ¦‚XW;<x˜cs.Š€è»Ë7âGÚÕça5O,Óq.ó¯›ğ[A.
q±âº¦ñ¾²d5kŒwÃòzätn#Ìô7sĞñ‚q`¡cœ…hcd®5ioªzÄ´K¸D˜àıp«ïÉW¹L{H  Ã‘l¥TåìÂp¹‹ñ#ş®ÿ©
Hö5ƒŠqeµ<­µC-qòlü!êG{èhèa&(–#7ÛTUXÑ>u•·<ÅFm:ä&¦Ë)FÀE–v8¿Ä™º€Î³8J,*›MmÃQ¢-ş’»Mìİ³©AZ¦Ñú»%şzÀÍ„m–¸Vøo&·xÖØgJ)qgÀSÁ¿Ç4~×wñ“õI©ÆÜùÙeÖ0\ÃìÌ7fú½s¾©æ\µ€”9»¸ŞxT[QYüîûb+»{×NC¾v“±¢R„&ö¢ñ6ÕQ¯„xªàCº‘ç/IY¼0»îó†ıÕeB]UGÉ‘Zwb‹òT+LÍòl–`™kD.Wğ?•?èµ
£^T“ñrÎ.pyÓißI¸F‹‰MÛ×Ö¢àà–ƒ÷Œã×/Ë°C§X™¾ÏµEuÔ%µ,ÈÏñÿØ,zgØ&ŒR™×<	ƒ}O{CĞ‘¸­3"ı‹1øÙÇMÿ¬X üYË$÷‚¯Cİ¶Şr¿±T“21"«¼¨“ò:ºÃ@Îf'Ö$ki`^{ÜhÄ9Ê ×ÒP_¿O1ò<}'«^·@¨EuÂK	^p?ÄİÃìgÅ
ëY»?Æ›cq~
¯ÿ1õâMË×…3‚G7Ş,
p8[kbUuJêNoI^Ûg	n''Ê÷NZç“i«WLçEèmxi˜gÁ—<¡%ÎŠ9½*am¸ë°IŞÌ»3e’n;¨z\9ŠÜ÷ÛÂ‡îz´=ŸR§¥£Wâˆôâ¬½4	Ûëùjs¹hŠ"éÅSé0œ‹—¯:Ø¸KÔê»xc­†u´@¨"^y³RG¾äIİŒ	±µ}bşö/s^œD’=ØvãC*$/X·<C|‡J‡’k³ş÷ƒªUÂÆ Éµ:Òí&ıàÚ¢ó¬É™¸ëÙ*qf'×ò:g3I2¦%ä›Ş-¸ìH–3•–Jµÿ9ñ©]t”¸é%W¯Æca©‚FeĞÃƒR•^µ€ƒ¡H•@O.K0–c;{Ü+q8RuŠ)(9)el—`¦òç5šklw%&µ}tòò£ÄûÔr0O¿ÅÉ«R¶m¹éÅhmXš!×ÕÎjëªgşÅRù¹Â»¦„!©äYUÒíêd)¬£>Oº$¸
|FWR(`oYÇOÉ½îà^~çFoY u§î9“qˆÎ„?Xå©CP’].I‚æ€ı–¢ÉTÈ
CM>øI˜c·&²ì yı9-ˆÇáìD!ÉÀP..%--_I«ß‚ø~~ì ˜º ›ã÷²"!F ãnAÇØ©‹q”p–ëÒØúAêqÉ”¡!Ôÿ8õñœ¹æ¬2ih
–,]Ú–uXñ®+}äæ×u§«÷î.ú@àJ»Y®­xÇÛ¦\mì¯%nQ0Õtâ­l²«f“ş(Á4i–äê\Œüß^TÃè$íÄˆä ªş*ûR†Èİ¼”aÉ‹ô³}cXÎ——P‚‹MTsï\iæ¾jn%¶*}¥şÃvß«­%ÕmåéÑŠ4­òK—.‘ (A'!Qîù{e±iŸp™-z§À£]_vF„ş[–‰0	q¹|gsÖ#
ÈA.n1ÿÍÔ»¿:%ÈDçô`ÿOyù‡6qÅœî^7»Àš]é¸´eÅ¤›ë"ËT¶`£6]@Hƒ†´V§ÊücÕqsÙ±M5¸”©²…ekS·u—U…@Ü¡ñtÎe£DUlZ±Ë¾/¼ö½‹d0»÷Ş÷¾ß÷÷ı~¾_OT'.EgÆÔxüC‹½?ÿªz¹+ÂÔ„X«7İç¡–×¨¶²¸I´’®Õ˜öbîõƒ´9‡@Êh•¦í7ÚŒ@»WlÆ
 Œh©í5öò«ñ—•Yë;°8³k¤QQ« †Øe14|°µ†¨…TAW´±–:hQ—¶3—\0wép‹zXó¾ĞãçŞù »sgåÁàa‹›ôE"½ç+ŒÉ7O[ ^C£UÚŞ«K{¯Âdş9Egæõ_Òôğìãbç†¬Â8JE.Ín‘!Ÿ„¼\”Ã·w4‡ãİéXû:[O¬Ò¾ËâuÙÇoí»0a'YpGƒdì¸]0£`bàÂŒ(É.ŞëÛgUMÖímoÿ5õÃÛaK
aøV0>hİ;™¶Àz²è;ç]n‰Ÿì²0'©“÷{Écîıufìêl}îëüeéÜ¢j’MN‹†Õ´-Ö.İÏó?`zúM	­gù¯NşbTü†8:?Úğ†ù•yÂìùÇÊ~½ÿ¦R‘™ƒzt³ÿ|XÜ#h‘Õ¸ğ(¶>‚É•ÿ5ƒê­õêÒ&Ú1ÃÙ†¡u˜³œÅsô8æ„v\áPR´›ÿQû´¤ÆÒ¥Æ?ş’vºÔlF£AØ T§ Õ+Pl™†\.“Éå26[CƒM=¶ßóŸf;õÕÓïò;tut‹~’=ºzËÌìw'6¼@_šï¬NR¿z‰^)O6›Je³”Ãáñ8ÄYS"O$âm[¶´©o<!–Ç©W÷õêiç¸ŸbnĞ¶)5_ÇQÓöíàfÚ3…=hâWû¯Ğ¯—Ğå¢tÈ85Ñ¡ÏŞ*Ø8ÏŞş³ûñ“°§9ãµ‘‹Ÿ+'&Ëù°|ÍH¬(êŸ5°“†I÷¤§›–…$aKàâ°ÒY‚F.IŠ5l7ç#´–}/HE›hÊ´FÒ'èMa#Eæâ°ZdÜFB«a7'‘ [Fe+*Š¶)ÏGxøløÎpñâ	Ò=ZŒ²=§ÊP²4\¼wê	ùÉ¹ÉP(-/O,Šîx†ş` ",33endstreamendobj28 0 obj<</Length 30686>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.011 Tc 0.029 Tw 8 0 0 8 36 727.248 Tm
[(under )0.5 (the cur)-17.5 (ve [AUC]\))0.5 (.)37.3 ( )37.4 (T)0.5 (hese \036ndings)0.5 ( reverse)0.5 (d after)0.5 ( cessa)-9.6 (ti)0.5 (on of )0.5 (dosing in t)0.5 (he 28-da)0.5 (y)-11.1 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.048 Td
[(s)0.5 (t)0.5 (u)0.5 (d)-9.6 (y)0.5 ( )0.5 (b)0.5 (ut)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.5 (t)0.5 (he)0.5 ( )0.5 (1)0.5 (3)0.5 (-)0.5 (we)0.5 (e)0.5 (k)0.5 ( )0.5 (s)0.5 (t)0.5 (ud)-9.5 (y)55.5 (,)37.5 ( )0.5 (p)0.5 (ig)0.5 (m)0.5 (e)0.5 (n)0.5 (t)0.5 (ed)0.5 ( )0.5 (m)0.5 (a)0.5 (c)0.5 (r)0.5 (op)0.5 (h)0.5 (a)-9.5 (g)0.5 (e)0.5 ( )0.5 (a)-9.6 (g)0.5 (g)0.5 (r)0.5 (e)0.5 (g)0.5 (a)-9.6 (t)0.5 (e)0.5 (s)0.5 ( )0.5 (w)0.5 (e)0.5 (re)0.5 ( )0.5 (o)0.5 (b)0.5 (s)0.5 (e)0.5 (r)-17.5 (ve)0.5 (d)0.5 ( )0.5 (i)0.5 (n )0.6 (th)0.5 (e)-17 ( )]TJ
0.001 Tw 0 -1.048 Td
[(ovaries of female ra)-9.8 (ts after the recover)-17.8 (y period.)37.2 ( In a 28-day repea)-9.8 (t-dose toxicolog)-9.8 (y stud)-9.8 (y)55.3 (,)20 ( )]TJ
-0.012 Tc 0.028 Tw 0 -1.048 Td
[(oral administra)-10.3 (tion of ada)-10.3 (grasib to male ra)-10.3 (ts induced a)-10.3 (trophy and epithelial vacuola)-10.3 (tion)-12 ( )]TJ
-0.008 Tc 0.044 Tw 0 -1.048 Td
[(of the prosta)-9.7 (te gland and seminal vesic)20.4 (les a)-9.7 (t 300 mg/kg \(a)-9.6 (pproxima)-9.7 (tely 1.6 times the)-8 ( )]TJ
-0.017 Tc 0.011 Tw 0 -1.048 Td
[(human exposure a)-9.8 (t the recommended dose based on )37.3 (AUC\).)37.2 ( )37.3 (These \036ndings resolved after)-17 ( )]TJ
0 Tw 0 -1.048 Td
[(cessa)-9.7 (tion of trea)-9.8 (tment.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.787 Td
(13.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Animal T)74.1 (oxicolog)-9.8 (y and/or Pharmacolog)-9.8 (y)]TJ
/T1_0 1 Tf
-0.005 Tc 0.059 Tw -3.375 -1.498 Td
[(Phospholipidosis \(vacuola)-9.7 (tion and/or presence of foamy macropha)-9.7 (ges\) was obser)-17.7 (ved)-5 ( )]TJ
-0.003 Tc 0.073 Tw 0 -1.048 Td
[(in multiple organs \(e.g.,)36.7 ( lung,)36.6 ( trachea,)36.7 ( heart,)36.7 ( skeletal,)36.7 ( ovaries,)36.7 ( uterus,)36.6 ( adrenal gland,)34.1 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.048 Td
[(kidney)55.1 (,)37.2 ( liver)74.2 (,)37.2 ( lymph nodes,)37.2 ( spleen,)37.2 ( thymus,)37.2 ( and thyroid in ra)-9.7 (ts; and heart and lung in dogs\))-17 ( )]TJ
-0.012 Tc 0.025 Tw 0 -1.048 Td
[(after repea)-9.7 (ted oral administra)-9.8 (tion of ada)-9.7 (grasib in ra)-9.8 (ts and dogs.)37.2 ( In toxicolog)-9.8 (y studies of)-12 ( )]TJ
-0.006 Tc 0.054 Tw 0 -1.048 Td
[(up to 13-week dura)-9.7 (tion in ra)-9.7 (ts,)37.3 ( phospholipidosis was obser)-17.7 (ved a)-9.6 (t doses \035150 mg/kg)-6 ( )]TJ
-0.014 Tc 0.014 Tw 0 -1.048 Td
[(\(a)-9.6 (pproxima)-9.6 (tely \0352 times the human exposure a)-9.6 (t the recommended dose based on )37.3 (AUC\).)23 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.003 Tc 0.072 Tw -31.5 -1.048 Td
[(In a dog 28-day toxicity stud)-10.1 (y)54.8 (,)36.8 ( this effect was obser)-18.2 (ved a)-10.2 (t 25 mg/kg \(a)-10.2 (pproxima)-10.2 (tely)-3 ( )]TJ
-0.008 Tc 0.045 Tw 0 -1.048 Td
[(equal to the human exposure a)-9.8 (t the recommended dose based on )37.3 (AUC\).)37.2 ( )37.3 (The extent of)-8 ( )]TJ
-0.01 Tc 0.033 Tw 0 -1.048 Td
[(v)0.5 (a)0.5 (c)0.5 (u)0.5 (o)0.6 (l)0.5 (i)0.5 (z)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.6 (n)0.5 ( a)0.5 (n)0.5 (d)0.5 ( t)0.5 (h)0.5 (e)0.5 ( p)0.5 (r)0.5 (e)0.5 (s)0.5 (e)0.5 (n)0.5 (c)0.5 (e)0.5 ( o)0.6 (f)0.5 ( f)0.5 (o)0.5 (a)0.6 (m)0.5 (y)0.5 ( m)0.5 (a)0.5 (c)0.5 (r)0.5 (o)0.6 (p)0.5 (h)0.5 (a)-9.5 (g)0.5 (e)0.5 (s)0.5 ( w)0.5 (e)0.6 (r)0.5 (e)0.5 ( m)0.5 (o)0.5 (r)0.6 (e)0.5 ( p)0.5 (r)0.5 (o)0.5 (m)0.5 (i)0.5 (n)0.5 (e)0.6 (n)0.5 (t)0.5 ( i)0.5 (n)0.5 ( t)0.5 (h)0.5 (e)0.6 ( r)0.5 (a)-9.5 (t)-10 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.048 Td
[(compared to dogs,)37.3 ( and evidence of reversibility after cessa)-9.7 (tion of trea)-9.7 (tment was noted for)-17 ( )]TJ
0 Tw 0 -1.048 Td
[(most organs.)37.2 ( )37.2 (The signi\036cance of this \036nding in humans in unkno)-9.8 (wn.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.85 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18.3 (AL STUDIES)]TJ
0.017 Tw -3.375 -1.697 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Non-Small Cell Lung Cancer)Tj
/T1_0 1 Tf
-0.008 Tc 0.046 Tw -3.375 -1.498 Td
[(The ef\036cac)20 (y of ada)-10.1 (grasib was evalua)-10 (ted in KR)17.9 (YST)54.9 (AL-1 \(NCT03785249\),)36.9 ( a multicenter)73.9 (,)29 ( )]TJ
0 -1.048 Td
[(single-arm,)37.1 ( open-label )0.5 (expansion cohort )0.5 (stud)-9.9 (y)55.1 (.)37 ( )0.5 (Eligible pa)-9.9 (tients were )0.5 (required to )0.5 (ha)-9.9 (ve)-8 ( )]TJ
-0.003 Tc 0.072 Tw 0 -1.048 Td
[(locally advanced or metasta)-10.1 (tic )]TJ
/T1_2 1 Tf
0.003 Tw (KRAS)Tj
/T1_0 1 Tf
0.072 Tw [( G12C-muta)-10.2 (ted NSCLC who previously received)-3 ( )]TJ
0.003 Tc 0.103 Tw 0 -1.048 Td
[(trea)-10.3 (tment with a pla)-10.3 (tinum-based regimen )0.5 (and an )0.5 (immune checkpoint inhibitor)73.7 (,)36.7 ( )0.5 (an)3 ( )]TJ
-0.005 Tc 0.059 Tw 0 -1.048 Td
[(Eastern Coopera)-9.6 (tive Oncolog)-9.6 (y Group P)18.3 (erformance Sta)-9.6 (tus \(ECOG PS\) of 0 or 1,)37.3 ( and a)-9.6 (t)-5 ( )]TJ
-0.011 Tc 0.03 Tw 0 -1.048 Td
[(least one measurable lesion as de\036ned by Response Evalua)-9.8 (tion criteria in Solid )37.2 (T)74.2 (umors)-11.1 ( )]TJ
-0.012 Tc 0.025 Tw 0 -1.048 Td
[(\(RECIST v1.1\).)37.2 ( Identi\036ca)-9.8 (tion of a )]TJ
/T1_2 1 Tf
0.012 Tw (KRAS)Tj
/T1_0 1 Tf
0.025 Tw [( G12C muta)-9.9 (tion was prospectively determined by)-12 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.048 Td
[(local testing using tissue specimens.)36.8 ( P)17.8 (a)-10.3 (tients received ada)-10.2 (grasib 600 mg orally twice daily)-21 ( )]TJ
-0.011 Tc 0.031 Tw 0 -1.048 Td
[(until unacceptable toxicity or disease progression.)37.1 ( )37.3 (T)74.1 (umor assessments were performed)-11 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.048 Td
[(ever)-18.3 (y 6 weeks.)36.6 ( )36.6 (The major ef\036cac)19.6 (y outcome measures were con\036rmed objective response)-18 ( )]TJ
-0.011 Tc 0.028 Tw 0 -1.048 Td
[(r)0.5 (a)-9.5 (t)0.5 (e)0.5 ( \()0.5 (O)0.5 (R)0.5 (R)0.5 (\))0.5 ( a)0.5 (n)0.5 (d)0.5 ( du)0.5 (r)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 ( o)0.6 (f r)0.5 (e)0.5 (s)0.5 (p)0.5 (o)0.5 (n)0.5 (s)0.5 (e \()0.5 (D)0.5 (OR)0.5 (\))0.5 ( a)0.5 (s)0.5 ( e)0.5 (v)0.5 (a)0.5 (l)0.5 (u)0.5 (a)-9.5 (t)0.5 (e)0.5 (d)0.5 ( b)0.5 (y)0.5 ( b)0.5 (l)0.5 (i)0.5 (n)0.5 (d)0.5 (e)0.5 (d)0.5 ( i)0.5 (n)0.5 (d)0.5 (e)0.5 (p)0.5 (e)0.5 (n)0.5 (d)0.5 (e)0.5 (n)0.5 (t c)0.5 (e)0.5 (n)0.5 (t)0.5 (r)0.5 (a)0.5 (l)-11 ( )]TJ
-0.017 Tc 0 Tw 0 -1.048 Td
(review \(BICR\) according to RECIST v1.1.)Tj
-0.009 Tc 0.042 Tw 0 -1.588 Td
[(In the ef\036cac)19.8 (y popula)-10.1 (tion,)36.8 ( )]TJ
/T1_2 1 Tf
0.009 Tw (KRAS)Tj
/T1_0 1 Tf
0.042 Tw [( G12C muta)-10.1 (tion sta)-10.1 (tus was determined by prospective)-8.9 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.048 Td
[(lo)0.5 (cal )0.5 (tes)0.5 (tin)0.5 (g us)0.5 (ing )0.5 (tum)0.5 (or )0.5 (tis)0.5 (sue )0.5 (spec)0.5 (ime)0.5 (ns.)37.4 ( )0.5 (Of )0.5 (the)0.5 ( 112)0.5 ( pa)-9.5 (tie)0.5 (nts )0.5 (wit)0.5 (h )]TJ
/T1_2 1 Tf
0.019 Tw [(KR)0.5 (AS)]TJ
/T1_0 1 Tf
-0.012 Tw [( G)0.5 (12C )0.5 (mut)0.5 (a)-9.6 (t)0.5 (ion,)18 ( )]TJ
-0.017 Tc 0 Tw 0 -1.048 Td
[(tissue samples from 88% \(98/112\) pa)-9.8 (tients were tested retrospectively using the QIAGEN)-17.1 ( )]TJ
/T1_2 1 Tf
-0.008 Tc 0.008 Tw 0 -1.048 Td
(therascreen)Tj
/T1_0 1 Tf
0 Tc 0 Tw ( )Tj
-0.008 Tc 0.008 Tw 4.575 0 Td
(KRAS)Tj
0.046 Tw [( RGQ PCR Kit.)37.1 ( )37.3 (While 89% \(87/98\) of pa)-9.9 (tients were positive for )]TJ
/T1_2 1 Tf
0.008 Tw (KRAS)Tj
/T1_0 1 Tf
0 Tc 0 Tw 26.925 0 Td
( )Tj
-0.012 Tc 0.023 Tw -31.5 -1.048 Td
[(G)0.6 (1)0.5 (2)0.6 (C)0.5 ( m)0.5 (u)0.6 (t)0.6 (a)-9.5 (t)0.6 (i)0.6 (o)0.5 (n)0.6 (,)37.5 ( 1)0.5 (1)0.6 (%)0.6 ( \()0.5 (1)0.6 (1)0.5 (/)0.6 (9)0.6 (8)0.5 (\))0.6 ( d)0.5 (i)0.6 (d)0.6 ( n)0.6 (o)0.5 (t)0.6 ( h)0.5 (a)-9.4 (v)0.6 (e)0.6 ( a)0.5 ( )]TJ
/T1_2 1 Tf
0.012 Tw [(K)0.5 (R)0.6 (A)0.5 (S)]TJ
/T1_0 1 Tf
0.023 Tw 17.94 0 Td
[( G)0.6 (1)0.5 (2)0.6 (C)0.6 ( m)0.6 (u)0.5 (t)0.6 (a)-9.4 (t)0.5 (i)0.6 (o)0.6 (n)0.5 ( i)0.6 (d)0.5 (e)0.6 (n)0.6 (t)0.5 (i)0.6 (\036)0.6 (e)0.5 (d)0.6 (.)37.5 ( I)0.5 (n)0.6 ( a)0.6 (d)0.5 (d)0.6 (i)0.5 (t)0.6 (i)0.6 (o)0.5 (n)0.6 (,)25 ( )]TJ
-0.008 Tc 0.044 Tw -17.94 -1.048 Td
[(plasma samples from 63% \(71/112\) pa)-9.6 (tients were tested retrospectively using )36.9 (Agilent)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(Resolution ctDx FIRST assay)54.6 (.)36.6 ( )36.6 (While 66% \(47/71\) of pa)-10.4 (tients were positive for )]TJ
/T1_2 1 Tf
0.017 Tw (KRAS)Tj
/T1_0 1 Tf
0.012 Tw [( G12C)-17 ( )]TJ
0 Tw 0 -1.048 Td
[(muta)-9.7 (tion,)37.2 ( 34% \(24/71\) did not ha)-9.8 (ve a )]TJ
/T1_2 1 Tf
0.017 Tw (KRAS)Tj
/T1_0 1 Tf
0 Tw [( G12C muta)-9.8 (tion identi\036ed.)]TJ
-0.019 Tc -0.012 Tw 0 -1.588 Td
[(A)0.5 ( t)0.5 (o)0.5 (t)0.5 (a)0.5 (l )0.5 (o)0.5 (f)0.5 ( )0.5 (11)0.5 (2)0.5 ( )0.5 (pa)-9.5 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s )0.5 (h)0.5 (a)0.5 (d )0.5 (a)-9.5 (t)0.5 ( )0.5 (l)0.5 (ea)0.5 (s)0.5 (t)0.5 ( o)0.5 (n)0.5 (e)0.5 ( )0.5 (me)0.5 (a)0.5 (s)0.5 (ur)0.5 (a)0.5 (b)0.5 (le)0.5 ( )0.5 (l)0.5 (es)0.5 (i)0.5 (o)0.5 (n )0.5 (a)-9.5 (t)0.5 ( b)0.5 (a)0.5 (s)0.5 (e)0.5 (li)0.5 (n)0.5 (e )0.5 (a)0.5 (s)0.5 ( )0.5 (as)0.5 (s)0.5 (es)0.5 (s)0.5 (e)0.5 (d )0.5 (b)0.5 (y)0.5 ( )0.5 (BI)0.5 (C)0.5 (R)-19 ( )]TJ
-0.017 Tc 0 Tw 0 -1.048 Td
(according to RECIST v1.1.)Tj
-0.009 Tc 0.04 Tw 0 -1.588 Td
[(The baseline demogra)-9.9 (phic and disease characteristics in the ef\036cac)20.1 (y popula)-9.9 (tion were:)28 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.048 Td
[(median a)-9.6 (ge 64 years \(range:)37.4 ( 25 to 89\),)37.3 ( 55% female,)37.3 ( 83% )37.4 (White,)37.4 ( 8% were Black or )37.3 (African)-19 ( )]TJ
-0.001 Tc 0.079 Tw 0 -1.048 Td
[(Ame)0.5 (rica)0.5 (n,)37.4 ( )0.5 (4% )37.6 (Asian,)37.4 ( )0.6 (4% )0.5 (ra)0.5 (ce )0.5 (n)0.5 (ot )0.5 (re)0.5 (port)0.5 (ed,)37.4 ( )0.5 (0.)0.5 (9% )37.5 (Am)0.5 (eric)0.5 (an )0.5 (Ind)0.5 (ian )0.5 (o)0.5 (r )37.5 (Alas)0.5 (ka )0.5 (N)0.5 (a)-9.6 (tiv)0.5 (e,)36 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.008 Tc 0.123 Tw -31.5 -1.048 Td
[(1)0.5 (6)0.5 (%)0.5 ( E)0.5 (a)0.6 (s)0.5 (t)0.5 (e)0.5 (r)0.5 (n)0.5 ( C)0.5 (o)0.5 (o)0.5 (p)0.5 (e)0.6 (r)0.5 (a)-9.5 (t)0.5 (i)0.5 (v)0.5 (e)0.5 ( O)0.5 (n)0.5 (c)0.5 (o)0.6 (l)0.5 (o)0.5 (g)-9.5 (y)0.5 ( G)0.5 (r)0.5 (o)0.5 (u)0.5 (p)0.6 ( \()0.5 (E)0.5 (C)0.5 (O)0.5 (G)0.5 (\))0.5 ( p)0.5 (e)0.5 (r)0.5 (f)0.6 (o)0.5 (r)0.5 (m)0.5 (a)0.5 (n)0.5 (c)0.5 (e)0.5 ( s)0.5 (t)0.5 (a)-9.4 (t)0.5 (u)0.5 (s)0.5 ( \()0.5 (P)0.5 (S)0.5 (\))0.5 ( 0)0.5 ( a)0.5 (n)0.5 (d)8 ( )]TJ
-0.009 Tc 0.042 Tw 0 -1.048 Td
[(83% ECOG PS 1.)36.7 ( )36.7 (T)73.7 (umor histolog)-10.2 (y was 97% adenocarcinoma and 89% of pa)-10.2 (tients had)-9 ( )]TJ
-0.007 Tc 0.052 Tw 0 -1.048 Td
[(metasta)-10.1 (tic )0.5 (disease.)36.9 ( )0.5 (P)17.9 (a)-10.1 (tients )0.5 (received )0.5 (a )0.5 (median of )0.5 (2 )0.5 (prior )0.5 (systemic )0.5 (thera)-10.1 (pies \(range )0.5 (1)-7 ( )]TJ
-0.01 Tc 0.037 Tw 0 -1.048 Td
[(to 7\); 43% received 1 prior line,)36.8 ( 35% received 2 prior lines,)36.8 ( 10% received 3 prior lines)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.003 Tc 0.069 Tw -31.5 -1.048 Td
[(and)0.5 ( )0.5 (12% )0.6 (rece)0.5 (ived )0.6 (4 )0.5 (or)0.5 ( )0.5 (more)0.5 ( )0.5 (pri)0.5 (or )0.5 (lin)0.5 (es,)37.4 ( )0.5 (9)0.5 (8% )0.5 (re)0.5 (ceiv)0.5 (ed )0.5 (bo)0.5 (th )0.5 (pr)0.5 (ior )0.6 (pla)-9.6 (ti)0.5 (num )0.6 (and )0.5 (p)0.5 (rior)-3 ( )]TJ
-0.015 Tc 0.012 Tw 0 -1.048 Td
[(anti-PD-1/PD-L1 thera)-10.1 (py)54.9 (.)36.9 ( Sites of extra-thoracic disease inc)19.9 (luded bone 42%,)36.9 ( brain 30%,)22 ( )]TJ
-0.017 Tc 0 Tw 0 -1.048 Td
[(adrenals 21%,)37.2 ( and liver 21%.)]TJ
0 -1.588 Td
[(Ef\036cac)20.2 (y results are summarized in )37.2 (T)74.2 (able 9.)]TJ
ET
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 170.1532 195.0437 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 170.1532 194.7937 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 170.1532 182.6018 cm
0 0 m
117.597 0 l
S
Q
1 w 
q 1 0 0 1 36 216.2057 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 170.1532 216.2057 cm
0 0 m
117.597 0 l
S
Q
0.5 w 
q 1 0 0 1 170.1532 158.218 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 170.1532 146.0261 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 36 83.9503 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 170.1532 83.9503 cm
0 0 m
117.597 0 l
S
Q
1 w 
q 1 0 0 1 170.1532 121.6423 cm
0 0 m
117.597 0 l
S
Q
0.5 w 
q 1 0 0 1 36 146.0261 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 170.1532 133.8342 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 170.1532 122.1423 cm
0 0 m
0 11.692 l
S
Q
1 w 
q 1 0 0 1 36 121.6423 cm
0 0 m
134.153 0 l
S
Q
0.5 w 
q 1 0 0 1 36 194.7937 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 170.1532 182.8518 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 182.6018 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 170.1532 170.4099 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 170.1532 158.468 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 36 158.218 cm
0 0 m
134.153 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
0.048 Tw 8 0 0 8 36 219.8057 Tm
[(T)74.2 (able 9:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Efficac)10.2 (y Results for KR)18.2 (Y)18.2 (ST)55.2 (AL-1)]TJ
-0.012 Tc 7.36 0 0 8 75.9498 202.6438 Tm
[(Efficac)10.2 (y P)24.2 (arameter)]TJ
0.012 Tw 18.837 0.531 Td
(Adagrasib)Tj
0 Tc 0 Tw 7.36 0 0 8 243.566 206.8938 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.36 0 0 8 216.9902 198.3938 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(112\))Tj
0.048 Tw -24.591 -1.569 Td
(Objective Response Rate \(95% CI\))Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.227 0 Td
[(*)-12 (\037)]TJ
/T1_0 1 Tf
7.6 0 0 8 213.8046 185.8418 Tm
[(43 \(34,)37.2 ( 53\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-23.395 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Complete response ra)-9.7 (te,)37.2 ( %)]TJ
0.012 Tw 24.225 0 Td
(0.9)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.817 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (artial response ra)-9.8 (te,)37.2 ( %)]TJ
0.012 Tw 24.339 0 Td
(42)Tj
/T1_1 1 Tf
0.048 Tw 7.36 0 0 8 36 149.2661 Tm
(Duration of Response)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.391 0 Td
[(*)-12 (\037)]TJ
/T1_0 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 36 137.0742 Tm
( )Tj
EMC 
(Median)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 60.8545 139.2382 Tm
(\206)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 63.3538 137.0742 Tm
[(\033)-47.8 (in months \(95% CI\))]TJ
19.221 0 Td
[(8.5 \(6.2,)37.2 ( 13.8\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-22.82 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (a)-9.8 (tients with dura)-9.8 (tion \0356 months)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 132.4506 127.0463 Tm
(\207)Tj
-0.224 Tc 0.26 Tw 7.6 0 0 8 134.9499 124.8823 Tm
[(\033,)-174.8 ( %)]TJ
-0.012 Tc 0.012 Tw 11.911 0 Td
(58)Tj
-0.017 Tc -0.115 Tw -24.931 -1.569 Td
(CI)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(Confidence )-162.8 (Inter)-17.8 (val)]TJ
0.048 Tw 0 -1.062 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.658 0 Td
(Assessed by BICR.)Tj
0 Tc 0 Tw 5.32 0 0 5.6 36 97.4944 Tm
(\206)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 38.4727 95.3304 Tm
( )Tj
EMC 
0.333 0 Td
[(Estima)-9.7 (te using Ka)-9.8 (plan-Meier method.)]TJ
0 Tc 0 Tw 5.32 0 0 5.6 36 88.9944 Tm
(\207)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 38.4727 86.8304 Tm
( )Tj
EMC 
0.333 0 Td
[(Obser)-17.7 (ved proportion of pa)-9.8 (tients with dura)-9.8 (tion of response beyond landmark time.)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8 36 64.7628 Tm
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Colorectal Cancer)Tj
/T1_0 1 Tf
-0.015 Tc 0.012 Tw -3.375 -1.498 Td
[(The ef\036cac)19.9 (y of ada)-10 (grasib in combina)-10.1 (tion with cetuximab was evalua)-10 (ted in KR)17.9 (YST)55 (AL-1,)36.9 ( a)-14.9 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.048 Td
[(multicenter)74.2 (,)37.1 ( single-arm,)37.2 ( open-label expansion cohort stud)-9.8 (y)55.2 (.)37.1 ( Eligible pa)-9.8 (tients were required)-19 ( )]TJ
-0.014 Tc 0.019 Tw 0 -1.048 Td
[(to )0.5 (ha)-10.4 (ve )0.5 (locally )0.5 (advanced )0.5 (or )0.5 (metasta)-10.4 (tic )]TJ
/T1_2 1 Tf
0.014 Tw 13.991 0 Td
(KRAS)Tj
/T1_0 1 Tf
0.019 Tw [( )0.5 (G1)39.6 (2C-muta)-10.4 (ted )0.5 (CRC )0.5 (and )0.5 (to )0.6 (ha)-10.4 (ve )0.5 (previously)-14 ( )]TJ
ET
q 1 0 0 1 324 271.7848 cm
0 0 m
39.15 0 l
S
Q
q 1 0 0 1 324 183.0958 cm
0 0 m
60.992 0 l
S
Q
q 1 0 0 1 324 107.6116 cm
0 0 m
97.465 0 l
S
Q
q 1 0 0 1 324 64.6921 cm
0 0 m
70.952 0 l
S
Q
BT
-0.017 Tc -0.004 Tw 8 0 0 8 324 727.2481 Tm
[(received thera)-9.8 (py with \037uoropyrimidine-,)37.2 ( oxalipla)-9.8 (tin-,)37.2 ( and irinotecan-based chemothera)-9.7 (py)55.2 (,)20 ( )]TJ
0 Tw 0 -1.072 Td
[(a )37.2 (VEGF inhibitor if eligible,)37.2 ( and an ECOG PS of 0 or 1.)]TJ
-0.002 Tc 0.073 Tw 0 -1.612 Td
[(P)18.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (nt)0.5 (s)0.5 ( i)0.5 (n)0.5 (i)0.5 (t)0.5 (ia)-9.5 (t)0.6 (ed)0.5 ( t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (m)0.5 (e)0.5 (n)0.5 (t)0.5 ( wi)0.5 (t)0.5 (h)0.5 ( a)0.5 (d)0.5 (a)-9.5 (gr)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( 6)0.5 (0)0.5 (0 m)0.5 (g)0.5 ( o)0.5 (r)0.5 (a)0.5 (l)0.5 (ly)0.5 ( t)0.5 (w)0.5 (i)0.5 (c)0.5 (e)0.5 ( d)0.5 (ai)0.5 (l)0.5 (y)0.5 ( i)0.5 (n)0.5 ( c)0.5 (om)0.5 (b)0.5 (i)0.5 (n)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)-2 ( )]TJ
0.008 Tc 0.124 Tw 0 -1.072 Td
[(wit)0.5 (h )0.5 (ce)0.5 (tux)0.5 (imab )0.6 (adm)0.5 (inist)0.5 (ere)0.5 (d )0.5 (ei)0.5 (ther)0.5 ( )0.5 (biwe)0.5 (ekl)0.5 (y )0.5 (\(7)0.5 (7 )0.5 (pa)-9.5 (tien)0.5 (ts )0.5 (w)0.5 (ith )0.6 (500 )0.5 (m)0.5 (g/m)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 553.9439 699.36 Tm
(2)Tj
0.008 Tc 0.124 Tw 8 0 0 8 556.6743 697.196 Tm
[( )0.5 (ev)0.5 (er)-17.6 (y)8.1 ( )]TJ
-0.011 Tc 0.028 Tw -29.084 -1.072 Td
[(t)0.6 (w)0.5 (o)0.6 ( w)0.6 (e)0.5 (e)0.6 (k)0.6 (s)0.5 (\))0.5 ( o)0.6 (r)0.5 ( w)0.6 (e)0.5 (e)0.6 (k)0.5 (l)0.6 (y)0.5 ( \()0.6 (1)0.5 (7)0.5 ( p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.5 ( w)0.6 (i)0.5 (t)0.6 (h)0.5 ( 4)0.5 (0)0.6 (0)0.5 ( m)0.6 (g)0.5 (/)0.6 (m)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 470.1218 690.7826 Tm
(2)Tj
-0.011 Tc 0.028 Tw 8 0 0 8 472.7451 688.6186 Tm
[( i)0.5 (n)0.6 (i)0.5 (t)0.6 (i)0.5 (a)0.6 (l)0.5 ( d)0.5 (o)0.6 (s)0.6 (e)0.5 ( f)0.5 (o)0.6 (l)0.5 (l)0.6 (o)-9.4 (w)0.5 (e)0.6 (d)0.5 ( b)0.5 (y)0.6 ( 2)0.5 (5)0.5 (0)0.6 ( m)0.5 (g)0.6 (/)0.5 (m)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 573.312 690.7826 Tm
(2)Tj
8 0 0 8 576 688.6186 Tm
( )Tj
-0.01 Tc 0.036 Tw -31.5 -1.072 Td
[(weekly\).)36.9 ( )36.9 (T)74 (rea)-10 (tment continued until unacceptable toxicity or disease progression.)37 ( )36.8 (T)74 (umor)-10 ( )]TJ
0.009 Tc 0.128 Tw 0 -1.072 Td
[(a)0.5 (sse)0.5 (ss)0.5 (me)0.5 (nt)0.5 (s we)0.5 (re)0.5 ( p)0.5 (er)0.5 (fo)0.5 (rm)0.5 (e)0.5 (d e)0.5 (v)0.5 (er)-17.5 (y 6 w)0.5 (e)0.5 (ek)0.5 (s.)37.4 ( )36.7 (Ad)0.5 (a)-9.6 (g)0.5 (ra)0.5 (sib)0.5 ( d)0.5 (is)0.5 (co)0.5 (nt)0.5 (in)0.5 (ua)-9.5 (ti)0.5 (on)0.5 ( r)0.5 (eq)0.5 (uir)0.5 (e)0.5 (d)8.9 ( )]TJ
0.001 Tc 0.093 Tw 0 -1.072 Td
[(cetuximab discontinua)-10.3 (tion,)36.7 ( ho)-10.3 (wever pa)-10.4 (tients could continue to receive ada)-10.3 (grasib if)1 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.072 Td
(cetuximab was discontinued )Tj
/T1_2 1 Tf
[([see Dosa)-10 (ge and )36.9 (Administra)-10.1 (tion \(2.3\)])]TJ
/T1_0 1 Tf
[(.)36.9 ( Six pa)-10 (tients continued)-19 ( )]TJ
-0.007 Tc 0.051 Tw 0 -1.072 Td
[(with ada)-10 (grasib single a)-9.9 (gent thera)-9.9 (py after discontinuing cetuximab.)37 ( )37 (The length of time)-7 ( )]TJ
0.001 Tc 0.091 Tw 0 -1.072 Td
[(these 6 pa)-9.9 (tients received ada)-9.9 (grasib alone ranged from 43 days to 3 years.)37 ( P)18 (a)-9.9 (tient)1 ( )]TJ
-0.01 Tc 0.033 Tw 0 -1.072 Td
[(t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (m)0.5 (e)0.6 (nt)0.6 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( a)0.5 (d)0.5 (a)-9.4 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( a)0.5 (f)0.5 (t)0.5 (e)0.5 (r)0.5 ( d)0.5 (i)0.5 (s)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 ( p)0.5 (r)0.5 (o)0.5 (g)0.5 (r)0.5 (e)0.5 (s)0.5 (s)0.5 (i)0.5 (o)0.5 (n)0.5 ( c)0.5 (o)0.5 (n)0.5 (t)0.5 (i)0.5 (n)0.5 (u)0.5 (e)0.5 (d)0.5 ( i)0.5 (f)0.5 ( a)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.6 (en)0.6 (t)0.5 ( w)0.5 (a)0.5 (s)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.5 (c)0.5 (a)0.5 (l)0.5 (l)0.5 (y)-10 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(stable and considered to be deriving c)20.1 (linical bene\036t by the investiga)-9.8 (tor)74.2 (.)20 ( )]TJ
-0.035 Tc -0.045 Tw 0 -1.612 Td
[(The major ef\036cac)20.1 (y outcome measures were con\036rmed ORR and DOR according to RECIST v1.1\)-35 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc -31.5 -1.072 Td
[(as assessed by BICR.)20.1 ( )]TJ
-0.009 Tc 0.043 Tw 0 -1.612 Td
[(In the ef\036cac)19.5 (y popula)-10.4 (tion,)36.6 ( )]TJ
/T1_2 1 Tf
0.009 Tw (KRAS)Tj
/T1_0 1 Tf
0.044 Tw [( )0.5 (G1)39.6 (2C )0.5 (muta)-10.4 (tion )0.6 (sta)-10.4 (tus )0.5 (was )0.6 (determined )0.6 (by )0.6 (prospective)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.072 Td
[(local testing using tumor tissue specimens.)37.2 ( Of the 94 pa)-9.7 (tients with )]TJ
/T1_2 1 Tf
0.017 Tw (KRAS)Tj
/T1_0 1 Tf
0.012 Tw [( G1)40.2 (2C muta)-9.8 (tion,)20 ( )]TJ
-0.014 Tc 0.017 Tw 0 -1.072 Td
[(tissue samples from 79% \(74/94\) pa)-10.2 (tients were tested retrospectively using the QIAGEN)-14.1 ( )]TJ
/T1_2 1 Tf
-0.017 Tc 0 -1.072 Td
(therascreen)Tj
/T1_0 1 Tf
-0.003 Tw ( KR)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.426 0 Td
[(AS RGQ PCR Kit.)37.2 ( Of the 74 tissue samples submitted,)37.2 ( 81% \(60/74\) yielded)-17 ( )]TJ
-0.011 Tc 0.032 Tw -5.426 -1.072 Td
(a result with 93% \(56/60\) positive for )Tj
/T1_2 1 Tf
0.011 Tw (KRAS)Tj
/T1_0 1 Tf
0.032 Tw [( G1)39.9 (2C and 7% \(4/60\) without a )]TJ
/T1_2 1 Tf
0.011 Tw (KRAS)Tj
/T1_0 1 Tf
0.032 Tw [( G1)39.9 (2C)-11 ( )]TJ
-0.017 Tc 0 Tw -0 -1.072 Td
[(muta)-9.7 (tion identi\036ed.)]TJ
-0.009 Tc 0.04 Tw 0 -1.612 Td
[(The baseline demogra)-9.9 (phic and disease characteristics in the ef\036cac)20.1 (y popula)-9.9 (tion were:)28 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.072 Td
[(median a)-10.3 (ge 57 years \(range:)36.7 ( 24 to 75 years\),)36.7 ( 53% female,)36.7 ( 71% )36.7 (White,)36.7 ( 14% were Black or)-19 ( )]TJ
-0.021 Tc 0 -1.072 Td
[(African )37 (American,)37 ( 5% )36.9 (Asian,)36.9 ( 1.1% )37 (American Indian or )37 (Alaska Na)-10.1 (tive,)36.9 ( 9% reported as other;)-21 ( )]TJ
-0.013 Tc 0.019 Tw 0 -1.072 Td
[(51% ECOG PS 0 and 49% ECOG PS 1.)37.3 ( )36.5 (T)74.2 (umor histolog)-9.7 (y was 100% adenocarcinoma and)-13 ( )]TJ
-0.012 Tc 0.026 Tw 0 -1.072 Td
[(99% of pa)-10 (tients had metasta)-10 (tic disease.)37 ( P)18 (a)-10 (tients received a median of 3 prior systemic)-12 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.072 Td
[(thera)-9.6 (pies \(range 1 to 9\); 9% received 1 prior line,)37.3 ( 36% received 2 prior lines,)37.3 ( 31% received)-21 ( )]TJ
-0.016 Tc 0.012 Tw 0 -1.072 Td
[(3)0.5 ( )0.6 (p)0.5 (r)0.6 (i)0.5 (o)0.6 (r)0.5 ( )0.5 (l)0.6 (i)0.5 (n)0.6 (e)0.5 (s)0.5 ( )0.6 (a)0.5 (n)0.6 (d)0.5 ( )0.6 (2)0.5 (5)0.5 (%)0.6 ( )0.5 (r)0.6 (e)0.5 (c)0.6 (e)0.5 (i)0.5 (v)0.6 (e)0.5 (d)0.6 ( )0.5 (4)0.6 ( )0.5 (o)0.5 (r)0.6 ( )0.5 (m)0.6 (o)0.5 (r)0.6 (e)0.5 ( )0.6 (p)0.5 (r)0.5 (i)0.6 (o)0.5 (r)0.6 ( )0.5 (l)0.6 (i)0.5 (n)0.5 (e)0.6 (s)0.5 (.)37.6 ( )0.5 (S)0.5 (i)0.6 (t)0.5 (e)0.6 (s)0.5 ( )0.6 (o)0.5 (f)0.6 ( )0.5 (m)0.5 (e)0.6 (t)0.5 (a)0.6 (s)0.5 (t)0.6 (a)-9.5 (t)0.6 (i)0.5 (c)0.6 ( )0.5 (d)0.5 (i)0.6 (s)0.5 (e)0.6 (a)0.5 (s)0.6 (e)0.5 ( )0.6 (i)0.5 (n)0.5 (c)20.6 (l)0.5 (u)0.5 (d)0.6 (e)0.5 (d)-16 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(lung \(71%\),)37.2 ( liver \(64%\) and bone \(14%\).)]TJ
0 -1.612 Td
[(Ef\036cac)20.2 (y results are summarized in )37.2 (T)74.2 (able 10.)]TJ
ET
/GS2 gs
q 1 0 0 1 458.1531 411.043 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 458.1531 410.793 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 458.1531 400.0411 cm
0 0 m
117.597 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 432.2049 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 458.1531 432.2049 cm
0 0 m
117.597 0 l
S
Q
0.5 w 
q 1 0 0 1 458.1531 378.5372 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 458.1531 367.7853 cm
0 0 m
117.597 0 l
S
Q
q 1 0 0 1 323.9999 307.8696 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 458.1531 307.8696 cm
0 0 m
117.597 0 l
S
Q
1 w 
q 1 0 0 1 458.1531 345.5615 cm
0 0 m
117.597 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 367.7853 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 458.1531 357.0334 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 458.1531 346.0615 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 323.9999 345.5615 cm
0 0 m
134.153 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 410.793 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 458.1531 400.2911 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 323.9999 400.0411 cm
0 0 m
134.153 0 l
S
Q
q 1 0 0 1 458.1531 389.2892 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 458.1531 378.7872 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 323.9999 378.5372 cm
0 0 m
134.153 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
0.048 Tw 8 0 0 8 323.9999 435.8049 Tm
[(T)74.2 (able 10:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Efficac)10.2 (y Results for KR)18.2 (Y)18.2 (ST)55.2 (AL-1)]TJ
-0.012 Tc 7.36 0 0 8 363.9497 418.6429 Tm
[(Efficac)10.2 (y P)24.2 (arameter)]TJ
0.012 Tw 18.837 0.531 Td
(Adagrasib)Tj
0 Tc 0 Tw 7.36 0 0 8 531.5659 422.8929 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.36 0 0 8 506.7116 414.3929 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(94\))Tj
0.048 Tw 7.6 0 0 8 323.9999 402.561 Tm
(Objective Response Rate \(95% CI\))Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.227 0 Td
[(*)-12 (\037)]TJ
/T1_0 1 Tf
10.169 0 Td
[(34 \(25,)37.2 ( 45\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-23.395 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Complete response ra)-9.7 (te,)37.2 ( %)]TJ
0 Tc 0 Tw 24.573 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.165 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (artial response ra)-9.8 (te,)37.2 ( %)]TJ
0.012 Tw 23.991 0 Td
(34.0)Tj
/T1_1 1 Tf
0.048 Tw 7.36 0 0 8 323.9999 370.3053 Tm
(Duration of Response)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.391 0 Td
[(*)-12 (\037)]TJ
/T1_0 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 323.9999 359.5534 Tm
( )Tj
EMC 
(Median)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 348.8544 361.7174 Tm
(\206)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 351.3537 359.5534 Tm
[(\033)-47.8 (in months \(95% CI\))]TJ
19.454 0 Td
[(5.8 \(4.2,)37.2 ( 7.6\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-23.054 -1.389 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (a)-9.8 (tients with dura)-9.8 (tion \0356 months)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 420.4505 350.6055 Tm
(\207)Tj
-0.224 Tc 0.26 Tw 7.6 0 0 8 422.9498 348.4415 Tm
[(\033,)-174.8 ( %)]TJ
-0.012 Tc 0.012 Tw 11.911 0 Td
(31)Tj
-0.017 Tc -0.115 Tw -24.931 -1.524 Td
(CI)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(Confidence )-162.8 (Inter)-17.8 (val)]TJ
0.048 Tw 0 -1.062 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.658 0 Td
(Assessed by BICR.)Tj
0 Tc 0 Tw 5.32 0 0 5.6 323.9999 321.4136 Tm
(\206)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 326.4727 319.2496 Tm
( )Tj
EMC 
0.333 0 Td
[(Estima)-9.7 (te using Ka)-9.8 (plan-Meier method.)]TJ
0 Tc 0 Tw 5.32 0 0 5.6 323.9999 312.9136 Tm
(\207)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 326.4727 310.7496 Tm
( )Tj
EMC 
0.333 0 Td
[(Obser)-17.7 (ved proportion of pa)-9.8 (tients with dura)-9.8 (tion of response beyond landmark time.)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8 323.9999 285.2922 Tm
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
/T1_0 1 Tf
-3.375 -1.563 Td
[(Ho)-9.8 (w Supplied)]TJ
0.012 Tw 0 -1.567 Td
[(KRAZA)54.6 (TI \(ada)-10.3 (grasib\) tablets,)36.6 ( 200 mg,)36.7 ( oval sha)-10.3 (ped,)36.6 ( white to off-white,)36.7 ( immedia)-10.3 (te release,)20 ( )]TJ
0 Tw 0 -1.072 Td
[(\036lm coa)-9.8 (ted tablets with )37.1 (\223200\224)37.2 ( on one side and stylized )37.2 (\223M\224)37.2 ( on the other side.)]TJ
-0.007 Tc 0.048 Tw 0 -1.612 Td
[(K)0.5 (R)0.5 (A)0.5 (Z)0.5 (A)55.4 (T)0.6 (I \()0.5 (a)0.5 (d)0.5 (a)-9.5 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 (\))0.5 ( t)0.5 (a)0.5 (b)0.5 (l)0.5 (e)0.5 (t)0.5 (s)0.5 ( a)0.5 (r)0.5 (e)0.5 ( p)0.5 (a)0.5 (c)0.5 (k)0.5 (a)-9.5 (g)0.5 (e)0.5 (d)0.5 ( in)0.5 ( h)0.5 (i)0.5 (g)0.5 (h)0.5 (-)0.5 (d)0.5 (e)0.5 (n)0.5 (s)0.5 (i)0.5 (t)0.5 (y)0.5 ( p)0.5 (o)0.5 (l)0.5 (y)0.5 (e)0.5 (t)0.5 (h)0.5 (y)0.5 (l)0.5 (e)0.5 (n)0.5 (e)0.5 (,)37.5 ( w)0.5 (h)0.6 (it)0.5 (e)0.6 ( o)0.5 (p)0.5 (a)0.5 (q)0.5 (u)0.5 (e)0.5 (,)30 ( )]TJ
-0.008 Tc 0.045 Tw 0 -1.072 Td
[(square )0.5 (bottles )0.5 (with )0.5 (desiccant and )0.5 (polypropylene,)37.3 ( white,)37.3 ( child )0.5 (resistant )0.5 (c)20.2 (losures )0.5 (with a)-7.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(tamper)37.2 (-proof hea)-9.8 (t induction seal.)]TJ
1.125 -1.653 Td
[(NDC 80739-812-12:)37.2 ( 200 mg,)37.2 ( bottle containing 120 tablets.)]TJ
0 -1.518 Td
[(NDC 80739-812-18:)37.2 ( 200 mg,)37.2 ( bottle containing 180 tablets.)]TJ
-1.125 -1.518 Td
[(Stora)-9.7 (ge and Handling)]TJ
-0.016 Tc 0.012 Tw 0 -1.567 Td
[(Store tablets a)-9.9 (t room tempera)-9.9 (ture,)37.1 ( 20\260C to 25\260C \(68\260F to 77\260F\).)37 ( )37.1 (T)74 (empera)-9.9 (ture excursions)-16 ( )]TJ
0.006 Tc 0.118 Tw 0 -1.072 Td
(between 15\260C and 30\260C \(59\260F to 86\260F\) are permitted )Tj
/T1_2 1 Tf
[([see USP Controlled Room)6 ( )]TJ
-0.091 Tc 0.091 Tw 0 -1.072 Td
[(Te)-73.8 (m)]TJ
-0.017 Tc 0.017 Tw 1.503 0 Td
[(pera)-9.7 (ture])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -1.503 -2.548 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.1 (TION)]TJ
/T1_0 1 Tf
-3.375 -1.522 Td
[(Advise the pa)-9.8 (tient to read the FDA-a)-9.8 (pproved pa)-9.8 (tient labeling \(P)18.3 (a)-9.8 (tient Informa)-9.8 (tion\).)]TJ
-0.037 Tw 0 -1.653 Td
[(Gastrointestinal Adverse )-36.8 (Reactions)]TJ
0.006 Tc 0.116 Tw 0 -1.567 Td
[(Advise pa)-10 (tients tha)-10.1 (t KRAZA)55 (TI can cause severe gastrointestinal adverse reactions)6 ( )]TJ
-0.008 Tc 0.048 Tw 0 -1.072 Td
[(and to contact their healthcare provider for signs or symptoms of severe\ or persistent)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
(gastrointestinal adverse reactions )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.1\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.017 Tc 0 -1.653 Td
[(QTc Inter)-17.8 (val Prolonga)-9.8 (tion)]TJ
0.007 Tc 0.12 Tw 0 -1.567 Td
[(Advise pa)-9.9 (tients tha)-9.9 (t KRAZA)55.1 (TI can cause QTc inter)-17.9 (val prolonga)-9.9 (tion and to contact)7.1 ( )]TJ
0.003 Tc 0.101 Tw 0 -1.072 Td
(their healthcare provider for signs or symptoms of arrhythmias )Tj
/T1_2 1 Tf
0.064 Tw [([see W)18.1 (arnings )-36.7 (and)2.9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.072 Td
(Precautio)Tj
0 Tw (ns \(5.2\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
ET
endstreamendobj22 0 obj<</BaseFont/UEAMSO+HelveticaNeueLTStd-BdCn/Encoding 72 0 R/FirstChar 30/FontDescriptor 73 0 R/LastChar 174/Subtype/Type1/ToUnicode 74 0 R/Type/Font/Widths[487 240 240 0 0 0 0 778 0 0 296 296 390 0 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 0 0 0 556 556 537 574 481 463 556 556 258 463 537 463 740 574 556 519 556 556 519 480 538 519 760 537 520 481 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 0 0 0 0 0 0 0 0 0 0 0 0 480 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj72 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/greaterequal/uni00A0]/Type/Encoding>>endobj73 0 obj<</Ascent 961/CapHeight 714/CharSet(/greaterequal/uni00A0/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y\/dagger/bullet/registered)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 75 0 R/FontName/UEAMSO+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj74 0 obj<</Filter/FlateDecode/Length 566>>stream
H‰\Ô_kâ@ğ÷|ŠylJ4sï
A°jÁ‡ıÃºûb2º5	1>øíwNNéÂ
­GLz~šÉ·‡İ¡k'—ûú'wn»fŒ·ş>ÖÑâ¥í²eáš¶>>Í¿ëk5dyºùø¸MñzèÎ}V–.ÿ‘¾¼MãÃ=mšşŸ³üÛØÄ±í.îé×öøìòã}şÄkì&·pëµkâ9ı¡/ÕğµºF—Ï·½šô};=^Ò=ÿ®øù¢+æÏKbê¾‰·¡ªãXu—˜•‹ôZ»ò=½ÖYìšÿ¾·ÎõïjÌÊå>]\¦ë”ßS^,6‹”‹Åœ‹9+3®)^™_‘WÌ+äóyË¼EŞ1ï÷Ì{dv¥·¬ôìòèòKæ%rÁ\ {f,Ì‚L›‡Í³!æ€L³‡ÙÓìaö4{˜=N¡A`¡A`¡A`¡A`¡A`yc~Cæ†‚…6™mÜP°¡pCÁ†Ê*ı
¿Ò¯ğ+ı
¿Ò¯ğ+ı
¿Ò¯ğ+ı
¿Ò¯ğ+ı
¿Ò¯ğ{½Æ^C¯±×Ğkì5ô{çÿ=c¯¡×Økè5öz½†^c¯Í½ÜÍ°›q7ÃnÆİ»w3ìfÜÍ°[àn»úüş  ?Àèğúüş  ?Àèğúü¯¸¾àóµRftmèLoxx?R<Æé´qŸgD}Çt<ÌGÒ|.àDh»øyjıàÒ]øÉş
0 ûÃ"%endstreamendobj75 0 obj<</Filter/FlateDecode/Length 4771/Subtype/Type1C>>stream
H‰tT{TçßawgaXvŠ ³£`=²İuÃ±#ÈAy#®4$N—eÀUØÅİ*¥Mr 	`ñÔƒ1¨P1¦Š¯ ¨E-D«’L{¢MÁàÑª›;xÉi¿]óìãù^sïïûİßwï¥d
EQÚÜ¤ÄLS¶.E,­]V‹9K¬3V›\Eú¥EËl^i&%…($>€ÃXt=9ó$W)Í’–_ŸÚ®ñÉe!Ô<ja‰C4»D‡¸¡Â\Za³‰ÆeöòkÉZ—ğÌ¢EÆŸ	1FcŒXd/ÓF§K,s
©6‹İQnw×"ƒXZ*xœ‚CtŠJÏáwü«S0.‡¹H,3;Ööb!Ãj³»6–‹Â2‚b N%V§‡D‘`µ	®µ¢k0„•İæÌ¶"aõwŞÙÅÅV‹è=,3o§{[D‡ËLf;që*Vg‘Õâ²ÚmÎoÁmæ2ñ°°;+‰ ”ÀÛœ¢øıïe…)†ùÉ¦ÕÍ¡H,–ı(™Œ–Éü|dŒŒ—ÉfO—-“•Ëd.™¬SFÕQ²,Ê™²,Ùj&•Km¥Ş¥ú©aê¡ÏŸBŸ“r£Ü&¿©HWÔ(ie¥r‡ò}%Ğyô»ô˜ŠS-V½¥º¬úÜ7Ì7Ë×êûßa?ÁoßEÿXÿCşCÓ|§ÅLÛ4íè´Û­÷Ÿ	l
üœÑ2Ì_™=TôjĞßÕ‘êRõåà9Áæà!£I×Thú5_³KX+ÛÂ‡¤‡dìiì•&z)2FõÊRıäÊ©zšñO.íJ£QÀsx6S­ª)ºÀ»†%Hö´t–ó¬Ğ³cè«†êa³gh¯Òt¹o»AMöD-;\+õA*w­¥»»»Å²<®Îb±Ôuğ³ê8ä:3AêÎà€Û0€jToÈD'~Sq0öÿÜ-ÿÈ¾WÛ:uš»CKÑ“õÊšÁT|¶òIhÕarX5YÀÍC£õ(„£põ÷ĞÈ»éXĞ•ôøpˆ? Üg ã¿wšxN(>Cİä0>ãK‘‹Eñ»Æc !3èç‘gH'« ‹¸nÉÁ@îÃ2İx`,	‘ƒkn>º9x*á³O±(!DÅ4‚‘ê#×ô‘CãÙMªâê’µ¯ñIª¯~·ï¦;BUŒ ÕàO€Còğ€C8şÿéa`T18§µr²ºŠª‡/äõ5(h {%*h¦¹f\:0Ní‚(0B”J¤íì¿4ğf!&óKT˜ö²)#sÓQHæ1ê ‡-g %; ^€–¼1LÀ’ZLÃ<i~»Rªš„šæÁ	Ì›¥Š¯É)ÑGlÖÃ,’ILs#(¤­yˆ&FÒ‹ àp7İÚµ÷È±ÃŸŞ½¾ÿÂ?ÂIº†³Q—œˆ?áËWİ|½õÒ_"Nî³­\Z»>c•6'W9;:ojÂ¥o°e|c%Ôkv!$îÙdÖ@;²,\½
#†ba&Ï¾yG àîµ—mÚ&{|pçÑş¿…CpÂyÁğÄ$ÔòFî85ĞÓQÊ³#9¹Ù|¾f?9E´åddşæù¤Œš“·´ˆa.	(·ŠjŒzŞàP I|Ê&·Ms°çFs‡@±BÊÅy4n™ÊVÖ÷Á	Šüû …Æ£ˆğ=-ÅO¦qSJšİ0Å)£ÙÓİÛ:ö¸²kúÍßğRNæ+õh‘ÿ·Ÿ<{
¤ü
æƒ¢hœÁ³£YæMÅåÚz'ü\	mOÕérƒa\ÓFYOtaÉ=YIÊ•öq0³Áp|Nn®Cæcâ>Œµìcˆ¹ö,65™ùÎb§¶áıèáa•Nµ¯ÏÕâOñ"÷eÇáó<û¸¿CÔ-~%;IËJ)µnõJ#‚šêRä$ TÃjqe6–T`‚/èè=?vğƒE¾à£òÒ$é“ç¥I'z>}Â	öaäsÏíÇé$é^ØÓGïX®.~“'ï71¼»óÊ™pĞÆõ“ZäâL¨ÍëL®âTìÃÅ›,I1áìÉí«Üå={zö¬KOµ¯3›íÿÌ³·à7ÔŞwåJ{îŠ”êÕiiÕò^"7t=%Â"z¯^`‡3šÆ~ùÏØÜ«à%Ht@zäÂ˜åF\ˆl4={ßÛ«m²Ò‘[xvbMõ;çˆI-pŸn¿pupÇÊç^çuâ*SÅá/yOÉ‚ømÙ†zJÃhß¬ºêq¢eÔ,ïsœÔê©fï*¾Y1#$uà7@İX¥i”Î±7* š>:%¬¢"™¢iÌ™,Pb2ÍİF5×D„7”$U™‘F7¬¿ÙnMïÓ>@
(š•zC¡&‰÷Á(îæ]ˆÛá)éÚî?~øq8Ì\xıy|†¨YÜYúÚAÇŠ”’ò8m!=W1@Ü.õ8ccóÉZÍ\¨qK]nÍ!‚¾œ óDÎ1öT'•q^bi9°ËºĞ ¥<;9‡a:´E£A,>³ì”BAûõë<ûàÊÛ‘Zf¢Ñ-muSç	hé$çC¡ŠSéÎ¿…â˜‰ùZ¬õ²»HƒÏïcÉëü¢*c®6fZ‰V«ÉG:(‰YŞKÚò×’üqùñ*™_%?·{:jÑöÒmCÉ—~h3I4¬q/¯„wÜğk·æ81H~›í!åÜ$må`Nú(Æ`†	ƒğß|WkTT×ñŞ©™E¸™Î˜;1´F¾-Ñ„ Q—ò;%¨HxÓ5 8bÕPÔˆá!/PAAÁ€ø T|D˜«$5iRÁĞØ‡¸=ãZİçh’Õö‹9÷Ş}Îw¾³¿ıí³ƒî¬£*ğ‘Ä–®ÖŠZ­‰Ó—%5Lzè%ˆ-ƒ×oôÈÀ¢ğ6øVİî‘ÄÖË‹Cµò!÷ ñU2ïrÆ¥G°ô€'íçáÕÔ™VRO¨DÒ4¡T?¼:•ÑcNìåÓÕ¸ÃĞğØT›Ì­	ìMn}|Qæ†°°Ì½RUÅ
tÜÉi0\n]ƒéÙ/(:­s=g
W.öÁŠ-Š;OcÉt…+uãÑ8#4ğ
²Lú­a$Ä	ùÚKú­0 P.Î6AE˜^Ä¼']&DKÇJ$]œÉÒ*D¾‘w¶ärFşu’ËÑ^18
Gë1v’Šd›ğ¶dsàA*‹ÁÈS/bàØÙ`úÙ°ô[…Xê`X9’i{‹nÄ%Â›4v$1= ÈüÅıûæw°&¼ÜİŸC°¤hÄ¨‚¸!ù æŒ@ı&şµ¦>	B]´t·œuüíª|¼¢6²”CóõÇôÃc­2@b‘¨#§¶*ş‰kéŞûwxQıbÑÊCE¹¦Iô,4ì:¸ÛNÔİŸÍáËcd…ò¿ãd™Òş"­‚ö@É½Šë%•âãnşÓº˜%£â|µş<u¶¸(ñ£v^$wøË‡7™´»è+¹	y‰æÔ_ƒÛ>ÑüÇ†œ/ğÆæ¶ß´Ã
ğ¸¯¨şÆCôèw¯±
pˆW4Zõ]†©eb˜ÅLûË E/PÕE0O?·İğÆ·	ítú—íYÎ¯rË‘3êÆ¢ÓŸJâöò¨ÅZJxxåÍvôâ‰îŞè¿º
Ş—ÄïÆOYªö_›ğş¢´¦.©T-¦E)+á k¬^ 7K?8ãS7¦Ü«Öd?="–Ó,×³¶Qè:ö`{–J$)È¼ÓC/N¿øvÎ,ÁòÈ>Û<§«9XÎ³¼âĞ¾'YsÙ¼9Ì)àÄNğ£óÙç{‡7‹Ø«8Á\ş)@ó¿g)àp N,LâÅ“häça çÉOë`Tb{H™-–³§JêKŸr0‹ÿdı“fÉ"ó…§° †8:“w£®ÁÑÙ¼¢É¸Cìr‹GkqÏµ,'>L“Sh5.5ª9¹ô‘dd­‚øØV8”e%$ƒ‹+Rhh¡%¿4è‰¤¿?àX**`åÁ¾JLõğ±WeUÍÅÉ‘‘[¥·ôœØ2=)2ÒEıníün6˜;IXÚô»6íÒç§ÛaSe8š]~N'„ÁØnê1Ù}-u¶`ÁÃşh½2àw)ë×o®=}¶ìHÇ©hWyş!³¢Ü0äú {ªc3:ñë ‰›‘ 2%Øè¼ÚyÀŸÚSûL¿ÌN°—¨Dñ
[¦K&!¼¦^ß¦îÂ× ]Ø×”‹Ö¯‰×AÏ7`ëk÷È¦g„U„,A%ˆKú¨HE·å4‰Ævc—+wa’„><G±<³mÉag÷…}AaÒÏàoÑ¼Î«£ğüüexhuV'‰ê|S|ti˜ay W‰­TwÁ¸¶úÒs5HÃ_Á„ŸBÌU`şCçR¿ªÆ’¯Ş‹5BN=ğÒn‰:ğK¶§EGhV¦_»®m¾W*œ+¼Ô~i_Äü<v‰AÑ|ÿ(;Õ±Áö÷:Dîü¶…?j>ĞŸ¿3'Åø7Aì7%§ä&kf8Mëç3£GP”Óe™ÎÍCğíWVÇ$ú2ÖàÉ˜ĞCê”b­¿QèHÒ¯ÓĞiit*u¤áíoÃØ3M•§ª´&o>8um$JÏØ“¿E+¦lÉßn.V#·â)×›a¨È¹×oÁkÙ+ˆ´š6 oîo½Ú^´Š¾ì–¾lÅŠ­7¿@ÎqŒq–*l›q0ÌwVV·œ.Ö‡H÷4YZÙ2w…î÷I’2Ø‰c`]ê7˜ûç1è<Ûx>¾9£_`ï©÷#òïçìSd%®Ú¾c§i‡4EÈ))É)Ô€Cmë÷Zr›JÂó¸rybX™j³Ú‘3…Ö Ğ$¦3ñŞÅ=š£ø[K#8#y‘bÒEÃÒ»½Z¶?Æ/Û£õoÂD±UŞåşZUÍ™†‚äÕ’e<?ğ¯5—Ü–†Çê%#ß¾9âè2ÍŠ5©«¢ñ> öµS•`åot~¤O¼ó?ø?‘O	Ç¹Ä;×Y4»0*lª0b*â®ÂT§şÍSaA³Ú~DiúGüHdké¬©t™–ÕÃ±{îvwc¶ª7½÷Ñ]‹ÇH]õà>OF¡0íş?i[Ğî$Ğ›ø5Õuú#ÂÖŠ}Vm‡¬Ó‡Ç1œƒ—ä]ştúãÏ¦¿Åğ>äs‘âäãäÀ\ì4
çâÖ•†ŒHÓªËu¥MÕØ«)¨3è*ƒ\‘Ä“Œ=^¼½Âí¶ÃgÍ99fäUÈİ¾-w»&0jcXãşäm†*FfÏ±èxäŞÑú_ü®¼•i‚sÓ{˜#vî ®ïÃ3sªñh<ª¸ˆCY¥º¾¦¤î“ÂÄ	ÊøÁ€ú}-ÈkÖ¢]o"ºã`4wäåÑê5	úµºä£-R±€bÿè‘“»,õÄ^T(ê˜^E4Ô¦$Æ«ÊË«‘~r¶mÍÙªù`[Q£Î`-À.D¬Å¦>K”4ø’µi(:Ìû'Åë"7•¶IDÀ£aÙ2é¼î›Ëç*.V³ê#kÂf7ñµ…4˜¡4ò‰’ÃÎ´–:æğ !u²óA*^€¨FOÁ//ûŠ+ÁÁ	?£»ˆ#úègGfò`Ç"ğ€.ÅFŞ_Òiüby°Œp¶ÍÖu?&Á¶AÆ+ßwyÕW©/¬58ó÷Àûõf¿¨Ôà-ÓÌ¾PÄXå/Cn¦ŞÊÿp\ı 	DqõşX]7yg$‚GSƒ˜w‚CHMMe`AÒˆR6œ—à*D¶äPA´m%È•n9Y˜“ü¼ú)ßğñ¾á{¼á{¿ïÇç¶kÏ~ğ’‹‘yÂvãMqğ[çÇé™l6™Å•—„€$Îâ8&âäZ¢1Ê@Ì®ajØAlçÉñ+@—…eTik½^»İëimEÑ4Eá#3€£æ_ómà¸AS®¾N®‹RÂU®KÃì/‚([/<Ş¿ûZ›Og}'!½rwgÛ;éÜ®•£‰ê Rt„
cÆ“JuêT—ñb@œ €‚pR#V#=(‹W§–ƒ×ù‘"<´è‹]á‹FÙOfaıäóöœdÙe^3¥aªD×K0_â Rø.Øõ"R¦Êtßt£Ò/Ø]sb0	òTÓ4Ã0«‚ĞG6Š†!Lçrr(ı0 Yş2endstreamendobj21 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj18 0 obj<</Length 30202>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 369.6486 cm
0 0 m
72.584 0 l
S
Q
q 1 0 0 1 36 238.5942 cm
0 0 m
30.305 0 l
S
Q
q 1 0 0 1 36 171.9644 cm
0 0 m
32.262 0 l
S
Q
q 1 0 0 1 36 138.2896 cm
0 0 m
31.295 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.248 Tm
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_1 1 Tf
-0.018 Tc -0.012 Tw -3.375 -1.494 Td
[(Ada)-10.2 (grasib is an irreversible inhibitor of KR)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.651 0 Td
[(AS G12C and belongs to the RAS GTP)17.7 (ase family)54.8 (.)19 ( )]TJ
-0.011 Tc 0.029 Tw -14.651 -1.044 Td
(The molecular formula is C)Tj
0.011 Tw 5.6 0 0 5.6 114.1139 706.1981 Tm
(32)Tj
0 Tc 0 Tw 8 0 0 8 119.3636 706.9381 Tm
(H)Tj
-0.011 Tc 0.011 Tw 5.6 0 0 5.6 123.5694 706.1981 Tm
(35)Tj
8 0 0 8 128.819 706.9381 Tm
(C1FN)Tj
0 Tc 0 Tw 5.6 0 0 5.6 144.4502 706.1981 Tm
(7)Tj
8 0 0 8 147.075 706.9381 Tm
(O)Tj
5.6 0 0 5.6 151.4328 706.1981 Tm
(2)Tj
-0.011 Tc 0.029 Tw 8 0 0 8 154.0577 706.9381 Tm
[( and the molecular weight is 604.1 g/mol.)37.3 ( )36.6 (The)-11 ( )]TJ
-0.005 Tc 0.059 Tw -14.757 -1.044 Td
(chemical name is {\(2)Tj
/T1_2 1 Tf
0 Tc 0 Tw 7.726 0 Td
(S)Tj
/T1_1 1 Tf
-0.005 Tc 0.005 Tw 0.575 0 Td
[(\)-4-[7-\(8-chlorona)-9.6 (phthalen-1-yl\)-2-{[\(2)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 14.193 0 Td
(S)Tj
/T1_1 1 Tf
-0.005 Tc 0.005 Tw 0.575 0 Td
(\)-1-methylpyrrolidin-2-)Tj
0 Tc 0 Tw -23.069 -1.044 Td
(yl]-methoxy}-5,6,7,8-tetrahydropyrido[3,4-)Tj
/T1_2 1 Tf
15.76 0 Td
(d)Tj
/T1_1 1 Tf
0.563 0 Td
[(]pyrimidin-4-yl]-1-\(2-\037uoroprop-2-eno)-10.2 (yl\))]TJ
-0.017 Tc -16.324 -1.044 Td
[(piperazin-2-yl}acetonitrile.)37.2 ( )37.2 (Ada)-9.8 (grasib has the follo)-9.8 (wing chemical structure:)]TJ
ET
/PlacedGraphic /MC0 BDC 
EMC 
q
118.566 591.685 86.868 74.79 re
W n
0.39 w 
/GS0 gs
q 1 0 0 1 135.5833 620.1039 cm
0 0 m
-3.59 -2.283 l
-3.59 -10.696 l
3.026 -14.903 l
6.187 -12.893 l
12.664 -12.217 m
16.946 -14.94 l
23.562 -10.733 l
23.562 -2.32 l
16.946 1.887 l
10.33 -2.32 l
10.33 -6.945 l
33.391 11.729 m
36.794 13.894 l
36.794 22.307 l
33.391 24.471 l
27.068 24.537 m
23.562 22.307 l
23.562 13.894 l
27.039 11.683 l
16.946 26.514 m
12.441 23.65 l
46.222 -13.15 m
50.026 -10.731 l
36.794 -5.762 m
36.794 -10.948 l
40.834 -13.3 l
61.193 -23.255 m
65.458 -24.256 l
69.614 -17.075 l
64.602 -10.858 l
57.348 -14.197 l
57.706 -19.799 l
30.146 6.63 m
30.146 1.889 l
41.141 35.728 m
36.967 38.382 l
30.003 33.954 l
30.003 29.156 l
36.075 46.34 m
36.075 37.883 l
37.851 46.371 m
37.851 37.914 l
26.394 37.234 m
30.92 34.537 l
25.51 35.517 m
30.036 32.82 l
-16.822 -2.283 m
-16.822 -10.696 l
-10.206 -14.903 l
-3.59 -10.696 l
-3.59 -2.283 l
-10.206 1.924 l
-16.822 -2.283 l
h
-10.613 0.456 m
-4.942 -2.981 l
-15.655 -2.981 m
-15.655 -9.798 l
-10.206 -14.903 m
-10.206 -23.316 l
-3.59 -27.523 l
3.026 -23.316 l
3.026 -14.903 l
-3.59 -10.696 l
-10.206 -14.903 l
h
-3.801 -12.456 m
1.87 -15.893 l
-8.946 -16.101 m
-8.946 -22.918 l
1.609 -22.41 m
-3.747 -25.79 l
32.674 -13.56 m
36.786 -10.945 l
33.827 -0.431 m
30.178 1.889 l
23.562 -2.317 l
23.562 -10.731 l
26.963 -12.893 l
29.831 0.456 m
33.236 -1.608 l
24.79 -2.981 m
24.79 -9.798 l
35.345 -9.798 m
32.31 -11.714 l
18.812 26.237 m
17.754 24.517 l
19.985 25.262 m
19.155 23.91 l
21.157 24.283 m
20.557 23.307 l
22.328 23.303 m
21.961 22.706 l
52.558 -10.24 m
51.367 -11.871 l
53.65 -11.305 m
52.714 -12.587 l
54.74 -12.374 m
54.064 -13.3 l
55.829 -13.445 m
55.415 -14.012 l
51.28 -27.292 m
55.084 -24.873 l
S
Q
Q
BT
/GS0 gs
/T1_3 1 Tf
0 Tc 8.32 0 0 8.32 156.227 655.5046 Tm
(O)Tj
2.477 -6.31 Td
(O)Tj
0.058 5.794 Td
(F)Tj
-0.892 -4.338 Td
(N)Tj
-0.811 1.492 Td
(N)Tj
3.362 -4.085 Td
(N)Tj
-3.38 0.973 Td
(N)Tj
-2.468 0.527 Td
(N)Tj
2.489 4.4 Td
(N)Tj
-3.077 -0.382 Td
(NC)Tj
-0.181 -2.471 Td
(CI)Tj
/GS1 gs
/T1_1 1 Tf
-0.02 Tc -0.012 Tw 8 0 0 8 36 571.4278 Tm
[(Ada)-9.6 (gr)0.5 (asib is )0.5 (a cr)-17.5 (ystalline)0.5 ( solid.)37.5 ( )37.4 (The solu)0.5 (bility o)0.5 (f ada)-9.5 (grasib )0.5 (in the )0.5 (aqueous )0.5 (media)0.5 ( decre)0.5 (ases)-20 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(over the range pH 1.2 to 7.4 from >262 mg/mL to < 0.010 mg/mL.)Tj
-0.005 Tc 0.062 Tw 0 -1.584 Td
[(KRAZA)54.8 (TI \(ada)-10.2 (grasib\) tablets for oral administra)-10.2 (tion contain 200 mg of ada)-10.2 (grasib.)36.7 ( )36.6 (The)-5 ( )]TJ
-0.004 Tc 0.068 Tw 0 -1.044 Td
[(follo)-10.3 (wing are inactive ingredients:)36.8 ( colloidal silicon dioxide,)36.7 ( crospovidone,)36.7 ( ma)-10.2 (gnesium)-4 ( )]TJ
0.066 Tw 0 -1.044 Td
[(steara)-10 (te \(vegetable sourced\),)37 ( mannitol,)37 ( and microcr)-18 (ystalline cellulose.)37 ( )37 (The tablet \036lm)-4 ( )]TJ
0.001 Tc 0.09 Tw 0 -1.044 Td
[(coa)-9.8 (ting contains hypromellose,)37.2 ( maltodextrin,)37.2 ( medium chain triglycerides \(vegetable)1 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(sourced\),)37.2 ( polydextrose,)37.2 ( talc,)37.2 ( and titanium dioxide.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.846 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18.3 (AL PHARMACOLOGY)]TJ
0.017 Tw -3.375 -1.693 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_1 1 Tf
-0.009 Tc 0.039 Tw -3.375 -1.494 Td
[(Ada)-9.7 (grasib is an irreversible inhibitor of K)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.833 0 Td
[(RAS G1)40.3 (2C tha)-9.7 (t covalently binds to the mutant)-9 ( )]TJ
-0.001 Tc 0.081 Tw -14.833 -1.044 Td
[(c)20 (ysteine in KR)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.388 0 Td
[(AS G1)40 (2C and locks the mutant KR)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.003 0 Td
[(AS protein in its inactive sta)-10 (te tha)-10 (t)-1 ( )]TJ
0.082 Tw -18.391 -1.044 Td
[(prevents do)-10.2 (wnstream signaling without affecting wild-type KR)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
23.44 0 Td
[(AS protein.)36.8 ( )37 (Ada)-10.1 (grasib)-1 ( )]TJ
-0.005 Tc 0.061 Tw -23.44 -1.044 Td
[(inhibited tumor cell gro)-10 (wth and viability in cells harboring )]TJ
/T1_2 1 Tf
0.005 Tw (KRAS)Tj
/T1_1 1 Tf
0.061 Tw [( G1)40 (2C muta)-10 (tions and)-5.1 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.044 Td
(resulted in tumor regression in )Tj
/T1_2 1 Tf
0.02 Tw (KRAS)Tj
/T1_1 1 Tf
-0.012 Tw [( G1)39.8 (2C-muta)-10.2 (ted tumor xenograft models with minimal)-20 ( )]TJ
-0.004 Tc 0.069 Tw 0 -1.044 Td
[(off-target )0.5 (activity)54.6 (.)36.5 ( )37.5 (Ada)-10.4 (grasib )0.5 (in )0.5 (combina)-10.4 (tion )0.5 (with )0.5 (cetuximab )0.5 (had )0.5 (increased )0.5 (antitumor)-4 ( )]TJ
-0.003 Tc 0.07 Tw 0 -1.044 Td
[(activity in some cell line-derived and pa)-9.9 (tient-derived )]TJ
/T1_2 1 Tf
0.003 Tw (KRAS)Tj
/T1_1 1 Tf
0.07 Tw [( G1)40.1 (2C-mutant CRC tumor)-3 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(xenograft models compared to ada)-9.8 (grasib or cetuximab alone.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.783 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
/T1_1 1 Tf
-0.007 Tc 0.053 Tw -3.375 -1.494 Td
[(Ada)-10.3 (grasib exposure-response rela)-10.3 (tionships and the time course of pharmacod)-10.4 (ynamic)-6.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(response are unkno)-9.8 (wn.)]TJ
0 -1.626 Td
[(Cardiac Electrophysiolog)-9.8 (y)]TJ
0.018 Tc 0.176 Tw 0 -1.539 Td
[(Ada)-10 (grasib increased QTc in a concentra)-10 (tion-dependent manner)73.9 (.)37 ( Based on the)18 ( )]TJ
-0.016 Tc 0.012 Tw 0 -1.044 Td
[(concentra)-10.4 (tion-QTcF rela)-10.3 (tionship,)36.6 ( the mean \(90% CI\) QTcF change from baseline \(\032QTcF\))-16 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.044 Td
[(was 18 \(15,)37.2 ( 21\) ms a)-9.8 (t the mean stead)-9.7 (y-sta)-9.8 (te maximum concentra)-9.8 (tion \(C)]TJ
0.02 Tw 5.6 0 0 5.6 238.9943 340.8838 Tm
(max)Tj
-0.012 Tw 8 0 0 8 247.4578 341.6237 Tm
[(,ss\) in pa)-9.8 (tients)-20 ( )]TJ
-0.019 Tc -26.432 -1.044 Td
[(after administra)-9.9 (tion of ada)-9.9 (grasib 600 mg twice daily )]TJ
/T1_2 1 Tf
[([see )37.1 (W)18.1 (arnings and Precautio)]TJ
(ns \(5.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -0 -1.783 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_1 1 Tf
-0.015 Tc 0.012 Tw -3.375 -1.494 Td
[(The pharmacokinetics of ada)-9.8 (grasib were studied in healthy subjects and in pa)-9.8 (tients with)-15 ( )]TJ
/T1_2 1 Tf
-0.011 Tc 0.011 Tw 0 -1.044 Td
(KRAS)Tj
/T1_1 1 Tf
0.032 Tw [( G12C-muta)-10.1 (ted NSCLC or CRC.)36.8 ( )37.1 (Ada)-10.1 (grasib pharmacokinetic da)-10.1 (ta are presented as)-11 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(mean \(percent coef\036cient of varia)-9.7 (tion\) unless otherwise speci\036ed.)]TJ
-0.012 Tc 0.026 Tw 0 -1.584 Td
[(Ada)-10 (grasib )36.9 (AUC and C)]TJ
0.012 Tw 5.6 0 0 5.6 97.2356 276.924 Tm
(max)Tj
0.026 Tw 8 0 0 8 105.8373 277.664 Tm
[( increase dose proportionally over the dose range of 400 mg to)-12 ( )]TJ
-0.015 Tc 0.013 Tw -8.73 -1.044 Td
[(600 mg \(0.67 to 1 times the a)-10.3 (pproved recommended dose\).)36.7 ( )37.2 (Ada)-10.3 (grasib stead)-10.3 (y-sta)-10.3 (te was)-15 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.044 Td
[(reached within 8 days follo)-10.3 (wing administra)-10.3 (tion of the a)-10.3 (pproved recommended dosa)-10.4 (ge and)-21 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(accumula)-9.8 (tion was a)-9.8 (pproxima)-9.8 (tely 6-fold.)]TJ
0.017 Tw 0 -1.626 Td
(Absorption)Tj
0 Tw 0 -1.539 Td
[(The median \(min,)37.1 ( max\) )37.2 (T)]TJ
0.017 Tw 5.6 0 0 5.6 105.9699 226.5392 Tm
(max)Tj
0 Tw 8 0 0 8 114.4839 227.2792 Tm
[( of ada)-9.8 (grasib is a)-9.8 (pproxima)-9.8 (tely 6 \(6,)37.2 ( 12\) hours.)]TJ
/T1_2 1 Tf
-9.81 -1.626 Td
[(Effect of F)20.2 (ood)]TJ
/T1_1 1 Tf
-0.013 Tc 0.021 Tw 0 -1.449 Td
[(No c)20.1 (linically signi\036cant differences in the pharmacokinetics of ada)-10 (grasib were obser)-18 (ved)-13 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.044 Td
[(follo)-9.7 (wing administra)-9.8 (tion of a high-fa)-9.8 (t and high-calorie meal \(containing a)-9.8 (pproxima)-9.8 (tely 900)-20 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(to 1000 calories,)37.2 ( 50% from fa)-9.8 (t\).)]TJ
0.017 Tw 0 -1.626 Td
(Distribution)Tj
-0.014 Tc 0.018 Tw 0 -1.539 Td
[(The a)-10.3 (pparent volume of distribution of ada)-10.3 (grasib is 942 L \(57%\).)36.6 ( Human plasma protein)-14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(binding of ada)-9.8 (grasib is a)-9.8 (pproxima)-9.8 (tely 98% in vitro.)]TJ
0.017 Tw 0 -1.626 Td
[(Elimina)-9.7 (tion)]TJ
-0.003 Tc 0.072 Tw 0 -1.539 Td
[(The ada)-10.1 (grasib terminal elimina)-10.1 (tion half-life is 23 hours \(16%\) and the a)-10.2 (pparent oral)-3 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(c)20.2 (learance \(CL/F\) is 37 L/h \(54%\) in pa)-9.8 (tients.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.626 Td
(Metabolism)Tj
/T1_1 1 Tf
0 Tc 0.085 Tw 0 -1.449 Td
[(Ada)-9.8 (grasib is metabolized primarily by CYP3A4 follo)-9.8 (wing single dose administra)-9.8 (tion.)37 ( )]TJ
-0.014 Tc 0.018 Tw 0 -1.044 Td
[(Ada)-10.3 (grasib inhibits its o)-10.3 (wn CYP3A4 metabolism follo)-10.3 (wing multiple dosing to stead)-10.3 (y-sta)-10.2 (te)-14 ( )]TJ
0 Tc 0.087 Tw 0 -1.044 Td
[(which permits CYP2C8,)36.8 ( CYP1A2,)36.8 ( CYP2B6,)36.9 ( CYP2C9,)36.9 ( and CYP2D6 to contribute to its )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(metabolism a)-9.7 (t stead)-9.8 (y-sta)-9.8 (te.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.626 Td
(Excretion)Tj
/T1_1 1 Tf
-0.021 Tc -0.012 Tw 0 -1.449 Td
[(F)20.3 (ollo)-9.7 (wing a single oral dose of radiolabeled ada)-9.7 (grasib,)37.2 ( a)-9.7 (pproxima)-9.7 (tely 75% of the dose was)-21 ( )]TJ
-0.017 Tc -0.003 Tw 0 -1.044 Td
[(recovered in )0.5 (feces \(14% as unchanged\) and 4.5% recovered in )0.5 (urine \(2% )0.5 (as unchanged\).)]TJ
ET
q 1 0 0 1 324 726.248 cm
0 0 m
56.994 0 l
S
Q
q 1 0 0 1 324 658.6599 cm
0 0 m
68.066 0 l
S
Q
BT
0 Tw 8 0 0 8 324 727.248 Tm
[(Speci\036c P)18.3 (opula)-9.8 (tions)]TJ
-0.01 Tc 0.037 Tw 0 -1.548 Td
[(No c)19.8 (linically signi\036cant differences in the pharmacokinetics of ada)-10.2 (grasib based on a)-10.2 (ge)-10 ( )]TJ
-0.003 Tc 0.073 Tw 0 -1.053 Td
[(\(19 to 89 years\),)36.6 ( sex,)36.6 ( race \(White,)36.6 ( Black or )36.7 (African )36.7 (American,)36.7 ( or )36.7 (Asian\),)36.6 ( bod)-10.4 (y weight)-3 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.01 Tw -31.5 -1.053 Td
[(\(36 to 146 kg\),)37.2 ( ECOG PS \(0,)37.2 ( 1\),)37.2 ( tumor type \(NSCLC or CRC\),)37.2 ( or tumor burden.)37.2 ( No c)20.2 (linically)-16.9 ( )]TJ
0.001 Tw 0 -1.053 Td
[(signi\036cant differences in the pharmacokinetics of ada)-9.8 (grasib are expected in pa)-9.8 (tients with)-17 ( )]TJ
-0.011 Tc 0.034 Tw 0 -1.053 Td
[(mild )0.5 (to )0.5 (severe )0.5 (renal )0.5 (impairment )0.6 (\(CLcr )0.5 (15 )0.5 (to )0.5 (<90 )0.5 (mL/min )0.5 (estima)-10.4 (ted )0.5 (by )0.5 (Cockcroft-Gault)-11 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.053 Td
[(equa)-10.1 (tion\) or in pa)-10.2 (tients with mild to severe hepa)-10.2 (tic impairment \(Child-Pugh c)19.8 (lasses )36.9 (A to C\).)]TJ
-0.017 Tc 0 Tw 0 -1.634 Td
(Drug Interaction Studies)Tj
/T1_2 1 Tf
0 -1.589 Td
[(Clinical Studies and Model-Informed )37.2 (A)-9.8 (pproaches)]TJ
/T1_1 1 Tf
0.002 Tc 0.093 Tw 0 -1.458 Td
[(Th)0.5 (e f)0.5 (ol)0.5 (lo)-9.5 (win)0.5 (g t)0.5 (ab)0.5 (le des)0.5 (cr)0.5 (ibe)0.5 (s t)0.5 (he)0.5 ( ef)0.5 (fe)0.5 (ct)0.5 ( of)0.5 ( ot)0.5 (he)0.5 (r d)0.5 (ru)0.5 (gs o)0.5 (n t)0.5 (he)0.5 ( ph)0.5 (arm)0.5 (ac)0.5 (ok)0.5 (in)0.5 (eti)0.5 (cs)0.5 ( of)2 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.053 Td
[(ada)-9.8 (grasib.)]TJ
ET
/GS2 gs
q 1 0 0 1 407.52 586.2942 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 463.68 586.5442 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 407.52 565.1323 cm
0 0 m
0 21.162 l
S
Q
1 w 
q 1 0 0 1 324 607.7061 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 407.52 607.7061 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 463.68 607.7061 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 607.7061 cm
0 0 m
56.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324 564.8823 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 463.43 586.2942 cm
0 0 m
56.41 0 l
S
Q
q 1 0 0 1 463.68 565.1323 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 407.52 543.7203 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 463.68 543.7203 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 407.52 522.5584 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 463.68 522.5584 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 407.52 564.8823 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 463.68 564.8823 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 407.27 543.4703 cm
0 0 m
56.41 0 l
S
Q
q 1 0 0 1 463.68 543.4703 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 586.2942 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 565.1323 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 519.84 564.8823 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 543.7203 cm
0 0 m
0 20.912 l
S
Q
q 1 0 0 1 519.84 543.4703 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 522.5584 cm
0 0 m
0 20.662 l
S
Q
1 w 
q 1 0 0 1 324 522.0584 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 407.52 522.0584 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 463.68 522.0584 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 522.0584 cm
0 0 m
56.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324 500.6465 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 407.52 500.6465 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 463.68 500.6465 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.84 500.6465 cm
0 0 m
56.16 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
0.048 Tw 8 0 0 8 324 611.306 Tm
[(T)74.2 (able 7:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Effect of Other Drugs on Adagrasib)Tj
-0.012 Tc 7.6 0 0 8 336.997 583.4382 Tm
(Concomitant Drug)Tj
0.012 Tw 11.005 0.531 Td
(Adagrasib)Tj
0 Tc 0 Tw 7.6 0 0 8 450.5619 587.6882 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 424.6523 579.1882 Tm
(Dosage)Tj
0.048 Tw 7.406 2.401 Td
(Changes in C)Tj
0.012 Tw 5.32 0 0 5.6 519.9359 597.6541 Tm
(max)Tj
0.048 Tw 7.6 0 0 8 528.7903 598.3941 Tm
( or AUC of)Tj
0.012 Tw -3.13 -1.062 Td
(Adagrasib)Tj
0 Tc 0 Tw -2.592 -1.614 Td
(C)Tj
-0.012 Tc 0.012 Tw 5.32 0 0 5.6 489.2945 576.2422 Tm
(max)Tj
0 Tc 0 Tw 7.6 0 0 8 498.2139 576.9822 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 474.1276 568.4822 Tm
(% Decrease)Tj
0.012 Tw 8.923 1.062 Td
(AUC)Tj
0.048 Tw -1.517 -1.062 Td
(% Decrease)Tj
/T1_1 1 Tf
0.012 Tw -23.524 -2.952 Td
(Rifampin)Tj
0 Tc 0 Tw 7.6 0 0 8 375.8917 544.8643 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 329.3997 536.3643 Tm
(\(a strong CYP3A inducer\))Tj
12.548 2.401 Td
(600 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 446.4375 555.5703 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 419.9862 547.0703 Tm
(single dose)Tj
0.012 Tw 8.597 0.531 Td
(88%)Tj
7.406 0 Td
(95%)Tj
0.048 Tw -15.374 -2.145 Td
(600 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 446.4375 534.1584 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 415.6224 525.6584 Tm
(multiple doses)Tj
0.012 Tw 8.707 0.531 Td
[(>61%*)-12 (\033)]TJ
7.406 0 Td
[(>66%*)-12 (\033)]TJ
0 Tc 0 Tw -28.169 -2.145 Td
(C)Tj
-0.025 Tc 0.025 Tw 5.32 0 0 5.6 327.7518 512.0065 Tm
(max)Tj
0.036 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 335.7101 512.7465 Tm
( )Tj
EMC 
0.1 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.674 0 Td
[(maximum plasma concentra)-9.6 (tion; )37.4 (AUC)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.244 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.674 0 Td
[(area under the plasma concentra)-9.7 (tion-time cur)-17.6 (ve)]TJ
-0.017 Tc 0.048 Tw -16.233 -1.062 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.658 0 Td
(Predicted changes in C)Tj
0.017 Tw 5.32 0 0 5.6 391.7868 503.5065 Tm
(max)Tj
0.048 Tw 7.6 0 0 8 399.8751 504.2465 Tm
[( or )37.3 (AUC of ada)-9.8 (grasib.)]TJ
/T1_2 1 Tf
-0.005 Tc 0.063 Tw 8 0 0 8 324.0001 484.811 Tm
(Strong CYP3A Inhibitors:)Tj
/T1_1 1 Tf
-0.198 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
[( )-224.2 (Ada)-10.4 (grasib )-261.2 (C)]TJ
0.005 Tw 5.6 0 0 5.6 434.1711 484.071 Tm
(max)Tj
0.063 Tw 8 0 0 8 442.8963 484.811 Tm
[( increased by 2.4-fold and )36.8 (AUC increased by)-5 ( )]TJ
-0.009 Tc 0.038 Tw -14.862 -1.053 Td
[(4)0.5 (-)0.5 (f)0.5 (o)0.5 (ld)0.5 ( f)0.5 (o)0.5 (ll)0.5 (o)-9.5 (w)0.5 (i)0.5 (n)0.5 (g c)0.5 (o)0.5 (n)0.5 (co)0.5 (m)0.5 (i)0.5 (t)0.5 (a)0.5 (n)0.5 (t)0.5 ( u)0.5 (s)0.5 (e)0.5 ( o)0.5 (f a)0.5 ( si)0.5 (n)0.5 (g)0.5 (l)0.5 (e)0.5 ( d)0.5 (o)0.5 (s)0.5 (e)0.5 ( of)0.5 ( 2)0.5 (0)0.5 (0)0.5 ( m)0.5 (g)0.5 ( \(0)0.5 (.)0.5 (3)0.5 (3)0.5 ( t)0.5 (i)0.5 (m)0.5 (e)0.5 (s)0.5 ( th)0.5 (e)0.5 ( a)-9.5 (p)0.5 (pr)0.5 (o)0.5 (v)0.5 (e)0.5 (d)-9 ( )]TJ
-0.014 Tc 0.013 Tw 0 -1.053 Td
[(r)0.5 (e)0.5 (c)0.6 (o)0.5 (m)0.5 (m)0.5 (e)0.5 (n)0.5 (d)0.5 (e)0.6 (d)0.5 ( d)0.5 (o)0.5 (s)0.5 (e)0.5 (\))0.5 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 ( i)0.6 (t)0.5 (r)0.5 (a)0.5 (c)0.5 (o)0.5 (n)0.5 (a)0.6 (z)0.5 (o)0.5 (l)0.5 (e)0.5 ( \()0.5 (a)0.5 ( s)0.5 (t)0.5 (r)0.6 (o)0.5 (n)0.5 (g)0.5 ( C)0.5 (Y)0.5 (P)0.5 (3)0.5 (A)0.6 ( i)0.5 (n)0.6 (h)0.5 (i)0.5 (b)0.5 (i)0.5 (t)0.5 (o)0.5 (r)0.6 (\).)37.6 ( N)0.5 (o)0.6 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.5 (c)0.5 (a)0.5 (l)0.5 (l)0.6 (y)0.5 ( s)0.5 (i)0.6 (g)0.5 (n)0.5 (i)0.5 (\036)0.5 (c)0.5 (a)0.5 (n)0.5 (t)-14 ( )]TJ
-0.009 Tc 0.043 Tw 0 -1.053 Td
[(differences in the pharmacokinetics of ada)-10.2 (grasib a)-10.2 (t stead)-10.3 (y sta)-10.3 (te were predicted when)-9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.053 Td
(used concomitantly with itraconazole.)Tj
-0.013 Tc 0.018 Tw 0 -1.593 Td
[(N)0.5 (o)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.5 (c)0.5 (a)0.5 (l)0.6 (l)0.5 (y)0.5 ( s)0.5 (i)0.6 (gn)0.6 (i)0.5 (\036)0.5 (c)0.5 (a)0.5 (n)0.5 (t)0.5 ( d)0.5 (i)0.5 (f)0.5 (f)0.5 (e)0.6 (r)0.5 (e)0.5 (n)0.5 (c)0.5 (e)0.5 (s)0.5 ( i)0.5 (n)0.5 ( t)0.5 (h)0.5 (e)0.5 ( p)0.6 (h)0.5 (a)0.5 (r)0.5 (m)0.5 (a)0.5 (c)0.6 (o)0.5 (k)0.5 (i)0.5 (n)0.5 (e)0.5 (t)0.5 (i)0.6 (c)0.5 (s)0.5 ( o)0.6 (f)0.5 ( a)0.5 (d)0.6 (a)-9.5 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.6 ( p)0.5 (r)0.5 (e)0.5 (d)0.6 (i)0.5 (c)0.5 (t)0.5 (e)0.5 (d)-13 ( )]TJ
0.003 Tc 0.1 Tw 0 -1.053 Td
[(or obser)-17.9 (ved when used concomitantly with efa)-9.8 (virenz \(a modera)-9.8 (te CYP3A inducer\),)40 ( )]TJ
-0.017 Tc 0 Tw 0 -1.053 Td
[(pantoprazole \(a proton pump inhibitor\),)37.2 ( or rosuvasta)-9.8 (tin \(a BCRP/OA)55.2 (TP substra)-9.8 (te\).)]TJ
0.007 Tc 0.12 Tw 0 -1.593 Td
[(The follo)-9.7 (wing )0.5 (table describes the effect of ada)-9.8 (grasib on the pharmacokinetics of)7 ( )]TJ
-0.017 Tc 0 Tw 0 -1.053 Td
(other drugs.)Tj
ET
/GS2 gs
q 1 0 0 1 411.8401 368.2826 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 463.6801 368.5326 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 411.8401 355.6206 cm
0 0 m
0 12.662 l
S
Q
1 w 
q 1 0 0 1 324.0001 381.1945 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 411.8401 381.1945 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 381.1945 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 381.1945 cm
0 0 m
56.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324.0001 355.3706 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 324.0001 316.8668 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 324.0001 297.6149 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 324.0001 259.1111 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 463.4301 368.2826 cm
0 0 m
56.41 0 l
S
Q
q 1 0 0 1 463.6801 355.6206 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 411.8401 336.3687 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 463.6801 336.3687 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 411.8401 317.1168 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 463.6801 317.1168 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 411.8401 297.8649 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 463.6801 297.8649 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 411.8401 278.613 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 463.6801 278.613 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 411.8401 259.3611 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 463.6801 259.3611 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 411.8401 240.3591 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 463.6801 240.3591 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 411.8401 355.3706 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 355.3706 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 411.5901 336.1187 cm
0 0 m
52.09 0 l
S
Q
q 1 0 0 1 463.6801 336.1187 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 411.8401 316.8668 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 316.8668 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 411.8401 297.6149 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 297.6149 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 411.5901 278.363 cm
0 0 m
52.09 0 l
S
Q
q 1 0 0 1 463.6801 278.363 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 411.8401 259.1111 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 259.1111 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 368.2826 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 355.6206 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 519.8401 355.3706 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 336.3687 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 519.8401 336.1187 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 317.1168 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 519.8401 316.8668 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 297.8649 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 519.8401 297.6149 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 278.613 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 519.8401 278.363 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 259.3611 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 519.8401 259.1111 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 240.3591 cm
0 0 m
0 18.502 l
S
Q
1 w 
q 1 0 0 1 324.0001 239.8591 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 411.8401 239.8591 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 239.8591 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 239.8591 cm
0 0 m
56.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324.0001 209.9472 cm
0 0 m
87.84 0 l
S
Q
q 1 0 0 1 411.8401 209.9472 cm
0 0 m
51.84 0 l
S
Q
q 1 0 0 1 463.6801 209.9472 cm
0 0 m
56.16 0 l
S
Q
q 1 0 0 1 519.8401 209.9472 cm
0 0 m
56.16 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
0.048 Tw 8 0 0 8 324.0001 384.7945 Tm
[(T)74.2 (able 8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Effect of Adagrasib on Other Drugs)Tj
-0.012 Tc 7.6 0 0 8 339.1571 365.4266 Tm
(Concomitant Drug)Tj
0.012 Tw 11.005 0.531 Td
(Adagrasib)Tj
0 Tc 0 Tw 7.6 0 0 8 452.722 369.6766 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 426.8125 361.1766 Tm
(Dosage)Tj
0.048 Tw 5.475 1.338 Td
(Fold Increase of Concomitant Drug)Tj
0 Tc 0 Tw 2.221 -1.614 Td
(C)Tj
-0.012 Tc 0.012 Tw 5.32 0 0 5.6 489.2946 358.2307 Tm
(max)Tj
7.6 0 0 8 541.9401 358.9707 Tm
(AUC)Tj
/T1_1 1 Tf
-24.874 -2.682 Td
(Midazolam)Tj
0 Tc 0 Tw 7.6 0 0 8 382.6923 337.5128 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 327.5905 329.0128 Tm
[(\(a sensitive CYP3A substra)-9.8 (te\))]TJ
-0.198 Tw 12.885 2.266 Td
[(400 )-245.7 (mg)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.869 0 Td
(*)Tj
0.048 Tw -3.193 -1.062 Td
(twice daily)Tj
0.012 Tw 7.621 0.531 Td
(4.8-fold)Tj
7.52 0 Td
(21-fold)Tj
0.048 Tw -14.633 -1.875 Td
(600 mg)Tj
-0.508 -1.062 Td
(twice daily)Tj
0.012 Tw 7.444 0.531 Td
(3.1-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 501.3224 325.8008 Tm
(\206)Tj
7.6 0 0 8 503.8866 323.6368 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 4.329 0 Td
(31-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 556.7418 325.8008 Tm
(\206)Tj
7.6 0 0 8 559.306 323.6368 Tm
(\033)Tj
-0.032 Tc 0.032 Tw -26.641 -1.875 Td
[(W)18.2 (arfarin)]TJ
0 Tc 0 Tw 7.6 0 0 8 378.7563 308.6349 Tm
( )Tj
-0.032 Tc 0.048 Tw 7.6 0 0 8 327.9447 300.1349 Tm
[(\(a sensitive CYP2C9 substra)-9.8 (te\))]TJ
-0.012 Tc 13.023 1.062 Td
(600 mg)Tj
-0.508 -1.062 Td
(twice daily)Tj
0.012 Tw 7.444 0.531 Td
(1.1-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 501.3224 306.5489 Tm
(\206)Tj
7.6 0 0 8 503.8866 304.3849 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 4.215 0 Td
(2.9-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 557.6074 306.5489 Tm
(\206)Tj
7.6 0 0 8 560.1716 304.3849 Tm
(\033)Tj
-0.012 Tc 0.012 Tw -28.654 -3.078 Td
(Dextromethorphan)Tj
0.048 Tw -2.211 -1.062 Td
[(\(a sensitive CYP2D6 substra)-9.8 (te\))]TJ
13.162 2.266 Td
[(400 mg*)-12 (\033)]TJ
-0.338 -1.062 Td
(twice daily)Tj
0.012 Tw 7.621 0.531 Td
(1.9-fold)Tj
7.406 0 Td
(1.8-fold)Tj
0.048 Tw -14.519 -1.875 Td
(600 mg)Tj
-0.508 -1.062 Td
(twice daily)Tj
0.012 Tw 7.444 0.531 Td
(1.7-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 501.3224 268.0451 Tm
(\206)Tj
7.6 0 0 8 503.8866 265.8811 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 4.215 0 Td
(2.4-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 557.6074 268.0451 Tm
(\206)Tj
7.6 0 0 8 560.1716 265.8811 Tm
(\033)Tj
-0.012 Tc 0.012 Tw -26.646 -1.875 Td
(Digoxin)Tj
0 Tc 0 Tw 7.6 0 0 8 377.9288 250.8792 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 343.0745 242.3792 Tm
[(\(a P-gp substra)-9.8 (te\))]TJ
11.033 1.062 Td
(600 mg)Tj
-0.508 -1.062 Td
(twice daily)Tj
0.012 Tw 7.444 0.531 Td
(1.9-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 501.3224 248.7932 Tm
(\206)Tj
7.6 0 0 8 503.8866 246.6292 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 4.215 0 Td
(1.5-fold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 557.6074 248.7932 Tm
(\206)Tj
7.6 0 0 8 560.1716 246.6292 Tm
(\033)Tj
-31.075 -2.01 Td
(C)Tj
-0.025 Tc 0.025 Tw 5.32 0 0 5.6 327.7518 229.8073 Tm
(max)Tj
0.036 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 335.7101 230.5473 Tm
( )Tj
EMC 
0.1 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.674 0 Td
[(maximum plasma concentra)-9.6 (tion; )37.4 (AUC)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.244 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.674 0 Td
[(area under the plasma concentra)-9.7 (tion-time cur)-17.6 (ve)]TJ
-0.017 Tc 0.048 Tw -16.233 -1.062 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.658 0 Td
[(0.66 times the a)-9.8 (pproved recommended dosa)-9.8 (ge.)]TJ
0 Tc 0 Tw 5.32 0 0 5.6 324.0001 215.7113 Tm
(\206)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 326.4728 213.5473 Tm
( )Tj
EMC 
0.333 0 Td
(Predicted changes in C)Tj
0.017 Tw 5.32 0 0 5.6 391.7868 212.8073 Tm
(max)Tj
0.048 Tw 7.6 0 0 8 399.8751 213.5473 Tm
[( or )37.3 (AUC of concomitant drug.)]TJ
/T1_2 1 Tf
-0.037 Tw 8 0 0 8 324.0001 193.7819 Tm
[(In Vitro )-36.8 (Studies)]TJ
0 Tw 0 -1.458 Td
(Cytochrome P450 \(CYP\) Enzymes:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.05 0 Td
[( )37.2 (Ada)-9.8 (grasib may inhibit CYP2B6.)]TJ
/T1_2 1 Tf
-0.008 Tc 0.043 Tw -12.05 -1.593 Td
[(T)74.5 (r)0.5 (a)0.5 (n)0.6 (s)0.5 (p)0.5 (o)0.5 (r)0.5 (t)0.5 (e)0.6 (r)0.5 ( S)0.5 (y)0.5 (s)0.6 (t)0.5 (e)0.5 (m)0.5 (s)0.5 (:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
7.699 0 Td
( )Tj
EMC 
0.033 0 Td
[( )37 (A)0.5 (d)0.5 (a)-9.4 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.6 ( m)0.5 (a)0.5 (y)0.6 ( b)0.5 (e)0.5 ( a)0.5 ( s)0.5 (u)0.5 (b)0.6 (s)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.6 (e)0.5 ( o)0.5 (f)0.6 ( B)0.5 (C)0.5 (R)0.5 (P)0.5 ( a)0.5 (n)0.5 (d)0.5 ( m)0.5 (a)0.5 (y)0.5 ( i)0.5 (n)0.5 (h)0.5 (i)0.5 (b)0.5 (i)0.5 (t)0.6 ( M)0.5 (A)55.5 (T)0.5 (E)0.5 (-)0.6 (1)0.5 (/)]TJ
0 Tc 0 Tw 23.768 0 Td
( )Tj
-0.017 Tc 0.017 Tw -31.5 -1.053 Td
[(MA)55.2 (TE-2K.)]TJ
/T1_0 1 Tf
0 -1.854 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
0.017 Tw -3.375 -1.702 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Carcinogenesis,)37.2 ( Mutagenesis,)37.2 ( Impairment of F)20.2 (ertility)]TJ
/T1_1 1 Tf
-3.375 -1.503 Td
[(Carcinogenicity studies ha)-9.8 (ve not been conducted with ada)-9.8 (grasib.)]TJ
-0.014 Tc 0.017 Tw 0 -1.593 Td
[(Ada)-10.2 (grasib was not muta)-10.2 (genic in an in vitro bacterial reverse muta)-10.2 (tion \(Ames\) assay and)-14 ( )]TJ
-0.017 Tc -0.003 Tw 0 -1.053 Td
[(was not genotoxic in an in vitro chromosomal aberra)-9.8 (tion assay or an in vivo micronuc)20.2 (leus)-17 ( )]TJ
0 Tw 0 -1.053 Td
[(assay in ra)-9.8 (ts.)]TJ
0.004 Tc 0.108 Tw 0 -1.593 Td
[(F)23.6 (ertility studies were not conducted with ada)-10.4 (grasib.)36.6 ( In toxicolog)-10.3 (y studies of up to)4 ( )]TJ
-0.011 Tc 0.029 Tw 0 -1.053 Td
[(13-weeks in dura)-9.6 (tion in ra)-9.6 (ts,)37.4 ( oral administra)-9.6 (tion of ada)-9.6 (grasib induced phospholipidosis)-11 ( )]TJ
-0.001 Tc 0.079 Tw 0 -1.053 Td
[(which increased vacuola)-9.7 (tion in female reproductive organs,)37.2 ( inc)20.2 (luding vacuola)-9.7 (tion in)-1 ( )]TJ
-0.015 Tc 0.012 Tw 0 -1.053 Td
[(ovaries \(corpora lutea,)37 ( macropha)-9.9 (ge or interstitial cells\) and uterus \(glandular epithelium\),)22 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.053 Td
[(a)0.5 (nd)0.5 ( a)-9.5 (t)0.5 (ro)0.5 (ph)0.5 (y)0.5 ( w)0.5 (it)0.5 (h)0.5 ( m)0.5 (uc)0.5 (i\036)0.5 (c)0.5 (a)-9.6 (t)0.5 (io)0.5 (n )0.5 (o)0.5 (f)0.5 ( t)0.5 (he)0.5 ( )0.5 (va)-9.5 (gi)0.5 (n)0.5 (al)0.5 ( m)0.5 (u)0.5 (co)0.5 (sa)0.5 ( a)-9.5 (t)0.5 ( )0.5 (do)0.5 (se)0.5 (s )0.5 (\035)0.5 (15)0.5 (0 )0.5 (m)0.5 (g/)0.5 (kg)0.5 ( \()0.5 (a)-9.5 (pp)0.5 (ro)0.5 (xi)0.5 (m)0.5 (a)-9.6 (t)0.5 (e)0.5 (ly)-18 ( )]TJ
-0.011 Tc 0.032 Tw 0 -1.053 Td
[(equal to or grea)-10.2 (ter than the human exposure a)-10.2 (t the recommended dose based on area)-11 ( )]TJ
ET
endstreamendobj26 0 obj<</Metadata 76 0 R>>endobj76 0 obj<</Length 37523/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:stFnt="http://ns.adobe.com/xap/1.0/sType/Font#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <dc:format>application/postscript</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">KRAZATI Chemical Structure</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>(Steve Burgos)</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <xmp:MetadataDate>2024-04-01T08:03:56-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-04-01T08:03:56-04:00</xmp:ModifyDate>
         <xmp:CreateDate>2024-04-01T08:03:56-04:00</xmp:CreateDate>
         <xmp:CreatorTool>Adobe Illustrator 28.3 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>xmp.iid:512d01fe-be97-4642-b445-e3a8da911d83</xmpMM:InstanceID>
         <xmpMM:DocumentID>xmp.did:512d01fe-be97-4642-b445-e3a8da911d83</xmpMM:DocumentID>
         <xmpMM:OriginalDocumentID>uuid:5D20892493BFDB11914A8590D31508C8</xmpMM:OriginalDocumentID>
         <xmpMM:RenditionClass>default</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:25d8ef9e-efcf-3744-9518-d90891d363b1</stRef:instanceID>
            <stRef:documentID>xmp.did:1f0ce348-4f36-4d74-a7aa-dfc9c7a2d122</stRef:documentID>
            <stRef:originalDocumentID>uuid:5D20892493BFDB11914A8590D31508C8</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:1f0ce348-4f36-4d74-a7aa-dfc9c7a2d122</stEvt:instanceID>
                  <stEvt:when>2024-03-29T15:43:07-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 28.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:512d01fe-be97-4642-b445-e3a8da911d83</stEvt:instanceID>
                  <stEvt:when>2024-04-01T08:03:56-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 28.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Print</illustrator:StartupProfile>
         <illustrator:CreatorSubTool>Adobe Illustrator</illustrator:CreatorSubTool>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>8.500000</stDim:w>
            <stDim:h>11.000000</stDim:h>
            <stDim:unit>Inches</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:Fonts>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <stFnt:fontName>HelveticaNeueLTStd-BdCn</stFnt:fontName>
                  <stFnt:fontFamily>Helvetica Neue LT Std</stFnt:fontFamily>
                  <stFnt:fontFace>77 Bold Condensed</stFnt:fontFace>
                  <stFnt:fontType>Open Type</stFnt:fontType>
                  <stFnt:versionString>Version 2.035;PS 002.000;hotconv 1.0.51;makeotf.lib2.0.18671</stFnt:versionString>
                  <stFnt:composite>False</stFnt:composite>
                  <stFnt:fontFileName>HelveticaNeueLTStd-BdCn.otf</stFnt:fontFileName>
               </rdf:li>
            </rdf:Bag>
         </xmpTPg:Fonts>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>White</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Red</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Yellow</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Green</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Cyan</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Blue</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>CMYK Magenta</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=15 M=100 Y=90 K=10</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>15.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>90.000000</xmpG:yellow>
                           <xmpG:black>10.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=90 Y=85 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>90.000000</xmpG:magenta>
                           <xmpG:yellow>85.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=80 Y=95 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>80.000000</xmpG:magenta>
                           <xmpG:yellow>95.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=50 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>50.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=35 Y=85 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>35.000000</xmpG:magenta>
                           <xmpG:yellow>85.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=5 M=0 Y=90 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>5.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>90.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=20 M=0 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>20.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=50 M=0 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>50.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=75 M=0 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>75.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=85 M=10 Y=100 K=10</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>85.000000</xmpG:cyan>
                           <xmpG:magenta>10.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>10.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=90 M=30 Y=95 K=30</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>90.000000</xmpG:cyan>
                           <xmpG:magenta>30.000000</xmpG:magenta>
                           <xmpG:yellow>95.000000</xmpG:yellow>
                           <xmpG:black>30.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=75 M=0 Y=75 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>75.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>75.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=80 M=10 Y=45 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>80.000000</xmpG:cyan>
                           <xmpG:magenta>10.000000</xmpG:magenta>
                           <xmpG:yellow>45.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=70 M=15 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>70.000000</xmpG:cyan>
                           <xmpG:magenta>15.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=85 M=50 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>85.000000</xmpG:cyan>
                           <xmpG:magenta>50.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=100 M=95 Y=5 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>95.000000</xmpG:magenta>
                           <xmpG:yellow>5.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=100 M=100 Y=25 K=25</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>25.000000</xmpG:yellow>
                           <xmpG:black>25.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=75 M=100 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>75.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=50 M=100 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>50.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=35 M=100 Y=35 K=10</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>35.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>35.000000</xmpG:yellow>
                           <xmpG:black>10.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=10 M=100 Y=50 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>10.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>50.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=95 Y=20 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>95.000000</xmpG:magenta>
                           <xmpG:yellow>20.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=25 M=25 Y=40 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>25.000000</xmpG:cyan>
                           <xmpG:magenta>25.000000</xmpG:magenta>
                           <xmpG:yellow>40.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=40 M=45 Y=50 K=5</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>40.000000</xmpG:cyan>
                           <xmpG:magenta>45.000000</xmpG:magenta>
                           <xmpG:yellow>50.000000</xmpG:yellow>
                           <xmpG:black>5.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=50 M=50 Y=60 K=25</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>50.000000</xmpG:cyan>
                           <xmpG:magenta>50.000000</xmpG:magenta>
                           <xmpG:yellow>60.000000</xmpG:yellow>
                           <xmpG:black>25.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=55 M=60 Y=65 K=40</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>55.000000</xmpG:cyan>
                           <xmpG:magenta>60.000000</xmpG:magenta>
                           <xmpG:yellow>65.000000</xmpG:yellow>
                           <xmpG:black>40.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=25 M=40 Y=65 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>25.000000</xmpG:cyan>
                           <xmpG:magenta>40.000000</xmpG:magenta>
                           <xmpG:yellow>65.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=30 M=50 Y=75 K=10</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>30.000000</xmpG:cyan>
                           <xmpG:magenta>50.000000</xmpG:magenta>
                           <xmpG:yellow>75.000000</xmpG:yellow>
                           <xmpG:black>10.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=35 M=60 Y=80 K=25</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>35.000000</xmpG:cyan>
                           <xmpG:magenta>60.000000</xmpG:magenta>
                           <xmpG:yellow>80.000000</xmpG:yellow>
                           <xmpG:black>25.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=40 M=65 Y=90 K=35</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>40.000000</xmpG:cyan>
                           <xmpG:magenta>65.000000</xmpG:magenta>
                           <xmpG:yellow>90.000000</xmpG:yellow>
                           <xmpG:black>35.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=40 M=70 Y=100 K=50</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>40.000000</xmpG:cyan>
                           <xmpG:magenta>70.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>50.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=50 M=70 Y=80 K=70</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>50.000000</xmpG:cyan>
                           <xmpG:magenta>70.000000</xmpG:magenta>
                           <xmpG:yellow>80.000000</xmpG:yellow>
                           <xmpG:black>70.000000</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Grays</xmpG:groupName>
                  <xmpG:groupType>1</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=100</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=90</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>89.999400</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=80</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>79.998800</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=70</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>69.999700</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=60</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>59.999100</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=50</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>50.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=40</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>39.999400</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=30</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>29.998800</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=20</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>19.999700</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=10</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>9.999100</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=5</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>4.998800</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Brights</xmpG:groupName>
                  <xmpG:groupType>1</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=100 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>100.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=75 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>75.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=10 Y=95 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>10.000000</xmpG:magenta>
                           <xmpG:yellow>95.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=85 M=10 Y=100 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>85.000000</xmpG:cyan>
                           <xmpG:magenta>10.000000</xmpG:magenta>
                           <xmpG:yellow>100.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=100 M=90 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>100.000000</xmpG:cyan>
                           <xmpG:magenta>90.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>0.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=60 M=90 Y=0 K=0</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>60.000000</xmpG:cyan>
                           <xmpG:magenta>90.000000</xmpG:magenta>
                           <xmpG:yellow>0.003100</xmpG:yellow>
                           <xmpG:black>0.003100</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj25 0 obj<</BaseFont/UEAMSO+HelveticaNeueLTStd-BdCn/Encoding/WinAnsiEncoding/FirstChar 67/FontDescriptor 77 0 R/LastChar 79/Subtype/Type1/Type/Font/Widths[537 0 0 463 0 0 258 0 0 0 0 574 556]>>endobj77 0 obj<</Ascent 961/CapHeight 700/CharSet(/C/F/I/N/O)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFile3 78 0 R/FontName/UEAMSO+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 500>>endobj78 0 obj<</Filter/FlateDecode/Length 694/Subtype/Type1C>>stream
H‰tMhAÇwM³Ñ4Fl›QÓ¡¬nc‘ÒŠÒ­ĞÚjRÁ…mvR·îGØl#s+©$†@¹Ø‹PĞ{TD=„xòR<UZò6œÄZt3ïıç½ÿ÷X¦é Ã²lûôhh"<Ù=†•$6å¨xÏãñHØ”ÎIÃZ½¤Ã:ÎZmMÖ	—Ç:éò’~bî¼Ü™¶[]G¬Ş£•êRc«³¼l'{~X§yö–‰ÎO£Ş`°…$}£p*ab5.kQİˆë†hb‰G!EA†2pÉº¸ïÉ	$"Ó%¬ŠÆm¤ÇĞ¸¬éf*Ñ0¥ğ´iV¦\KHÖy£i>Ì£)J×L$jŠìwOÆbr7DUL!êéïî(6L‘¾:ÅhnŞ’5e]Kü†k¢ŠÿáB7L'P(^K`üçû’:3Æ÷\GêÉ9$áØÿ6MO€ébN1=LáèB™	¦Ä¼g¾°Íldt±l}/³ô”m‹MV¦:UËpğ˜¼óAÈÛaƒ#ˆ¼ö@=©å5NhÄ0HhÎY¯<õˆÔ3÷\zÛZÙnY… Œ@€ø!Ğºeİ·TÏ{ĞMfˆ'<Q‰ºBxPü­põ9¾8Âãøõ	õ( ,W*şÖ­%¡³İJIX'\ '[†€­ì¥ğ5X 'Y bœµNÎ]JV…;ì[ú7½Uv‡ûÉ/µ>ˆÏV®
]|Væ‘Fj;ôÓJ_-ı€#CVÚîN7Ü³u÷7(iª=« ¬ *¨qà‰²7Îáâçõõbˆ„I$=Ô×—®@ÄïN«B‘\+BG‘ƒ§¹¯¹Ú›¼ãîrUX&s…ƒTÙÌÕ¾m;Áßü©PÈf³…g.×&}³ùlÖuø¡ËKmÖGÏO ±gpÆendstreamendobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 79 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 20 0 R>>/Font<</T1_0 22 0 R/T1_1 23 0 R/T1_2 24 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 474>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 80 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 21 0 R>>/Font<</T1_0 22 0 R/T1_1 81 0 R/T1_2 23 0 R/T1_3 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 573>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 82 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</T1_0 23 0 R/T1_1 24 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 678>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 83 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 21 0 R>>/Font<</T1_0 22 0 R/T1_1 81 0 R/T1_2 23 0 R/T1_3 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 730>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 84 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 21 0 R>>/Font<</T1_0 22 0 R/T1_1 23 0 R/T1_2 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 27 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00620032003300390065006400660032002D0038006400360066002D0034003700650034002D0061003100380038002D003200630034003700630037003300340032006100640066>/LastModified<FEFF0044003A00320030003200340030003700310037003100300030003200310034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 784>>/PageWidthList<</0 612.0>>>>>>>>endobj84 0 obj<</Length 23638>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 447.4816 cm
0 0 m
69.053 0 l
S
Q
q 1 0 0 1 36 391.6847 cm
0 0 m
70.706 0 l
S
Q
q 1 0 0 1 36 304.9777 cm
0 0 m
78.198 0 l
S
Q
q 1 0 0 1 36 240.6075 cm
0 0 m
82.053 0 l
S
Q
q 1 0 0 1 36 167.6638 cm
0 0 m
82.349 0 l
S
Q
q 1 0 0 1 36 94.7202 cm
0 0 m
45.681 0 l
S
Q
/GS2 gs
q 1 0 0 1 36 497.3217 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 497.3217 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 497.3217 cm
0 0 m
70.024 0 l
S
Q
1 w 
q 1 0 0 1 36 715.1481 cm
0 0 m
111.702 0 l
S
Q
0.5 w 
q 1 0 0 1 36 690.7642 cm
0 0 m
111.702 0 l
S
Q
1 w 
q 1 0 0 1 147.7016 715.1481 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 715.1481 cm
0 0 m
70.024 0 l
S
Q
0.5 w 
q 1 0 0 1 147.7016 703.2061 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 147.4516 702.9561 cm
0 0 m
70.274 0 l
S
Q
q 1 0 0 1 147.7016 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 217.7258 702.9561 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 147.7016 690.7642 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 690.7642 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 36 680.0123 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 680.0123 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 147.7016 669.2604 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 680.0123 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 669.2604 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 147.7016 658.5085 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 658.5085 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 648.0066 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 648.0066 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 36 647.7566 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 647.7566 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 647.7566 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 36 637.0046 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 637.0046 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 147.7016 626.2527 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 637.0046 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 626.2527 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 147.7016 615.5009 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 615.5009 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 604.7489 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 604.7489 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 593.997 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 593.997 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 583.2451 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 583.2451 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 572.4932 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 572.4932 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 561.7413 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 561.7413 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 550.9893 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 550.9893 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 540.2374 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 540.2374 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 529.4855 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 529.4855 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 519.2336 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.7258 519.2336 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 36 518.7336 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 518.7336 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 518.7336 cm
0 0 m
70.024 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(T)74.2 (able 6:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Selected Laborator)-17.8 (y Abnormalities \(\03625%\) in P)24.2 (atients Who Received)-17 ( )]TJ
0 Tc 0 Tw 26.383 0 Td
( )Tj
-0.017 Tc 0.048 Tw -26.383 -1.062 Td
[(Adagrasib in Combination with Cetuximab in KR)18.2 (Y)18.2 (ST)55.2 (AL-1)-17 (\037)]TJ
-0.012 Tc 7.6 0 0 8 36 700.1002 Tm
[(Laborator)-17.8 (y Abnormality)]TJ
15.513 0.762 Td
(Adagrasib in Combination with Cetuximab*)Tj
0.992 -1.524 Td
(All Grades \(%\))Tj
8.808 0 Td
(Grade 3 or 4 \(%\))Tj
0.012 Tw -25.312 -1.434 Td
[(Hematolog)-9.8 (y)]TJ
/T1_1 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(L)37.2 (ymphoc)20.2 (ytes decreased)]TJ
0.012 Tw 18.238 0 Td
(63)Tj
9.23 0 Td
(17)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.061 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Hemoglobin decreased)Tj
0.012 Tw 18.238 0 Td
(48)Tj
0 Tc 0 Tw 9.464 0 Td
(5)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Leukoc)20.2 (ytes decreased)]TJ
0.012 Tw 18.238 0 Td
(27)Tj
9.116 0 Td
(1.1)Tj
/T1_0 1 Tf
-27.947 -1.344 Td
[(Chemistr)-17.8 (y)]TJ
/T1_1 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Alanine aminotransferase increased)-12 ( )]TJ
0.012 Tw 18.238 0 Td
(51)Tj
9.116 0 Td
(2.2)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Ma)-9.8 (gnesium decreased)]TJ
0.012 Tw 18.238 0 Td
(49)Tj
0 Tc 0 Tw 9.464 0 Td
(7)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Albumin decreased)Tj
0.012 Tw 18.238 0 Td
(46)Tj
9.116 0 Td
(2.2)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Lipase increased)Tj
0.012 Tw 18.238 0 Td
(41)Tj
9.116 0 Td
(3.3)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (otassium decreased)]TJ
0.012 Tw 18.238 0 Td
(40)Tj
0 Tc 0 Tw 9.464 0 Td
(9)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Asparta)-9.8 (te aminotransferase increased)]TJ
0.012 Tw 18.238 0 Td
(39)Tj
9.116 0 Td
(4.3)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Crea)-9.8 (tinine increased)]TJ
0.012 Tw 18.238 0 Td
(30)Tj
9.116 0 Td
(1.1)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Sodium decreased)Tj
0.012 Tw 18.238 0 Td
(30)Tj
0 Tc 0 Tw 9.464 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Calcium decreased)Tj
0.012 Tw 18.238 0 Td
(29)Tj
9.116 0 Td
(1.1)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Amylase increased)Tj
0.012 Tw 18.238 0 Td
(29)Tj
0 Tc 0 Tw 9.464 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Alkaline phospha)-9.7 (tase increased)]TJ
0.012 Tw 18.238 0 Td
(29)Tj
9.116 0 Td
(1.1)Tj
-0.015 Tc 0.061 Tw -27.947 -1.479 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.335 0 Td
( )Tj
EMC 
0.323 0 Td
[(The denomina)-10.4 (tor used to calcula)-10.3 (te the ra)-10.3 (te varied from 82 to 92 based on the number of)-15 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(pa)-9.8 (tients with a baseline value and a)-9.7 (t least one post-trea)-9.8 (tment value.)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 474.7483 Tm
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
0.017 Tw -3.375 -1.72 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Effects of Other Drugs on KRAZA)55.2 (TI)]TJ
/T1_1 1 Tf
-3.375 -1.563 Td
(Strong CYP3A4 Inducers)Tj
0 -1.567 Td
[(Avoid concomitant use of KRAZA)55.2 (TI with strong CYP3A inducers.)]TJ
-0.002 Tc 0.076 Tw 0 -1.612 Td
[(Ada)-9.9 (grasib )0.5 (is )0.5 (a )0.5 (CYP3A4 )0.5 (substra)-9.9 (te.)37.1 ( )0.5 (Concomitant )0.5 (use )0.5 (of )0.5 (KRAZA)55 (TI )0.5 (with )0.5 (a )0.5 (strong )0.5 (CYP3A)-2 ( )]TJ
0 Tc 0.086 Tw 0 -1.072 Td
[(inducer reduces )0.5 (ada)-9.9 (grasib )0.5 (exposure )]TJ
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.9 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.1 ( which )0.5 (may )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(reduce the effectiveness of KRAZA)55.2 (TI.)]TJ
0 -1.653 Td
(Strong CYP3A4 Inhibitors)Tj
0.013 Tc 0.148 Tw 0 -1.567 Td
[(A)0.5 (v)0.5 (o)0.6 (i)0.5 (d)0.5 ( c)0.5 (o)0.5 (n)0.5 (c)0.6 (o)0.5 (m)0.5 (i)0.5 (t)0.6 (a)0.5 (n)0.5 (t)0.6 ( u)0.5 (s)0.5 (e)0.6 ( o)0.5 (f)0.6 ( K)0.5 (R)0.5 (A)0.5 (Z)0.6 (A)55.5 (T)0.5 (I)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.6 ( s)0.5 (t)0.5 (r)0.6 (o)0.5 (n)0.5 (g)0.5 ( C)0.5 (Y)0.5 (P)0.6 (3)0.5 (A)0.5 ( i)0.6 (n)0.5 (h)0.5 (i)0.5 (b)0.5 (i)0.6 (t)0.5 (o)0.5 (r)0.6 (s)0.5 ( u)0.5 (n)0.6 (t)0.5 (i)0.5 (l)0.5 ( a)0.5 (d)0.5 (a)-9.5 (g)0.6 (r)0.5 (a)0.5 (s)0.6 (i)0.5 (b)13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(concentra)-9.8 (tions ha)-9.8 (ve reached stead)-9.7 (y sta)-9.8 (te \(after a)-9.8 (pproxima)-9.8 (tely 8 days\).)]TJ
-0.009 Tc 0.038 Tw 0 -1.612 Td
[(A)0.5 (d)0.5 (a)-9.5 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( i)0.5 (s)0.5 ( a)0.5 ( C)0.5 (Y)0.5 (P)0.5 (3)0.5 (A)0.5 (4)0.5 ( su)0.5 (b)0.5 (s)0.5 (t)0.5 (r)0.5 (a)-9.4 (t)0.5 (e)0.5 (.)37.4 ( I)0.5 (f)0.5 ( a)0.5 (d)0.5 (a)-9.5 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( c)0.5 (o)0.5 (n)0.5 (c)0.5 (e)0.5 (n)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (s)0.5 ( h)0.5 (a)-9.5 (v)0.5 (e)0.5 ( n)0.5 (o)0.5 (t)0.5 ( r)0.5 (e)0.5 (a)0.5 (c)0.5 (h)0.5 (e)0.5 (d)0.5 ( s)0.5 (t)0.5 (e)0.5 (a)0.5 (d)-9.5 (y)-9 ( )]TJ
-0.017 Tc -0.01 Tw 0 -1.072 Td
[(sta)-9.8 (te,)37.2 ( concomitant use of a strong CYP3A inhibitor will increase ada)-9.8 (grasib concentra)-9.7 (tions,)20 ( )]TJ
/T1_2 1 Tf
-0.002 Tc 0.075 Tw 0 -1.072 Td
[([see Clinical Pharmacolog)-9.8 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.2 ( which may increase the risk of KRAZA)55.2 (TI adverse)-1.9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.072 Td
(reactions.)Tj
/T1_0 1 Tf
0 -1.81 Td
(7.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Effects of KRAZA)55.1 (TI on Other Drugs)]TJ
/T1_1 1 Tf
-3.375 -1.563 Td
[(Sensitive CYP3A Substra)-9.8 (tes)]TJ
-0.004 Tc 0.065 Tw 0 -1.567 Td
[(Avoid concomitant )0.5 (use )0.5 (of KRAZA)55.3 (TI with )0.5 (sensitive CYP3A substra)-9.7 (tes )0.5 (unless )0.5 (otherwise)-4 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(recommended in the Prescribing Informa)-9.8 (tion for these substra)-9.8 (tes.)]TJ
-0.005 Tc 0.063 Tw 0 -1.612 Td
[(Ada)-10.3 (grasib is a CYP3A inhibitor)73.7 (.)36.6 ( Concomitant use with KRAZA)54.7 (TI increases exposure of)-5 ( )]TJ
-0.004 Tc 0.064 Tw 0 -1.072 Td
[(CYP3A)0.5 ( substr)0.5 (a)-9.6 (tes )]TJ
/T1_2 1 Tf
6.834 0 Td
[([se)0.5 (e Clinic)0.5 (al Pha)0.5 (rmaco)0.5 (log)-9.6 (y )0.5 (\(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.4 ( )0.5 (which m)0.5 (ay in)0.5 (crease )0.5 (the )0.5 (risk o)0.5 (f)-4 ( )]TJ
-0.017 Tc 0 Tw -6.834 -1.072 Td
[(adverse reactions rela)-9.7 (ted to these substra)-9.7 (tes.)]TJ
0 -1.653 Td
[(Sensitive CYP2C9 Substra)-9.8 (tes)]TJ
-0.002 Tc 0.073 Tw 0 -1.567 Td
[(Av)0.5 (oi)0.5 (d co)0.5 (nc)0.5 (om)0.5 (ita)0.5 (nt)0.5 ( us)0.5 (e o)0.5 (f KR)0.5 (AZ)0.5 (A)55.4 (TI)0.5 ( wit)0.5 (h s)0.5 (en)0.5 (sit)0.5 (iv)0.5 (e CY)0.5 (P2)0.5 (C9)0.5 ( s)0.5 (ub)0.5 (str)0.5 (a)-9.6 (t)0.5 (es)0.5 ( wh)0.5 (er)0.5 (e m)0.5 (ini)0.5 (ma)0.5 (l)-2 ( )]TJ
0.014 Tc 0.153 Tw 0 -1.072 Td
[(co)0.5 (nc)0.5 (en)0.5 (tra)-9.5 (t)0.5 (ion)0.5 ( cha)0.5 (ng)0.5 (es)0.5 ( m)0.5 (ay)0.5 ( le)0.5 (ad t)0.5 (o s)0.5 (eri)0.5 (ou)0.5 (s ad)0.5 (ve)0.5 (rs)0.5 (e r)0.5 (eac)0.5 (ti)0.5 (on)0.5 (s unl)0.5 (es)0.5 (s o)0.5 (the)0.5 (rw)0.5 (is)0.5 (e)14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(recommended in the Prescribing Informa)-9.8 (tion for these substra)-9.8 (tes.)]TJ
-0.008 Tc 0.044 Tw 0 -1.612 Td
[(Ada)-9.6 (grasib is a CYP2C9 inhibitor)74.4 (.)37.3 ( Concomitant use with KRAZA)55.3 (TI increases exposure of)-8 ( )]TJ
0.046 Tw 0 -1.072 Td
[(CYP2C9 substra)-10 (tes )]TJ
/T1_2 1 Tf
[([see Clinical Pharmacolog)-10 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)37 ( which may increase the risk of)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(adverse reactions rela)-9.7 (ted to these substra)-9.7 (tes.)]TJ
0 -1.653 Td
[(Sensitive CYP2D6 Substra)-9.8 (tes)]TJ
-0.003 Tc 0.073 Tw 0 -1.567 Td
[(Avoid concomitant use of KRAZA)54.7 (TI with sensitive CYP2D6 substra)-10.2 (tes where minimal)-3 ( )]TJ
0.014 Tc 0.153 Tw 0 -1.072 Td
[(co)0.5 (nc)0.5 (en)0.5 (tra)-9.5 (t)0.5 (ion)0.5 ( cha)0.5 (ng)0.5 (es)0.5 ( m)0.5 (ay)0.5 ( le)0.5 (ad t)0.5 (o s)0.5 (eri)0.5 (ou)0.5 (s ad)0.5 (ve)0.5 (rs)0.5 (e r)0.5 (eac)0.5 (ti)0.5 (on)0.5 (s unl)0.5 (es)0.5 (s o)0.5 (the)0.5 (rw)0.5 (is)0.5 (e)14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(recommended in the Prescribing Informa)-9.8 (tion for these substra)-9.8 (tes.)]TJ
-0.009 Tc 0.044 Tw 0 -1.612 Td
[(Ada)-10.4 (grasib is )0.5 (a )0.5 (CYP2D6 )0.5 (inhibitor)73.6 (.)36.6 ( )0.5 (Concomitant )0.5 (use with )0.5 (KRAZA)54.6 (TI )0.5 (increases )0.5 (exposure )0.5 (of)-8.9 ( )]TJ
-0.008 Tc 0.045 Tw 0 -1.072 Td
[(CYP2D6 )0.5 (substra)-9.7 (tes )]TJ
/T1_2 1 Tf
7.258 0 Td
[([see )0.5 (Clinical )0.5 (Pharmacolog)-9.7 (y )0.5 (\(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.2 ( )0.6 (which )0.5 (may )0.5 (increase )0.5 (the )0.6 (risk )0.6 (of)-8 ( )]TJ
-0.017 Tc 0 Tw -7.258 -1.072 Td
[(adverse reactions rela)-9.7 (ted to these substra)-9.7 (tes.)]TJ
0 -1.653 Td
[(P-gp Substra)-9.8 (tes)]TJ
-0.007 Tc 0.05 Tw 0 -1.567 Td
[(Avoid concomitant use of KRAZA)55.1 (TI with P-gp substra)-9.8 (tes where minimal concentra)-9.8 (tion)-7 ( )]TJ
-0.008 Tc 0.043 Tw 0 -1.072 Td
[(c)0.5 (ha)0.5 (n)0.5 (ge)0.5 (s)0.5 ( m)0.5 (ay)0.5 ( l)0.5 (e)0.5 (ad)0.5 ( t)0.5 (o s)0.5 (e)0.5 (r)0.5 (io)0.5 (u)0.5 (s a)0.5 (d)0.5 (ve)0.5 (r)0.5 (s)0.5 (e r)0.5 (e)0.5 (a)0.5 (ct)0.5 (i)0.5 (o)0.5 (ns)0.5 ( un)0.5 (l)0.5 (e)0.5 (ss)0.5 ( o)0.5 (th)0.5 (e)0.5 (r)0.5 (wi)0.5 (s)0.5 (e)0.5 ( r)0.5 (e)0.5 (c)0.5 (o)0.5 (mm)0.5 (e)0.5 (n)0.5 (de)0.5 (d)0.5 ( in)0.5 ( t)0.5 (he)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.072 Td
[(Prescribing Informa)-9.8 (tion for these substra)-9.8 (tes.)]TJ
-0.014 Tc 0.016 Tw 0 -1.612 Td
[(Ada)-9.9 (grasib )0.5 (is )0.5 (a )0.5 (P-gp )0.5 (inhibitor)74 (.)37.1 ( )0.5 (Concomitant )0.5 (use )0.5 (with )0.5 (KRAZA)55.1 (TI increases )0.5 (exposure of )0.5 (P-gp)-14 ( )]TJ
-0.008 Tc 0.008 Tw 0 -1.072 Td
[(substra)-10.3 (tes )]TJ
/T1_2 1 Tf
0.048 Tw 4.062 0 Td
[([see Clinical Pharmacolog)-10.3 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)36.7 ( which may increase the risk of adverse)-7.9 ( )]TJ
-0.017 Tc 0 Tw -4.062 -1.072 Td
[(reactions rela)-9.7 (ted to these substra)-9.8 (tes.)]TJ
ET
0.5 w 
q 1 0 0 1 324 594.248 cm
0 0 m
41.566 0 l
S
Q
q 1 0 0 1 324 506.168 cm
0 0 m
13.291 0 l
S
Q
q 1 0 0 1 324 325.828 cm
0 0 m
41.566 0 l
S
Q
q 1 0 0 1 324 261.928 cm
0 0 m
24.239 0 l
S
Q
BT
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324 727.248 Tm
(7.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Drugs That Prolong QTc Inter)-17.8 (v)16.2 (al)]TJ
/T1_1 1 Tf
-0.011 Tw -3.375 -1.494 Td
[(Avoid concomitant use of KRAZA)55.2 (TI with other product\(s\) with a kno)-9.8 (wn potential to prolong)-17 ( )]TJ
-0.01 Tc 0.037 Tw 0 -1.044 Td
[(the QTc inter)-18.1 (val.)36.9 ( If concomitant use cannot be a)-10.1 (voided,)36.9 ( monitor electrocardiogram and)-10 ( )]TJ
-0.014 Tc 0.017 Tw 0 -1.044 Td
[(electrolytes prior to starting KRAZA)54.8 (TI,)36.9 ( during concomitant use,)36.8 ( and as c)19.9 (linically indica)-10.1 (ted)-14 ( )]TJ
/T1_2 1 Tf
-0.017 Tc 0.012 Tw 0 -1.044 Td
[([see )36.5 (W)17.7 (arnings and Precautions \(5.2\)])]TJ
/T1_1 1 Tf
[(.)36.6 ( )36.6 (Withhold KRAZA)54.6 (TI if the QTc inter)-18.4 (val is >500 ms or)-16.9 ( )]TJ
0 Tw 0 -1.044 Td
(the change from baseline is >60 ms )Tj
/T1_2 1 Tf
[([see Dosa)-9.7 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.3\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
0.015 Tc 0.16 Tw 0 -1.584 Td
[(Ada)-9.7 (grasib causes QTc inter)-17.8 (val prolonga)-9.7 (tion )]TJ
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.8 (y \(12.2\)])]TJ
/T1_1 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(Concomitant use of KRAZA)54.7 (TI with other products tha)-10.2 (t prolong the QTc inter)-18.2 (val may result)-17 ( )]TJ
-0.002 Tc 0.077 Tw 0 -1.044 Td
[(in )0.5 (a grea)-10.1 (ter increase )0.5 (in )0.5 (the )0.5 (QTc inter)-18.1 (val and adverse )0.5 (reactions )0.5 (associa)-10.1 (ted with QTc)-2 ( )]TJ
-0.015 Tc 0.012 Tw 0 -1.044 Td
[(inter)-17.7 (val prolonga)-9.7 (tion,)37.3 ( inc)20.3 (luding )37.2 (T)74.3 (orsade de pointes,)37.2 ( other serious arr)-17.7 (ythmias,)37.3 ( and sudden)-15 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(dea)-9.8 (th )]TJ
/T1_2 1 Tf
0 Tw 2.22 0 Td
[([see )37.3 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.2\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -2.22 -1.845 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
0.017 Tw -3.375 -1.692 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10.2 (y)]TJ
/T1_1 1 Tf
0 Tw -3.375 -1.535 Td
[(Risk Summar)-17.8 (y)]TJ
0.004 Tc 0.108 Tw 0 -1.539 Td
[(There are no a)-10.3 (vailable da)-10.3 (ta on the use of KRAZA)54.7 (TI in pregnant women.)36.7 ( In animal)4 ( )]TJ
-0.017 Tc 0.013 Tw 0 -1.044 Td
[(reproduction )0.5 (studies,)36.5 ( )0.6 (oral )0.6 (administra)-10.5 (tion )0.6 (of )0.6 (ada)-10.4 (grasib )0.6 (to )0.6 (pregnant )0.6 (ra)-10.4 (ts )0.6 (and )0.6 (rabbits )0.6 (during)-17 ( )]TJ
-0.013 Tc 0.022 Tw 0 -1.044 Td
[(the period of organogenesis did not cause adverse development effects or\ embr)-18.1 (yo-fetal)-13 ( )]TJ
-0.012 Tc 0.027 Tw 0 -1.044 Td
[(lethality a)-10.2 (t exposures belo)-10.2 (w the human exposure a)-10.2 (t the recommended dose of 600 mg)-12 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(twice daily )Tj
/T1_2 1 Tf
0 Tc (\()Tj
-0.017 Tc 4.199 0 Td
[(see Da)-9.8 (ta\))]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.002 Tc 0.077 Tw -4.199 -1.584 Td
[(In the U.S.)36.9 ( general popula)-10 (tion,)36.8 ( the estima)-10 (ted background risk of major birth defects)-2 ( )]TJ
0.073 Tw 0 -1.044 Td
[(a)0.5 (n)0.5 (d)0.5 ( m)0.5 (i)0.5 (s)0.5 (c)0.5 (a)0.5 (r)0.5 (r)0.5 (i)0.5 (a)-9.5 (g)0.5 (e)0.5 ( i)0.5 (n)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (ic)0.5 (a)0.6 (ll)0.5 (y)0.6 ( r)0.5 (e)0.5 (c)0.5 (o)0.5 (g)0.5 (n)0.5 (i)0.5 (z)0.5 (e)0.5 (d)0.5 ( p)0.5 (r)0.5 (e)0.5 (g)0.5 (n)0.5 (a)0.5 (n)0.5 (c)0.5 (i)0.5 (e)0.5 (s)0.5 ( i)0.5 (s)0.5 ( 2)0.5 (%)0.5 ( t)0.5 (o)0.5 ( 4)0.5 (%)0.5 ( a)0.5 (n)0.5 (d)0.5 ( 1)0.5 (5)0.5 (%)0.5 ( t)0.5 (o)0.5 ( 2)0.5 (0)0.5 (%)0.5 (,)35 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(respectively)55.2 (.)]TJ
0 -1.625 Td
[(Da)-9.8 (ta)]TJ
/T1_2 1 Tf
0 Tw 0 -1.58 Td
[(Animal Da)-9.8 (ta)]TJ
/T1_1 1 Tf
-0.01 Tc 0.038 Tw 0 -1.449 Td
[(In a ra)-10.3 (t embr)-18.3 (yo-fetal development stud)-10.3 (y)54.7 (,)36.7 ( once daily oral administra)-10.3 (tion of ada)-10.3 (grasib to)-10 ( )]TJ
-0.011 Tc 0.033 Tw 0 -1.044 Td
[(pregnant ra)-10.4 (ts during the period of organogenesis resulted in ma)-10.3 (ternal toxicity \(reduced)-11 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(bod)-10 (y weight and food intake,)37 ( and adverse c)20.1 (linical signs leading to moribund condition and)-18 ( )]TJ
-0.015 Tc 0.014 Tw 0 -1.044 Td
[(early )0.5 (termina)-10.4 (tion\) )0.5 (and lo)-10.4 (wer fetal )0.5 (bod)-10.4 (y weight a)-10.4 (t 270 mg/kg dose level )0.5 (\(a)-10.4 (pproxima)-10.4 (tely )0.5 (2)-15 ( )]TJ
-0.014 Tc 0.015 Tw 0 -1.044 Td
[(times the recommended dose of 600 mg twice daily based on bod)-9.9 (y surface area [BSA]\).)23 ( )]TJ
-0.009 Tc 0.042 Tw 0 -1.044 Td
[(Ada)-10.1 (grasib induced skeletal malforma)-10.1 (tions,)36.9 ( such as bent limbs,)36.9 ( and skeletal varia)-10.1 (tions,)28 ( )]TJ
0.04 Tw 0 -1.044 Td
[(such as bent sca)-9.9 (pula,)37.1 ( wa)-9.8 (vy ribs,)37.2 ( and supernumerar)-17.9 (y short cer)-17.8 (vical ribs a)-9.9 (t 270 mg/kg,)28 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(which were secondar)-17.8 (y to ma)-9.8 (ternal toxicity and reduced fetal bod)-9.8 (y weight.)]TJ
-0.011 Tc 0.033 Tw 0 -1.584 Td
[(In a rabbit embr)-18.3 (yo-fetal development stud)-10.3 (y)54.7 (,)36.7 ( once daily oral administra)-10.3 (tion of ada)-10.3 (grasib)-11 ( )]TJ
-0.006 Tc 0.056 Tw 0 -1.044 Td
[(during the period of organogenesis resulted in lo)-9.9 (wer fetal bod)-10 (y weight and increased)-6 ( )]TJ
-0.017 Tc -0.011 Tw 0 -1.044 Td
[(litter frequenc)20.2 (y of unossi\036ed sternebra a)-9.8 (t 30 mg/kg \(a)-9.8 (pproxima)-9.8 (tely 0.11 times the human)-17 ( )]TJ
-0.001 Tw 0 -1.044 Td
[(exposure based on area under the cur)-17.8 (ve [AUC] a)-9.8 (t the c)20.2 (linical dose of 600 mg twice daily\).)20 ( )]TJ
-0.011 Tc 0.031 Tw 0 -1.044 Td
[(This skeletal varia)-10 (tion was associa)-10 (ted with ma)-10 (ternal toxicities,)37 ( inc)19.9 (luding reduced mean)-11 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.044 Td
[(b)0.5 (o)0.6 (d)-9.5 (y)0.5 ( )0.6 (w)0.5 (e)0.5 (i)0.6 (g)0.5 (h)0.5 (t)0.6 ( )0.5 (a)0.5 (n)0.6 (d)0.5 ( )0.5 (d)0.6 (e)0.5 (c)0.5 (r)0.5 (e)0.6 (a)0.5 (s)0.6 (e)0.5 (d)0.5 ( )0.6 (f)0.5 (o)0.5 (o)0.6 (d)0.5 ( )0.5 (c)0.6 (o)0.5 (n)0.5 (s)0.6 (u)0.5 (m)0.5 (p)0.6 (t)0.5 (i)0.5 (o)0.6 (n)0.5 (.)37.5 ( )37.5 (A)0.6 (d)0.5 (a)-9.5 (g)0.6 (r)0.5 (a)0.5 (s)0.6 (i)0.5 (b)0.5 ( )0.5 (e)0.6 (x)0.5 (p)0.5 (o)0.6 (s)0.5 (u)0.5 (r)0.6 (e)0.5 ( )0.5 (d)0.6 (i)0.5 (d)0.5 ( )0.6 (n)0.5 (o)0.5 (t)0.6 ( )0.5 (c)0.5 (a)0.6 (u)0.5 (s)0.5 (e)0.6 ( )0.5 (a)0.6 (d)0.5 (v)0.5 (e)0.5 (r)0.6 (s)0.5 (e)-17 ( )]TJ
-0.011 Tc 0.03 Tw 0 -1.044 Td
[(developmental )0.5 (effects )0.5 (and did )0.5 (not )0.5 (affect )0.5 (embr)-17.7 (yo-fetal )0.5 (sur)-17.7 (vival )0.5 (in )0.5 (rabbits )0.5 (a)-9.7 (t )0.5 (doses )0.5 (up )0.5 (to)-11 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(30 mg/kg once daily)55.2 (.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_1 1 Tf
0 Tw -3.375 -1.535 Td
[(Risk Summar)-17.8 (y)]TJ
-0.007 Tc 0.052 Tw 0 -1.539 Td
[(There are no da)-10.2 (ta on the presence of ada)-10.2 (grasib or its metabolites in human milk,)36.8 ( the)-7 ( )]TJ
-0.014 Tc 0.014 Tw 0 -1.044 Td
[(effects on the breastfed child,)37.3 ( or on milk production.)37.3 ( Because of the potential for serious)-14 ( )]TJ
-0.017 Tc -0.007 Tw 0 -1.044 Td
[(adverse reactions in breastfed children,)37.2 ( advise women not to breastfeed during trea)-9.8 (tment)-17 ( )]TJ
0 Tw 0 -1.044 Td
[(with KRAZA)55.1 (TI and for 1 week after the last dose.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(F)20.2 (emales and Males of Reproductive P)24.2 (otential)]TJ
/T1_1 1 Tf
0.017 Tw -3.375 -1.535 Td
(Infertility)Tj
-0.002 Tw 0 -1.539 Td
[(Based on \036ndings from animal studies,)37.2 ( KRAZA)55.2 (TI may impair fertility in females and males)-17 ( )]TJ
0 Tw 0 -1.044 Td
(of reproductive potential )Tj
/T1_2 1 Tf
-0.037 Tw [([see )-36.8 (Nonc)20.2 (linical T)74.2 (oxicolog)]TJ
0 Tw 17.769 0 Td
(y \(13.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -17.769 -1.782 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24.2 (ediatric Use)]TJ
/T1_1 1 Tf
-3.375 -1.494 Td
[(The safety and effectiveness of KRAZA)55.2 (TI has not been established in pedia)-9.8 (tric pa)-9.8 (tients.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_1 1 Tf
-3.375 -1.494 Td
[(Of 116 pa)-9.8 (tients with metasta)-9.8 (tic NSCLC who received ada)-9.8 (grasib 600 mg orally twice daily)-17 ( )]TJ
-0.006 Tc 0.057 Tw 0 -1.044 Td
[(in KR)17.8 (YST)54.8 (AL-1,)36.7 ( 49% \(57 pa)-10.2 (tients\) were \03565 years of a)-10.2 (ge and 13% \(15 pa)-10.2 (tients\) were)-5.9 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(\03575 years of a)-9.7 (ge.)37.2 ( No overall differences in safety or effectiveness were obser)-17.7 (ved between)-18 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(older and younger pa)-9.8 (tients.)]TJ
-0.014 Tc 0.018 Tw 0 -1.584 Td
[(Of 94 pa)-10.4 (tients with metasta)-10.3 (tic CRC who received ada)-10.4 (grasib 600 mg orally twice daily in)-14 ( )]TJ
-0.016 Tc 0.012 Tw 0 -1.044 Td
[(combina)-9.9 (tion with cetuximab in KRIST)55.1 (AL-1,)37.1 ( 33% \(31 pa)-9.9 (tients\) were \03565 years of a)-9.9 (ge and)-16 ( )]TJ
-0.017 Tc 0 -1.044 Td
[(2.1% \(2 pa)-10.2 (tients\) were \03575 years of a)-10.1 (ge.)36.9 ( No overall differences in safety or effectiveness)-17 ( )]TJ
0 Tw 0 -1.044 Td
[(were obser)-17.8 (ved between older and younger pa)-9.7 (tients.)]TJ
ET
endstreamendobj83 0 obj<</Length 37500>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 89.6666 cm
0 0 m
49.925 0 l
S
Q
/GS2 gs
q 1 0 0 1 36 659.3204 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 648.5685 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 637.8165 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 627.0646 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 594.8089 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 455.034 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 36 433.5302 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 693.9861 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 146.63 693.7361 cm
0 0 m
70.81 0 l
S
Q
q 1 0 0 1 146.88 681.0742 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 217.44 693.7361 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 681.0742 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 146.88 659.5704 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 659.5704 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 659.3204 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 648.8185 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 659.3204 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 648.8185 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 648.5685 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 638.0665 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 648.5685 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 638.0665 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 637.8165 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 627.3146 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 637.8165 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 627.3146 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 627.0646 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 616.5627 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 627.0646 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 616.5627 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 595.0589 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 595.0589 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 594.8089 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 584.307 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 594.8089 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 584.307 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 562.8032 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 562.8032 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 541.2993 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 541.2993 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 519.7955 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 519.7955 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 498.2917 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 498.2917 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 487.5398 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 487.5398 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 466.0359 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 466.0359 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 455.034 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 444.5321 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 455.034 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 444.5321 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 146.88 433.5302 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 423.0283 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.44 433.5302 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 423.0283 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 36 715.1481 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 715.1481 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 715.1481 cm
0 0 m
70.56 0 l
S
Q
0.5 w 
q 1 0 0 1 36 551.8013 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 551.8013 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 551.8013 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 680.8242 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 680.8242 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 680.8242 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 670.0723 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 670.0723 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 670.0723 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 616.3127 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 616.3127 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 616.3127 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 605.5608 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 605.5608 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 605.5608 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 465.7859 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 465.7859 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 465.7859 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 584.057 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 584.057 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 584.057 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 573.3051 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 573.3051 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 573.3051 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 562.5532 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 562.5532 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 562.5532 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 444.2821 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 444.2821 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 444.2821 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 541.0493 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 541.0493 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 541.0493 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 530.2974 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 530.2974 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 530.2974 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 498.0417 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 498.0417 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 498.0417 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 354.3625 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 354.3625 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 354.3625 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 422.7783 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 422.7783 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 422.7783 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 412.0264 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 412.0264 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 146.88 401.7744 cm
0 0 m
0 10.002 l
S
Q
q 1 0 0 1 217.44 412.0264 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 401.7744 cm
0 0 m
0 10.002 l
S
Q
1 w 
q 1 0 0 1 36 401.2744 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 401.2744 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 401.2744 cm
0 0 m
70.56 0 l
S
Q
0.5 w 
q 1 0 0 1 36 519.5455 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 519.5455 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 519.5455 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 508.7936 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 508.7936 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 508.7936 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 487.2898 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 487.2898 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 487.2898 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 36 476.5378 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 146.88 476.5378 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 217.44 476.5378 cm
0 0 m
70.56 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(T)74.2 (able 3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Adverse Reactions \(\03620%\) in P)24.2 (atients with )]TJ
/T1_1 1 Tf
0.017 Tw (KRAS )Tj
/T1_0 1 Tf
19.013 0 Td
[(G12C-mutated)-17 ( )]TJ
0.048 Tw -19.013 -1.062 Td
[(NSCLC Who Received Adagrasib in KR)18.2 (Y)18.2 (ST)55.2 (AL-1)]TJ
-0.012 Tc 7.6 0 0 8 36 695.1302 Tm
(Adverse Reaction)Tj
0.012 Tw 21.921 1.338 Td
(Adagrasib)Tj
0 Tc 0 Tw 7.6 0 0 8 232.5269 705.8361 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 206.9601 697.3361 Tm
(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(116)Tj
0.048 Tw -6.063 -1.614 Td
(All Grades \(%\))Tj
8.878 0 Td
(Grade 3 or 4 \(%\))Tj
-25.31 -1.479 Td
(Gastrointestinal Disorders)Tj
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
(Diarrhea*)Tj
0.012 Tw 18.758 0 Td
(70)Tj
9.187 0 Td
(0.9)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
(Nausea)Tj
0.012 Tw 18.758 0 Td
(69)Tj
9.187 0 Td
(4.3)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
[(V)18.2 (omiting*)]TJ
0.012 Tw 18.758 0 Td
(56)Tj
9.187 0 Td
(0.9)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
[(Constipa)-9.8 (tion)]TJ
0.012 Tw 18.758 0 Td
(22)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
-0.012 Tc -0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.292 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Abdominal )-245.7 (pain)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.628 0 Td
(*)Tj
0.012 Tw 12.538 0 Td
(21)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
(General Disorders and Administration Site Conditions)Tj
/T1_2 1 Tf
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(F)20.2 (a)-9.8 (tigue)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.655 0 Td
(*)Tj
0.012 Tw 15.511 0 Td
(59)Tj
0 Tc 0 Tw 9.535 0 Td
(7)Tj
-0.012 Tc -0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.292 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Edema)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.504 0 Td
(*)Tj
0.012 Tw 15.661 0 Td
(32)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
[(Musculoskeletal and Connective T)18.2 (issue Disorders)]TJ
/T1_2 1 Tf
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Musculoskeletal )-245.7 (pain)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.608 0 Td
(*)Tj
0.012 Tw 10.557 0 Td
(41)Tj
0 Tc 0 Tw 9.535 0 Td
(7)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
[(Hepatobiliar)-17.7 (y Disorders)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(Hepa)-9.7 (totoxicity*)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.012 Tw 5.32 0 0 5.6 81.5954 545.7333 Tm
(,\206)Tj
0 Tc 0 Tw 7.6 0 0 8 85.3715 543.5693 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 12.261 0 Td
(37)Tj
9.301 0 Td
(10)Tj
/T1_0 1 Tf
0.048 Tw -28.058 -1.344 Td
[(Renal and Urinar)-17.8 (y Disorders)]TJ
/T1_2 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Renal impairment*)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.012 Tw 5.32 0 0 5.6 91.8524 524.2295 Tm
(,\207)Tj
0 Tc 0 Tw 7.6 0 0 8 95.6284 522.0655 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 10.912 0 Td
(36)Tj
0 Tc 0 Tw 9.535 0 Td
(6)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -28.292 -1.344 Td
[(Respirator)-17.7 (y)]TJ
/T1_2 1 Tf
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Dyspnea)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.127 0 Td
(*)Tj
0.012 Tw 15.039 0 Td
(35)Tj
9.301 0 Td
(10)Tj
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.058 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Cough)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.32 0 Td
(*)Tj
0.012 Tw 15.845 0 Td
(24)Tj
9.187 0 Td
(0.9)Tj
/T1_0 1 Tf
0.048 Tw -27.944 -1.344 Td
(Metabolism and Nutrition Disorders)Tj
/T1_2 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Decreased a)-9.8 (ppetite)-12 (\033)]TJ
0.012 Tw 18.166 0 Td
(30)Tj
9.187 0 Td
(4.3)Tj
/T1_0 1 Tf
0.048 Tw -27.944 -1.344 Td
[(Infections and Infestations)-12 (\037)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(Pneumonia*)-11.9 (\033)]TJ
0.012 Tw 18.758 0 Td
(24)Tj
9.301 0 Td
(17)Tj
/T1_0 1 Tf
0.048 Tw -28.058 -1.344 Td
[(Ner)-17.7 (vous System Disorders)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(Dizziness*)-12 (\033)]TJ
0.012 Tw 18.758 0 Td
(23)Tj
9.187 0 Td
(0.9)Tj
/T1_0 1 Tf
0.048 Tw -27.944 -1.344 Td
(Cardiac Disorders)Tj
/T1_2 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Electrocardiogram QT prolonged)Tj
0.012 Tw 18.166 0 Td
(20)Tj
0 Tc 0 Tw 9.535 0 Td
(6)Tj
-0.017 Tc 0.048 Tw -28.292 -1.479 Td
(*Grouped term.)Tj
0 Tc 0 Tw 5.32 0 0 5.6 36 385.6265 Tm
(\206)Tj
-0.009 Tc 0.091 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 38.4727 383.4625 Tm
( )Tj
EMC 
0.333 0 Td
[(Hepa)-10.3 (totoxicity inc)19.8 (ludes )0.5 (mixed )0.5 (liver )0.5 (injur)-18.2 (y)54.7 (,)36.8 ( blood )0.5 (alkaline )0.5 (phospha)-10.2 (tase )0.5 (increased,)36.8 ( )0.5 (alanine)-9 ( )]TJ
0 Tc 0.136 Tw 0 -1.062 Td
[(aminotransferase increased,)36.7 ( asparta)-10.3 (te aminotransferase increased,)36.7 ( liver function test )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(increased,)37.2 ( blood bilirubin increased,)37.2 ( and bilirubin conjuga)-9.8 (ted increased.)]TJ
0 Tc 0 Tw 5.32 0 0 5.6 36 360.1265 Tm
(\207)Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 38.4727 357.9625 Tm
( )Tj
EMC 
0.333 0 Td
[(Renal impairment inc)20.2 (ludes acute kidney injur)-17.8 (y and increased blood crea)-9.8 (tinine.)]TJ
0 Tw 8 0 0 8 36 334.0014 Tm
[(T)74.2 (able 4 summarizes the labora)-9.8 (tor)-17.7 (y abnormalities in KR)18.2 (YST)55.3 (AL-1.)]TJ
ET
/GS2 gs
q 1 0 0 1 36 108.6578 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 108.6578 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 108.6578 cm
0 0 m
70.024 0 l
S
Q
1 w 
q 1 0 0 1 36 294.2284 cm
0 0 m
111.702 0 l
S
Q
0.5 w 
q 1 0 0 1 36 269.8446 cm
0 0 m
111.702 0 l
S
Q
1 w 
q 1 0 0 1 147.7016 294.2284 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 294.2284 cm
0 0 m
70.024 0 l
S
Q
0.5 w 
q 1 0 0 1 147.7016 282.2865 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 147.4516 282.0365 cm
0 0 m
70.274 0 l
S
Q
q 1 0 0 1 147.7016 270.0946 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 217.7258 282.0365 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 270.0946 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 147.7016 269.8446 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 269.8446 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 36 259.0927 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 259.0927 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 147.7016 248.3407 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 259.0927 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 248.3407 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 147.7016 237.5888 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 237.5888 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 227.0869 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 227.0869 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 36 226.8369 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 226.8369 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 226.8369 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 36 216.085 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 216.085 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 147.7016 205.3331 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 217.7258 216.085 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 205.3331 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 147.7016 194.5812 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 194.5812 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 183.8293 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 183.8293 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 173.0773 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 173.0773 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 162.3254 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 162.3254 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 151.5735 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 151.5735 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 140.8216 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 217.7258 140.8216 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 147.7016 130.5697 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 217.7258 130.5697 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 36 130.0697 cm
0 0 m
111.702 0 l
S
Q
q 1 0 0 1 147.7016 130.0697 cm
0 0 m
70.024 0 l
S
Q
q 1 0 0 1 217.7258 130.0697 cm
0 0 m
70.024 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
0.048 Tw 8 0 0 8 36 314.8284 Tm
[(T)74.2 (able 4:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Select Laborator)-17.8 (y Abnormalities Occurring \(\03625%\) That W)18.2 (orsened)-17 ( )]TJ
0 -1.062 Td
[(from Baseline in P)24.2 (atients with )]TJ
/T1_1 1 Tf
0.017 Tw (KRAS )Tj
/T1_0 1 Tf
0.048 Tw 14.226 0 Td
[(G1)40.2 (2C-mutated NSCLC Who)-17 ( )]TJ
-14.226 -1.062 Td
[(Received Adagrasib in KR)18.2 (Y)18.2 (ST)55.2 (AL-1)-17 (\037)]TJ
-0.012 Tc 7.6 0 0 8 36 279.1806 Tm
[(Laborator)-17.8 (y Abnormality)]TJ
0.012 Tw 21.77 0.762 Td
(Adagrasib*)Tj
0.048 Tw -5.266 -1.524 Td
(All Grades \(%\))Tj
8.808 0 Td
(Grade 3 or 4 \(%\))Tj
0.012 Tw -25.312 -1.434 Td
[(Hematolog)-9.8 (y)]TJ
/T1_2 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(L)37.2 (ymphoc)20.2 (ytes decreased)]TJ
0.012 Tw 18.238 0 Td
(64)Tj
9.23 0 Td
(25)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.061 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Hemoglobin decreased)Tj
0.012 Tw 18.238 0 Td
(51)Tj
0 Tc 0 Tw 9.464 0 Td
(8)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Pla)-9.7 (telets decreased)]TJ
0.012 Tw 18.238 0 Td
(27)Tj
0 Tc 0 Tw 9.464 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -28.295 -1.344 Td
[(Chemistr)-17.8 (y)]TJ
/T1_2 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Asparta)-9.8 (te aminotransferase increased)-12 ( )]TJ
0.012 Tw 18.238 0 Td
(52)Tj
0 Tc 0 Tw 9.464 0 Td
(6)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Sodium decreased)Tj
0.012 Tw 18.238 0 Td
(52)Tj
0 Tc 0 Tw 9.464 0 Td
(8)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Crea)-9.8 (tinine increased)]TJ
0.012 Tw 18.238 0 Td
(50)Tj
0 Tc 0 Tw 9.464 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Albumin decreased)Tj
0.012 Tw 18.238 0 Td
(50)Tj
9.116 0 Td
(0.9)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Alanine aminotransferase increased)Tj
0.012 Tw 18.238 0 Td
(46)Tj
0 Tc 0 Tw 9.464 0 Td
(5)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Lipase increased)Tj
0.012 Tw 18.238 0 Td
(35)Tj
9.116 0 Td
(1.8)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.947 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Ma)-9.8 (gnesium decreased)]TJ
0.012 Tw 18.238 0 Td
(26)Tj
0 Tc 0 Tw 9.464 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.295 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (otassium decreased)]TJ
0.012 Tw 18.238 0 Td
(26)Tj
9.116 0 Td
(3.5)Tj
-0.011 Tc 0.081 Tw -27.947 -1.479 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.335 0 Td
( )Tj
EMC 
0.323 0 Td
[(Denomina)-10.3 (tor used to calcula)-10.3 (te the ra)-10.3 (te varied from 1)59.7 (0)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
20.075 0 Td
[(6 to 113 based on the number of)-11 ( )]TJ
-0.017 Tc 0.048 Tw -20.075 -1.062 Td
[(pa)-9.8 (tients with a baseline value and a)-9.7 (t least one post-trea)-9.8 (tment value.)]TJ
0 Tw 8 0 0 8 36 90.6666 Tm
(Colorectal Cancer)Tj
-0.02 Tc -0.012 Tw 0 -1.551 Td
[(The safety of ada)-10.2 (grasib combined with cetuximab was evalua)-10.2 (ted in 94 pa)-10.2 (tients with )]TJ
/T1_3 1 Tf
0.02 Tw (KRAS)Tj
/T1_2 1 Tf
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.009 Tc 0.041 Tw -31.5 -1.056 Td
[(G1)40 (2C-muta)-10 (ted,)37 ( locally advanced or metasta)-9.9 (tic CRC in KR)18 (YST)55.1 (AL-1 )]TJ
/T1_3 1 Tf
[([see Clinical Studies)-9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.056 Td
(\(14.2\)])Tj
/T1_2 1 Tf
0.005 Tw [(.)37.3 ( P)18.2 (a)-9.8 (tients started trea)-9.8 (tment with ada)-9.7 (grasib 600 mg twice daily in combina)-9.8 (tion with)-17 ( )]TJ
-0.007 Tc 0.051 Tw 0 -1.056 Td
(cetuximab weekly \(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.694 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.711 0 Td
[(17\) or ever)-18 (y two weeks \(n)]TJ
/Span<</ActualText<FEFF2006>>> BDC 
( )Tj
EMC 
9.84 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.711 0 Td
[(77\).)36.9 ( )36.6 (Among pa)-10 (tients who received)-7 ( )]TJ
-0.014 Tc 0.015 Tw -18.956 -1.056 Td
[(ada)-9.8 (grasib in combina)-9.8 (tion with cetuximab,)37.2 ( 60% were exposed for grea)-9.8 (ter than 6 months)-14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.056 Td
[(and 1)40.2 (2% were exposed for grea)-9.8 (ter than 1)40.2 (2 months.)]TJ
0.004 Tc 0.108 Tw 36 86.406 Td
[(Serious adverse reactions occurred in 30% of pa)-10.4 (tients who received ada)-10.3 (grasib in)3.9 ( )]TJ
-0.01 Tc 0.035 Tw 0 -1.044 Td
[(combina)-9.9 (tion with cetuximab.)37.2 ( )36.7 (The most common serious adverse reactions \(\0352%\) were)-10 ( )]TJ
-0.012 Tc 0.027 Tw 0 -1.044 Td
[(pneumonia \(4.3%\),)36.8 ( pleural effusion,)36.8 ( pyrexia,)36.8 ( acute kidney injur)-18.2 (y)54.8 (,)36.8 ( dehydra)-10.2 (tion,)36.8 ( and small)-12 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(intestinal obstruction \(2.1% each\).)Tj
-0.01 Tc 0.036 Tw 0 -1.584 Td
[(A fa)-9.9 (tal adverse reaction of pneumonia occurred in 1 pa)-10 (tient who received ada)-10 (grasib in)-10 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(combina)-9.8 (tion with cetuximab.)]TJ
-0.016 Tc 0.012 Tw 0 -1.584 Td
[(A)0.5 (d)0.5 (v)0.5 (e)0.5 (r)0.5 (s)0.5 (e )0.5 (r)0.5 (e)0.5 (a)0.5 (c)0.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (s)0.5 ( )0.5 (l)0.5 (e)0.5 (a)0.5 (d)0.5 (i)0.5 (ng)0.5 ( )0.5 (t)0.5 (o)0.5 ( )0.5 (d)0.5 (i)0.5 (s)0.5 (c)0.5 (o)0.5 (n)0.5 (ti)0.5 (n)0.5 (u)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (a)0.5 (d)0.5 (a)-9.5 (gr)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( )0.5 (o)0.5 (c)0.5 (c)0.5 (u)0.5 (r)0.5 (r)0.5 (e)0.5 (d)0.5 ( i)0.5 (n)0.5 ( )0.5 (2)0.5 ( )0.5 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (ts)0.5 (.)37.5 ( )37.5 (A)0.5 (d)0.5 (v)0.5 (e)0.5 (rs)0.5 (e)-16 ( )]TJ
-0.002 Tc 0.077 Tw 0 -1.044 Td
[(reactions which resulted in permanent discontinua)-10.2 (tion of ada)-10.2 (grasib \(1 pa)-10.2 (tient each\))-2 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(inc)20.2 (luded abdominal pain and prolonged QT inter)-17.8 (val.)]TJ
0.008 Tc 0.126 Tw 0 -1.584 Td
[(Adverse reactions leading to dose interruptions of ada)-10 (grasib occurred in 62% of)8 ( )]TJ
-0.003 Tc 0.069 Tw 0 -1.044 Td
[(pa)-9.6 (ti)0.5 (en)0.5 (ts.)37.4 ( )37.4 (The )0.5 (most c)0.5 (ommon )0.5 (adverse )0.5 (reactio)0.5 (ns or )0.5 (labora)-9.6 (t)0.5 (or)-17.6 (y a)0.5 (bnormalitie)0.5 (s leadin)0.5 (g to)-3 ( )]TJ
-0.012 Tc 0.025 Tw 0 -1.044 Td
[(dose )0.5 (interruption )0.5 (in )0.6 (\0352% )0.5 (of )0.6 (pa)-9.7 (tients )0.5 (who )0.6 (received )0.5 (ada)-9.8 (grasib )0.5 (inc)20.2 (luded )0.6 (diarrhea,)37.3 ( )0.5 (nausea,)25 ( )]TJ
-0.005 Tc 0.062 Tw 0 -1.044 Td
[(vomiting,)36.8 ( abdominal pain,)36.8 ( dizziness,)36.8 ( headache,)36.8 ( pneumonia,)36.8 ( alanine aminotransferase)-5 ( )]TJ
-0.017 Tc 0.01 Tw 0 -1.044 Td
[(increased,)37.2 ( asparta)-9.8 (te aminotransferase increased,)37.2 ( d)-9.8 (yspnea,)37.2 ( fa)-9.8 (tigue,)37.2 ( pleural effusion,)37.2 ( rash,)20 ( )]TJ
-0.008 Tc 0.045 Tw 0 -1.044 Td
[(anemia,)37.2 ( electrocardiogram QT prolonga)-9.8 (tion,)37.2 ( blood bilirubin increased,)37.2 ( blood crea)-9.8 (tinine)-7.9 ( )]TJ
0.005 Tc 0.112 Tw 0 -1.044 Td
[(increased,)36.7 ( decreased a)-10.2 (ppetite,)36.8 ( dehydra)-10.2 (tion,)36.7 ( hemorrha)-10.3 (ge,)36.8 ( hypoma)-10.2 (gnesemia,)36.7 ( lipase)5.1 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(increased,)37.2 ( muscular weakness,)37.2 ( musculoskeletal pain,)37.2 ( and pyrexia.)]TJ
-0.011 Tc 0.03 Tw 0 -1.584 Td
[(Adverse reactions leading to dose reductions of ada)-9.8 (grasib occurred in 35% of pa)-9.8 (tients.)26.1 ( )]TJ
0.007 Tc 0.123 Tw 0 -1.044 Td
[(The )0.5 (most )0.5 (common )0.5 (adverse )0.5 (reactions or )0.5 (labora)-10.3 (tor)-18.2 (y abnormalities )0.5 (leading )0.5 (to dose)7 ( )]TJ
0.004 Tc 0.107 Tw 0 -1.044 Td
[(reductions in \0352% of pa)-10.2 (tients who received ada)-10.2 (grasib inc)19.8 (luded fa)-10.2 (tigue,)36.8 ( increased)4 ( )]TJ
-0.001 Tc 0.078 Tw 0 -1.044 Td
[(a)0.5 (s)0.5 (p)0.6 (a)0.5 (r)0.5 (t)0.5 (a)-9.4 (t)0.5 (e)0.5 ( a)0.6 (m)0.5 (i)0.5 (n)0.5 (o)0.6 (t)0.5 (r)0.5 (a)0.5 (n)0.6 (s)0.5 (f)0.5 (e)0.5 (r)0.6 (a)0.5 (s)0.5 (e)0.5 (,)37.5 ( i)0.5 (n)0.5 (c)0.5 (r)0.6 (e)0.5 (a)0.5 (s)0.5 (e)0.6 (d)0.5 ( a)0.5 (l)0.5 (a)0.6 (n)0.5 (i)0.5 (n)0.5 (e)0.5 ( a)0.5 (m)0.5 (i)0.6 (n)0.5 (o)0.5 (t)0.5 (r)0.6 (a)0.5 (n)0.5 (s)0.5 (f)0.5 (e)0.6 (r)0.5 (a)0.5 (s)0.5 (e)0.6 (,)37.5 ( n)0.5 (a)0.5 (u)0.6 (s)0.5 (e)0.5 (a)0.5 (,)37.5 ( d)0.5 (e)0.5 (c)0.5 (r)0.6 (e)0.5 (a)0.5 (s)0.5 (e)0.6 (d)-1.1 ( )]TJ
-0.003 Tc 0.073 Tw 0 -1.044 Td
[(a)-10.3 (ppetite,)36.7 ( electrocardiogram QT prolonga)-10.4 (tion,)36.6 ( dizziness,)36.7 ( acute kidney injur)-18.3 (y)54.6 (,)36.7 ( diarrhea,)34 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(d)-9.8 (ysarthria,)37.2 ( and vomiting.)]TJ
-0.026 Tc -0.013 Tw 0 -1.584 Td
[(The most common adverse r)0.5 (eactions \(\03520%\) were rash,)37.4 ( nausea,)37.4 ( diarrhea,)37.4 ( vomiting,)37.4 ( f)0.5 (a)-9.7 (tigue,)11 ( )]TJ
-0.004 Tc 0.087 Tw 0 -1.044 Td
[(musculoskeletal pain,)36.8 ( hepa)-10.2 (totoxicity)54.8 (,)36.8 ( headache,)36.8 ( dr)-18.2 (y skin,)36.8 ( abdominal pain,)36.8 ( decreased)-4 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(a)-9.8 (ppetite,)37.2 ( edema,)37.2 ( anemia,)37.2 ( dizziness,)37.2 ( cough,)37.2 ( constipa)-9.8 (tion,)37.2 ( and peripheral neuropa)-9.8 (thy)55.2 (.)]TJ
0.005 Tc 0.11 Tw 0 -1.584 Td
[(The most common labora)-9.8 (tor)-17.9 (y abnormalities \(\03525%\) were decreased lymphoc)20.1 (ytes,)42 ( )]TJ
0.003 Tc 0.102 Tw 0 -1.044 Td
[(decreased hemoglobin,)36.8 ( decreased leukoc)19.8 (ytes,)36.8 ( increased alanine aminotransferase,)40 ( )]TJ
0 Tc 0.088 Tw 0 -1.044 Td
[(decreased ma)-10.3 (gnesium,)36.6 ( decreased albumin,)36.7 ( increased lipase,)36.7 ( decreased potassium,)37 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.044 Td
[(increased asparta)-9.9 (te aminotransferase,)37.2 ( increased crea)-9.9 (tinine,)37.2 ( decreased sodium,)37.2 ( decreased)-21 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(calcium,)37.2 ( increased amylase,)37.3 ( and increased alkaline phospha)-9.7 (tase.)]TJ
0 -1.584 Td
[(T)74.2 (able 5 summarizes the adverse reactions in pa)-9.8 (tients with metasta)-9.8 (tic CRC in KR)18.2 (YST)55.2 (AL-1.)]TJ
ET
0.5 w 
/GS2 gs
q 1 0 0 1 324 332.1747 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 324 310.6708 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 324 299.9189 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 324 289.167 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 324 246.1593 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 324 203.1517 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 388.3442 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 434.63 388.0942 cm
0 0 m
70.81 0 l
S
Q
q 1 0 0 1 434.88 375.4323 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 505.44 388.0942 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 375.4323 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 434.88 332.1747 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 321.6727 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 332.1747 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 321.6727 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 310.9208 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 310.9208 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 310.6708 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 300.1689 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 310.6708 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 300.1689 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 299.9189 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 289.417 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 299.9189 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 289.417 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 289.167 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 278.6651 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 289.167 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 278.6651 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 257.1613 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 257.1613 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 246.4093 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 246.4093 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 246.1593 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 235.6574 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 246.1593 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 235.6574 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 214.1536 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 214.1536 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 203.1517 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 192.6498 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 203.1517 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 192.6498 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 181.8979 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 181.8979 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 171.1459 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 171.1459 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 149.6421 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 149.6421 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 434.88 128.1383 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 128.1383 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 324 409.5061 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 409.5061 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 409.5061 cm
0 0 m
70.56 0 l
S
Q
0.5 w 
q 1 0 0 1 324 224.6555 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 224.6555 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 224.6555 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 278.4151 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 278.4151 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 278.4151 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 267.6632 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 267.6632 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 267.6632 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 256.9113 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 256.9113 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 256.9113 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 160.144 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 160.144 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 160.144 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 138.6402 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 138.6402 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 138.6402 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 235.4074 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 235.4074 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 235.4074 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 213.9036 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 213.9036 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 213.9036 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 192.3998 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 192.3998 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 192.3998 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 181.6479 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 181.6479 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 181.6479 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 170.8959 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 170.8959 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 170.8959 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 84.9725 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 84.9725 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 84.9725 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 375.1823 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 375.1823 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 375.1823 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 149.3921 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 149.3921 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 149.3921 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 127.8883 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 127.8883 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 127.8883 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 343.1766 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 343.1766 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 324 117.1364 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 117.1364 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 106.8845 cm
0 0 m
0 10.002 l
S
Q
q 1 0 0 1 505.44 117.1364 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 106.8845 cm
0 0 m
0 10.002 l
S
Q
1 w 
q 1 0 0 1 324 106.3845 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 106.3845 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 106.3845 cm
0 0 m
70.56 0 l
S
Q
0.5 w 
q 1 0 0 1 324 364.4304 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 364.4304 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 434.88 353.9285 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 505.44 364.4304 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 353.9285 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 324 353.6785 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 353.6785 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 353.6785 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 342.9266 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 342.9266 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 342.9266 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 324 321.4227 cm
0 0 m
110.88 0 l
S
Q
q 1 0 0 1 434.88 321.4227 cm
0 0 m
70.56 0 l
S
Q
q 1 0 0 1 505.44 321.4227 cm
0 0 m
70.56 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
0.048 Tw 8 0 0 8 324 421.6061 Tm
[(T)74.2 (able 5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.02 Tc 5 0 Td
[(Adverse Reactions \(\03620%\) in P)24.2 (atients with )]TJ
/T1_1 1 Tf
0.02 Tw (KRAS )Tj
/T1_0 1 Tf
0.048 Tw 18.872 0 Td
[(G1)40.2 (2C-mutated CRC)-20 ( )]TJ
0 Tc 0 Tw 7.474 0 Td
( )Tj
-0.017 Tc 0.048 Tw -26.346 -1.062 Td
[(Received Adagrasib in Combination with Cetuximab in KR)18.2 (Y)18.2 (ST)55.2 (AL-1)]TJ
-0.012 Tc 7.6 0 0 8 324 389.4883 Tm
(Adverse Reaction*)Tj
15.664 1.338 Td
(Adagrasib in Combination with Cetuximab)Tj
0 Tc 0 Tw 7.6 0 0 8 568.083 400.1942 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 496.7377 391.6942 Tm
(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(94)Tj
0.048 Tw -6.297 -1.614 Td
(All Grades \(%\))Tj
8.878 0 Td
(Grade 3 or 4 \(%\))Tj
-25.31 -1.479 Td
(Skin and subcutaneous tissue disorders)Tj
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
(Rash)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 342.2837 358.3625 Tm
(\206)Tj
7.6 0 0 8 344.8479 356.1985 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 16.015 0 Td
(84)Tj
9.187 0 Td
(4.3)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Dr)-17.8 (y Skin)-12 (\033)]TJ
0.012 Tw 18.166 0 Td
(36)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
(Gastrointestinal Disorders)Tj
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
(Nausea)Tj
0.012 Tw 18.758 0 Td
(68)Tj
9.187 0 Td
(2.1)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
(Diarrhea)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 351.8987 315.3548 Tm
(\206)Tj
7.6 0 0 8 354.4629 313.1908 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 14.749 0 Td
(65)Tj
0 Tc 0 Tw 9.535 0 Td
(5)Tj
-0.012 Tc 0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.292 -1.344 Td
( )Tj
EMC 
[(V)18.2 (omiting)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 352.3243 304.6029 Tm
(\206)Tj
7.6 0 0 8 354.8885 302.4389 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 14.693 0 Td
(57)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.292 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Abdominal pain)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 371.2693 293.851 Tm
(\206)Tj
7.6 0 0 8 373.8335 291.687 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 12.201 0 Td
(30)Tj
9.187 0 Td
(4.3)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
[(Constipa)-9.8 (tion)]TJ
0.012 Tw 18.758 0 Td
(23)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
(General Disorders and Administration Site Conditions)Tj
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(F)20.2 (a)-9.8 (tigue)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 348.6778 261.5953 Tm
(\206)Tj
7.6 0 0 8 351.242 259.4313 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 15.173 0 Td
(57)Tj
9.187 0 Td
(3.2)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
0.592 0 Td
(Musculoskeletal pain)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 386.3228 250.8433 Tm
(\206)Tj
7.6 0 0 8 388.887 248.6793 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 10.22 0 Td
(47)Tj
9.187 0 Td
(4.3)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
(Edema)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 347.5333 240.0914 Tm
(\206)Tj
7.6 0 0 8 350.0975 237.9274 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 15.324 0 Td
(28)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
[(Hepatobiliar)-17.7 (y Disorders)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(Hepa)-9.7 (totoxicity)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 367.0128 218.5876 Tm
(\206)Tj
7.6 0 0 8 369.577 216.4236 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 12.761 0 Td
(38)Tj
9.301 0 Td
(10)Tj
/T1_0 1 Tf
0.048 Tw -28.058 -1.344 Td
[(Ner)-17.7 (vous System Disorders)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
[(Headache)-12 (\033)]TJ
0.012 Tw 18.758 0 Td
(37)Tj
9.187 0 Td
(4.3)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
(Dizziness)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 354.2076 186.3319 Tm
(\206)Tj
7.6 0 0 8 356.7718 184.1679 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 14.446 0 Td
(24)Tj
9.187 0 Td
(2.1)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.944 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (eripheral neuropa)-9.8 (thy)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 388.8214 175.5799 Tm
(\206)Tj
7.6 0 0 8 391.3856 173.4159 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 9.891 0 Td
(20)Tj
9.187 0 Td
(1.1)Tj
/T1_0 1 Tf
0.048 Tw -27.944 -1.344 Td
(Metabolism and Nutrition Disorders)Tj
/T1_2 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.592 0 Td
[(Decreased a)-9.8 (ppetite)]TJ
0.012 Tw 18.166 0 Td
(30)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.048 Tw -28.292 -1.344 Td
(Blood and lymphatic system disorders)Tj
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
(Anemia)Tj
0.012 Tw 18.758 0 Td
(27)Tj
0 Tc 0 Tw 9.535 0 Td
(7)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -28.292 -1.344 Td
[(Respirator)-17.7 (y)]TJ
/T1_2 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
(Cough)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 346.135 111.0685 Tm
(\206)Tj
7.6 0 0 8 348.6992 108.9044 Tm
(\033)Tj
-0.012 Tc 0.012 Tw 15.508 0 Td
(25)Tj
0 Tc 0 Tw 9.535 0 Td
(0)Tj
-0.017 Tc 0.048 Tw -28.292 -1.479 Td
(* Graded per CTCAE version 5.0.)Tj
0 Tc 0 Tw 5.32 0 0 5.6 323.9997 90.7365 Tm
(\206)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 326.4724 88.5725 Tm
[( Grouped term; inc)20.2 (ludes multiple rela)-9.8 (ted terms.)]TJ
-0.008 Tc 0.045 Tw 8 0 0 8 323.9996 65.6125 Tm
[(Other c)20.3 (linically relevant )0.5 (adverse )0.5 (reactions obser)-17.7 (ved )0.5 (in less than )0.5 (20% )0.5 (of pa)-9.7 (tients )0.5 (were)-7.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(infusion rela)-9.8 (ted reactions \(15%\).)]TJ
-0.001 Tc 0.078 Tw 0 -1.584 Td
[(T)74.4 (a)0.5 (ble)0.5 ( 6 s)0.5 (umm)0.5 (ar)0.5 (ize)0.5 (s t)0.5 (he la)0.5 (bor)0.5 (a)-9.6 (t)0.5 (or)-17.5 (y ab)0.5 (no)0.5 (rma)0.5 (lit)0.5 (ie)0.5 (s i)0.5 (n pa)-9.5 (ti)0.5 (ent)0.5 (s w)0.5 (ith)0.5 ( me)0.5 (ta)0.5 (sta)-9.5 (ti)0.5 (c CR)0.5 (C i)0.5 (n)-1 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(KR)18.2 (YST)55.2 (AL-1.)]TJ
ET
1 w 4 M 
q 1 0 0 1 319.5 41.6519 cm
0 0 m
S
Q
endstreamendobj81 0 obj<</BaseFont/UEAMSO+HelveticaNeueLTStd-BdCnO/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 85 0 R/LastChar 83/Subtype/Type1/ToUnicode 86 0 R/Type/Font/Widths[240 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 0 0 0 0 0 537 0 0 0 0 0 0 556 519]>>endobj85 0 obj<</Ascent 961/CapHeight 714/CharSet(/space/A/K/R/S)/Descent -271/Flags 96/FontBBox[-171 -271 1116 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 87 0 R/FontName/UEAMSO+HelveticaNeueLTStd-BdCnO/FontStretch/Condensed/FontWeight 700/ItalicAngle -12/StemV 140/Type/FontDescriptor/XHeight 538>>endobj86 0 obj<</Filter/FlateDecode/Length 250>>stream
H‰\PÁjÃ0½û+tlÅIºŞL`íäĞn,Û8¶’Û(Î!?Å)L`¿'¤'?K^š—Æ»ò‚i1Aï¼%œÂL¡ÃÁyQV`I÷,ßfÔQH·Ë”pl|„R ?¸8%Z`÷lC‡{!ßÈ"9?ÀîëÒîA¶sŒ?8¢OP@]ƒÅ]u¼éAfÙ¡±\wi9°æ¯ãs‰UÎËÍŒ	§¨’ö
UpÔ ^9jŞş«Ÿ6U×›oMBUkoQ0õTfÎÀü¼ñ3óS•9óãÆyö}Êú
/_03»ÏË¶WÃÎãc©1D`ÕzÄ¯  X x€endstreamendobj87 0 obj<</Filter/FlateDecode/Length 834/Subtype/Type1C>>stream
H‰l]hW†gbæd×5ÍdÄ°êµø·ëvE±	1“¢np“Ş”LvÎšI³3afLØÊ"‚?‘ÄŸMuK¬)Û«ĞVÛÖnQC­ m.¼ëEZ
ÉE—oÆ³…ÔRğÜ|ç}ÏyŸï;‡çÊË8çqÇîÆ}±h°…ôô[‹+ûÉa²·=f«›wªMz´tgµãçšò£Ş2g…W¢ôÊËù—‚ã[êÔ¾ùØ}QÍ••XËøµMFoÊÔuÙø;"!\‰ÔáFÕè$8–²l’´p«7Ì^ÃTl¢†qcO^XØ$1ûJæ«Y°faÛ¦¢’¤b~„Ş«é†ê%¸‰QÂ,tHc\“¨XÓ±İEpG8ÆmŒ®ÛXÑUÜş*M$´8Y0“J
³™şŸÓVX5ÆÄİ‡MÍRµ¸­ºõ/\W’ä5S&ÖØz^·ùïxO²³%üvs¬½$¶b•$8¶xnâ¶p[9ÄşkáZ¹“\ßÎO~68åü9ÅÃ†eÎ€ÛV@p–Ş‘h=Œ0‹(¦·%(‰âpEÉ{¨§L#ç{©´£%åóíëƒ TÂ¨ì¯tn‹3ƒå°	MCP€hˆ²²	%\Y ÍHœ½G«¤3Ì}"PŒ|uc}®ÜÏO¹U‹@ve‰†ş–xİ‚®GOŸÑoØ†¨ä„ wAôN£{0!,4ÎÏAg¡Ú©€õ2„ÄyøÕùKg¢ékİ­é@ı‘“Íş(¢©â:‰Q@^çgĞKZìXÀ¤+O½úk!‚†2VîüDî—Ú<õCè¢çLÅ³ÑïŒıágÁ7ŞvŸVúé§È‡Óçj¡úGØ°‚ó°%kÅ?ƒ%ĞºÜ˜l€í~q"…‡ü"péù‘üÆo×M.¿zá¦G|üÕÈø—Óşü'jK: «Ğ¹Ë¬¼şnÖøéŠõ»h ÉÆZ<ù>Tdë¾f¥ßóD~`ô7ûú§\àÜ˜àKç\9Gä`MÁøğóáb~¤âãQW¥İYsæ†‹¿gß(TÂªÅ²ÙL&“ıÜëc53’Éx—y}p¼ÆEÒ? –ÁŠÈendstreamendobj82 0 obj<</Length 27428>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.025 Tc -0.019 Tw 8 0 0 8 36 727.248 Tm
[(bleeding in 3.8% inc)20 (luding 0.8% Grade 3 or 4,)37 ( gastrointestinal obstruction in 1.6% inc)20 (luding)-25 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.016 Tc 0.012 Tw -31.5 -1.091 Td
[(1.4% Grade 3 or 4,)36.8 ( colitis in 0.5% inc)19.7 (luding 0.3% Grade 3,)36.8 ( ileus in 0.5%,)36.8 ( and stenosis in)-16 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.091 Td
[(0.3%.)37.4 ( In additio)0.5 (n,)37.3 ( )0.5 (nausea,)37.4 ( diarrhea,)37.4 ( or )0.5 (vomiting occurred )0.5 (in )0.5 (89%)0.5 ( of 366 pa)-9.6 (tie)0.5 (nt)0.5 (s,)37.4 ( )0.5 (inc)20.3 (l)0.5 (uding)-19 ( )]TJ
-0.017 Tc 0.004 Tw 0 -1.091 Td
[(9% )0.6 (Grade )0.6 (3.)37.2 ( )0.5 (Nausea,)37.2 ( )0.5 (diarrhea,)37.2 ( )0.5 (or )0.5 (vomiting )0.5 (led )0.5 (to )0.6 (dosa)-9.8 (ge )0.6 (interruption )0.5 (or )0.5 (dose )0.6 (reduction )0.5 (in)-17 ( )]TJ
0 Tw 0 -1.091 Td
[(29% of pa)-9.8 (tients and permanent discontinua)-9.8 (tion of ada)-9.8 (grasib in 0.3%.)]TJ
-0.016 Tc 0.012 Tw 0 -1.631 Td
[(In pa)-9.6 (tients who received KRAZA)55.3 (TI in combina)-9.6 (tion with cetuximab )]TJ
/T1_1 1 Tf
-0.025 Tw [([see Adverse )-36.6 (Reactions)-16 ( )]TJ
-0.02 Tc 0.02 Tw 0 -1.091 Td
(\(6)Tj
0 Tc 0 Tw (.)Tj
-0.02 Tc 0.02 Tw 0.842 0 Td
(1\)])Tj
/T1_0 1 Tf
-0.012 Tw [(,)36.6 ( serious gastrointestinal adverse reactions inc)19.6 (luded gastrointestinal bleeding in 8.5%)-20 ( )]TJ
-0.017 Tc 0.009 Tw -0.842 -1.091 Td
[(inc)20.2 (luding 1.1% Grade 3 or 4,)37.2 ( gastrointestinal obstruction in 5.3% inc)20.2 (luding 5.3% Grade 3)-17 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.091 Td
[(or 4,)37.3 ( colitis in 1)60.4 (.)60.3 (1% inc)20.3 (luding 1)60.4 (.)60.3 (1% Grade 3 and ileus in 1)60.4 (.)60.4 (1%.)37.4 ( In addition,)37.4 ( nausea,)37.3 ( diarrhea,)18 ( )]TJ
-0.012 Tc 0.027 Tw 0 -1.091 Td
[(or vomiting occurred in 92% of 94 pa)-10.2 (tients,)36.7 ( inc)19.7 (luding 6% Grade 3.)36.8 ( Nausea,)36.8 ( diarrhea,)36.7 ( or)-11.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(vomiting led to ada)-9.8 (grasib dose interruption or dose reduction in 23% of pa)-9.7 (tients.)]TJ
0.002 Tw 0 -1.631 Td
[(Monitor )0.5 (and )0.5 (mana)-9.8 (ge )0.5 (pa)-9.8 (tients )0.5 (using )0.5 (supportive )0.6 (care,)37.2 ( )0.5 (inc)20.2 (luding )0.5 (antidiarrheals,)37.2 ( )0.5 (antiemetics,)20 ( )]TJ
0.012 Tw 0 -1.091 Td
[(or \037uid replacement,)37.1 ( as indica)-9.9 (ted.)37.1 ( )37.1 (Withhold,)37.1 ( reduce the dose,)37.1 ( or permanently discontinue)-17 ( )]TJ
0 Tw 0 -1.091 Td
[(KRAZA)55.2 (TI based on severity )]TJ
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.3\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.83 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(QTc Inter)-17.7 (v)16.2 (al Prolongation)]TJ
/T1_0 1 Tf
-0.014 Tc 0.015 Tw -3.375 -1.541 Td
[(KRAZA)55.2 (TI )0.6 (can )0.5 (cause )0.5 (QTc )0.5 (inter)-17.7 (val )0.5 (prolonga)-9.8 (tion,)37.3 ( )0.5 (which )0.5 (can )0.6 (increase )0.5 (the )0.5 (risk )0.5 (for )0.5 (ventricular)-14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(tachy)-9.7 (arrhythmias \(e.g.,)37.2 ( torsades de pointes\) or sudden dea)-9.8 (th.)]TJ
-0.012 Tc 0.024 Tw 0 -1.631 Td
[(In the pooled safety popula)-9.7 (tion )]TJ
/T1_1 1 Tf
[([see )36.7 (Adverse Reactions \(6)]TJ
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.012 Tw 20.768 0 Td
(1\)])Tj
/T1_0 1 Tf
0.024 Tw [( who received single-a)-9.7 (gent)-12 ( )]TJ
-0.006 Tc 0.056 Tw -20.768 -1.091 Td
[(KRAZA)55.1 (TI,)37.1 ( 6% of )0.5 (366 pa)-9.9 (tients with a)-9.9 (t least one post-baseline )0.5 (electrocardiogram )0.5 (\(ECG\))-6 ( )]TJ
-0.013 Tc 0.02 Tw 0 -1.091 Td
[(assessment had an a)-9.8 (vera)-9.8 (ge QTc \035501 msec and 11% of pa)-9.9 (tients had an increase from)-13 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.091 Td
[(baseline of QTc >60 msec.)37.4 ( KRAZA)55.4 (TI causes concentra)-9.6 (tion-dependent increases in the QTc)-21 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.091 Td
[(inter)-17.7 (val )]TJ
/T1_1 1 Tf
0 Tw 2.823 0 Td
([see Clinical Pharmacolog)Tj
9.113 0 Td
(y \(12.2\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.016 Tc 0.012 Tw -11.936 -1.631 Td
[(In pa)-9.6 (tients who received KRAZA)55.3 (TI in combina)-9.6 (tion with cetuximab )]TJ
/T1_1 1 Tf
-0.025 Tw [([see Adverse )-36.6 (Reactions)-16 ( )]TJ
0.006 Tc -0.006 Tw 0 -1.091 Td
(\(6)Tj
0 Tc 0 Tw (.)Tj
0.006 Tc -0.006 Tw 0.92 0 Td
(1\)])Tj
/T1_0 1 Tf
0.118 Tw [(,)36.6 ( 5% of 93 pa)-10.3 (tients with a)-10.4 (t least one post-baseline electrocardiogram \(ECG\))6 ( )]TJ
-0.013 Tc 0.02 Tw -0.92 -1.091 Td
[(assessment had an a)-9.8 (vera)-9.8 (ge QTc \035501 msec and 16% of pa)-9.9 (tients had an increase from)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
(baseline of QTc >60 msec.)Tj
-0.015 Tc 0.012 Tw 0 -1.631 Td
[(Av)0.5 (oi)0.5 (d )0.5 (co)0.5 (nc)0.5 (om)0.5 (it)0.5 (an)0.5 (t u)0.5 (se)0.5 ( o)0.5 (f )0.5 (KR)0.5 (AZA)55.5 (TI)0.5 ( wi)0.5 (th)0.5 ( o)0.5 (th)0.5 (er)0.5 ( p)0.5 (ro)0.5 (du)0.5 (ct)0.5 (s w)0.5 (it)0.5 (h )0.5 (a )0.5 (kn)0.5 (o)-9.6 (w)0.5 (n p)0.5 (ot)0.5 (en)0.5 (ti)0.5 (al)0.5 ( t)0.5 (o )0.5 (pr)0.5 (ol)0.5 (on)0.5 (g)-15 ( )]TJ
-0.016 Tc 0 -1.091 Td
[(the QTc inter)-18.3 (val )]TJ
/T1_1 1 Tf
[([see Drug Interactions \(7.3\) and Clinical Pharmacolog)-10.2 (y \(12.2\)])]TJ
/T1_0 1 Tf
-0.025 Tw [(.)36.8 ( Avoid )-37.3 (use)-15.9 ( )]TJ
0.012 Tw 0 -1.091 Td
[(of KRAZA)54.8 (TI in pa)-10.2 (tients with congenital long QT syndrome and in pa)-10.1 (tients with concurrent)-16 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(QTc prolonga)-9.8 (tion.)]TJ
-0.01 Tc 0.036 Tw 0 -1.631 Td
[(Monitor ECGs and electrolytes,)37 ( particularly potassium and ma)-10 (gnesium,)37 ( prior to starting)-10 ( )]TJ
-0.012 Tc 0.025 Tw 0 -1.091 Td
[(KRAZA)55.2 (TI,)37.2 ( during concomitant use,)37.2 ( and as c)20.2 (linically indica)-9.9 (ted in pa)-9.9 (tients with congestive)-12 ( )]TJ
-0.015 Tc 0.012 Tw 0 -1.091 Td
[(h)0.5 (e)0.6 (a)0.5 (r)0.6 (t)0.5 ( )0.5 (f)0.6 (a)0.5 (i)0.6 (l)0.5 (u)0.5 (r)0.6 (e)0.5 (,)37.6 ( )0.5 (b)0.5 (r)0.6 (a)0.5 (d)-9.5 (y)-9.4 (a)0.5 (r)0.6 (r)0.5 (h)0.6 (y)0.5 (t)0.5 (h)0.6 (m)0.5 (i)0.5 (a)0.6 (s)0.5 (,)37.6 ( )0.5 (e)0.5 (l)0.6 (e)0.5 (c)0.6 (t)0.5 (r)0.5 (o)0.6 (l)0.5 (y)0.6 (t)0.5 (e)0.6 ( )0.5 (a)0.5 (b)0.6 (n)0.5 (o)0.5 (r)0.6 (m)0.5 (a)0.6 (l)0.5 (i)0.5 (t)0.6 (i)0.5 (e)0.6 (s)0.5 (,)37.5 ( )0.6 (a)0.5 (n)0.5 (d)0.6 ( )0.5 (i)0.6 (n)0.5 ( )0.5 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.5 (n)0.6 (t)0.5 (s)0.5 ( )0.6 (w)0.5 (h)0.5 (o)0.6 ( )0.5 (a)0.6 (r)0.5 (e)0.6 ( )0.5 (u)0.5 (n)0.6 (a)0.5 (b)0.5 (l)0.6 (e)-15 ( )]TJ
-0.004 Tc 0.068 Tw 0 -1.091 Td
[(to a)-10.4 (void concomitant medica)-10.4 (tions tha)-10.4 (t are kno)-10.4 (wn to prolong the QT inter)-18.4 (val.)36.6 ( Correct)-4 ( )]TJ
-0.017 Tc 0.008 Tw 0 -1.091 Td
[(electrolyte abnormalities.)37.2 ( )37 (Withhold,)37.2 ( reduce the dose,)37.2 ( or permanently discontinue KRAZA)55.2 (TI)-17 ( )]TJ
0 Tw 0 -1.091 Td
(depending on severity )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.3\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.83 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Hepatotoxicity)Tj
/T1_0 1 Tf
0 Tc 0.088 Tw -3.375 -1.541 Td
[(KRAZA)54.6 (TI can cause hepa)-10.3 (totoxicity)54.6 (,)36.7 ( which may lead to drug-induced liver injur)-18.3 (y and )]TJ
-0.017 Tc 0.017 Tw 0 -1.091 Td
[(hepa)-9.8 (titis.)]TJ
-0.018 Tc -0.012 Tw 0 -1.631 Td
[(In the pooled safety popula)-10.2 (tion of 366 pa)-10.2 (tients )]TJ
/T1_1 1 Tf
[([see )36.8 (Adverse Reactions \(6)]TJ
0 Tc 0 Tw (.)Tj
-0.018 Tc 0.018 Tw 25.649 0 Td
(1\)])Tj
/T1_0 1 Tf
-0.012 Tw [( who received)-18 ( )]TJ
0.005 Tc 0.111 Tw -25.649 -1.091 Td
[(single-a)-10.1 (gent KRAZA)54.9 (TI,)37 ( drug-induced liver injur)-18 (y was reported in 0.3% of pa)-10 (tients,)42 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.091 Td
[(inc)20.2 (luding 0.3% Grade 3.)37.2 ( )37.1 (A total of 32% of pa)-9.8 (tients who received ada)-9.8 (grasib had increased)-17 ( )]TJ
-0.006 Tc 0.055 Tw 0 -1.091 Td
[(alanine aminotransferase \(AL)94.2 (T\)/increased asparta)-9.8 (te aminotransferase \(AST\); 5% were)-6 ( )]TJ
-0.008 Tc 0.046 Tw 0 -1.091 Td
[(Grade 3 and 0.5% were Grade 4.)37 ( )37 (The median time to \036rst onset of increased )37 (AL)94 (T/AST)-8 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.008 Tc 0.044 Tw -31.5 -1.091 Td
[(was 3 weeks \(range:)37.3 ( 0.1 to 48\).)37.3 ( Overall hepa)-9.7 (totoxicity occurred in 37%,)37.3 ( and 7% were)-8 ( )]TJ
-0.015 Tc 0.013 Tw 0 -1.091 Td
[(Grade 3 or 4.)36.7 ( Hepa)-10.3 (totoxicity leading to dose interruption or reduction occurred in 12% of)-14.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(pa)-9.8 (tients.)37.2 ( )37.2 (Ada)-9.8 (grasib was discontinued due to hepa)-9.8 (totoxicity in 0.5% of pa)-9.8 (tients.)]TJ
0.014 Tc 0.157 Tw 0 -1.631 Td
[(In pa)-10.1 (tients who received KRAZA)54.9 (TI in combina)-10.1 (tion with cetuximab )]TJ
/T1_1 1 Tf
0.12 Tw [([see Adverse)14 ( )]TJ
-0.014 Tc 0.015 Tw 0 -1.091 Td
[(Reactions )0.5 (\(6.1\)])]TJ
/T1_0 1 Tf
[(,)37.2 ( )0.5 (29% )0.5 (had )0.5 (increased alanine )0.5 (aminotransferase )0.5 (\(AL)94.2 (T\)/increased )0.5 (asparta)-9.7 (te)-14 ( )]TJ
-0.012 Tc 0.029 Tw 0 -1.091 Td
[(aminotransferase \(AST\); 5% )0.5 (were )0.5 (Grade )0.5 (3 and )0.5 (1)59.5 (.)59.6 (1% )0.5 (were Grade )0.5 (4.)36.5 ( )37.5 (The median )0.5 (time )0.5 (to)-12 ( )]TJ
-0.009 Tc 0.041 Tw 0 -1.091 Td
[(\036rst onset of increased )36.9 (AL)94 (T/AST was 4 weeks \(range:)37 ( 0.)60 (1 to 27\).)37 ( Overall hepa)-10 (totoxicity)-9 ( )]TJ
-0.012 Tc 0.023 Tw 0 -1.091 Td
[(o)0.5 (c)0.5 (c)0.5 (u)0.5 (r)0.5 (r)0.5 (e)0.6 (d)0.5 ( i)0.5 (n)0.5 ( 3)0.5 (8)0.5 (%)0.5 (,)37.5 ( a)0.5 (n)0.5 (d)0.5 ( 1)0.5 (0)0.5 (%)0.6 ( w)0.5 (e)0.5 (r)0.5 (e)0.6 ( G)0.5 (r)0.5 (a)0.6 (d)0.5 (e)0.5 ( 3)0.5 ( o)0.5 (r)0.5 ( 4)0.5 (.)37.5 ( H)0.6 (e)0.5 (p)0.5 (a)-9.5 (t)0.5 (o)0.5 (t)0.5 (o)0.5 (x)0.5 (i)0.6 (c)0.5 (i)0.5 (t)0.5 (y)0.5 ( l)0.5 (e)0.5 (a)0.6 (d)0.5 (i)0.5 (n)0.5 (g)0.5 ( t)0.5 (o)0.6 ( a)0.5 (d)0.5 (a)-9.4 (g)0.5 (r)0.5 (a)0.5 (s)0.5 (i)0.5 (b)0.5 ( do)0.6 (s)0.5 (e)-12 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(interruption or reduction occurred in 1)40.2 (2% of pa)-9.8 (tients.)]TJ
-0.019 Tc -0.012 Tw 0 -1.631 Td
[(M)0.5 (o)0.6 (n)0.6 (i)0.5 (t)0.5 (o)0.6 (r)0.6 ( )0.5 (l)0.6 (i)0.5 (v)0.6 (e)0.5 (r)0.6 ( )0.5 (l)0.6 (a)0.5 (b)0.6 (o)0.5 (r)0.6 (a)-9.4 (t)0.5 (o)0.6 (r)-17.5 (y)0.6 ( )0.5 (t)0.6 (e)0.5 (s)0.6 (t)0.5 (s)0.6 ( )0.5 (\()0.6 (A)0.5 (S)0.6 (T)92.5 (,)37.5 ( )37.6 (A)0.5 (L)94.6 (T)92.5 (,)37.6 ( )0.5 (a)0.6 (l)0.5 (k)0.6 (a)0.5 (l)0.6 (i)0.5 (n)0.6 (e)0.5 ( )0.6 (p)0.5 (h)0.6 (o)0.5 (s)0.6 (p)0.5 (h)0.6 (a)-9.5 (t)0.6 (a)0.5 (s)0.6 (e)0.6 ( )0.5 (a)0.6 (n)0.5 (d)0.6 ( )0.5 (t)0.6 (o)0.5 (t)0.6 (a)0.5 (l)0.6 ( )0.5 (b)0.6 (i)0.5 (l)0.6 (i)0.5 (r)0.6 (u)0.5 (b)0.6 (i)0.5 (n)0.6 (\))0.5 ( )0.6 (p)0.5 (r)0.5 (i)0.6 (o)0.6 (r)0.5 ( )0.6 (t)0.5 (o)0.6 ( )0.5 (t)0.6 (h)0.5 (e)-18.9 ( )]TJ
-0.013 Tc 0.022 Tw 0 -1.091 Td
[(start of KRAZA)54.7 (TI and monthly for 3 months or as c)19.7 (linically indica)-10.2 (ted,)36.7 ( with more frequent)-13 ( )]TJ
-0.011 Tc 0.031 Tw 0 -1.091 Td
[(testing in pa)-10 (tients who develop transaminase eleva)-10 (tions.)36.9 ( Reduce the dose,)37 ( withhold,)36.9 ( or)-11 ( )]TJ
-0.017 Tc -0.005 Tw 0 -1.091 Td
[(permanently )0.5 (discontinue )0.5 (KRAZA)55.2 (TI )0.5 (based on severity )]TJ
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.4 (Administra)-9.8 (tion )0.5 (\(2.3\))-17 ( )]TJ
-0.037 Tw 0 -1.091 Td
[(and Adverse )-36.8 (Reactio)]TJ
0 Tw (ns \(6.1\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.83 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Interstitial Lung Disease/Pneumonitis)Tj
/T1_0 1 Tf
-3.375 -1.541 Td
[(KRAZA)55.2 (TI can cause interstitial lung disease \(ILD\)/pneumonitis,)37.2 ( which can be fa)-9.8 (tal.)]TJ
-0.012 Tc 0.024 Tw 0 -1.631 Td
[(In the pooled safety popula)-9.7 (tion )]TJ
/T1_1 1 Tf
[([see )36.7 (Adverse Reactions \(6)]TJ
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.012 Tw 20.768 0 Td
(1\)])Tj
/T1_0 1 Tf
0.024 Tw [( who received single-a)-9.7 (gent)-12 ( )]TJ
-0.017 Tc 0.005 Tw -20.768 -1.091 Td
[(KRAZA)55.2 (TI,)37.2 ( )0.5 (ILD/pneumonitis )0.5 (occurred )0.5 (in )0.5 (4.)60.2 (1% )0.5 (of )0.6 (pa)-9.8 (tients,)37.2 ( )0.6 (1)60.2 (.4% )0.5 (were )0.5 (Grade )0.5 (3 )0.5 (or )0.5 (4,)37.2 ( )0.5 (and )0.6 (one)-17 ( )]TJ
-0.016 Tc 0.012 Tw 0 -1.091 Td
[(case was fa)-10.3 (tal.)36.7 ( )36.7 (The median time to \036rst onset for ILD/pneumonitis was 12 weeks \(rang\e:)20.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
[(5 to 31 weeks\).)37.3 ( )37.1 (Ada)-9.7 (grasib was discontinued due to ILD/pneumonitis in 0.8% of pa)-9.8 (tients.)]TJ
-0.016 Tc 0.012 Tw 0 -1.631 Td
[(In pa)-9.6 (tients who received KRAZA)55.3 (TI in combina)-9.6 (tion with cetuximab )]TJ
/T1_1 1 Tf
-0.025 Tw [([see Adverse )-36.6 (Reactions)-16 ( )]TJ
-0.021 Tc 0.021 Tw 0 -1.091 Td
(\(6)Tj
0 Tc 0 Tw (.)Tj
-0.021 Tc 0.021 Tw 0.839 0 Td
(1\)])Tj
/T1_0 1 Tf
-0.012 Tw [(,)36.6 ( Grade 1 ILD/pneumonitis occurred in 1)59.6 (.)59.6 (1% of pa)-10.4 (tients.)36.6 ( )36.6 (The time to \036rst onset for ILD/)]TJ
-0.017 Tc 0 Tw -0.839 -1.091 Td
(pneumonitis was 38 weeks.)Tj
-0.02 Tc -0.012 Tw 0 -1.631 Td
[(Monitor pa)-10.1 (tients for new or worsening respira)-10 (tor)-18.1 (y symptoms indica)-10 (tive of ILD/pneumonitis)-20 ( )]TJ
-0.017 Tc -0.003 Tw 0 -1.091 Td
[(\(e.g.,)37.1 ( d)-9.8 (yspnea,)37.2 ( cough,)37.2 ( fever\) during trea)-9.8 (tment with KRAZA)55.2 (TI.)37.2 ( )37.3 (Withhold KRAZA)55.2 (TI in pa)-9.8 (tients)-17 ( )]TJ
0.005 Tc 0.111 Tw 0 -1.091 Td
[(with suspected ILD/pneumonitis and permanently discontinue KRAZA)55 (TI if no other)5 ( )]TJ
-0.017 Tc 0 Tw 0 -1.091 Td
(potential causes of ILD/pneumonitis are identi\036ed )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.3\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
ET
0 0 0 1 K
4 M 
q 1 0 0 1 31.5 685.6875 cm
0 0 m
0 -54.608 l
S
Q
q 1 0 0 1 31.5 515.088 cm
0 0 m
0 -37.224 l
S
Q
q 1 0 0 1 31.5 270 cm
0 0 m
0 -54.504 l
S
Q
q 1 0 0 1 31.5 99 cm
0 0 m
0 -27.864 l
S
Q
0.5 w 10 M 
q 1 0 0 1 324 459.398 cm
0 0 m
79.798 0 l
S
Q
BT
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.248 Tm
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_0 1 Tf
-0.001 Tc 0.08 Tw -3.375 -1.494 Td
[(The follo)-9.9 (wing c)20.1 (linically signi\036cant adverse reactions are described elsewhere in the\)-1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.017 Tw -31.5 -1.044 Td
(labeling:)Tj
1.192 -1.558 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.037 Tw 1.508 0 Td
[(Gastrointestinal Adverse )-36.8 (Reactions )]TJ
/T1_1 1 Tf
0 Tw 12.389 0 Td
[([see )37.3 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_0 1 Tf
0.017 Tw -13.896 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.508 0 Td
[(QTc Inter)-17.8 (val Prolonga)-9.8 (tion )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.2\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.508 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.508 0 Td
[(Hepa)-9.7 (totoxicity )]TJ
/T1_1 1 Tf
0 Tw 5.191 0 Td
[([see )37.3 (W)18.2 (arnings and Precautions \(5.3\)])]TJ
/T1_0 1 Tf
0.017 Tw -6.698 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.508 0 Td
(Interstitial Lung Disease \(ILD\)/Pneumonitis )Tj
/T1_1 1 Tf
[([see )37.2 (W)18.3 (arnings and Precautions \(5.4\)])]TJ
/T1_2 1 Tf
0.017 Tw -2.7 -1.737 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Clinical T)74.2 (rials Experience)]TJ
/T1_0 1 Tf
-0.01 Tc 0.036 Tw -3.375 -1.494 Td
[(Because )0.6 (c)20.1 (linical )0.5 (trials )0.5 (are )0.6 (conducted )0.6 (under )0.5 (widely )0.5 (var)-17.9 (ying )0.5 (conditions,)37.1 ( )0.6 (adverse )0.6 (reaction)-10 ( )]TJ
-0.013 Tc 0.021 Tw 0 -1.044 Td
[(ra)-10 (tes obser)-18 (ved in the c)19.9 (linical trials of a drug cannot be directly compared to ra)-10.1 (tes in the)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(c)20.2 (linical trials of another drug and may not re\037ect the ra)-9.8 (tes obser)-17.8 (ved in practice.)]TJ
-0.003 Tc 0.073 Tw 0 -1.584 Td
[(The pooled safety popula)-10.2 (tion described in the )37.2 (W)17.7 (ARNINGS )37.2 (AND PRECAUTIONS re\037ect)-3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(exposure to ada)-10.3 (grasib as a single a)-10.2 (gent a)-10.2 (t 600 mg orally twice daily in 366 pa)-10.2 (tients with)-17 ( )]TJ
-0.013 Tc 0.021 Tw 0 -1.044 Td
[(NSCLC and other solid tumors enrolled in KR)18 (YST)55.1 (AL-1 and KR)18 (YST)55 (AL-1)40 (2 \(NCT04685135\),)24 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(respectively)55.2 (.)37.2 ( )36.7 (Among 366 pa)-9.8 (tients who received ada)-9.7 (grasib,)37.2 ( 39% of pa)-9.8 (tients were exposed)-17 ( )]TJ
-0.011 Tc 0.032 Tw 0 -1.044 Td
[(for 6 months or longer and 1)39.9 (2% were exposed for grea)-10.1 (ter than one year)73.8 (.)36.8 ( In this pooled)-11 ( )]TJ
-0.001 Tc 0.08 Tw 0 -1.044 Td
[(safety popula)-9.8 (tion,)37.1 ( the most common \(\03525%\) adverse reactions were nausea \(70%\),)36 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(diar)0.5 (rhea )0.5 (\(69%\),)37.4 ( v)0.5 (omiti)0.5 (ng \(57%\))0.5 (,)37.4 ( fa)-9.6 (t)0.5 (igue \(55)0.5 (%\),)37.4 ( mu)0.5 (sculosk)0.5 (eleta)0.5 (l pain )0.5 (\(38%\),)37.4 ( h)0.5 (epa)-9.6 (to)0.5 (toxici)0.5 (ty)-18 ( )]TJ
-0.01 Tc 0.038 Tw 0 -1.044 Td
[(\(37%\),)36.7 ( renal impairment \(33%\),)36.6 ( edema \(30%\),)36.7 ( d)-10.3 (yspnea \(26%\),)36.7 ( and decreased a)-10.3 (ppetite)-10 ( )]TJ
-0.015 Tc 0.014 Tw 0 -1.044 Td
[(\(29%\).)36.6 ( )0.5 (In )0.5 (this )0.6 (pooled )0.5 (safety )0.6 (popula)-10.4 (tion,)36.6 ( )0.6 (the )0.5 (most )0.6 (common )0.5 (Grade )0.6 (3 )0.5 (or )0.6 (4 )0.5 (\(\0352%\) )0.5 (labora)-10.4 (tor)-18.4 (y)-14.9 ( )]TJ
0.014 Tc 0.153 Tw 0 -1.044 Td
[(a)0.5 (b)0.5 (n)0.5 (o)0.5 (r)0.5 (m)0.5 (a)0.5 (l)0.5 (it)0.5 (i)0.5 (e)0.5 (s)0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.5 ( d)0.5 (e)0.5 (c)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 (d)0.5 ( l)0.5 (y)0.5 (m)0.5 (p)0.5 (h)0.5 (o)0.5 (c)20.5 (yt)0.6 (es)0.5 ( \()0.5 (2)0.5 (0)0.5 (%)0.5 (\),)37.5 ( d)0.5 (e)0.5 (c)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (ed)0.5 ( h)0.5 (e)0.5 (m)0.5 (o)0.5 (g)0.5 (l)0.5 (o)0.5 (bi)0.5 (n)0.5 ( \()0.5 (7)0.5 (%)0.5 (\))0.5 (,)51 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(increased alanine aminotransferase \(4.5%\),)37.4 ( increased asparta)-9.6 (te aminotra)0.5 (nsferase \(4.2%\),)19 ( )]TJ
0 -1.044 Td
[(hypokalemia \(3.6%\),)36.7 ( hypona)-10.2 (tremia \(3.4%\),)36.7 ( increased lipase \(2.5%\),)36.7 ( decreased leukoc)19.7 (ytes)-18 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(\(2.5%\),)37.1 ( decreased neutrophils \(2.3%\),)37.2 ( and increased alkaline phospha)-9.8 (tase \(2.0%\).)]TJ
-0.005 Tw 0 -1.584 Td
[(The da)-9.7 (ta described in )36.9 (W)18.2 (ARNINGS )36.8 (AND PRECAUTIONS and belo)-9.8 (w also re\037ects exposure to)-17 ( )]TJ
-0.003 Tw 0 -1.044 Td
[(ada)-9.8 (grasib in combina)-9.7 (tion with cetuximab in 94 pa)-9.8 (tients with )]TJ
/T1_1 1 Tf
0.017 Tw (KRAS)Tj
/T1_0 1 Tf
-0.003 Tw [( G1)40.2 (2C-muta)-9.8 (ted,)37.2 ( locally)-17 ( )]TJ
0 Tw 0 -1.044 Td
[(advanced or metasta)-9.8 (tic CRC in KR)18.2 (YST)55.2 (AL-1.)]TJ
0 -1.625 Td
(Non-Small Cell Lung Cancer)Tj
-0.002 Tc 0.078 Tw 0 -1.539 Td
[(The safety of )0.5 (ada)-10.2 (grasib )0.5 (was )0.5 (evalua)-10.3 (ted in )0.5 (pa)-10.3 (tients )0.5 (with )]TJ
/T1_1 1 Tf
0.002 Tw 20.963 0 Td
(KRAS)Tj
/T1_0 1 Tf
0.078 Tw [( G1)39.8 (2C-muta)-10.3 (ted,)36.7 ( )0.5 (locally)-2 ( )]TJ
0.002 Tc 0.095 Tw -20.963 -1.044 Td
[(advanced or metasta)-9.8 (tic NSCLC in KR)18.2 (YST)55.2 (AL-1 )]TJ
/T1_1 1 Tf
([see Clinical Studies \(14)Tj
0 Tc 0 Tw (.)Tj
0.002 Tc -0.002 Tw 27.007 0 Td
(1\)])Tj
/T1_0 1 Tf
0.095 Tw [(.)37.2 ( P)18.1 (a)-9.8 (tients)2 ( )]TJ
-0.005 Tc 0.06 Tw -27.007 -1.044 Td
[(received ada)-9.9 (grasib 600 mg orally twice daily \(n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
17.774 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.715 0 Td
[(1)60.1 (1)40.2 (6\).)37.2 ( )36.8 (Among pa)-9.9 (tients who received)-5 ( )]TJ
-0.013 Tc 0.02 Tw -18.489 -1.044 Td
[(ada)-9.8 (grasib,)37.2 ( 45% were exposed for 6 months or longer and 4% were exposed for grea)-9.8 (ter)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(than one year)74.2 (.)]TJ
-0.003 Tc 0.074 Tw 0 -1.584 Td
[(The )0.5 (median )0.5 (a)-10.4 (ge of )0.5 (pa)-10.4 (tients who )0.5 (received )0.5 (ada)-10.4 (grasib )0.5 (was )0.5 (64 )0.5 (years )0.5 (\(range )0.5 (25 )0.5 (to )0.5 (89\),)34 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc -31.5 -1.044 Td
[(56% female,)37.2 ( 84% )37.2 (White,)37.2 ( 8% Black or )37.2 (African )37.2 (American,)37.2 ( and 4.3% )37.2 (Asian.)]TJ
-0.012 Tc 0.024 Tw 0 -1.584 Td
[(Serious adverse reactions occurred in 57% of pa)-9.7 (tients who received ada)-9.7 (grasib.)37.4 ( Serious)-12 ( )]TJ
0.003 Tc 0.099 Tw 0 -1.044 Td
[(adver)0.5 (se reactio)0.5 (ns in \0352% of)0.5 ( pa)-9.5 (tients we)0.5 (re pneumo)0.5 (nia)0.5 ( \(17%\),)37.4 ( d)-9.6 (yspne)0.5 (a \(9%\),)37.4 ( renal)3.1 ( )]TJ
-0.015 Tc 0.013 Tw 0 -1.044 Td
[(impairment \(8%\),)36.7 ( sepsis \(5%\),)36.7 ( hypoxia \(4.3%\),)36.6 ( pleural effusion \(4.3%\),)36.7 ( respira)-10.3 (tor)-18.3 (y failure)-14.9 ( )]TJ
0 -1.044 Td
[(\(4.3%\),)36.6 ( anemia \(3.4%\),)36.6 ( cardiac failure \(3.4%\),)36.6 ( hypona)-10.4 (tremia \(3.4%\),)36.6 ( hypotension \(3.4%\),)22 ( )]TJ
-0.013 Tc 0.018 Tw 0 -1.044 Td
[(m)0.6 (u)0.5 (s)0.6 (c)0.5 (u)0.6 (l)0.5 (a)0.6 (r)0.5 ( w)0.5 (e)0.6 (a)0.6 (k)0.5 (n)0.6 (e)0.5 (s)0.6 (s)0.5 ( \()0.6 (3)0.5 (.)0.6 (4)0.5 (%)0.6 (\))0.5 (,)37.6 ( p)0.5 (y)0.6 (r)0.5 (e)0.6 (x)0.5 (i)0.6 (a)0.5 ( \()0.6 (3)0.5 (.)0.6 (4)0.5 (%)0.6 (\))0.5 (,)37.6 ( d)0.5 (e)0.6 (h)0.5 (y)0.6 (d)0.5 (r)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.6 (n)0.5 ( \()0.6 (2)0.5 (.)0.6 (6)0.5 (%)0.6 (\))0.5 (,)37.6 ( d)0.5 (i)0.6 (a)0.5 (r)0.6 (r)0.5 (h)0.6 (e)0.5 (a)0.6 ( \()0.5 (2)0.6 (.)0.5 (6)0.6 (%)0.6 (\))0.5 (,)37.5 ( m)0.6 (e)0.5 (n)0.6 (t)0.5 (a)0.6 (l)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(sta)-10 (tus changes \(2.6%\),)37 ( pulmonar)-18 (y embolism \(2.6%\),)36.9 ( and pulmonar)-18 (y hemorrha)-10 (ge \(2.6%\).)20 ( )]TJ
-0.001 Tc 0.079 Tw 0 -1.044 Td
[(F)20.3 (a)-9.7 (tal adverse reactions occurred in 11% of pa)-9.7 (tients who received ada)-9.7 (grasib due to)-1 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(pneumonia \(3.4%\),)36.6 ( respira)-10.3 (tor)-18.4 (y failure \(1.7%\),)36.6 ( sudden dea)-10.4 (th \(1.7%\),)36.7 ( cardiac failure \(0.9%\),)19 ( )]TJ
-0.004 Tc 0.067 Tw 0 -1.044 Td
[(cerebrovascular accident \(0.9%\),)36.8 ( mental sta)-10.2 (tus change \(0.9%\),)36.8 ( pulmonar)-18.2 (y embolism)-4 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(\(0.9%\),)37.1 ( and pulmonar)-17.8 (y hemorrha)-9.8 (ge \(0.9%\).)]TJ
-0.011 Tc 0.031 Tw 0 -1.584 Td
[(P)18.1 (ermanent discontinua)-10 (tion of ada)-9.9 (grasib due to an adverse reaction occurred in 13% of)-11 ( )]TJ
-0.005 Tc 0.058 Tw 0 -1.044 Td
[(p)0.5 (a)-9.4 (t)0.6 (i)0.5 (e)0.5 (n)0.6 (t)0.5 (s)0.6 (.)37.5 ( )37.2 (A)0.6 (d)0.5 (v)0.6 (e)0.5 (r)0.6 (s)0.5 (e)0.6 ( r)0.5 (e)0.6 (a)0.6 (c)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 (s)0.5 ( w)0.5 (h)0.5 (i)0.6 (c)0.5 (h)0.6 ( r)0.6 (e)0.5 (s)0.6 (u)0.5 (l)0.5 (t)0.6 (e)0.5 (d)0.6 ( i)0.6 (n)0.5 ( p)0.5 (e)0.6 (r)0.5 (m)0.6 (a)0.5 (n)0.6 (e)0.5 (n)0.5 (t)0.6 ( d)0.5 (i)0.5 (s)0.6 (c)0.5 (o)0.6 (n)0.5 (t)0.5 (i)0.6 (n)0.5 (u)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.6 (n)0.5 ( o)0.5 (f)0.6 ( a)0.6 (d)0.5 (a)-9.4 (g)0.5 (r)0.5 (a)0.6 (s)0.5 (i)0.6 (b)-5 ( )]TJ
-0.011 Tc 0.033 Tw 0 -1.044 Td
[(occurring in two pa)-10.3 (tients each \(1.7%\) were pneumonia and pneumonitis and occurring)-11 ( )]TJ
0.013 Tc 0.152 Tw 0 -1.044 Td
[(in one pa)-10.2 (tient each \(0.9%\) were cerebrovascular accident,)36.8 ( d)-10.2 (yspnea,)36.8 ( decreased)13 ( )]TJ
-0.008 Tc 0.047 Tw 0 -1.044 Td
[(ejection fraction,)36.9 ( encephalitis,)36.9 ( gastrointestinal obstruction,)36.9 ( hemorrha)-10.1 (ge,)36.9 ( hepa)-10.1 (totoxicity)54.9 (,)29 ( )]TJ
0.003 Tc 0.1 Tw 0 -1.044 Td
[(hypotension,)37.2 ( muscular weakness,)37.2 ( pulmonar)-17.8 (y embolism,)37.2 ( pyrexia,)37.1 ( respira)-9.9 (tor)-17.8 (y failure)3 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(and sepsis.)Tj
-0.013 Tc 0.021 Tw 0 -1.584 Td
[(Dose interruptions of ada)-10 (grasib due to an adverse reaction occurred in 77% of pa)-10 (tients.)24 ( )]TJ
-0.022 Tc -0.013 Tw 0 -1.044 Td
[(Adverse reactions requiring dosa)-9.8 (ge interruption in \0352% of pa)-9.7 (tients who received ada)-9.7 (grasib)-22 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.044 Td
[(inc)20.3 (luded nausea,)37.4 ( hepa)-9.7 (totoxicity)55.4 (,)37.4 ( fa)-9.6 (tigue,)37.3 ( vomiting,)37.4 ( pneumonia,)37.4 ( renal impairment,)37.3 ( diarrhea,)20 ( )]TJ
0.006 Tc 0.115 Tw 0 -1.044 Td
[(QTc inter)-17.8 (val prolonga)-9.8 (tion,)37.3 ( anemia,)37.2 ( d)-9.8 (yspnea,)37.2 ( increased lipase,)37.2 ( decreased a)-9.7 (ppetite,)43 ( )]TJ
-0.008 Tc 0.048 Tw 0 -1.044 Td
[(dizziness,)36.6 ( hypona)-10.4 (tremia,)36.6 ( muscular weakness,)36.6 ( increased amylase,)36.7 ( pneumonitis,)36.7 ( sepsis)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(and decreased weight.)Tj
-0.008 Tc 0.047 Tw 0 -1.584 Td
[(Dose reductions of ada)-10.1 (grasib due to an adverse reaction occurred in 28% of pa)-10.1 (tients.)29 ( )]TJ
-0.001 Tc 0.084 Tw 0 -1.044 Td
[(Adverse )0.5 (reactions )0.5 (which required )0.5 (dose )0.5 (reductions in \0352% of )0.5 (pa)-10.4 (tients )0.5 (who )0.5 (received)-1 ( )]TJ
0.012 Tc 0.144 Tw 0 -1.044 Td
[(ada)-9.6 (grasib inc)20.3 (luded hepa)-9.6 (totoxicity)55.4 (,)37.3 ( fa)-9.6 (tigue,)37.3 ( nausea,)37.3 ( diarrhea,)37.3 ( vomiting,)37.4 ( and renal)12 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(impairment.)Tj
-0.009 Tc 0.038 Tw 0 -1.584 Td
[(T)0.5 (h)0.5 (e)0.5 ( m)0.5 (o)0.5 (s)0.5 (t)0.5 ( c)0.5 (o)0.5 (m)0.5 (m)0.5 (o)0.5 (n)0.5 ( a)0.5 (d)0.5 (v)0.5 (e)0.6 (r)0.5 (s)0.5 (e)0.5 ( r)0.5 (e)0.6 (a)0.5 (c)0.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (s)0.5 ( \()0.5 (\035)0.5 (2)0.5 (0)0.5 (%)0.5 (\))0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.5 ( d)0.5 (i)0.5 (a)0.5 (r)0.5 (r)0.5 (h)0.5 (e)0.5 (a)0.6 (,)37.4 ( n)0.5 (a)0.5 (u)0.5 (s)0.5 (e)0.6 (a)0.5 (,)37.5 ( f)0.5 (a)-9.5 (t)0.6 (i)0.5 (g)0.5 (u)0.5 (e)0.5 (,)37.5 ( v)0.5 (o)0.6 (m)0.5 (i)0.5 (t)0.5 (i)0.5 (n)0.5 (g)0.5 (,)28 ( )]TJ
0 Tc 0.089 Tw 0 -1.044 Td
[(musculoskeletal pain,)36.5 ( hepa)-10.4 (totoxicity)54.5 (,)36.6 ( renal impairment,)36.5 ( d)-10.4 (yspnea,)36.5 ( edema,)36.5 ( decreased )]TJ
-0.007 Tc 0.054 Tw 0 -1.044 Td
[(a)-10.4 (ppetite,)36.5 ( )0.5 (cough,)36.6 ( pneumonia,)36.5 ( )0.5 (dizziness,)36.6 ( constipa)-10.4 (tion,)36.6 ( abdominal pain,)36.5 ( )0.5 (and )0.5 (QTc )0.5 (inter)-18.4 (val)-7 ( )]TJ
0.005 Tc 0.113 Tw 0 -1.044 Td
[(prolonga)-10.3 (tion.)36.7 ( )36.9 (The most common labora)-10.3 (tor)-18.3 (y abnormalities \(\03525%\) were decreased)5 ( )]TJ
0.004 Tc 0.107 Tw 0 -1.044 Td
[(lymphoc)19.9 (ytes,)36.9 ( increased asparta)-10.1 (te aminotransferase,)36.9 ( decreased sodium,)36.8 ( decreased)4 ( )]TJ
-0.022 Tc -0.013 Tw 0 -1.044 Td
[(he)0.5 (m)0.5 (ogl)0.5 (o)0.5 (bin)0.5 (,)37.4 ( )0.6 (in)0.5 (cre)0.5 (a)0.5 (se)0.5 (d )0.6 (cre)0.5 (a)-9.5 (ti)0.5 (nin)0.5 (e)0.5 (,)37.4 ( )0.5 (d)0.5 (ec)0.5 (re)0.5 (as)0.5 (ed)0.5 ( )0.5 (a)0.5 (lb)0.5 (um)0.5 (in)0.5 (,)37.4 ( )0.6 (inc)0.5 (re)0.5 (as)0.5 (ed)0.5 ( )0.5 (a)0.5 (la)0.5 (ni)0.5 (ne)0.5 ( )0.5 (a)0.5 (mi)0.5 (no)0.5 (tr)0.5 (an)0.5 (sf)0.5 (er)0.5 (as)0.5 (e,)15 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(increased lipase,)37.2 ( decreased pla)-9.8 (telets,)37.2 ( decreased ma)-9.8 (gnesium,)37.2 ( and decreased potassium.)]TJ
0 -1.584 Td
[(T)74.2 (able 3 summarizes the adverse reactions in KR)18.2 (YST)55.1 (AL-1.)]TJ
ET
endstreamendobj80 0 obj<</Length 25014>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 483.728 cm
0 0 m
79.798 0 l
S
Q
q 1 0 0 1 36 441.718 cm
0 0 m
49.925 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 8 0 0 8 36 727.248 Tm
[(FULL PRESCRIBING INFORMA)55.2 (TION)]TJ
0.017 Tw 0 -2.025 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.017 Tw -3.375 -1.692 Td
(1.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 3.375 0 Td
[(K)0.5 (R)0.5 (A)0.5 (S)]TJ
/T1_0 1 Tf
0.012 Tw 2.106 0 Td
[( )0.5 (G)0.5 (1)40.5 (2)0.5 (C)0.5 (-M)0.6 (ut)0.5 (a)0.5 (t)0.5 (e)0.5 (d)0.5 ( )0.5 (L)0.5 (o)0.5 (c)0.5 (a)0.5 (ll)0.6 (y)0.5 ( A)0.5 (d)0.5 (v)16.5 (a)0.5 (n)0.5 (c)0.5 (e)0.5 (d )0.5 (o)0.5 (r)0.5 ( )0.5 (M)0.5 (e)0.5 (t)0.5 (a)0.5 (s)0.5 (t)0.5 (a)0.5 (t)0.5 (i)0.5 (c)0.5 ( )0.5 (N)0.5 (o)0.5 (n-)0.5 (S)0.5 (m)0.5 (a)0.5 (l)0.5 (l)0.5 ( )0.5 (C)0.5 (e)0.5 (l)0.5 (l)0.5 ( )0.5 (Lu)0.5 (n)0.5 (g)-15 ( )]TJ
-0.017 Tc 0.017 Tw -2.106 -1.062 Td
(Cancer)Tj
/T1_2 1 Tf
-0.007 Tc 0.053 Tw -3.375 -1.494 Td
[(KRAZA)54.6 (TI,)36.6 ( as a single-a)-10.4 (gent,)36.6 ( is indica)-10.4 (ted for the trea)-10.3 (tment of adult pa)-10.4 (tients with )]TJ
/T1_3 1 Tf
0.007 Tw (KRAS)Tj
/T1_2 1 Tf
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.006 Tc 0.054 Tw -31.5 -1.044 Td
[(G1)0.5 (2C-)0.5 (mut)0.5 (a)-9.6 (te)0.5 (d )0.6 (loc)0.5 (all)0.5 (y )0.5 (a)0.5 (dv)0.5 (anc)0.5 (ed )0.6 (or )0.6 (me)0.5 (ta)0.5 (sta)-9.5 (tic)0.5 ( )0.5 (no)0.5 (n-s)0.5 (ma)0.5 (ll )0.6 (cel)0.5 (l )0.5 (l)0.5 (ung)0.5 ( )0.5 (ca)0.5 (nce)0.5 (r )0.6 (\(NSC)0.5 (LC\))0.5 (,)37.4 ( )0.5 (a)0.5 (s)-6 ( )]TJ
-0.009 Tc 0.043 Tw 0 -1.044 Td
[(determined by an FDA-a)-10.2 (pproved test )]TJ
/T1_3 1 Tf
[([see Dosa)-10.3 (ge and )37.1 (Administra)-10.3 (tion \(2.1\)])]TJ
/T1_2 1 Tf
[(,)36.7 ( who ha)-10.3 (ve)-8.9 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(received a)-9.8 (t least one prior systemic thera)-9.8 (py)55.2 (.)]TJ
-0.015 Tc 0.012 Tw 0 -1.584 Td
[(This indica)-10 (tion is a)-10 (pproved under accelera)-10 (ted a)-10.1 (pproval based on objective response ra)-10 (te)-15 ( )]TJ
-0.017 Tc -0.001 Tw 0 -1.044 Td
[(\(ORR\) and dura)-9.8 (tion of response \(DOR\) )]TJ
/T1_3 1 Tf
([see Clinical Studies \(14.1\)])Tj
/T1_2 1 Tf
[(.)37.2 ( Continued a)-9.8 (pproval for)-17 ( )]TJ
-0.015 Tc 0.013 Tw 0 -1.044 Td
[(this indica)-10.3 (tion may be contingent upon veri\036ca)-10.3 (tion and description of a c)19.7 (linical bene\036t in)-15 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(a con\036rma)-9.8 (tor)-17.7 (y trial.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(1.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_1 1 Tf
3.375 0 Td
(KRAS)Tj
/T1_0 1 Tf
0 Tw [( G1)40.2 (2C-Mutated Locally Adv)16.2 (anced or Metastatic Colorectal Cancer)]TJ
/T1_2 1 Tf
-0.009 Tc 0.038 Tw -3.375 -1.494 Td
[(KR)0.5 (AZA)55.5 (TI in com)0.5 (bi)0.5 (na)-9.5 (tio)0.5 (n w)0.5 (it)0.5 (h c)0.5 (et)0.5 (uxi)0.5 (ma)0.5 (b i)0.5 (s i)0.5 (ndi)0.5 (ca)-9.5 (te)0.5 (d f)0.5 (or)0.5 ( th)0.5 (e t)0.5 (re)0.5 (a)-9.6 (t)0.5 (me)0.5 (nt of)0.5 ( ad)0.5 (ult)0.5 ( pa)-9.5 (ti)0.5 (en)0.5 (ts)-9 ( )]TJ
-0.004 Tc 0.004 Tw 0 -1.044 Td
(with )Tj
/T1_3 1 Tf
1.864 0 Td
(KRAS)Tj
/T1_2 1 Tf
0.068 Tw [( G12C-muta)-10.3 (ted locally advanced or metasta)-10.4 (tic colorectal cancer \(CRC\),)36.7 ( as)-4 ( )]TJ
-0.009 Tc 0.043 Tw -1.864 -1.044 Td
[(determined by an FDA-a)-10.2 (pproved test )]TJ
/T1_3 1 Tf
[([see Dosa)-10.3 (ge and )37.1 (Administra)-10.3 (tion \(2.1\)])]TJ
/T1_2 1 Tf
[(,)36.7 ( who ha)-10.3 (ve)-8.9 ( )]TJ
0.007 Tc 0.119 Tw 0 -1.044 Td
[(received prior trea)-9.7 (tment with fluoropyrimidine-,)37.3 ( oxalipla)-9.7 (tin-,)37.3 ( and irinotecan-based)7 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(chemothera)-9.8 (py)55.2 (.)]TJ
-0.003 Tc 0.069 Tw 0 -1.584 Td
[(This indica)-9.7 (tion is a)-9.7 (pproved under accelera)-9.7 (ted a)-9.7 (pproval based on ORR and DOR )]TJ
/T1_3 1 Tf
0.003 Tw [([see)-3 ( )]TJ
-0.008 Tc 0.046 Tw 0 -1.044 Td
(Clinical Studies \(14.2\)])Tj
/T1_2 1 Tf
[(.)37 ( Continued a)-9.9 (pproval for this indica)-10 (tion may be contingent upon)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(veri\036ca)-9.8 (tion and description of a c)20.1 (linical bene\036t in a con\036rma)-9.8 (tor)-17.7 (y trial.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.845 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
0.017 Tw -3.375 -1.692 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24.2 (atient Selection)]TJ
/T1_2 1 Tf
-3.375 -1.535 Td
(Non-Small Cell Lung Cancer)Tj
-0.019 Tc -0.012 Tw 0 -1.539 Td
[(S)0.5 (e)0.5 (l)0.6 (e)0.5 (c)0.5 (t)0.5 ( )0.6 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 ( )0.5 (f)0.6 (o)0.5 (r)0.5 ( )0.5 (t)0.6 (r)0.5 (e)0.5 (a)-9.5 (t)0.6 (m)0.5 (e)0.5 (n)0.5 (t)0.6 ( )0.5 (o)0.5 (f)0.5 ( )0.6 (l)0.5 (o)0.5 (c)0.5 (a)0.5 (l)0.6 (l)0.5 (y)0.5 ( )0.5 (a)0.5 (d)0.6 (v)0.5 (a)0.5 (n)0.5 (c)0.5 (e)0.6 (d)0.5 ( )0.5 (o)0.5 (r)0.5 ( )0.6 (m)0.5 (e)0.5 (t)0.6 (a)0.5 (s)0.5 (t)0.5 (a)-9.5 (t)0.6 (i)0.5 (c)0.5 ( )0.5 (N)0.5 (S)0.6 (C)0.5 (L)0.5 (C)0.5 ( )0.5 (w)0.6 (i)0.5 (t)0.5 (h)0.5 ( )0.5 (K)0.6 (R)0.5 (A)0.5 (Z)0.5 (A)55.5 (T)0.5 (I)0.5 ( )0.5 (b)0.6 (a)0.5 (s)0.5 (e)0.5 (d)-19 ( )]TJ
-0.004 Tc 0.064 Tw 0 -1.044 Td
(on the presence of )Tj
/T1_3 1 Tf
0.004 Tw (KRAS)Tj
/T1_2 1 Tf
0.064 Tw [( G1)60.3 (2C muta)-9.7 (tion in plasma or tumor specimens )]TJ
/T1_3 1 Tf
[([see Clinical)-4 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(Studies \(14)Tj
0 Tc (.)Tj
-0.017 Tc 0.017 Tw 4.155 0 Td
(1\)])Tj
/T1_2 1 Tf
0 Tw [(.)37.2 ( If no muta)-9.7 (tion is detected in a plasma specimen,)37.2 ( test tumor tissue.)]TJ
-4.155 -1.625 Td
(Colorectal Cancer)Tj
-0.013 Tc 0.021 Tw 0 -1.539 Td
[(Select pa)-9.9 (tients for trea)-9.9 (tment of locally advanced or metasta)-9.9 (tic CRC with KRAZA)55.1 (TI based)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(on the presence of )Tj
/T1_3 1 Tf
0.017 Tw (KRAS)Tj
/T1_2 1 Tf
0 Tw [( G1)60.2 (2C muta)-9.8 (tion in tumor specimens )]TJ
/T1_3 1 Tf
([see Clinical Studie)Tj
(s \(14.2\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
-0.018 Tc -0.012 Tw 0 -1.584 Td
[(Informa)-10.3 (tion on FDA-a)-10.3 (pproved tests for the detection of a )]TJ
/T1_3 1 Tf
0.018 Tw (KRAS)Tj
/T1_2 1 Tf
-0.012 Tw [( G12C muta)-10.3 (tion is a)-10.3 (vailable)-18 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(a)-9.8 (t:)37.2 ( https://www)37.2 (.fda.gov/CompanionDia)-9.8 (gnostics)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Recommended Dosage)Tj
/T1_2 1 Tf
-0.018 Tc -0.012 Tw -3.412 -1.494 Td
[(The recommended dosa)-9.7 (ge of KRAZA)55.3 (TI as a single a)-9.6 (gent or in combina)-9.6 (tion with cetuximab)-18.1 ( )]TJ
-0.017 Tc 0 Tw 0.037 -1.044 Td
[(is 600 mg orally twice daily until disease progression or unacceptable t\oxicity)55.2 (.)]TJ
-0.008 Tc 0.047 Tw 0 -1.584 Td
[(Refer to the cetuximab prescribing informa)-10.2 (tion for cetuximab dosa)-10.3 (ge informa)-10.2 (tion )]TJ
/T1_3 1 Tf
0.008 Tw [([see)-8 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
(Clinical Studie)Tj
(s \(14.2\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
-0.017 Tc -0.012 Tw 0 -1.584 Td
[(T)74.3 (ake KRAZA)55.4 (TI a)-9.6 (t the same time ever)-17.6 (y day with or without food )]TJ
/T1_3 1 Tf
[([see Clinical Pharmacolog)-9.7 (y)-17 ( )]TJ
0.017 Tw 0 -1.044 Td
(\(12.3\)])Tj
/T1_2 1 Tf
0 Tw [(.)37.3 ( Swallo)-9.8 (w tablets whole.)37.2 ( Do not chew)37.2 (,)37.2 ( crush or split tablets.)]TJ
0 -1.584 Td
[(If vomiting occurs after taking KRAZA)55.2 (TI,)37.2 ( do not take an additional dose.)37.2 ( Resume dosing a)-9.8 (t)-17 ( )]TJ
0 -1.044 Td
(the next scheduled time.)Tj
-0.018 Tc -0.012 Tw 0 -1.584 Td
[(If)0.5 ( a)0.5 ( do)0.5 (se )0.5 (is )0.5 (ina)0.5 (dve)0.5 (rt)0.5 (ent)0.5 (ly )0.5 (mis)0.5 (sed)0.5 (,)37.4 ( i)0.5 (t s)0.5 (hou)0.5 (ld )0.5 (be )0.5 (ski)0.5 (ppe)0.5 (d )0.5 (if )0.5 (gre)0.5 (a)-9.6 (te)0.5 (r )0.5 (tha)0.5 (n 4)0.5 ( ho)0.5 (urs)0.5 ( ha)-9.5 (ve)0.5 ( el)0.5 (a)-9.6 (p)0.5 (sed)-18 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(from the expected dosing time.)37.2 ( Resume dosing a)-9.8 (t the next scheduled time.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Dosage Modifications for Adverse Reactions)Tj
/T1_2 1 Tf
-0.019 Tc -0.012 Tw -3.375 -1.494 Td
[(Recommended dose reductions for adverse reactions for use of KRAZA)54.9 (TI as a single a)-10 (gent)-19 ( )]TJ
-0.008 Tc 0.048 Tw 0 -1.044 Td
[(or in combina)-10.3 (tion with cetuximab are outlined in )36.7 (T)73.6 (able 1.)36.6 ( If adverse reactions occur)73.6 (,)36.6 ( a)-8 ( )]TJ
-0.005 Tc 0.06 Tw 0 -1.044 Td
[(maximum of two dose reductions are permitted.)37.2 ( P)18.2 (ermanently discontinue KRAZA)55.2 (TI in)-5 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(pa)-9.8 (tients who are unable to tolera)-9.8 (te 600 mg once daily)55.2 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 219.978 252 -9.312 re
36 210.666 126 -13.412 re
162 210.666 126 -13.412 re
36 197.254 126 -10.752 re
162 197.254 126 -10.752 re
36 186.502 126 -10.752 re
162 186.502 126 -10.752 re
f
1 w 
/GS2 gs
q 1 0 0 1 36 210.6661 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 210.6661 cm
0 0 m
126 0 l
S
Q
0.5 w 
q 1 0 0 1 162 197.5042 cm
0 0 m
0 12.662 l
S
Q
q 1 0 0 1 36 197.2542 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 197.2542 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 186.7523 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 36 186.5023 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 186.5023 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 176.2504 cm
0 0 m
0 10.002 l
S
Q
1 w 
q 1 0 0 1 36 175.7504 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 175.7504 cm
0 0 m
126 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.048 Tw 8 0 0 8 36 214.2661 Tm
[(T)74.2 (able 1:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Recommended KRAZA)55.2 (TI Dosage Reductions for Adverse Reactions)]TJ
-0.012 Tc 7.6 0 0 8 75.7393 200.8542 Tm
(Dose Reduction)Tj
0.012 Tw 18.216 0 Td
(Dosage)Tj
/T1_2 1 Tf
0.048 Tw -18.749 -1.479 Td
[(F)18.2 (irst dose reduction)]TJ
16.698 0 Td
(400 mg twice daily)Tj
-17.266 -1.344 Td
(Second dose reduction)Tj
17.362 0 Td
(600 mg once daily)Tj
0.005 Tc 0.11 Tw 8 0 0 8 36 155.7404 Tm
[(Refer to the cetuximab prescribing informa)-9.8 (tion for dose modifica)-9.8 (tions for adverse)5 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(reactions associa)-9.8 (ted with cetuximab.)]TJ
-0.013 Tc 0.022 Tw 0 -1.584 Td
[(When KRAZA)54.8 (TI is administered in combina)-10.2 (tion with cetuximab,)36.8 ( withhold or permanently)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(discontinue cetuximab when KRAZA)55.3 (TI is withheld or permanently discontinued.)]TJ
-0.016 Tc 0.012 Tw 0 -1.584 Td
[(T)74.1 (rea)-9.9 (tment with KRAZA)55.2 (TI as a single a)-9.8 (gent may be continued if cetuximab is permanently)-16 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(discontinued.)37.2 ( )]TJ
/T1_3 1 Tf
0 Tw 4.905 0 Td
[([see Clinical Pharmacolog)-9.7 (y \(12.1\),)37.2 ( Clinical Studie)]TJ
(s \(14.2\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
-0.017 Tc -4.905 -1.584 Td
[(The recommended dosa)-9.8 (ge modi\036ca)-9.8 (tions for adverse reactions are provided in )37.2 (T)74.2 (able 2.)]TJ
ET
4 M 
q 1 0 0 1 31.5 607.32 cm
0 0 m
0 -88.92 l
S
Q
q 1 0 0 1 31.5 494.28 cm
0 0 m
0 -41.4 l
S
Q
q 1 0 0 1 31.5 449.28 cm
0 0 m
0 -33.12 l
S
Q
q 1 0 0 1 31.5 381.96 cm
0 0 m
0 -41.688 l
S
Q
q 1 0 0 1 31.608 275.4 cm
0 0 m
0 -51.12 l
S
Q
q 1 0 0 1 31.5 162.72 cm
0 0 m
0 -62.928 l
S
Q
0 0 0 0 k
/GS0 gs
324 732.96 252 -10.212 re
324 722.748 71.28 -12.912 re
395.28 722.748 90.36 -12.912 re
485.64 722.748 90.36 -12.912 re
324 709.836 71.28 -71.832 re
395.28 709.836 90.36 -71.832 re
485.64 709.836 90.36 -71.832 re
324 638.004 71.28 -63.332 re
395.28 638.004 90.36 -63.332 re
485.64 638.004 90.36 -63.332 re
324 574.672 71.28 -109.664 re
395.28 574.672 90.36 -57.352 re
485.64 574.672 90.36 -57.352 re
395.28 517.32 90.36 -52.312 re
485.64 517.32 90.36 -52.312 re
324 465.008 71.28 -125.456 re
395.28 465.008 90.36 -26.812 re
485.64 465.008 90.36 -26.812 re
395.28 438.197 90.36 -54.832 re
485.64 438.197 90.36 -54.832 re
395.28 383.365 90.36 -43.812 re
485.64 383.365 90.36 -43.812 re
324 339.553 71.28 -54.832 re
395.28 339.553 90.36 -54.832 re
485.64 339.553 90.36 -54.832 re
324 284.721 71.28 -54.832 re
395.28 284.721 90.36 -54.832 re
485.64 284.721 90.36 -54.832 re
324 229.889 252 -63.912 re
f
10 M 
/GS2 gs
q 1 0 0 1 324 722.748 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 485.64 722.748 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.28 722.748 cm
0 0 m
90.36 0 l
S
Q
0.5 w 
q 1 0 0 1 395.28 710.0861 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 485.64 710.0861 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 324 709.8361 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 709.8361 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.28 638.2542 cm
0 0 m
0 71.332 l
S
Q
q 1 0 0 1 485.64 709.8361 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 638.2542 cm
0 0 m
0 71.332 l
S
Q
q 1 0 0 1 324 638.0042 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 638.0042 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.28 574.9223 cm
0 0 m
0 62.832 l
S
Q
q 1 0 0 1 485.64 638.0042 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 574.9223 cm
0 0 m
0 62.832 l
S
Q
q 1 0 0 1 395.28 517.5704 cm
0 0 m
0 56.852 l
S
Q
q 1 0 0 1 485.64 517.5704 cm
0 0 m
0 56.852 l
S
Q
q 1 0 0 1 395.28 465.2585 cm
0 0 m
0 51.812 l
S
Q
q 1 0 0 1 485.64 465.2585 cm
0 0 m
0 51.812 l
S
Q
q 1 0 0 1 395.28 438.4466 cm
0 0 m
0 26.312 l
S
Q
q 1 0 0 1 485.64 438.4466 cm
0 0 m
0 26.312 l
S
Q
q 1 0 0 1 395.28 383.6147 cm
0 0 m
0 54.332 l
S
Q
q 1 0 0 1 485.64 383.6147 cm
0 0 m
0 54.332 l
S
Q
q 1 0 0 1 395.28 339.8027 cm
0 0 m
0 43.312 l
S
Q
q 1 0 0 1 485.64 339.8027 cm
0 0 m
0 43.312 l
S
Q
q 1 0 0 1 395.28 284.9708 cm
0 0 m
0 54.332 l
S
Q
q 1 0 0 1 485.64 284.9708 cm
0 0 m
0 54.332 l
S
Q
q 1 0 0 1 395.28 230.3889 cm
0 0 m
0 54.082 l
S
Q
q 1 0 0 1 485.64 230.3889 cm
0 0 m
0 54.082 l
S
Q
q 1 0 0 1 324 574.6723 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 574.6723 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 574.6723 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.03 517.3204 cm
0 0 m
90.61 0 l
S
Q
q 1 0 0 1 485.64 517.3204 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 324 465.0085 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 465.0085 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 465.0085 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.03 438.1966 cm
0 0 m
90.61 0 l
S
Q
q 1 0 0 1 485.64 438.1966 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 395.03 383.3647 cm
0 0 m
90.61 0 l
S
Q
q 1 0 0 1 485.64 383.3647 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 324 339.5527 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 339.5527 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 339.5527 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 324 284.7208 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 284.7208 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 284.7208 cm
0 0 m
90.36 0 l
S
Q
1 w 
q 1 0 0 1 395.28 229.8889 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 229.8889 cm
0 0 m
90.36 0 l
S
Q
0.5 w 
q 1 0 0 1 324 165.977 cm
0 0 m
71.28 0 l
S
Q
q 1 0 0 1 395.28 165.977 cm
0 0 m
90.36 0 l
S
Q
q 1 0 0 1 485.64 165.977 cm
0 0 m
90.36 0 l
S
Q
1 w 
q 1 0 0 1 324 229.8889 cm
0 0 m
71.28 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.043 Tw 8 0 0 8 324 727.248 Tm
[(T)74.2 (able )-4.8 (2:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Recommended KRAZA)55.2 (TI Dosage Modifications for Adverse Reactions)]TJ
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 713.4362 Tm
(Adverse Reaction)Tj
-0.198 Tw 9.971 0 Td
(Severity)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.134 0 Td
[(*)-12 (\037)]TJ
0.048 Tw 8.756 0 Td
(Dosage Modification)Tj
0 Tc 0 Tw 5.32 0 0 5.6 550.5908 715.6002 Tm
(\206)Tj
/Span<</ActualText<FEFF200A>>> BDC 
7.6 0 0 8 553.1444 713.4362 Tm
( )Tj
EMC 
/T1_2 1 Tf
-0.012 Tc 0.048 Tw -30.151 -1.951 Td
[(Nausea or vomiting)-12 ( )]TJ
0 -1.062 Td
[(despite a)-9.7 (ppropria)-9.8 (te)-12 ( )]TJ
0 -1.062 Td
[(supportive care)-12 ( )]TJ
0 -1.062 Td
[(\(inc)20.2 (luding anti-emetic)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
[(thera)-9.8 (py\))]TJ
/T1_3 1 Tf
0.011 Tw 0 -1.377 Td
[([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
(Precautions \(5.1\)])Tj
/T1_2 1 Tf
9.971 6.69 Td
(Grade 3 or 4)Tj
0.012 Tw 11.905 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI until)-12 ( )]TJ
0 -1.062 Td
[(recover)-17.7 (y to \034Grade 1 or)-12 ( )]TJ
0 -1.062 Td
(return to baseline.)Tj
0.012 Tw -0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Resume KRAZA)55.2 (TI a)-9.8 (t the next)-12 ( )]TJ
0 -1.062 Td
[(lo)-9.8 (wer dose level.)]TJ
-22.666 -4.414 Td
[(Diarrhea despite)-11.9 ( )]TJ
0 -1.062 Td
[(a)-9.8 (ppropria)-9.7 (te supportive)-12 ( )]TJ
0 -1.062 Td
[(care \(inc)20.2 (luding anti-)]TJ
0 -1.062 Td
[(diarrheal thera)-9.8 (py\))]TJ
/T1_3 1 Tf
0.011 Tw 0 -1.377 Td
[([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
(Precautions \(5.1\)])Tj
/T1_2 1 Tf
9.971 5.628 Td
(Grade 3 or 4)Tj
0.012 Tw 11.905 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI until)-12 ( )]TJ
0 -1.062 Td
[(recover)-17.7 (y to \034Grade 1 or)-12 ( )]TJ
0 -1.062 Td
(return to baseline.)Tj
0.012 Tw -0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Resume KRAZA)55.2 (TI a)-9.8 (t the next)-12 ( )]TJ
0 -1.062 Td
[(lo)-9.8 (wer dose level.)]TJ
-22.666 -3.351 Td
[(QTc Inter)-17.8 (val)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
[(Prolonga)-9.8 (tion)]TJ
/T1_3 1 Tf
0.011 Tw 0 -1.377 Td
[([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
(Precautions \(5.2\)])Tj
/T1_2 1 Tf
9.971 3.503 Td
[(QTc absolute value grea)-9.8 (ter)-12 ( )]TJ
0 -1.062 Td
[(than 500\033)-47.8 (ms)]TJ
0.012 Tw 0 -1.377 Td
(or)Tj
0.048 Tw 0 -1.377 Td
[(Grea)-9.8 (ter than an increase of)-12 ( )]TJ
0 -1.062 Td
[(60\033)-47.8 (ms from baseline)]TJ
0.012 Tw 11.905 4.88 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI until QTc)-12 ( )]TJ
0 -1.062 Td
[(inter)-17.8 (val less than 481\033)-47.8 (ms or)-12 ( )]TJ
0 -1.062 Td
(return to baseline.)Tj
0.012 Tw -0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Resume KRAZA)55.2 (TI a)-9.8 (t the next)-12 ( )]TJ
0 -1.062 Td
[(lo)-9.8 (wer dose level.)]TJ
-12.695 -2.604 Td
[(T)74.2 (orsade de pointes,)25 ( )]TJ
0 -1.062 Td
[(polymorphic ventricular)-12 ( )]TJ
0 -1.062 Td
[(tachycardia or signs or)-12 ( )]TJ
0 -1.062 Td
(symptoms of serious or life-)Tj
0 -1.062 Td
[(threa)-9.8 (tening arrhythmia)]TJ
0.012 Tw 11.905 4.25 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(P)18.2 (ermanently discontinue)-11.9 ( )]TJ
0.012 Tw 0 -1.062 Td
[(KRAZA)55.2 (TI.)]TJ
-22.666 -5.476 Td
[(Hepa)-9.8 (totoxicity)]TJ
/T1_3 1 Tf
0.011 Tw 0 -1.423 Td
[([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
(Precautions \(5.3\)])Tj
/T1_2 1 Tf
9.971 2.485 Td
(Grade 2)Tj
0 Tc 0 Tw 7.6 0 0 8 421.6584 452.9966 Tm
( )Tj
-0.012 Tc 0.011 Tw 7.6 0 0 8 399.7801 444.4966 Tm
[(AST )-36.8 (or AL)94.2 (T)]TJ
0.012 Tw 11.905 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Decrease KRAZA)55.2 (TI to the)-12 ( )]TJ
0 -1.062 Td
[(next lo)-9.8 (wer dose level.)]TJ
-12.695 -2.289 Td
(Grade 3 or 4)Tj
0 Tc 0 Tw 7.6 0 0 8 434.8439 426.1847 Tm
( )Tj
-0.012 Tc 0.011 Tw 7.6 0 0 8 399.7801 417.6847 Tm
[(AST )-36.8 (or AL)94.2 (T)]TJ
0.012 Tw 11.905 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI until)-12 ( )]TJ
0 -1.062 Td
[(recover)-17.7 (y to \034Grade 1 or)-12 ( )]TJ
0 -1.062 Td
(return to baseline.)Tj
0.012 Tw -0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Resume KRAZA)55.2 (TI a)-9.8 (t the next)-12 ( )]TJ
0 -1.062 Td
[(lo)-9.8 (wer dose level.)]TJ
-12.695 -2.289 Td
[(AST or )37.2 (AL)94.2 (T >3 \327 ULN with)-11.9 ( )]TJ
0 -1.062 Td
[(total bilirubin >2 \327 ULN in)-12 ( )]TJ
0 -1.062 Td
[(the absence of alterna)-9.8 (tive)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(causes)Tj
11.905 3.188 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(P)18.2 (ermanently discontinue)-11.9 ( )]TJ
0.012 Tw 0 -1.062 Td
[(KRAZA)55.2 (TI.)]TJ
0.048 Tw -22.666 -4.414 Td
[(Interstitial Lung)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Disease/Pneumonitis)Tj
/T1_3 1 Tf
0.011 Tw 0 -1.377 Td
[([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
(Precautions \(5.4\)])Tj
/T1_2 1 Tf
9.971 3.503 Td
[(An)-9.8 (y Grade)]TJ
0.012 Tw 11.905 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI if ILD/)]TJ
0 -1.062 Td
(pneumonitis is suspected.)Tj
0.012 Tw -0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(P)18.2 (ermanently discontinue)-11.9 ( )]TJ
0 -1.062 Td
[(KRAZA)55.2 (TI if ILD/pneumonitis)-12 ( )]TJ
0 -1.062 Td
(is confirmed.)Tj
0.011 Tw -22.666 -2.289 Td
[(Other Adverse)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Reactions)Tj
/T1_3 1 Tf
0.011 Tw 0 -1.377 Td
[([see Adverse )-36.8 (Reactions)-11.9 ( )]TJ
0.012 Tw 0 -1.062 Td
(\(6.1\)])Tj
/T1_2 1 Tf
0.048 Tw 9.971 3.503 Td
(Grade 3 or 4)Tj
0.012 Tw 11.905 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Withhold KRAZA)55.2 (TI until)-12 ( )]TJ
0 -1.062 Td
[(\034Grade 1 or return to)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(baseline.)Tj
-0.789 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 0.789 0 Td
[(Resume KRAZA)55.2 (TI a)-9.8 (t the next)-12 ( )]TJ
0 -1.062 Td
[(lo)-9.8 (wer dose level.)]TJ
-0.002 Tc -0.115 Tw -22.666 -1.951 Td
[(AL)93.8 (T)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(alanine )-245.1 (aminotransferase; )-208.1 (AST)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(asparta)-10.2 (te )-245.1 (aminotransferase; )-245.1 (ILD)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(Interstitial )-245.1 (Lung)-2.1 ( )]TJ
-0.018 Tc 0.048 Tw 0 -1.062 Td
(Disease; ULN)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
4.841 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.689 0 Td
(upper limit of normal)Tj
-0.005 Tc 0.11 Tw -5.53 -1.062 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.335 0 Td
( )Tj
EMC 
0.323 0 Td
[(Grading )0.5 (defined )0.6 (by )0.5 (Na)-10 (tional )0.5 (Cancer )0.5 (Institute )0.5 (Common )37.5 (T)73.9 (erminolog)-10.1 (y )0.6 (Criteria )0.6 (for )37.6 (Adverse)-5 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
(Events \(NCI CTCAE\) version 5.0.)Tj
0 Tc 0 Tw 5.32 0 0 5.6 324.0001 188.741 Tm
(\206)Tj
/Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 326.4728 186.577 Tm
( )Tj
EMC 
-0.009 Tc 0.092 Tw 0.296 0 Td
[(When KRAZA)54.5 (TI is administered in combina)-10.4 (tion with cetuximab,)36.6 ( withhold or permanently)-9 ( )]TJ
-0.002 Tc 0.121 Tw 0.037 -1.062 Td
[(d)0.5 (i)0.6 (s)0.5 (c)0.6 (o)0.5 (n)0.5 (t)0.6 (i)0.5 (n)0.6 (u)0.5 (e)0.5 ( t)0.6 (r)0.5 (e)0.6 (a)-9.5 (t)0.6 (m)0.5 (e)0.6 (n)0.5 (t)0.6 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 ( c)0.6 (e)0.5 (t)0.6 (u)0.5 (x)0.5 (i)0.6 (m)0.5 (a)0.6 (b)0.5 ( w)0.5 (h)0.6 (e)0.5 (n)0.6 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 (h)0.5 (o)0.6 (l)0.5 (d)0.6 (i)0.5 (n)0.5 (g)0.6 ( o)0.5 (r)0.6 ( p)0.5 (e)0.6 (r)0.5 (m)0.5 (a)0.6 (n)0.5 (e)0.6 (n)0.5 (t)0.6 (l)0.5 (y)0.5 ( d)0.6 (i)0.5 (s)0.6 (c)0.5 (o)0.5 (n)0.6 (t)0.5 (i)0.6 (n)0.5 (u)0.5 (i)0.6 (n)0.5 (g)-2 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(trea)-9.7 (tment with KRAZA)55.2 (TI.)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324.0001 147.3823 Tm
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_2 1 Tf
-0.011 Tc 0.028 Tw -3.375 -1.537 Td
[(T)74.5 (ab)0.5 (le)0.5 (t)0.5 (s:)37.5 ( 2)0.5 (00)0.5 ( mg)0.5 (,)37.4 ( o)0.5 (va)0.5 (l)0.5 ( s)0.5 (ha)-9.5 (p)0.5 (ed)0.5 (,)37.4 ( wh)0.5 (i)0.5 (te)0.5 ( t)0.5 (o)0.5 ( o)0.5 (f)0.5 (f-)0.5 (w)0.5 (hi)0.5 (te)0.5 (,)37.5 ( i)0.5 (m)0.5 (me)0.5 (di)0.5 (a)-9.5 (t)0.5 (e re)0.5 (l)0.5 (ea)0.5 (s)0.5 (e \036l)0.5 (m)0.5 ( c)0.5 (oa)-9.5 (t)0.5 (e)0.5 (d ta)0.5 (b)0.5 (le)0.5 (t)0.5 (s)-11 ( )]TJ
-0.017 Tc 0 Tw 0 -1.087 Td
[(with )37.2 (\223200\224)37.2 ( on one side and stylized )37.2 (\223M\224)37.2 ( on the opposite side.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.888 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
/T1_2 1 Tf
-3.375 -1.537 Td
(None.)Tj
/T1_0 1 Tf
0 -1.888 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.017 Tw -3.375 -1.736 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Gastrointestinal Adverse Reactions)Tj
/T1_2 1 Tf
-3.375 -1.537 Td
[(KRAZA)55.2 (TI can cause severe gastrointestinal adverse reactions.)]TJ
-0.014 Tc 0.016 Tw 0 -1.627 Td
[(In the pooled safety popula)-10 (tion )]TJ
/T1_3 1 Tf
[([see )37.2 (Adverse Reactions \(6.1\)])]TJ
/T1_2 1 Tf
[(,)37 ( who received single-a)-9.9 (gent)-14 ( )]TJ
0.004 Tc 0.104 Tw 0 -1.087 Td
[(KRAZA)55.4 (TI,)37.4 ( serious gastrointestinal adverse reactions obser)-17.6 (ved were gastrointestinal)4 ( )]TJ
ET
4 M 
q 1 0 0 1 319.5 193.608 cm
0 0 m
0 -27.576 l
S
Q
endstreamendobj79 0 obj<</Length 23372>>stream
0 0 0 1 K
0.5 w 
/GS0 gs
q 1 0 0 1 36 619.7881 cm
0 0 m
103.15 0 l
S
Q
q 1 0 0 1 36 582.1881 cm
0 0 m
69.189 0 l
S
Q
q 1 0 0 1 45 399.3081 cm
0 0 m
96.623 0 l
S
Q
q 1 0 0 1 45 372.0081 cm
0 0 m
74.675 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc -0.005 Tw 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55.1 (TION)]TJ
-0.015 Tc 0.06 Tw 0 -1.197 Td
[(These highlights do not inc)20 (lude all the information needed to use KRAZA)55 (TI safely)-15 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(and effectively)55.2 (.)37.2 ( See full prescribing information for KRAZA)55.2 (TI.)]TJ
0.017 Tw 0 -1.805 Td
[(KRAZA)55.2 (TI)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 61.9886 719.9321 Tm
(\256)Tj
-0.017 Tc 0.048 Tw 8 0 0 8 66.3722 717.7681 Tm
[( \(adagrasib\) tablets,)37.2 ( for oral use)]TJ
-3.797 -1.242 Td
[(Initial U.S.)37.2 ( Appro)-9.8 (v)16.3 (al: 2022)]TJ
0.017 Tw 0 -2.62 Td
(------------------------------)Tj
-0.005 Tw 10.807 0 Td
(RECENT MAJOR CHANGES)Tj
-0.101 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(------------------------------)Tj
/T1_1 1 Tf
0.017 Tw -10.807 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
[(Indica)-9.7 (tions and Usa)-9.8 (ge \(1)60.2 (.)60.2 (1,)37.3 ( 1)60.2 (.)-19.8 (2\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
27.32 0 Td
(06/2024)Tj
0.017 Tw -28.445 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
[(Dosa)-9.7 (ge and )37.2 (Administra)-9.8 (tion \(2.)60.2 (1,)37.2 ( 2.2,)37.2 ( 2.3\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
27.32 0 Td
(06/2024)Tj
0.017 Tw -28.445 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
[(W)18.2 (arnings and Precautions \(5.)60.2 (1,)37.2 ( 5.2,)37.2 ( 5.3,)37.2 ( 5.4\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
27.32 0 Td
(06/2024)Tj
/T1_0 1 Tf
0.017 Tw -28.445 -1.445 Td
(-------------------------------)Tj
-0.005 Tw 10.983 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.075 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(------------------------------)Tj
/T1_1 1 Tf
-0.005 Tw -10.983 -1.445 Td
[(KRAZA)55.2 (TI is an inhibitor of the RAS GTP)18.2 (ase family indica)-9.8 (ted for:)]TJ
0 -1.288 Td
(Non-small cell lung cancer \(NSCLC\)*)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
12.894 0 Td
( )Tj
EMC 
-0.017 Tc 0.017 Tw -12.894 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.019 Tc 0.036 Tw 1.125 0 Td
[(As a single a)-10.1 (gent,)36.9 ( for the trea)-10.1 (tment of adult pa)-10.1 (tients with )]TJ
/T1_2 1 Tf
0.019 Tw (KRAS)Tj
/T1_1 1 Tf
0.036 Tw [( G1)59.8 (2C-muta)-10.1 (ted locally)-19 ( )]TJ
-0.013 Tc 0.071 Tw 0 -1.062 Td
[(advanced or metasta)-10.3 (tic NSCLC,)36.6 ( as determined by an FDA-a)-10.3 (pproved test,)36.7 ( who ha)-10.3 (ve)-13 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(received a)-9.8 (t least one prior systemic thera)-9.8 (py)55.2 (.)37.2 ( \(1)60.2 (.)60.3 (1\))]TJ
-0.005 Tw -1.125 -1.287 Td
(Colorectal cancer \(CRC\)*)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
8.649 0 Td
( )Tj
EMC 
-0.017 Tc 0.017 Tw -8.649 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.015 Tc 0.06 Tw 1.125 0 Td
[(In combina)-10.1 (tion with cetuximab,)36.8 ( for the trea)-10.2 (tment of adult pa)-10.1 (tients with )]TJ
/T1_2 1 Tf
0.015 Tw (KRAS)Tj
/T1_1 1 Tf
0.06 Tw [( G1)59.9 (2C-)]TJ
-0.021 Tc 0.036 Tw 0 -1.062 Td
[(muta)-10.3 (ted locally advanced or metasta)-10.3 (tic CRC,)36.6 ( as determined by an FDA-a)-10.3 (pproved test,)16 ( )]TJ
-0.019 Tc 0 -1.062 Td
[(who ha)-9.7 (ve received prior trea)-9.7 (tment with \037uoropyrimidine-,)37.3 ( oxalipla)-9.7 (tin-,)37.3 ( and irinotecan-)]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(based chemothera)-9.8 (py)55.2 (.)37.2 ( \(1)60.2 (.)-19.8 (2\))]TJ
-0.009 Tw -1.125 -1.288 Td
(*)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.406 0 Td
[(These indica)-9.8 (tions are a)-9.8 (pproved under accelera)-9.8 (ted a)-9.8 (pproval based on objective response)-17 ( )]TJ
-0.014 Tc 0.002 Tw -0.406 -1.062 Td
[(ra)-10 (te \(ORR\) and )0.5 (dura)-10 (tion of response )0.5 (\(DOR\).)37 ( )0.5 (Continued a)-10 (pproval )0.5 (for )0.5 (these indica)-10 (tions )0.5 (may)-14 ( )]TJ
-0.013 Tc 0.003 Tw 0 -1.062 Td
[(be contingent upon veri\036ca)-9.9 (tion and description of a c)20.2 (linical bene\036t in con\036rma)-9.9 (tor)-17.8 (y trials.)24 ( )]TJ
-0.017 Tc -0.005 Tw 0 -1.062 Td
[(\(1)60.2 (.)60.2 (1,)37.2 ( 1)80.2 (.)-19.7 (2\))]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.445 Td
(---------------------------)Tj
-0.005 Tw /Span<</ActualText<FEFF200A>>> BDC 
9.79 0 Td
( )Tj
EMC 
0.024 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
-0.059 Tw /Span<</ActualText<FEFF002D>>> BDC 
11.895 0 Td
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -21.71 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.006 Tc 0.166 Tw 1.125 0 Td
[(Recommended dosa)-10.3 (ge as )0.5 (a single )0.5 (a)-10.2 (gent for )0.5 (NSCLC )0.5 (and )0.5 (in )0.5 (combina)-10.3 (tion )0.5 (with)6 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(cetuximab for CRC:)37.2 ( 600 mg orally twice daily)55.2 (.)37.2 ( \(2.2\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
[(Swallo)-9.7 (w tablets whole with or without food.)37.2 ( \(2.2\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.445 Td
(--------------------------)Tj
-0.005 Tw 9.37 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
-0.126 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
12.856 0 Td
(--------------------------)Tj
/T1_1 1 Tf
-0.005 Tw -22.226 -1.445 Td
[(T)74.2 (ablets:)37.2 ( 200 mg.)37.2 ( \(3\))]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.445 Td
(---------------------------------)Tj
11.731 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
8.025 0 Td
(---------------------------------)Tj
/T1_1 1 Tf
-0.005 Tw -19.757 -1.445 Td
[(None.)37.2 ( \(4\))]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.445 Td
(----------------------------)Tj
-0.005 Tw 9.924 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.074 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.924 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.022 Tc -0.001 Tw 1.125 0 Td
[(Gastrointestinal Adverse )-37.1 (Reactions)]TJ
0.036 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.316 0 Td
[( Monitor pa)-10.1 (tients for diarrhea,)36.8 ( nausea and vomiting)-22 ( )]TJ
-0.009 Tc 0.086 Tw -12.316 -1.062 Td
[(a)0.5 (nd)0.5 ( pr)0.5 (o)0.5 (vi)0.5 (d)0.5 (e s)0.5 (up)0.5 (po)0.5 (r)0.5 (t)0.5 (iv)0.5 (e)0.5 ( c)0.5 (a)0.5 (r)0.5 (e a)0.5 (s n)0.5 (ee)0.5 (d)0.5 (e)0.5 (d.)37.5 ( )36.7 (W)0.5 (i)0.5 (th)0.5 (h)0.5 (ol)0.5 (d,)37.5 ( r)0.5 (ed)0.5 (uc)0.5 (e)0.5 ( th)0.5 (e)0.5 ( d)0.5 (o)0.5 (se)0.5 ( o)0.5 (r p)0.5 (er)0.5 (m)0.5 (an)0.5 (e)0.5 (nt)0.5 (l)0.5 (y)-9 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(discontinue based on severity)55.2 (.)37.2 ( \(2.3,)37.2 ( 5.1\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.006 Tc 0.103 Tw 1.125 0 Td
[(QTc Inter)-17.8 (val Prolonga)-9.8 (tion)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.604 0 Td
[( )36.9 (Avoid concomitant use of KRAZA)55.2 (TI with other products)-6 ( )]TJ
-0.005 Tc 0.106 Tw -9.604 -1.062 Td
[(w)0.5 (it)0.5 (h a kn)0.5 (o)-9.5 (wn)0.5 ( p)0.5 (ot)0.5 (e)0.5 (nt)0.5 (ia)0.5 (l t)0.5 (o pr)0.5 (ol)0.5 (on)0.5 (g)0.5 ( t)0.5 (he)0.5 ( Q)0.5 (Tc)0.5 ( i)0.5 (nt)0.5 (e)0.5 (r)-17.6 (v)0.5 (a)0.5 (l.)37.4 ( M)0.5 (on)0.5 (it)0.5 (o)0.5 (r EC)0.5 (G an)0.5 (d el)0.5 (e)0.5 (ct)0.5 (ro)0.5 (l)0.5 (yt)0.5 (es)-5 ( )]TJ
0.107 Tw 0 -1.062 Td
[(particularl)0.5 (y potassium )0.5 (an)0.5 (d ma)-9.6 (gnesium,)37.4 ( in )0.5 (pa)-9.5 (tients a)-9.6 (t )0.5 (risk,)37.4 ( and in pa)-9.5 (tients taki)0.5 (ng)-5 ( )]TJ
-0.002 Tc 0.123 Tw 0 -1.062 Td
[(medica)-9.8 (tions kno)-9.8 (wn to prolong the QT inter)-17.8 (val.)37.2 ( Correct electrolyte abnormalities.)35 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(Withhold,)37.2 ( reduce the dose,)37.2 ( or permanently discontinue based on severity)55.2 (.)37.2 ( \(2.3,)37.2 ( 5.2\))]TJ
ET
q 1 0 0 1 333 748.7881 cm
0 0 m
40.544 0 l
S
Q
q 1 0 0 1 333 721.4881 cm
0 0 m
121.272 0 l
S
Q
q 1 0 0 1 333 681.3681 cm
0 0 m
82.703 0 l
S
Q
q 1 0 0 1 333 620.0681 cm
0 0 m
109.484 0 l
S
Q
q 1 0 0 1 333 512.3481 cm
0 0 m
69.684 0 l
S
Q
q 1 0 0 1 333 502.0481 cm
0 0 m
71.111 0 l
S
Q
q 1 0 0 1 333 483.2481 cm
0 0 m
91.097 0 l
S
Q
q 1 0 0 1 333 464.4481 cm
0 0 m
173.435 0 l
S
Q
q 1 0 0 1 333 437.1481 cm
0 0 m
87.798 0 l
S
Q
q 1 0 0 1 333 414.0281 cm
0 0 m
25.937 0 l
S
Q
BT
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324 750.2881 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 1.125 0 Td
[(Hepa)-9.9 (totoxicity)]TJ
0.009 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.33 0 Td
[( Monitor liver labora)-9.9 (tor)-17.9 (y tests prior to the start of KRAZA)55 (TI \(ada)-9.9 (grasib\))-10 ( )]TJ
-0.014 Tc 0 Tw -5.33 -1.062 Td
[(a)0.5 (nd)0.5 ( mo)0.5 (n)0.5 (th)0.5 (ly)0.5 ( fo)0.5 (r)0.5 ( 3 m)0.5 (on)0.5 (th)0.5 (s)0.5 ( a)0.5 (f)0.5 (t)0.5 (er)0.5 ( an)0.5 (d a)0.5 (s c)20.5 (l)0.5 (in)0.5 (ic)0.5 (al)0.5 (l)0.5 (y i)0.5 (nd)0.5 (ic)0.5 (a)-9.5 (te)0.5 (d)0.5 (.)37.4 ( Re)0.5 (d)0.5 (uc)0.5 (e t)0.5 (h)0.5 (e d)0.5 (os)0.5 (e)0.5 (,)37.4 ( wi)0.5 (t)0.5 (hh)0.5 (ol)0.5 (d)0.5 (,)23 ( )]TJ
-0.017 Tc -0.005 Tw 0 -1.062 Td
[(or permanently discontinue based on severity)55.2 (.)37.2 ( \(2.3,)37.2 ( 5.3\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_1 1 Tf
-0.011 Tc 0.007 Tw 1.125 0 Td
(Interstitial Lung Disease \(ILD\)/Pneumonitis)Tj
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
15.418 0 Td
[( Monitor for new or worsening respira)-9.7 (tor)-17.6 (y)-11 ( )]TJ
0.017 Tc 0.062 Tw -15.418 -1.062 Td
[(s)0.5 (y)0.5 (mp)0.5 (t)0.5 (o)0.5 (ms)0.5 (.)37.4 ( )36.8 (W)0.5 (i)0.5 (t)0.5 (hh)0.5 (o)0.5 (l)0.5 (d K)0.5 (R)0.5 (AZ)0.5 (A)55.5 (TI)0.5 ( f)0.5 (o)0.5 (r s)0.5 (u)0.5 (sp)0.5 (e)0.5 (c)0.5 (te)0.5 (d)0.5 ( I)0.5 (LD)0.5 (/)0.5 (pn)0.5 (e)0.5 (u)0.5 (mo)0.5 (n)0.5 (i)0.5 (ti)0.5 (s)0.5 ( a)0.5 (nd)0.5 ( p)0.5 (er)0.5 (m)0.5 (a)0.5 (ne)0.5 (n)0.5 (t)0.5 (ly)17.1 ( )]TJ
-0.017 Tc -0.005 Tw 0 -1.062 Td
[(discontinue if no other potential causes of ILD/pneumonitis are identi\036\ed.)37.2 ( \(2.3,)37.2 ( 5.4\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.445 Td
(---------------------------------)Tj
-0.005 Tw 11.677 0 Td
(ADVERSE REACTIONS)Tj
0.064 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
8.432 0 Td
(--------------------------------)Tj
/T1_1 1 Tf
0.017 Tw -20.109 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.13 Tw 1.125 0 Td
[(Single a)-10.1 (gent use in NCSLC)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
10.618 0 Td
[( )37 (The most common adverse reactions \(\03525%\) were)-1 ( )]TJ
0.006 Tc 0.161 Tw -10.618 -1.062 Td
[(n)0.5 (a)0.5 (u)0.6 (s)0.5 (e)0.5 (a)0.5 (,)37.5 ( d)0.5 (i)0.5 (a)0.5 (r)0.5 (r)0.6 (h)0.5 (e)0.5 (a)0.5 (,)37.5 ( v)0.5 (o)0.5 (m)0.6 (i)0.5 (t)0.5 (i)0.5 (n)0.5 (g)0.5 (,)37.5 ( f)0.5 (a)-9.4 (t)0.5 (i)0.5 (g)0.5 (u)0.5 (e)0.5 (,)37.5 ( m)0.6 (u)0.5 (s)0.5 (c)0.5 (u)0.5 (l)0.5 (o)0.5 (s)0.5 (k)0.6 (e)0.5 (l)0.5 (e)0.5 (t)0.6 (a)0.5 (l)0.5 ( p)0.6 (a)0.5 (i)0.5 (n)0.5 (,)37.5 ( h)0.5 (e)0.5 (p)0.5 (a)-9.4 (t)0.5 (o)0.5 (t)0.5 (o)0.6 (x)0.5 (i)0.5 (c)0.5 (i)0.5 (t)0.5 (y)55.5 (,)37.5 ( r)0.6 (e)0.5 (n)0.5 (a)0.5 (l)6 ( )]TJ
0.02 Tc 0.236 Tw 0 -1.062 Td
[(impairment,)36.6 ( edema,)36.7 ( d)-10.3 (yspnea,)36.6 ( and decreased a)-10.3 (ppetite.)36.7 ( )36.9 (The most common)20 ( )]TJ
0.015 Tc 0.207 Tw 0 -1.062 Td
[(\(\0352%\) Grade 3 or 4 labora)-9.7 (tor)-17.7 (y abnormalities were decreased lymphoc)20.3 (ytes,)52 ( )]TJ
-0.002 Tc 0.126 Tw 0 -1.062 Td
[(decreased hemoglobin,)36.7 ( increased alanine aminotransferase,)36.7 ( increased asparta)-10.3 (te)-2 ( )]TJ
0.02 Tc 0.234 Tw 0 -1.062 Td
[(aminotransferase,)36.9 ( hypokalemia,)37 ( hypona)-10 (tremia,)37 ( increased lipase,)37 ( decreased)20 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(leukoc)20.2 (ytes,)37.2 ( decreased neutrophils and increased alkaline phospha)-9.8 (tase.)37.2 ( \(6.1\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.052 Tw 1.125 0 Td
[(In combina)-9.8 (tion with cetuximab in CRC)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.933 0 Td
[( )36.6 (The most common adverse reactions \(\03525%\))-17 ( )]TJ
-0.012 Tc 0.071 Tw -13.933 -1.062 Td
[(we)0.5 (r)0.5 (e ra)0.5 (sh)0.5 (,)37.4 ( na)0.5 (us)0.5 (ea)0.5 (,)37.4 ( di)0.5 (ar)0.5 (rh)0.5 (ea)0.5 (,)37.4 ( vo)0.5 (m)0.5 (it)0.5 (in)0.5 (g,)37.4 ( f)0.5 (a)-9.6 (t)0.5 (ig)0.5 (ue)0.5 (,)37.4 ( mu)0.5 (sc)0.5 (ul)0.5 (os)0.5 (ke)0.5 (le)0.5 (t)0.5 (al)0.5 ( pa)0.5 (i)0.5 (n,)37.4 ( he)0.5 (p)0.5 (a)-9.6 (t)0.5 (ot)0.5 (ox)0.5 (i)0.5 (ci)0.5 (ty)55.5 (,)25 ( )]TJ
-0.017 Tc 0.052 Tw 0 -1.062 Td
[(headache,)37.2 ( dr)-17.8 (y skin,)37.2 ( abdominal pain,)37.2 ( decreased a)-9.8 (ppetite,)37.2 ( edema,)37.2 ( anemia,)37.2 ( and cough.)20 ( )]TJ
-0.005 Tc 0.108 Tw 0 -1.062 Td
[(The most common \(\0352%\) Grade 3 or 4 labora)-9.9 (tor)-17.9 (y abnormalities were decreased)-5 ( )]TJ
-0.012 Tc 0.074 Tw 0 -1.062 Td
[(lymphoc)20 (ytes,)37.1 ( decreased potassium,)37.1 ( decreased ma)-10 (gnesium,)37 ( decreased hemoglobin,)25 ( )]TJ
-0.002 Tc 0.121 Tw 0 -1.062 Td
[(i)0.5 (ncr)0.5 (e)0.5 (as)0.5 (ed as)0.5 (p)0.5 (art)0.5 (a)-9.5 (te)0.5 ( a)0.5 (m)0.5 (ino)0.5 (tr)0.5 (a)0.5 (ns)0.5 (fe)0.5 (ra)0.5 (se)0.5 (,)37.4 ( in)0.5 (cre)0.5 (a)0.5 (se)0.5 (d li)0.5 (pa)0.5 (se)0.5 (,)37.4 ( de)0.5 (cr)0.5 (ea)0.5 (se)0.5 (d al)0.5 (bu)0.5 (mi)0.5 (n,)37.4 ( an)0.5 (d)-2 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(increased alanine aminotransferase.)37.2 ( \(6.1\))]TJ
/T1_0 1 Tf
0.002 Tc 0.147 Tw -1.125 -1.737 Td
[(T)73.6 (o report SUSPECTED ADVERSE REACTIONS,)36.5 ( contact Bristol-Myers Squibb at)2.1 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(1-800-721-5072 or FD)34.2 (A at 1-800-FD)34.3 (A-1088 or www)37.2 (.fda.go)-9.8 (v/medwatch.)]TJ
0.017 Tw 0 -1.558 Td
(---------------------------------)Tj
-0.005 Tw 11.747 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
-0.219 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------------)Tj
/T1_1 1 Tf
-0.018 Tc -0.012 Tw -11.747 -1.445 Td
[(See full prescribing informa)-10.1 (tion for c)19.8 (linically signi\036cant drug interactions with KRAZA)54.9 (TI.)36.8 ( \(7\))]TJ
-0.017 Tc 0.017 Tw 0 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
(Strong CYP3A4 Inducers)Tj
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.958 0 Td
[( )37.2 (Avoid concomitant use.)37.2 ( \(7.1\))]TJ
0.017 Tw -10.083 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.036 Tw 1.125 0 Td
(Strong CYP3A4 Inhibitors)Tj
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.136 0 Td
[( )37.4 (Avoid concomitant use until ada)-9.6 (grasib concentra)-9.6 (tions ha)-9.7 (ve)-16.9 ( )]TJ
0.048 Tw -9.136 -1.062 Td
[(reached stead)-9.7 (y sta)-9.8 (te.)37.1 ( \(7.1\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tc 0.192 Tw 1.125 0 Td
[(Sensitive CYP3A4 Substra)-9.8 (tes)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
11.692 0 Td
[( )36.5 (Avoid concomitant use with sensitive CYP3A4)12 ( )]TJ
-0.017 Tc 0.048 Tw -11.692 -1.062 Td
[(substra)-9.7 (tes.)37.2 ( \(7.2\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.015 Tc 0.061 Tw 1.125 0 Td
[(Sensitive CYP2C9 or CYP2D6 Substra)-10.4 (tes or P-gp Substra)-10.3 (tes)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
21.932 0 Td
[( )36.8 (Avoid concomitant use)-15 ( )]TJ
-0.002 Tc 0.121 Tw -21.932 -1.062 Td
[(w)0.5 (i)0.5 (t)0.5 (h)0.5 ( s)0.5 (e)0.5 (n)0.5 (s)0.5 (i)0.5 (t)0.5 (i)0.5 (v)0.6 (e)0.5 ( C)0.5 (Y)0.5 (P)0.6 (2)0.5 (C)0.5 (9)0.5 ( o)0.5 (r)0.5 ( C)0.5 (Y)0.5 (P)0.5 (2)0.5 (D)0.5 (6)0.5 ( s)0.5 (u)0.5 (b)0.5 (s)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.6 (e)0.5 (s)0.5 ( o)0.5 (r)0.6 ( P)0.5 (-)0.5 (g)0.5 (p)0.5 ( s)0.5 (u)0.5 (b)0.5 (s)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.6 (e)0.5 (s)0.5 ( w)0.5 (h)0.5 (e)0.6 (r)0.5 (e)0.5 ( m)0.5 (i)0.6 (n)0.5 (i)0.5 (m)0.5 (a)0.5 (l)-2 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(concentra)-9.8 (tion changes may lead to serious adverse reactions.)37.2 ( \(7.2\))]TJ
0.017 Tw -1.125 -1.288 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.125 0 Td
[(Drugs )37.2 (Tha)-9.7 (t Prolong QT Inter)-17.7 (val)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
11.222 0 Td
[( )37.2 (Avoid concomitant use with KRAZA)55.2 (TI.)37.2 ( \(7.3\))]TJ
/T1_0 1 Tf
0.017 Tw -12.347 -1.445 Td
(----------------------------)Tj
-0.005 Tw 9.917 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
0.067 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.917 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.125 0 Td
[(Lacta)-9.8 (tion)]TJ
0.048 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.489 0 Td
[( )37.2 (Advise not to breastfeed.)37.2 ( \(8.2\))]TJ
/T1_0 1 Tf
-0.005 Tw -4.614 -2.525 Td
[(See 17 for P)54.2 (A)55.1 (TIENT COUNSELING INFORMA)55.2 (TION and FD)34.2 (A-appro)-9.8 (ved patient labeling.)]TJ
24.961 -1.625 Td
(Revised: 07/2024)Tj
-60.961 -10.608 Td
[(FULL PRESCRIBING INFORMA)55.2 (TION: CONTENTS*)]TJ
0.017 Tw 0 -1.85 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(1.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
3 0 Td
(KRAS)Tj
/T1_1 1 Tf
0.048 Tw [( G12C-Muta)-9.8 (ted Locally )37.3 (Advanced or Metasta)-9.7 (tic)-17 ( )]TJ
0 Tc 0 Tw 19.062 0 Td
( )Tj
-0.017 Tc 0.048 Tw -19.062 -1.019 Td
(Non-Small Cell Lung Cancer)Tj
0.017 Tw -3 -1.343 Td
(1.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
3 0 Td
(KRAS)Tj
/T1_1 1 Tf
0.048 Tw [( G12C-Muta)-9.8 (ted Locally )37.3 (Advanced or Metasta)-9.7 (tic)-17 ( )]TJ
0 Tc 0 Tw 19.062 0 Td
( )Tj
-0.017 Tc 0.048 Tw -19.062 -1.019 Td
(Colorectal Cancer)Tj
/T1_0 1 Tf
0.017 Tw -6.125 -1.45 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(P)18.2 (a)-9.8 (tient Selection)]TJ
0.017 Tw -3 -1.343 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Recommended Dosa)-9.8 (ge)]TJ
0.017 Tw -3 -1.343 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Dosa)-9.7 (ge Modi\036ca)-9.8 (tions for )37.2 (Adverse Reactions)]TJ
/T1_0 1 Tf
0.017 Tw -6.125 -1.45 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.017 Tw -3.125 -1.512 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
-3.125 -1.512 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3 0 Td
[(Gastrointestinal Adverse )-36.8 (Reactions)]TJ
0.017 Tw -3 -1.343 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(QTc Inter)-17.8 (val Prolonga)-9.8 (tion)]TJ
0.017 Tw -3 -1.343 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3 0 Td
[(Hepa)-9.7 (totoxicity)]TJ
-3 -1.343 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
(Interstitial Lung Disease/Pneumonitis)Tj
/T1_0 1 Tf
0.017 Tw -6.125 -1.45 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.017 Tw 8 0 0 8.0947 61 97.486 Tm
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3 0 Td
[(Clinical T)74.1 (rials )-36.8 (Experience)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 86.8217 Tm
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Effects of Other Drugs on KRAZA)55.2 (TI)]TJ
0.017 Tw -3 -1.343 Td
(7.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Effects of KRAZA)55.3 (TI on Other Drugs)]TJ
0.017 Tw -3 -1.343 Td
(7.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Drugs )37.2 (Tha)-9.7 (t Prolong QTc Inter)-17.7 (val)]TJ
/T1_0 1 Tf
0.017 Tw 29.875 28.509 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8.0947 349 270.464 Tm
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3 0 Td
[(Pregnanc)20.2 (y)]TJ
-3 -1.268 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3 0 Td
[(Lacta)-9.8 (tion)]TJ
-3 -1.268 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(F)24.2 (emales and Males of Reproductive P)18.2 (otential)]TJ
0.017 Tw -3 -1.268 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(P)18.2 (edia)-9.7 (tric Use)]TJ
0.017 Tw -3 -1.268 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Geria)-9.7 (tric Use)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324 218.7563 Tm
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DESCRIPTION)Tj
-3.125 -1.512 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3 0 Td
[(Mechanism )-36.8 (of Action)]TJ
0.017 Tw -3 -1.343 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3 0 Td
[(Pharmacod)-9.8 (ynamics)]TJ
-3 -1.343 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
-6.125 -1.45 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Carcinogenesis,)37.2 ( Muta)-9.8 (genesis,)37.2 ( Impairment of F)24.2 (ertility)]TJ
0.017 Tw -3 -1.343 Td
(13.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
[(Animal )37.3 (T)74.1 (oxicolog)-9.8 (y and/or Pharmacolog)-9.8 (y)]TJ
/T1_0 1 Tf
0.017 Tw -6.125 -1.45 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL STUDIES)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.406 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
(Non-Small Cell Lung Cancer)Tj
0.017 Tw -3 -1.343 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3 0 Td
(Colorectal Cancer)Tj
/T1_0 1 Tf
0.017 Tw -6.125 -1.45 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
0.017 Tw -3.125 -1.512 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION)]TJ
/T1_1 1 Tf
-0.012 Tc -3.125 -1.85 Td
(*)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.453 0 Td
[(Sections or subsections omitted from the full prescribing informa)-9.8 (tion are not listed.)]TJ
ET
1 w 4 M 
q 1 0 0 1 36 320.7643 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 36 36.5 cm
0 0 m
540 0 l
S
Q
endstreamendobj88 0 obj<</CreationDate(D:20240717060214-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240717060215-04'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 89
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000009398 00000 n
0000000000 00000 f
0000313958 00000 n
0000314899 00000 n
0000316102 00000 n
0000317282 00000 n
0000318485 00000 n
0000009648 00000 n
0000010878 00000 n
0000012070 00000 n
0000013241 00000 n
0000009458 00000 n
0000009547 00000 n
0000014367 00000 n
0000015482 00000 n
0000244821 00000 n
0000145368 00000 n
0000050530 00000 n
0000244709 00000 n
0000237925 00000 n
0000193946 00000 n
0000194682 00000 n
0000312713 00000 n
0000275075 00000 n
0000190367 00000 n
0000207187 00000 n
0000186894 00000 n
0000160606 00000 n
0000056522 00000 n
0000056651 00000 n
0000057220 00000 n
0000173282 00000 n
0000029315 00000 n
0000145481 00000 n
0000016623 00000 n
0000050641 00000 n
0000029848 00000 n
0000030343 00000 n
0000030596 00000 n
0000030974 00000 n
0000050678 00000 n
0000120868 00000 n
0000120893 00000 n
0000091906 00000 n
0000092159 00000 n
0000057816 00000 n
0000058063 00000 n
0000058664 00000 n
0000092700 00000 n
0000121408 00000 n
0000121815 00000 n
0000121884 00000 n
0000122144 00000 n
0000122253 00000 n
0000173572 00000 n
0000173826 00000 n
0000174145 00000 n
0000191085 00000 n
0000191586 00000 n
0000191934 00000 n
0000192312 00000 n
0000200344 00000 n
0000200467 00000 n
0000201171 00000 n
0000195155 00000 n
0000195239 00000 n
0000195736 00000 n
0000196304 00000 n
0000201873 00000 n
0000238543 00000 n
0000238644 00000 n
0000239218 00000 n
0000239853 00000 n
0000275112 00000 n
0000312914 00000 n
0000313180 00000 n
0000435307 00000 n
0000410241 00000 n
0000380918 00000 n
0000382761 00000 n
0000343366 00000 n
0000319676 00000 n
0000381215 00000 n
0000381524 00000 n
0000381843 00000 n
0000458731 00000 n
trailer<</Size 89/Root 1 0 R/Info 88 0 R/ID[<748BE19F26294BE0B085DBC23E3132B0><6D1350896B554D27A227CF19FEB637AA>]>>startxref458913%%EOF1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R/DisplayDocTitle true>>>>endobj2 0 obj<</Length 11565/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-07-17T06:02:14-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-07-17T09:25:26-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-07-17T09:25:26-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:979f3fb0-721b-5e47-99ee-222dc14acd6d</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:9781fe1d-50de-4727-9e44-073511991c41</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:982928b7-5d59-44bd-8c19-d8a0b76c6023</stRef:instanceID>
            <stRef:documentID>xmp.did:b239edf2-8d6f-47e4-a188-2c47c7342adf</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-07-17T06:02:14-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">KRAZATI U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1392107873</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1392107873</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-ItalicMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.00.2</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1552261271</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1552261271</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.01.2</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3030352917</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3030352917</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4073973744</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4073973744</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3691150952</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3691150952</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj89 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20240717060214-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240717092526-04'00')/Producer(Adobe PDF Library 17.0)/Title(KRAZATI U.S. Prescribing Information)/Trapped/False>>endobjxref
0 3
0000000000 65535 f
0000460845 00000 n
0000460974 00000 n
89 1
0000472616 00000 n
trailer<</Size 90/Root 1 0 R/Info 89 0 R/ID[<748BE19F26294BE0B085DBC23E3132B0><B769F468286A44838064B8E4E9CD6783>]/Prev 458913>>startxref472871%%EOF